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Foreword 
 
Leishmaniases are vectorial parasitic infections caused by Leishmania species (Protista), 
affecting vertebrates particularly humans and dogs and present in all inhabited continents. 
Disease conditions are very variable ranging from self-limiting, although disfiguring, cutaneous 
infections to fatal visceral leishmaniasis. The human disease, in all its presentations, is a heavy 
burden for both patients and health systems if available. Visceral leishmaniasis, caused mainly 
by anthroponotic L.donovani and zoonotic L.infantum (=L.chagasi), is the second most lethal 
parasitic disease actually being responsible for over 40,000 deaths per year. The latter species is 
also the causative agent of canine leishmaniasis, a first order veterinary pathology in the 
Mediterranean basin and South America. Conservative estimations of L.infantum prevalence in 
Spain lead to more than 250,000 dogs presently infected with this species and more than 
probably millions of dogs are infected in Brazil. In addition to its relevance in veterinary clinics 
these infections are of public health concern since dogs are considered the main reservoir of 
human infection. 
Despite the financial effort made by international and national funding agencies, campaigns 
by health authorities and the research work done by laboratories around the world improvement 
of prevalence and incidence rates of the disease, especially in those regions where the processes 
are more severe, has been modest. Moreover, war- and famine-related human migrations, 
opening of rural areas for urban development, absence of reliable national health services in 
many endemic countries besides climatic changes, global economic crisis and emergence of 
new epidemiological patterns have contributed to the actual extension of the disease. In spite of 
the recent Madrid outbreak, the levels of human infection in Spain are low and linked, for the 
most part, to inmunocompromissed patients (e.g. HIV+, solid organs transplant recipients). By 
its part, in the veterinary arena, no actual evidence of reduction in incidence or prevalence of the 
infection is presently available.  
Given the difficulties of vector control and the impracticality –and probably unusefulness- of 
reservoirs control (i.e. dog culling) in the case of zoonotic visceral leishmaniasis caused by 
L.infantum, control relies on the use of antileishmanial drugs. Nonetheless, chemotherapeutic 
arsenal is very limited and the majority of the currently used drugs have serious shortcomings 
including toxicity at the required doses, easy selection of resistance when used in monotherapy, 
teratogenicity and high price of the most effective and less toxic presentations. To make matters 
Foreword │4 
 
Antileishmanial activity of Allicin: mechanism of action, in vivo efficacy and value in combined therapy with amphotericin B │ María Jesús Corral 
worse there is an increasing number of reports on Leishmania resistance to the first line drugs 
(i.e. pentavalent antimonials). Unfortunately no new affordable and short-course treatments of 
null or reduced toxicity for the treatment of leishmaniasis are foreseen either from the 
pharmaceutical industry pipelines or research laboratories. 
Among the strategies followed to identify leads that, eventually, could progress along the 
antileishmanial drug development, namely combinatorial chemistry, lower toxicity 
presentations, “piggy backing” strategy –new indications for old drugs-, discovery of new 
chemical entities, the exploration of the potential value of molecules from or derived from 
natural sources has been comparatively less developed. The investigation on natural products, 
once the drug store, is hampered by the complexity of the mixtures and their difficulties to fit 
well into the majority of drug screening methods. However, current technology improvements 
in analysis and separation of active molecules, and bioguided development could overcome 
some of the inconveniencies of these natural products thus allowing the study of more complex 
molecular scaffolds as potential antileishmanial drugs. Unstable Diallyl thiosulfinate (=allicin) 
and related compounds, present in plants belonging to the family Alliaceae, have shown 
antiproliferative activity on transformed mammalian cells and some Protista. Availability of a 
stabilised preparation of this molecule prompted us to evaluate its potential antileishmanial 
activity, alone or in combination, in vitro, ex vivo and in vivo and to determine the underlying 
mechanism of action. 
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1.1. History of the disease 
Leishmaniasis is a group of parasitic vectorial chronic diseases affecting man and other 
vertebrates caused by Protista from the Genus Leishmania (Kinetoplastida, Trypanosomatidae). 
The disease is present in all areas where the sandfly vectors (Phlebotomus and Lutzomyia, 
Psychodidae) are present and clinical courses range from self-limiting to fatal unless treated 
infections. Wide geographical distribution, high prevalence and incidence of the infection 
suggest that the relationship between man and Leishmania was probably established very early 
during human evolution.  
Paleopathological studies have shown that mummies, skeletons and bone marrow samples 
from Upper Nubia and Egypt dating back 4,000 years BC allowed the amplification of a 120-pb 
fragment of kinetoplastid mitochondrial DNA from Leishmania and showed the high prevalence 
of the infection (12.9% of positive examined mummies) (Zink et al., 2006). Extraordinary 
climatic conditions besides the expertise of the Egyptian embalmers were not present in the 
other ancient Middle East and Mediterranean empires. However, there are indirect references 
from medical texts, particularly related to the observed lesions. Insofar the first historical 
reference to leishmaniasis comes from a series of medical writings in cuneiform tablets from the 
library in Nineveh of Ashurbanipal (668 BC – c. 627 BC), the last great king of the Assyrian 
empire. These texts, dated around the VIIth century BC but probably corresponding to over 1500 
years BC, describe cutaneous processes compatible with the disease. In the Old Testament there 
are also references not only to the cutaneous leishmaniasis (CL) in the Egyptian population -
corresponding to the Exodus (Oumeish, 1999)- but also in the Deuteronomy, written ca. VIth BC 
century, using the  Jewish word ʿafolim – leishmaniasis (Deut. 28:27).  
Not many notices on leishmaniasis from Greece and the Roman Empire are known except 
for the description of a transmittable cutaneous disease, reported by Pliny the Younger, common 
among the wealthy people and apparently brought from Asia (Retief & Cilliers, 2000). 
However, these lesions could be ascribed to other disease conditions. This is most surprising 
given the geographical extension of the Roman Empire to places where previous leishmanial 
infections had been reported (see above).  
From Xth century onwards there are many reports on the so-called “oriental sore” in the Old 
World. Recently L.infantum infection has been diagnosed in bone samples from Eleonora di 
Toledo (1522-1562 AD) (Figure 1), wife of Cosimo I de Médici (Nerlich et al., 2012). Whether 
the infection was acquired in Italy or in Spain is not known but this finding supports that 
Leishmania infection was present in Southern Europe.  
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Similarly, in the Americas, facial lesions corresponding to 
CL have been extensively represented in pre-Inca pottery 
(Figure 2) (Lainson & Shaw, 2005). Texts from the 15th and 
16th centuries, and then during the Spanish colonization, 
mention the risk run by seasonal agricultural workers who 
returned from the Andes with skin ulcers which, in those 
times were attributed to "valley sickness" or "Andean 
sickness" (Bari, 2006). 
Medical services from the colonial armed forces, 
particularly British and French, recognized this “new” 
disease. Thus, the first clinical description by western 
standards of CL was done by Alexander Russell, in 1756, 
calling the clinical signs and lesions observed on a Turkish 
patient from Aleppo (presently known as Halab, Syria), 
“Aleppo boil” (Choi & Lerner, 2001; Cox, 2002). Using his 
words “After it is cicatrized, it leaves an ugly scar, which 
remains through life, and for many months has a livid color. 
When they are not irritated, they seldom give much pain". 
Besides this name many other regional synonyms of the 
diseases were and still are currently used (e.g. Jericho boil, 
Algerian boil). By its part, in 1824, VL is described in Jessore, 
India, as a feverish process with splenomegaly, caquexia, 
anemia and skin darkening. The clinical condition received the 
names of “kala-azar”, “black fever” or “Dum-Dum fever” 
among others. Before that date the disease was misdiagnosed 
as quinine-refractory cases of malaria (Gibson, 1983).  
The first observation within macrophages of the parasite 
causing Old World CL is attributed to the American 
pathologist James Homer Wright, in 1903, after the 
observation of protozoa in a case of tropical ulcer (Delhi sore) 
(J. Med. Res. 10:472–482). However, it seems clear that the 
Scottish Surgeon Major David Douglas Cunningham (1843–
1914) also observed it in a patient in Calcutta, India in 1885. 
Nevertheless he did not recognize the nature of the 
 
 
Figure 1. Portrait of Eleonora di 
Toledo with his son Giovanni de 
Médici. Painted by Agnolo 
Bronzino (1503-1572). Location: 
Uffici Gallery, Florence, Italy. 
 
 
 
Figure 2. Peruvian pottery (huaco) 
showing facial mutilations thought to 
represent mucosal leishmaniasis. 
(From Lainson & Shaw, 2005). 
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aetiological agent and described it as of fungal origin. Shortly afterwards, in 1898, the Russian 
sergeant D.F. Borovsky accurately described in Tashkent, Uzbekistan (then Russia), the 
morphology of the causative agent including the kinetoplast and identified it as a protozoan but 
he did not name it (Bari, 2006).   
In the case of VL, uncertainty about the relationship between the causative agent and the 
clinical disease continued fueled by the belief of Ronald Ross of being just an atypical 
presentation of malaria. Scientific communication at the end of the XIXth century and the first 
years of the XXth century was quite limited and more than probably these findings in CL were 
not known by the Scottish army doctor, William Leishman and the Professor of Physiology at 
Madras University, Charles Donovan. These two authors published in 1903, in the same journal 
(British Med. J.) and two months apart, the identification of a parasite in spleen samples from 
patients with kala-azar. In his contribution Leishman suggested the relationship of the described 
agent to the better known trypanosomes (Figure 3). Ronald Ross, at the end of the same year 
named the new agent as Leishmania donovani as homage to the two discoverers (Gibson, 1983).  
 
 
Figure 3. Reproduction of the original publication by W. Leishman (1903) in the British Med. J. showing the presence 
of amastigotes of Leishmania in spleen smears from a deceased patient with “Dum-dum fever”. 
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The next year in North Africa, Cathoire and Alphonse Laveran identified “Leishman bodies” 
in children with splenic anemia. This parasite was named L.infantum in 1908 by Nicolle who 
was also the first to culture it in medium NNN (Nicolle, Novy, McNeal) and to identify the dog 
as the main reservoir for this species. In the first half of the XXth century there were 
identifications and descriptions of Leishmania all over the world. Thus, in 1912, Leishmania 
was identified in Brazil from mucocutaneous lesions (WHO, 2010). The same year the Italian-
born Spanish parasitologist Pittaluga reported the presence of VL in Spain. In India, in 1922, 
Bramachari described the Post Kala-azar Dermal Leishmaniasis (PKDL). The life cycle of the 
parasite with the involvement of an insect (Psychodidae, Pheblotomus) took some more years 
up to the works from Adler and Ber in Palestine and the demonstration of the transmission of 
L.donovani in India, carried out in 1942 by Colonel Shortt and colleagues (Sewaminath and 
Anderson) (WHO, 2010). Along the rest of the past century and in present days, investigational 
effort has been focused on a variety of fields, including the development of research tools to 
unravel intimate aspects of parasite biology, transmission, species involved, epidemiological 
patterns, clinical course and its relationship to the aetiological agents involved with the final aim 
of controlling the extension of the disease and its severity. 
 
1.2. Parasite and vector 
Leishmania is a Protista (Kinetoplastida) with heteroxenous life cycle and two morphologies. 
The extracellular phase, the promastigote, is present in the digestive tract of the insect vector. It 
is elongated (10-20 µm long x 4-7 µm wide) and motility is achieved by a ca. 20 µm single 
anterior flagellum emerging from a flagellar pocket. Intracellular organelles, characteristic of 
kinetoplastids, include a single nucleus with central nucleolus; glycosomes, where glycolysis is 
performed; acidocalcisomes for intracellular calcium storage and also related to osmorregulation 
and pH buffering; megasomes, linked to lysosomes (Vannier-Santos et al., 2002) and Golgi 
body-endoplasmic reticulum (de Souza da & da Cunha-e-Silva, 2003). Besides these organelles 
the most striking feature of these protists is the presence of a single mitochondrion representing 
ca. 12% of the total volume of the cell intimately related to a singular structure, the kinetoplast, 
related to the flagellum and containing its own DNA, kDNA (Figure 8A) (Monzote-Fidalgo & 
Gille, 2011). The parasitic phase present in vertebrates, the amastigote, is ovoid, presenting a 
diameter of ca. 2-4 µm; it is sessile and devoid of flagellum. This phase presents the same 
intracellular organelles as promastigotes although Golgi body and endoplasmic reticulum are 
reduced. In addition electron microscopy shows that a vestigial flagellar pocket is present 
(Figure 8B). 
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Figure 8. Ultrastructure of Leishmania spp (A) promastigote (B) amastigote. From Teixeira et al., 2013. 
 
 
Transmission of Leishmania species is carried out through the bite of female sandflies from 
some species of the Genera Phlebotomus (Eurasia and Africa) and Lutzomyia (Americas) 
(Diptera, Psychodidae). Sandflies have a worldwide distribution although they are more 
frequent in arid zones of the Old World and forests in the New World. Some of the species from 
Eurasia and Africa breed in periurban areas and even inside households. On the contrary, 
transmission in the Americas is related to people working or living in or close to forests where 
Lutzomyia species are present.  
Sandflies have a very limited flight capacity (< 2.5 Km) and measure ~ 3 mm. Head, thorax, 
abdomen and appendages are covered with hairs, the palps extend beyond the proboscis and are 
almost folded in two. The wings are folded above the body and the legs are long and slender. 
They are more active at dawn and dusk. Males are phytophagous whereas females are 
anautogenous requiring blood-meals for maturation and egg development (Killick-Kendrick, 
1999). Transmission ability of Leishmania by sandflies is related to the concordance-
discordance of the gonotrophic cycle and the development in the midgut of these insects. As far 
as it is known, in Spain only two species, Ph.perniciosus and Ph.ariasi are proven vectors. 
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1.3. Life cycle of Leishmania species 
Female sandflies, when they take a blood-meal from an infected host, take also Leishmania-
infected macrophages (Mφ). Amastigotes, within a few hours after ingestion, are engulfed by a 
peritrophic membrane in the mid-gut where they transform into rapidly-dividing procyclic 
promastigotes. Two to five days later they acquire a characteristic slender form, nectomones 
and, subsequently, leptomones. Once digestion has finished, the peritrophic membrane is broken 
down and the free promastigotes adhere through the flagellum to the villi of epithelial cells of 
the insect’s intestine. This binding is critical for Leishmania survival since otherwise they 
would be expelled by defecation. The binding is achieved by the interaction of the 
lipophosphoglycan (LPG) layer from the leishmanial surface with galectins present in the 
epithelial cells from the host. Actually host-specificity is related to the compatibility of this 
binding (Kamhawi et al., 2004). 
When promastigotes detach from the epithelium they migrate towards the stomodeal valve in 
the upper intestine. At this moment, the promastigotes are contained in a proteophosphoglycan 
matrix, the promastigotes secretory gel, obstructing the valve. The obstruction plays a 
fundamental role in the transmission since it facilitates regurgitation. Promastigotes undergo 
several morphological changes in a process termed metacyclogenesis until they reach the 
infective or metcyclic stage which migrates to the proboscis. When the infected sandfly takes 
the next blood-meal, metacyclics are regurgitated and enter a new vertebrate host (Warburg & 
Sclein, 1986; Sacks, 1989).   
Metacyclic promastigotes are engulfed by cells from the mononuclear phagocytic system 
(MPS), including dendritic cells, fibroblasts, neutrophils, Langerhans cells and, particularly, 
macrophages (Mφ). In the cytosol they are surrounded by a parasitophorous vacuole where the 
promastigotes transform to amastigotes. Lysosomes fuse with the parasitophorous vacuole 
resulting in the formation of the phagolysosome. In spite of the extreme conditions within this 
vacuolar environment Leishmania amastigotes are able to survive and multiply. Intracellular 
proliferation of amastigotes eventually results in lysis of the host cell and the consequent 
amastigote release to the extracellular milieu or the blood. The free parasites can either be 
phagocytized invading new host cells or ingested by a sandfly thus continuing the transmission 
to a new host (Chang et al., 1990; Teixeira et al., 2013). L. infantum life cycle is illustrated in 
Figure 9. 
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Figure 9. The life cycle of Leishmania infantum. The sandfly feeds on a susceptible host and injects metacyclic 
infective promastigotes during the blood-meal. Promastigotes are phagocytized mainly by macrophages (Mφ) where 
they transform into amastigotes within the parasitophorous vacuole. Amastigotes actively multiply, eventually 
rupturing the infected cell releasing amastigotes into blood and tissues. The parasite continues to infect phagocytic 
cells in the host. Sandflies become infected through feeding on a parasitized host. Ingested amastigotes convert to 
promastigotes within the sandfly midgut. Promastigotes migrate from the midgut and transform into highly infectious 
metacyclic promastigotes. From Esch & Petersen, 2013. 
 
 
1.4. Epidemiology and distribution of leishmaniasis 
The disease is endemic in 98 countries and is present in all inhabited continents although in 
Australia -with autochthonous cases of cutaneous leishmaniasis in kangaroos, wallaroos and 
wallabies (Rose et al., 2004; Dougall et al., 2009)- no human cases have been yet reported 
(Alvar et al., 2012). Infection is more frequent in developing countries, where 90% of all the 
human cases take place. Available data for morbidity rates of leishmaniasis are surely biased, on 
the basis of the complex interaction between infection and disease (vide infra), and higher 
prevalence in areas of the world with public health and information systems well behind 
Literature review: chemotherapy of leishmaniasis │14 
 
Antileishmanial activity of Allicin: mechanism of action, in vivo efficacy and value in combined therapy with amphotericin B │ María Jesús Corral 
Western standards. Therefore, the WHO (2010) estimations of 350 million people living in 
areas at risk and 12 million people currently infected surely underestimate the real prevalence 
and incidence of the infections. Particularly those caused by visceralizing species, as most of the 
people infected with these species never develop any sign of leishmaniasis. It is estimated that 
only one out of ten infected people with L.donovani and one out of 100 infected with L.infantum 
develop the disease (Dujardin & Decuypere, 2013). In addition, 90% of all human cases of VL 
are concentrated in just six countries: India, Bangladesh, Sudan, South Sudan, Brazil and 
Ethiopia; while Afghanistan, Algeria, Colombia, Brazil, Iran, Syria, Ethiopia, Sudan, Costa Rica 
and Peru account for the 75% of the CL cases (Alvar et al., 2012). Most of these countries lack 
programs of surveillance or notification (e.g. Mongolia), they have no continuity of data 
reporting and the official figures are not accurate under-declaring the number of cases. In this 
sense, Alvar et al. (2012) indicated that the actual number of cases of CL in some countries such 
as Jordan or Guatemala was from 40 to 47 times higher than those officially recognized. 
Furthermore, focal distribution of leishmaniasis biases the extrapolation of many estimates.  
On these grounds, the annual incidence of VL could be in the range of 200,000-400,000 and 
of 700,000 to 1.2 million human cases for CL. Perhaps the extension of the infection is even 
higher since recent estimates based on databases and statistical modeling rise the current human 
population to 1.71 billion and 1.69 billion individuals living in areas suitable for CL and VL 
respectively (Piggot et al., 2014). VL reported and predicted distribution worldwide is 
represented in Figure 10. 
Mortality figures should also be carefully taken since only people with access to medical 
services and follow-up are included. Alvar et al. (2012) estimate that VL causes from 20,000 to 
40,000 annual casualties, a similar figure to WHO data (i.e. 50,000 fatal cases). In spite of 
limitations, these numbers place leishmaniasis as the second most lethal parasitic disease (after 
malaria) and the ninth within the context of transmittable diseases (WHO, 2010). 
Geographical distribution and extension of the disease is related mainly to the presence and 
population dynamics of sandfly vectors and the availability of reservoirs since most of 
Leishmania species pathogen for humans have a certain degree of zoonotical transmission (Esch 
& Petersen, 2013). Other transmission ways, although present, are less relevant in 
epidemiological terms. These include the venereal and vertical (congenital) transmission, blood 
transfusion in humans and dogs, syringe contamination in intravenous drug addicts (Killick-
Kendrick, 1999; Tabar et al., 2008). 
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Figure 10. Reported and predicted distribution of visceral leishmaniasis in the New World (A and A’) and in the Old 
World (B and B’). (A and B): Evidence consensus for presence of the disease ranging from green (complete 
consensus on the absence: −100%) to purple (complete consensus on the presence of disease: +100%). The blue 
spots indicate occurrence points or centroids of occurrences within small polygons. (A’ and B’) Predicted risk of 
visceral leishmaniasis from green (low probability of presence) to purple (high probability of presence). Adapted from 
Piggot et al., 2014. 
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Due to the dynamic nature of diseases, particularly those of complex epidemiology such as 
leishmaniasis, the appearance of the disease in previously thought free areas is frequent 
(Desjeux, 2001) and both human and canine cases have been reported in “non-typical” regions 
(e.g. Central Europe, USA and Canada) (Gaskin et al., 2002; Teske et al., 2002; Maroli et al., 
2008; Petersen, 2009; Lobsiger et al., 2010; Tánczos et al., 2012; Clarke et al., 2013). This 
apparent expansion and the fluctuations in endemic areas have been related to socioeconomic 
(e.g. poverty, deficient infrastructures, lack of sanitation), nutritional (e.g. access to water 
supply, malnutrition), wars, migrations, movement of pets (e.g. holidays) and people (e.g. 
workers, travelers, urbanization), the climatic change and the subsequent expansion of the 
geographical distribution of vector populations (Desjeux, 2004; Chappuis et al., 2007; WHO, 
2010; Gradoni, 2013; Ready, 2014).  
Other factors facilitating the expansion of the infection by Leishmania are related to the 
environmental modification carried out by the human population (e.g. deforestation, engineering 
interventions, agricultural practices); generation of new niches (e.g. HIV-induced immune 
suppression, iatrogenic immune suppression in recipients of solid organ transplants); reduction 
of public health investments in low-income countries as a consequence of economic crisis; 
unavailability of medical services and chemotherapy, besides the therapeutic failures and the 
reported appearance of resistant Leishmania isolates to standard drugs (Desjeux, 2004; 
Chappuis et al., 2007; Antinori et al., 2008, Dujardin & Decuypere, 2013). Surely all these 
factors influence Leishmania transmission although their relative importance for a given 
location and Leishmania spp is not known in most cases.  
In Spain three epidemiological patterns of leishmaniasis are recognized: 1) endemic, with 
sporadic cases and the dog acting as the main reservoir, 2) cases associated to immune 
depressing infections (e.g. HIV), non-infectious diseases eliciting an immune depression (e.g. 
systemic erythematosus lupus) or patients with iatrogenic immune depression (e.g. recipients of 
solid organs transplants), and 3) epidemic outbreaks (Suárez-Rodríguez et al., 2012). The 
number of cases of human leishmaniasis in Spain is low and in the period between the years 
1996 and 2011 a total of 1,755 cases have been reported according to the “Red Nacional de 
Vigilancia Epidemiológica” (RENAVE) (National Net of Epidemiological Surveillance). From 
2009 to 2012 an outbreak of leishmaniasis was reported in the southwest area of the Madrid 
autonomous community. The outbreak was related to L.infantum infection [confirmed in 421 
cases (94.4% of the patients)] although cutaneous lesions were more frequent (64.1%) than 
visceral processes (35.9%). The mean age was 44 years, though the age range was wide (from 2 
months to 95 years). The majority of the cases took place in immunocompetent individuals as 
only 15.2% of the cases were somehow related to inmmunosuppresive conditions. No 
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correlation was found between human and dog infections (Arce et al., 2014). Extensive research 
on potential alternative animal reservoirs showed that, apparently, hares were involved as 
reservoirs (Molina et al., 2012). This is the largest outbreak of leishmaniasis reported in Europe 
and, although not yet completely unraveled (e.g. anthroponotic infection), shows the dynamic 
nature of the disease and the potential new transmission patterns to be considered.  
 
1.5. Human leishmaniasis 
Over 30 species of Leishmania have been described and Table 1 shows the pathogenic 
species for humans and domestic animals. 
 
Table 1.  Leishmania species pathogenic for humans and domestic animals. 
Clinical form 
Subgenus (Old World) Subgenus (New World) 
L. (Leishmania) L. (Viannia) L. (Leishmania) L. (Viannia) 
Visceral 
Leishmaniasis 
L. donovani 
L.infantum 
L.tropica 
 L.infantum*  
Cutaneous 
Leishmaniasis  
 
L.major 
L.tropica 
L.killickia 
L.aethiopica 
L.infantum 
 
L.infantum* 
L.mexicana 
L.pifanoia 
L.venezuelensis 
L.garnhamia 
L.amazonensis 
 
L.braziliensis 
L.guyanensis 
L.panamensis 
L.shawi 
L.naïffi 
L.lainsoni 
L.lindenbergi 
L.peruviana 
L.colombiensisa 
 
Mucocutaneous 
Leishmaniasis 
   
 
L.braziliensis 
L.panamensis 
L.guyanensis 
 
a Discussed status; * L infantum (= L.chagasi) in America.                          (Adapted from: Baneth, 2006; WHO, 2010) 
 
1.5.1. Cutaneous leishmaniasis (CL) 
1.5.1.1. Localized cutaneous leishmaniasis (LCL) 
LCL is worldwide distributed although the clinical presentation varies depending of the 
geographical area and the particular Leishmania species. It is the most common form of 
leishmaniasis (WHO, 2010). In Africa and Eurasia the species incriminated in this presentation 
are L.infantum, L.tropica, L.major and L.aethiopica whereas in the Americas several species 
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from both Subgenera (Leishmania, Viannia) have been associated with the clinical form (Table 
1).  
LCL can present a single lesion (New World) or multiple lesions (Old World) at the 
inoculation site, being more frequent in exposed areas of the body (i.e. face, neck and arms). As 
a rule, lesions begin, after inoculation, with the appearance of a nodule or papule several days to 
months after infection by sandflies. Lesions progress to ulceration, formation of scars with 
hypertrophic edges of purple colour (Figure 4). These lesions tend to be self-healing, not painful 
and not pruriginous. Spontaneous healing takes months to years depending on the Leishmania 
spp involved and the immune response of the host. On occasion draining lymph nodes can be 
compromised (Choi & Lerner, 2001; WHO, 2010). 
 
 
Figure 4. Skin lesions found in localized cutaneous leishmaniasis (LCL). (A): Crusts in ulcerated lesions caused by 
L.major. (B): Ulcer with hypertrophic margins produced L.mexicana. Image from David & Craft, 2009. 
 
 
 
1.5.1.2. Disseminated cutaneous leishmaniasis (DCL) 
DCL is caused in the Old World by L.aethiopica while L.amazonensis and L.mexicana are 
the species responsible in the Americas (WHO, 2010). Moreover, in immune compromised 
patients (e.g. Leishmania + HIV coinfection, transplant organ recipients) some other 
Leishmania spp have been incriminated (Couppié et al., 2004). 
This clinical form is characterized by the presence of multiple cutaneous lesions in at least 
two non-adjacent regions of the body (Figure 5A). Although DCL is started with an initial, 
isolated lesion, patients subsequently develop up to hundreds of lesions of mixed types within a 
short period of time. Lesions tend to be non-ulcerative and can be papules, nodules or acne-like, 
with very few or no parasites in the skin tissue. Trunk, members and face are the most 
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frequently affected areas. Mucosal involvement may be present in ≤ 25 % of the cases (Turetz et 
al., 2002). Thickening of eyebrows and pinna eventually accompanied by mucosal affection (lip 
borders and nostrils) can resemble lepromatous leprosy although no nervous system 
involvement is present in DCL (Choi & Lender, 2001). The disease is chronic and, unlike LCL, 
not self-healing. Efficacy of chemotherapy is reduced and relapses are frequent (Couppié et al., 
2004).  
 
1.5.2. Post Kala-azar Dermal Leishmaniasis (PKDL) 
PKDL is a secondary complication of VL caused by L.donovani. It has been described in 
former Sudan (Sudan + South Sudan) and India in the 50% and 5-10% of the treated patients, 
respectively. Development of this condition takes ~ 6 months after the disappearance of VL in 
Sudan whereas in India the disease appears after 2-3 years. On occasion PKDL has been found 
in patients apparently not previously suffering VL (Zijilstra et al. 2003) and also in cases of 
L.infantum-HIV coinfection (Stark et al., 2006). Lesions (nodules, papules and hypo-pigmented 
or erythematosus maculae) are mainly facial and can spread to other body parts (Figure 5B). 
Risks factors eliciting PKDL remain unknown and the response to chemotherapy is poor 
(Zijilstra et al., 2003). African cases tend to be self-healing whereas Indian PKDL generally 
never disappears (WHO, 2010). 
 
Figure 5A. Skin lesions found in 
disseminated cutaneous leishmaniasis 
(DCL). (A): Multiple acneiform eruptions 
in the back. (A’): Ulcers in the fingers 
and breast. Images come from Turetz et 
al., 2002 (A) and Couppié et al., 2004 
(A’). 
 
 
Figure 5B. Post Kala-azar dermal 
leishmaniasis (PKDL). (B): Macular 
lesions. (B’): lesions in the face and 
trunk. Images taken from Zijilstra et al., 
2003. 
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1.5.3. Muco-Cutaneous Leishmaniasis (MCL) 
Aetiological agents belong to the Subgenus Viannia, particularly L.braziliensis and 
L.panamensis. This clinical form was well known by the autochthonous South Americans 
before the Spanish conquest. Accordingly, regional names are abundant (e.g. “espundia”, “uta”, 
“úlcera del chiclero”) in the countries with the highest prevalence such as Brazil, Bolivia and 
Peru. This clinical form is characterized by disfiguring lesions in oral and nasal mucosae and 
upper respiratory system (Figure 6). The infection is not self-healing and the secondary bacterial 
infections are frequent, being pneumonia the most common cause of death (WHO, 2010). It is 
worth pointing out that these lesions have been also observed in immune compromised patients 
infected with L. (Leishmania), in particular L.donovani, L.infantum, L.tropica and L.major 
(WHO, 2010). Factors eliciting the development of MCL are not known although both the 
immunological status of the patient and virulence of species or isolate seem to play a crucial 
role in the progression of lesions towards mucosae in 1-10% of the infections (David & Craft, 
2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Mucocutaneous leishmaniasis: (A) Destruction of the palate due to L.braziliensis; (B) and (C) Active lesion 
in nasal mucosa (B) with perforation of the nasal septum caused by L.braziliensis; Images (A) and (C) from Lainson 
& Shaw, 2005; and image (B) taken from Colvopina et al., 2006. 
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1.5.4. Visceral leishmaniasis (VL) 
VL is caused by L.donovani in the Indian subcontinent and East Africa, and by L.infantum 
(=L.chagasi) in Europe, North Africa and Central and South America (Chappuis et al., 2007). In 
addition some cases of VL caused by L.tropica have been described (Magill et al., 1993). 
Infections by L.donovani are more frequent in children and young adults although all ages are 
susceptible. Incubation period is highly variable (10 days to one year or more) and clinical signs 
and lesions include fever, weight loss, cutaneous paleness and liver and spleen enlargement 
(Figure 7). In India, L.donovani infections characteristically course with darkening of the skin in 
the face, hands, feet and abdomen. This darkening probably explains the local name of the 
disease since Kala-azar in Hindi can be translated as “Black fever” (WHO, 2010). Mortality 
associated to L.donovani infections is very high; actually is the second death-causing parasitic 
disease, after malaria.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Chronic visceral leishmaniasis by L.donovani. Six years old child from Sudan, showing extreme 
hepatosplenomegaly and emaciation. From Hoogstral & Heyneman, 1969.  
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1.5.4.1. Anthroponotic and zoonotic visceral leishmaniasis 
In previous pages it was stated that VL is the most severe form of leishmaniasis with fatal 
consequence unless treated (Desjeux et al., 2004). Generally speaking two forms of the disease 
have been traditionally considered: Anthroponotic Visceral Leishmaniasis, AVL, caused by 
the infections of L.donovani and present in the Indian subcontinent and Eastern Africa, and 
Zoonotic Visceral Leishmaniasis, ZVL, provoked by L.infantum (=L.chagasi) infections in the 
Mediterranean, including the Iberian peninsula, some parts of Asia (e.g. China) and South 
America (Chang et al., 1990; WHO, 2010). Transmission of L.donovani is considered 
anthroponotic, humans acting as the main reservoir although the potential role of other animal 
species has been suggested in India (Singh et al., 2013), Sudan (Dereure et al., 2003) or Nepal 
(Bhattarai et al., 2010). By its part, L.infantum can infect a variety of mammals although dogs 
are considered the primary reservoir for ZVL. In endemic areas high prevalence of the infection 
has been reported in red fox (Vulpes vulpes) (75%) and other carnivores (e.g. wolves: Canis 
lupus; jackals, Canis spp). Moreover, other species (e.g. Crab-eating fox from South America, 
Cerdocyon thous; opossum, Didelphis spp; cat, Felis silvestris catus; rat, Rattus rattus; hare, 
Lepus spp) can be experimentally infected but their role as primary or secondary reservoirs is 
not yet determined (Quinell & Courtenay, 2009; Domingues-Souza et al., 2014; Millán et al., 
2014). ZVL, besides its importance in public health in the distribution area of L.infantum, is a 
first order pathology in a strictly veterinary arena given the prevalence and severity of the 
disease. Thus it is justified, in our context, to review more extensively the canine leishmaniasis. 
 
 
1.6. Canine leishmaniasis (CanL) 
1.6.1. Distribution and epidemiology of CanL 
Dogs (Canis familiaris) can be naturally infected by a number of Leishmania spp, namely 
L.arabica, L.major, L.tropica, L.infantum and L.donovani in Eurasia and Africa, and by 
L.amazonensis, L.colombiensis, L.peruviana, L.mexicana, L.panamensis and L.braziliensis in 
America (Campino & Maia, 2013). Their relative role on the basis of the potential of 
transmission, zoonotic character and severity of the processes is very different. It is considered 
that L.infantum (=L.chagasi) is the most relevant species affecting dogs.  
CanL has been reported at least in 50 of the 98 countries where human leishmaniasis is 
present (WHO, 2010). The Mediterranean region and Brazil are the areas with higher incidence 
and prevalence. There are sporadic cases of CanL in non-endemic regions related to the animal 
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import or pet movement to recreational endemic areas (Shaw et al., 2009). In the last years an 
apparent expansion of the disease to previously-free areas in Central Europe has been reported 
(Teske et al., 2002; Maroli et al., 2008) and the connection between climatic change and the 
presence of those autochthonous cases has been suggested. More striking have been the North 
American reports, particularly from the USA (Gaskin et al., 2002; Clarke et al., 2013). CanL, 
caused by L.infantum, was originally diagnosed in some foxhound kennels in North Eastern 
states, and from 2000-2005 the infection has extended to over 20 states in the USA (Petersen, 
2009) and five Canadian provinces (Duprey et al., 2006). Since no recognized vector was 
known at the time, and other arthropods (fleas, ticks) have not conclusively shown to play any 
role in the transmission of Leishmania (Coutinho et al., 2005; Saridomichelakis, 2009; Dantas-
Torres et al., 2010; Colombo et al., 2011) vertical and horizontal transmission have been 
postulated in the USA and in some European countries (Petersen & Barr, 2009; Naucke & 
Lorentz, 2012). CanL can be transmitted through blood transfusions (Owens et al., 2001; Tabar 
et al., 2008) and other sandflies, not previously described as vectors of Leishmania, are present 
in the USA and Canada. Among them, Lutzomyia youngi and Lutzmoyia shannoni are present in 
the New World and the latter is a proven vector of the vesicular stomatitis virus. Even though 
both species can be infected after feeding on infected dogs no actual evidence of their role in the 
transmission of L.infantum has been yet presented (Travi et al., 2002). 
It is estimated that over 2.5 million dogs are infected in the endemic areas from Europe and 
probably millions of dogs and other wild canids in South America (Baneth et al., 2008). This 
high prevalence is possibly due to the intense infection pressure since animals living in endemic 
areas can receive up to one bite of an infected sandfly/hour (Saridomichelakis, 2009). In 
Southern Europe -the most affected area- seroprevalence ranges from 5 to 30% with “hot spots” 
where this value can reach 40-80% (Franco et al., 2011). Average values in some non-biased 
surveys carried in Spain were comparable, 5-7% of the total sampled dog population (e.g. 
Castillo-Hernández et al., 1985; Franco et al., 2011) and some high prevalence areas were also 
identified in South-eastern Spain with values over 20% (Martín Sánchez et al., 2009) or even ˃ 
30% (e.g. Axarquía, Málaga) (Morillas et al., 1996). Moreover, the disease once predominantly 
rural is becoming more frequent in residential areas around cities (Campino & Maia, 2013).  
Estimation of the incidence and prevalence of CanL, in a similar way to that indicated for 
human leishmaniasis, is challenging by a number of reasons. Among them the presence of 
asymptomatic carriers (Michel et al., 2011) and the frequent cases of the so-called cryptic 
infections with varying results depending on the diagnostic method used (Fernández Pérez et al., 
2003). In addition to the absence of compulsory notification of CanL some estimates are clearly 
biased since reports have been based on the clinical cases diagnosed by veterinary services or 
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practitioners thus producing an unreliable picture of the actual extension of the infections, their 
incidence and their prevalence (Gradoni, 2013). In the other hand canine census is surely 
inaccurate in many areas of the world with CanL (e.g. South America) and even in developed 
countries the actual population of dogs is thought to be considerable higher than the officially 
reported (Baneth et al., 2008). Biased canine sampled population is not the only source of data 
inaccuracy in the epidemiology of CanL. Both sensitivity and specificity of diagnostic methods 
(e.g. IFAT, ELISA, direct observation, PCR) employed in the surveys are variable (Maia & 
Campino, 2008) and, therefore, the direct comparison of the results reported in studies using 
different techniques is lacking in significance (Solano-Gallego et al., 2001; Leontides et al., 
2002).  
 
1.6.2. Differential canine breed susceptibility 
CanL is a chronic and systemic (visceral and cutaneous) parasitic disease with a long 
incubation period (months to years) (Slappendel, 1988) and affecting dog from both sexes and 
all breeds (Noli, 1999; Leontides et al., 2002). On occasion a higher prevalence has been 
reported in some breeds (e.g. Boxer, Cocker, German Shepherd, Rottweiler, Doberman) 
whereas in other cases prevalence values below the expected have been observed in other 
breeds, including some local ones (e.g. Ibizan hound, Poodle, Yorkshire terrier) (Ciamarella et 
al., 1997; Solano-Gallego et al., 2000; França-Silva et al., 2003, Miranda et al., 2008). Insofar 
no convincing genetic basis for the variable susceptibility has been produced and these 
differences are surely related to the aptitude and life style of the breeds studied (e.g. guard dog, 
indoor pet) (Moreno & Alvar, 2002; Miranda et al., 2008; Martín Sánchez et al., 2009; Gálvez 
et al., 2010). In fact, Pozio et al. (1981) did not observe, in Italy, any relationship between breed 
and infection.  
Another point raised has been the relationship between age and susceptibility. A peak of 
infection prevalence between 2-3 and 7-8 years age has been reported (Zivicnjak et al., 2005; 
Gálvez et al., 2010). This apparent age-related finding has been related to the repeated exposure 
of animals to sandflies (Koutinas et al., 1999; Saridomichelakis, 2009; Martín Sánchez et al., 
2009) and not to the differential receptivity. It seems, therefore, that all dog ages are equally 
sensitive to L.infantum (Noli, 1999; Leontides et al., 2002) provided that they have contact with 
infected sandflies and, actually, a wide sampling (33.937 animals) carried out by França-Silva et 
al. (2003) could not ascertain any relationship between age of dogs and disease. 
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1.6.3. Infection and disease in CanL 
1.6.3.1. Pathogenesis and immune response in CanL 
L.infantum infection does not necessarily lead to CanL. Disease outcome is strongly 
dependent on the immune response of the hosts and the fate of parasites. Once metacyclic 
promastigotes are inoculated in the skin of the dogs, and if they overcome the innate immune 
mechanisms (e.g. complement lysis), they infect different phagocytic cells (macrophages, 
dendritic cells, Langerhans cells) where they, subsequently, transform into amastigotes. This 
local infection can be cleared, in which case no further progress of the disease will be seen (self-
limited infection). If not cleared infection can be disseminated, transported via infected 
macrophages, to regional lymph nodes. Amastigotes will survive and multiply within the 
phagolysosomes, eventually leading to the lysis of the host infected cells. Free amastigotes can 
then invade new target cells from the mononuclear phagocytic system (MPS). From this point 
on, the outcome of the infection will vary depending on many factors related to the vector (e.g. 
repeated infectious bites, intradermal injection of sandfly saliva), the parasite (e.g. virulence) 
and the host (e.g. genetic background, cell-mediated and humoral immune response, cytokine 
milieu, concurrent diseases) (Saridomichelakis, 2009). 
 Dogs can control the infection thus being locally eliminated (i.e. self-limited infection) or 
restricted to the skin and lymph nodes (i.e. localized generally asymptomatic infection). 
Parasites can reach by lymphatic and blood systems the target organs, namely bone marrow, 
spleen, liver, kidneys, ganglions, eyes and digestive tract. Disseminated infection can lead to the 
appearance of clinical signs and lesions (i.e. symptomatic disseminated infection) or not 
(asymptomatic disseminated infection) (Solbach & Laskay, 2000; Baneth, 2005). Routinely, 
infected dogs are classified as susceptible (CanL) characterized by parasite unrestricted 
multiplication inducing multiple organ pathology through granulomatous inflammation and 
immune-mediated mechanisms; or resistant (all the remaining outcomes). Resistant phenotypes 
can effectively kill or control parasite infection remaining clinically normal (Figure 11).  
It is generally considered that the wide range of clinical courses found in leishmaniasis are 
related to the events taking place in the host-Leishmania interface (e.g. immune status of the 
host, virulence of Leishmania spp and strain) and the subsequent immune response elicited 
(Stanley & Engwerda, 2007). For the most part studies have been carried out in experimental 
models, particularly mice (Kedzierski & Evans, 2014). Experimentally infected resistant mice 
with L.major develop a predominant CD4+ T helper 1 (Th1) phenotype response with IFN-γ 
production whereas susceptible mice show a dominant CD4+ Th2 response with interleukin IL-
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4, IL-5 and IL-3 secretion. This correlation between the polarized response and the outcome of 
the disease led to the paradigm of the balance between Th1/Th2 being the actual responsible of 
the disease outcome (Roberts, 2006).  
 
 
Figure 11. Possible disease outcome after an infection by L.infantum (=L.chagasi) in the dog. Modified from 
Saridomichelakis, 2009. 
 
The information on the immune response, after a primary infection, in visceral leishmaniasis 
and in particular in CanL, is comparatively low (Veras et al., 2010). Generally speaking in 
leishmaniasis both innate (Mφ, neutrophils, dendritic cells) and adaptive (T cells) response are 
involved and CD4+ subtype seems to play a crucial role in the final result of the infection. CanL 
uncontrolled infections are characterized by polyclonal B-cell activation, with high levels of 
specific and unspecific antibody production, and specific immunosuppression (Mendes Roatt et 
al., 2014).  
With the scarce data available L.infantum (=L.chagasi) infections in dogs elicit a mixed 
Th1/Th2 response. Disease progression is associated to a predominant Th2 phenotype, with a 
low lymphoproliferative response and high levels of IL-4, IL-10, TGF-β whereas resistant 
animals exhibit a Th1 phenotype, with positive lymphoproliferation and production of Th1 
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cytokines: IFN-γ, TNF-α and IL-2 (Fernández-Pérez et al., 2003; Reis et al., 2010; Veras et al., 
2010; Mendes Roatt et al., 2014). This model of response (Th1/Th2 dichotomy) is more evident 
in cutaneous leishmaniasis (McMahon-Pratt & Alexander, 2004) and not directly applicable to 
CanL. As illustrated in Figure 12, probably the actual pattern of immune response in 
leishmaniasis, particularly in VL, is more complex given the different cell types involved (e.g. 
Th17, Th9, Tfh2, Treg) (Alexander & Brombacher, 2012), the differential role and importance 
of signalling molecules along the infection and the limitations of the experimental models used. 
As a consequence it is anticipated that this dichotomy model should be challenged. 
 
 
 
Figure 12. Cellular mechanisms involved in the immune response to a chronic infection by L.donovani. A population 
of regulatory dendritic cells (DCr) in the spleen produces IL-10 this inducing the proliferation of T regulatory cells 
producing IL-10 (Tr1) besides inhibiting death effector mechanisms in macrophages (monocytes, MO, and MФ) and 
other phagocytic cells (including the suppression of ROI and RNI production). IL-27 produced by DCr and MO 
together with T cell produced IL-21 induce the differentiation of Th1 to Tr1 besides inhibiting Th17. IL-10 produced by 
Tr1 inhibits antigen presentation thus contributing to a T-cell general dysfunction and diminished IFN-γ production by 
CD4+. Bone marrow Tregs can also produce IL-10. Image from Faleiro et al., 2014. 
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1.6.3.2. Clinical signs and lesions in CanL 
In CanL almost any organ from infected animals can be affected and no clear cut separation 
between visceral and cutaneous infections is frequently observed. Actually over 50% of infected 
dogs exhibit cutaneous lesions (Podaliri Vulpiani et al., 2011). In chronic generalized infections 
infected animals show lack of appetite, leading to weight loss, and may also present epistaxis, 
polyuria-polydipsia, irregular fever, neurological and locomotory disturbances and 
gastrointestinal disorders (e.g. diarrhea, vomiting). Skin lesions, generally not pruriginous, 
range from nodules, papules or pustules and can be accompanied by exfoliative dermatitis, with 
or without alopecia and ulcerations. Hyperkeratosis of muzzle and footpads is another common 
clinical finding. In addition, dogs with CanL can present cachexia, pale mucous and 
onychogryphosis, generalized lymphadenomegaly, ocular lesions (e.g. blepharitis and 
conjunctivitis, panophtalmitis and uveitis), muscle atrophy (easily observed in temporal 
muscles), vascular disturbances (e.g. systemic vasculitis, arterial tromboembolism), liver and, 
specially, spleen enlargement and bone and muscular disorders (e.g. polyarthritis, polymyositis 
and osteomyelitis) (Ciamarella et al., 1997; Solano-Gallego et al., 2011). Figure 13 depicts 
some of the most frequent lesions observed in CanL. 
 
 
 
 
 
 
 
 
 
 
Figure 13. Lesions and clinical signs observed in CanL. (A): Lymphadenomegaly, popliteal lymph node; (B & D): 
Ocular lesions [B: blepharitis and conjunctivitis; D: panophtalmitis]; (C): ulcerative pustular dermatitis; (E): temporal 
muscular atrophy; (F): Muzzle hyperkeratosis; (G): onychogryphosis; (H): cachexia; (I): exfoliative dermatitis. Image 
from Corral & Alunda, 2014.  
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Haematological findings most frequently observed are non-regenerative anemia, leucopenia 
and hyperproteinemia with hypergammaglobulinemia and hypoalbunemia. Clinical biochemical 
profile of infected animals shows elevated levels of liver function marker enzymes and urea and 
creatinine. Proteinuria is a common finding if there is nephropathy (Noli, 1999; Solano-Gallego 
et al., 2011). L.infantum infection in dogs elicits a high production of immunoglobulins 
unrelated to the parasite. Once surpassed the renal threshold immunocomplexes (IC) are 
deposited in the kidney inducing glomerulonephritis and interstitial nephritis (Poli et al., 1991; 
Costa et al., 2000; Clementi et al., 2011) and, finally a renal failure, this dysfunction being 
actually the ultimate cause of death in most cases (Noli, 1999; Clementi et al., 2011).  
 
1.7. Control of zoonotic visceral leishmaniasis (ZVL) 
Control of CanL has the objective, within the wide context of public health, of reducing the 
prevalence and intensity of dog infections, the main recognized reservoir, with the final aim of 
lowering the human cases of ZVL (Podaliri Vulpiani et al., 2011). Moreover, CanL caused by 
L.infantum (=L.chagasi) is a first order veterinary pathology in many areas of the world 
particularly the Western Mediterranean and South America. Fossil and molecular evidences 
suggest that domestic dogs evolved from a population of wolves in Europe, which may have 
gone extinct. Molecular dating suggests domestication of dogs took place at some point 18,800 
to 32,100 years ago (Thalmann et al., 2013). From then up to date men and dogs have been in 
close relation and therefore dogs have played a fundamental role in many life cycles of human 
parasites. Similarly, both of them can be infected by L.infantum dogs acting as the reservoir. 
Consequently, any control of ZVL must include measures (e.g. vector control, transmission 
control, immunoprophylaxis, chemotherapy and chemoprophylaxis, and eventually dog culling) 
to control dog infections.  
 
1.7.1. Control of vector populations and Leishmania transmission 
The rationale behind the control of sandfly populations is the reduction or interruption of the 
transmission of Leishmania infection (Alvar et al., 2004). During the last century many 
government campaigns, particularly in urban and periurban areas, were carried out to control 
vectorial diseases such as leishmaniasis, filariasis, dengue, malaria. Most control operations 
involved the modification of vector habitats (environmental management), personal protection 
measures and, mainly, insecticides due to the affordable cost, rapid response and easy 
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administration. These measures require to be successful a deep knowledge of the epidemiology, 
insect fauna biology, ecology of the target territory (WHO, 2010) and the understanding and 
acceptance of the human population inhabiting the area.  
Chemical control of vectors comprises the indoor and outdoor residual insecticide spraying, 
use of repellents, topical insecticides or insecticide-impregnated materials (Sharma & Singh, 
2008). Insecticide spraying is a low cost method and its efficacy is dependent of the type of 
insecticide, sandfly sensitivity, manner of administration and dosage. Chemicals more widely 
used were organochlorines (e.g. DDT), organophosphates (e.g. Malathion), carbamates (e.g. 
Propoxur) and synthetic pyrethroids (e.g. Deltametrin).  
In the XIXth century, and even until the 1950s, malaria was endemic in Europe and in the 
USA (de Zulueta, 1998). Control, and finally eradication, in the continent and the USA was 
possible through the establishment of different measures (e.g. desiccation of damped areas) 
although the main role is attributed to DDT (Beard, 2006; Tognotti, 2009). The use of this 
compound drastically reduced the prevalence of leishmaniasis in many foci and the levels of 
infection rose again once spraying with DDT was interrupted (Killick-Kendrick, 1999). 
Toxicity, impact on the environment and risks associated to the use of DDT is still a 
controversial issue. In fact, despite its proven efficacy, there are many studies describing its 
toxicity and discouraging its use (Beard, 2006) although this toxicity has been challenged in 
some retrospective studies (Tognotti, 2009). Moreover resistant populations of insects have 
been reported (Khishore et al., 2004). Presently WHO (2010) does not completely discourage its 
use and actually it is employed in hyperendemic areas in India (Sharma & Singh, 2008). 
In humans, the use of impregnated bed nets, bed sheets and curtains with insecticides is an 
effective and low cost method to reduce the transmission rate of Leishmania and its value has 
been confirmed in soldiers in Afghanistan (Reyburn et al., 2000). Nonetheless, individual 
protection with repellents is also strongly advised.  
In the case of CanL some of these approaches are also available. The use of topical 
insecticides for dogs as strategy to reduce leishmaniasis transmission has gained popularity in 
the last decades (Foglia Manzillo et al., 2006; Solano-Gallego et al., 2009). The system seems to 
reduce the CanL prevalence (Ferroglio et al., 2008) and, therefore, the transmission to humans 
(Gavgani et al., 2002). In Western countries the use of repellents and insecticides in dogs is 
frequent. Available specialties include collars, spot-on and sprays. Marketed products have a 
double action acting as repellents for incoming sandflies and lethal for the insects after biting 
(Podaliri Vulpiani et al., 2011). Delmathrin-impregnated collars reduce by over 80% the number 
of sandfly bites (Halbig et al., 2000; Reithinger et al., 2001) and there are enough evidences to 
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recommend their use in dogs in endemic areas (Noli & Auxilia, 2005). They are long-lasting 
and the effect is maintained at least for six months (Killick-Kendrick et al., 1997). The effect of 
spot-on formulations with imidacloprid (neonicotinoid insecticide), permethrin (pyrethroid) and 
combinations is short-lived (ca. 1 month) although their repellent action could be higher 
(Reithinger et al., 2001; Quinell & Courtenay, 2009; Podaliri Vulpiani et al., 2011). 
 
1.7.2. Control of reservoir population 
Control of the canine population includes the availability of an accurate census, recovery of 
stray dogs and euthanasia. Culling of L.infantum-positive dogs is not easily accepted, based on 
ethical grounds, in Western countries; frequently not practicable and of doubtful efficacy when 
other sympatric reservoirs are not controlled (e.g. wild infected animals, dogs with “cryptic” 
undetected infections). Results obtained with this strategy are contradictory (Dietze, 1997; 
Ashford et al., 1998) and the active selective euthanasia campaign supported by Brazilian health 
authorities in the 1970s had null or very modest impact on the number of cases of HVL 
(Moreira, 2004; Costa, 2011). Recently, a randomized community intervention trial carried out 
in the Brazilian city of Teresina also described the low efficacy of dog culling on HVL 
incidence (Werneck et al., 2014). Cost-benefit of dog culling has been argued by many authors 
(vide supra) and, although this policy can produce positive results (e.g. China), low success in 
culling programs has been the rule. The failure has been associated to several factors as: lack of 
continuity of these programs due to deficient surveillance systems, economic issues, absence of 
adequately trained professionals; absence of co-implementation of other control strategies; 
logistic problems that favour late diagnosis (e.g. lack of standardized techniques) and the 
existence of asymptomatic infectious dogs that guarantee the continuity of the transmission 
cycle (Costa et al., 2013).  
 The reported success of the leishmaniasis (AVL, ZVL) control programs in China in the 
1950s was probably related to the implementation of combined control measures [non-selective 
euthanasia of all dogs from the target area, massive chemotherapeutic treatment of humans with 
antimonials, use of insecticides (DDT and pyrethroids) and strict government control] (Zhi-
Biao, 1989). Actually, dog culling alone is not an effective control strategy as it has not 
eliminated leishmaniasis transmission in any place (Quinell & Courtenay, 2009). Furthermore, 
ZVL is present in locations were CanL is also prevalent, the association between both diseases 
is possibly not so tight, and Leishmania infections in both hosts (i.e. canids and humans) could 
have different epidemiological patterns establishing a complex relationship not yet completely 
elucidated (Costa, 2011). 
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1.7.3. Immunoprophylactic control of leishmaniasis 
The development of a vaccine against leishmaniasis does not seem to be out of reach since a 
large proportion of infected humans and dogs develop a natural immune response against 
Leishmania thus preventing the outcome of the disease. Furthermore both host species, once the 
primary infection has been controlled, mount an effective immune response against homologous 
reinfections (Kumar & Engwerda, 2014) whereas the results with heterologous challenges have 
been variable and inconsistent (e.g. Porrozzi et al., 2004). Insofar no vaccine for human use 
against leishmaniasis has been yet registered. There are intrinsic difficulties inherent to the 
development of an antiparasitic vaccine and actually the number of vaccines for parasitic 
diseases is very limited (e.g.  toxoplasmosis, Bm86, poultry coccidiosis, cattle dictyocaulosis). 
In addition, the strict present requirements for an ideal antileishmanial vaccine for human use 
(safe even in immune compromised patients, high efficacy, low number of doses, eliciting 
sterile immunity thus preventing disease and transmission, low cost, thermal stability to 
guarantee transport and storage, multispecies) (Ada, 1991) possibly renders the endeavour of 
achieving a vaccine candidate an almost insurmountable task. 
Since the recognition of the disease, well before the identification of the etiological agent, 
there were attempts of preventing the outcome of the clinical sings and lesions. Within the 
framework of vaccine development, first generation vaccines include the use of live non- 
attenuated parasites (i.e. “leishmanization”), heterologous protection using as immunizing 
agents non-pathogenic species (e.g. L.tarentolae to confer protection in BALB/c challenged 
with L.donovani: Breton et al., 2005), inoculation of attenuated parasites without genetic 
modification, and of dead autoclaved parasites. Unfortunately, elicited protection appears to be 
negatively correlated to the manipulation of Leishmania. Thus, the most effective inoculums are 
those involving infective promastigotes. 
Historically, leishmanization has been an effective immunoprophylactic method against CL. 
Deliberate inoculation of live parasites in a hidden area (e.g. behind the ears, armpits, gluteus) 
to protect against lesion development in visible areas (e.g. face, arms) has been practiced for 
centuries in Middle East endemic areas for cutaneous forms of the disease (Handman, 2001; 
Dunning, 2009). Saul Adler (1895-1966), from the Hebrew University of Jerusalem observed in 
Lebanon how mothers exposed the arms of their children to sandfly bites since on experiential 
store knew that the first self-healing lesion would protect the children in the future against 
leishmanial challenge (Gavron, 1997). This process, based on the inoculation of alive and 
virulent parasites, was traditionally implemented in massive vaccination campaigns in the 
former Soviet Union, Iran and Israel (Greenblatt, 1980; Kellina, 1981; Nadim et al., 1983). 
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Probably the most impressive use of this immunization took place in the Isfahan (Iran) area 
during the first years (1982-1986) of the Irak-Iran war (1980-1988) since over two million 
people, largely military and revolutionary Guard members, were inoculated with 2-3 x 105 
promastigotes of L.major, with a notable success (reduction to 1/6 to 1/8 of the original disease 
level) (Nadim et al., 1997). Leishmanization is still employed in some areas of Uzbekistan 
(Khamesipour et al., 2006) and more recently leishmanization with a Sri Lankan naturally 
attenuated cutaneous isolate of L.donovani has been claimed to protect against VL in a mouse 
model (McCall et al., 2013). Despite the success in most countries this practice has been 
abandoned by safety concerns (e.g. uncontrolled development of lesions, exacerbation of 
concurrent dermal diseases such as psoriasis, immune suppression); practical impossibility of 
standardization, and lack of efficacy and development of delayed type hypersensitivity in turn 
related to the variability of virulence and infectivity of the inoculated isolates (Handman, 2001). 
On these grounds the WHO does not further recommend leishmanization (Reithinger et al., 
2007). 
Pioneer assays with dead parasites carried out in Brazil in the 1940s yielded inconclusive 
results. Mayrick et al. (1979, 1985) developed two vaccines with autoclaved parasites. The first 
one, Leishvacin®, included four Leishmania species, and the second only L.amazonensis. Both 
were safe and immunogenic but failed to provide any protective response (Dunning, 2009). 
Given the simple and economic preparation of these autoclaved vaccines several Phase III 
clinical trials have been performed with and without BCG (Bacille Calmette-Guérin) both 
against CL (Sharifi et al., 1998; Monemi et al., 1999; Armijos et al., 2004; Vélez et al., 2005) 
and VL (Antunes et al., 1986; Khalil et al., 2000). Some vaccine candidates achieved a 
reduction of CL incidence ranging from 18-78% depending on the study (Marzochi et al., 1998; 
Shariffi et al., 1998; Monemi et al., 1999) although, in general, efficacy was moderate, low or 
null (Convit et al., 1987; Genaro et al, 1996; Vélez et al., 2000; Handman, 2001; Armijos et al., 
2004). In spite of autoclaving Leishmania being an economic solution for endemic areas in 
developing countries, difficulties of standardization and the destruction of many immunogenic 
proteins during autoclaving (de Luca et al., 1999) possibly could explain the variable results 
obtained in clinical trials and therefore precluded the extensive use of this immunoprophylactic 
approach. 
Attenuated Leishmania could constitute an alternative since virulence was lowered without 
compromising the immunogenicity of the parasites. Attenuation can be mainly carried out by 
two mechanisms, i.e. non-directed and directed (genetically engineered) modifications (Färber 
& Moll, 2013). In our review only non-directed attenuated parasites are considered first 
generation vaccines. Reduction of Leishmania virulence can be achieved by prolonged in vitro 
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subculture (Mitchell et al., 1985); clonal selection (e.g. thermal sensitivity: Gorczynski, 1985); 
chemical mutagenesis (Kimsey et al., 1993); gamma ray irradiation (Rivier et al., 1993) and 
pharmacological selection of clones (Daneshvar et al., 2003), among other possible methods. 
The search for safe, stable and efficacious anti-Leishmania vaccines lead to the attenuation 
through genetic manipulation (attenuated live vaccines with directed alterations) of wild 
Leishmania stocks and native and recombinant isolated antigens. Both methodologies would 
constitute second generation vaccines. Directed mutagenesis aims to reduce the virulence while 
maintaining the majority of antigens present in wild-type Leishmania thus inducing immune 
response and memory (Färber & Moll, 2013). Several approaches have been employed. Among 
them knockout Leishmania mutants apparently induced protection in experimental models (e.g. 
Souza et al., 1994; Alexander et al., 1998; Veras et al., 1999; Amaral et al., 2002; Uzonna et al., 
2004; Silvestre et al., 2007). The introduction of genes (e.g. conferring sensibility to a given 
drug) within suicide cassettes in the Leishmania genome (Ghedin et al., 1998; Davoudi et al., 
2003), although appealing, has the potential risk of reactivation or the reversion of the lowered 
virulence and have not been tested in animal models (Handman, 2001). 
Much safer would be the use of purified fractions or antigens. Among them, Leishmune® 
was the first registered vaccine for CanL. It is presently marketed in Brazil although it is not 
registered for Europe (Palatnik de Souza, 2012). The vaccine contains fucose-mannan ligand 
(FML) from L.donovani formulated with saponins (Palatnik de Sousa, 1994). A 54 kDa 
secretory/excretory antigen of L.infantum, LiESAp/MDP, apparently elicited a significant 
protection in field trials with dogs (Lemesre et al., 2005, 2007). More recently, in 2011, Virbac 
laboratories registered in Europe the vaccine LiESP/QA-21, under the trade name CaniLeish® 
(EMA/CVMP/296014/2010). This preparation, similar to the former, uses QA-21 as adjuvant 
(Oliva et al., 2014). The protection elicited by this vaccine seems to be related to the biased 
development of a long lasting cell response (Moreno et al., 2012; Martín et al., 2014) 
diminishing the risk of an active infection thus resulting in milder clinical presentations 
(Palatnik de Sousa, 2008, 2012). A randomised, double-blind, controlled efficacy trial of the 
LiESP/QA-21 vaccine in naive dogs exposed to two L.infantum transmission seasons has been 
recently published (Oliva et al., 2014). This study corroborated the reduced risk of progression 
to an active infection or clinical disease after vaccination although it did not prevent Leishmania 
infection.  
This vaccine is currently marketed in Spain, Portugal, Greece and Italy. Its use, however, is 
not exempt of controversy. Besides the high price (100-150 Euros) it requires annual 
revaccination and given the interference of post-vaccination antibodies with standard IFAT the 
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use of a rapid serological test (Speed Leish KTM) is recommended. Moreover post-vaccination 
secondary effects have been reported (Coedo, 2013) although other studies described it was well 
tolerated (Oliva et al., 2014). It should be stated that the complex standardization of the 
purification process for the massive production of these vaccines surely will preclude their use 
in human medicine (Fäber & Moll, 2013). In addition, none of the previously mentioned 
vaccines protects completely from Leishmania infection and therefore the immunoprophylaxis 
of leishmaniasis has not been yet achieved.  
Recombinant antigens could solve some of these hurdles since, in principle, they could be 
produced at low cost, be safe and standardized. The first recombinant protein used as vaccine 
was gp63 (leishmaniolysin) (Handman, 2001) and subsequently bacterial and viral expression 
systems to deliver the recombinant products have been developed, among them Salmonella 
typhimurium (Yang et al., 1990); BCG (Connell et al., 1993); Toxoplasma gondii (Ramírez et 
al., 2001); Vaccinia virus (McMahon-Pratt et al., 1993; Ramos et al., 2008) although concerns 
on their safety and efficacy have been raised. A comprehensive review of the recombinant 
candidates for leishmanial vaccination during the last decades has been published (Nagill & 
Kaur, 2011). Most of them have only been tested in animal models and only a reduced number 
went through clinical trials. One of them, Leish-111f, a recombinant protein with three subunits 
(Coler et al., 2002), induced a significant protection in murine models of CL and VL when 
formulated with MPL-SE but failed in the prevention of CanL under natural conditions (Kumar 
& Engwerda, 2014). In spite of this drawback Leish-111f/MPL-SE is the first defined candidate 
to be tested in healthy human volunteers in the USA (Fäber & Moll, 2013) and clinical studies 
have been performed in Brazil, Peru, Colombia and in VL patients in India (Vélez et al., 2009; 
Nascimento et al., 2010; Llanos-Cuentas et al., 2010; Chakravarty et al., 2011). Another 
recombinant vaccine, Leish-Tec®, has been registered in Brazil for CanL. The vaccine contains 
the recombinant A2 antigen from Leishmania amastigotes and saponins as adjuvant and a recent 
study has shown similar efficacy profiles as Leishmune® (Fernandes et al., 2014). 
Third generation vaccines (i.e. DNA vaccines) could overcome some of the constraints of 
native or recombinant protein-based vaccine candidates. Their reduced cost, easy manufacturing 
and conservation, and stability make this approach attractive. Furthermore they have shown to 
exhibit a high immunogenic capacity to booster both cellular and antibody immune responses, 
and multiple genes encoding more than one antigen from one Leishmania spp, antigens from 
different Leishmania spp, and even cytokines or adjuvants can be incorporated. Bacterial 
plasmids containing unmethylated CpG (cytosine-phosphodiester-guanine), as vaccine vectors, 
provide an additional advantage since CpG motifs have shown to trigger an innate immune 
response characterized by the production of a predominantly Th1-type cytokines, with increase 
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of IFN-γ and higher levels of CD8+ T-cell (Klinman, 2004). Nagill & Kaur (2011) and more 
recently Kumar & Engwerda (2014) have summarized the state of the art of DNA vaccination to 
control CL and VL.  
Scientific community efforts to produce a safe vaccine against leishmaniasis, stable, 
efficacious, specific, easily manufactured and capable of eliciting long lasting immunological 
memory continue. However, up to now despite the investments made and the suggestive results 
using some of the approaches effective immunoprophylaxis of human leishmaniasis has not 
been yet achieved. By its part the registered vaccines for CanL do not protect against the 
infection but rather limit the severity of the disease. Thus chemotherapy still is the main 
available tool to control the extension of this infection in humans and dogs. 
 
 
1.7.4. Chemotherapeutic control of leishmaniasis  
1.7.4.1. Current scenario of the chemotherapy of leishmaniasis 
In spite of the high number of drugs, over 25, approved for use in Leishmania infections 
chemotherapy is far from ideal. This large number constitutes an evidence of the shortcomings 
of the present-day antileishmanial chemotherapy. In the last decades there was a feeling of 
optimism within the scientific community as new drugs and new formulations of old drugs were 
undergoing clinical trials (Croft et al., 2006). Actually, since 2002 miltefosine and 
paromomycin have been registered for the treatment of visceral leishmaniasis. Combination 
therapy is now increasingly being explored in clinical trials (http://www.dndi.org/diseases-
projects/clinical-trial-protocols.html) as a new approach, endorsed by the WHO (2010), to 
overcome default treatment options.  
Nevertheless, the chemotherapeutic arsenal available is still scarce and the efficacy of some 
compounds is limited and others exhibit high toxicity and severe side effects. Moreover, socio-
economic conditions allowing treatment administration -most drugs need monitoring, 
hospitalization and parenteral administration- are lacking in remote regions. Additionally, 
variability in the sensitivity of different Leishmania species and isolates has been described. 
More concerning is the high rate of clinical unresponsiveness due to the development of 
resistance to the most commonly used drug for the past 60 years (i.e. pentavalent antimonials) 
(Croft & Coombs, 2003; Croft et al., 2006). Furthermore, first line drugs against these infections 
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have a high price (Sundar & Chatterjee, 2006) making them simply unaffordable under the 
economic conditions prevailing in many areas of the world where leishmaniasis is endemic.  
This scenario has favoured the research and development (R&D) efforts towards the 
discovery of new treatments for leishmaniasis. However, up to now, the attempts for rational 
therapy –parasite target-oriented compounds- have yielded only limited success and the deep 
knowledge on the physiology and molecular biology of Leishmania has not yet fostered the 
development of new drugs. Actually the compounds used in both human medicine and 
veterinary clinics or those under clinical study are more a consequence of incidental findings 
than of focused research (Guerin et al., 2002). In 2004 WHO/TDR identified liposomal 
amphotericin, miltefosine and paromomycin as the most promising anti-Leishmania compounds 
(www.who.int/tdr/diseases/leish). However, none of these compounds is new. Amphotericin B 
(AmB), in addition to its antifungal properties, has been used as an effective treatment against 
leishmaniasis for decades; miltefosine (hexadecylphosphocholine) was originally developed as 
an antineoplastic agent; the aminoglycoside antibiotic paromomycin (aminosidine) has been 
used as antimicrobial since the 1960s of the past century. Presently, these three drugs and the 
pentavalent antimonials still constitute the chemotherapeutic agents of reference for the 
treatment of leishmaniasis.  
Pentavalent antimonials -sodium stibogluconate and meglumine antimoniate- are the 
standard treatment for leishmaniasis in most parts of the world although resistance and 
treatment failure in the Bihar state (India) and the neighbouring Nepal have been a matter of 
concern (Croft et al., 2006). These compounds are still effective in other countries alone or in 
combination although variable drug sensitivity of Leishmania has been reported. Other 
drawbacks of antimonial therapy include length of treatment and toxicity in HIV coinfected 
patients (Sundar & Chakravarty, 2013).   
In the past years, the major chemotherapeutic breakthrough has been the approval of 
miltefosine as the first oral drug for the treatment of leishmaniasis (Sundar et al., 2002). 
Although it has showed promising results in clinical trials, there are important concerns 
regarding its long half-life (>150 h) and the possible emergence of resistance (Bryceson, 2001) 
in addition to its teratogenicity. This precludes its use during the reproductive life, unless a 
contraception method is applied (Sindermann & Engel, 2006). Under laboratory conditions, the 
relatively easy selection of resistant clonal lines of L. donovani has been reported (Seifert et al., 
2003). Dorlo et al. (2012b) pointed out the high cost of the complete 28 day treatment in 
monotherapy and also demonstrated that children were relatively underexposed to miltefosine 
compared to adults using the standard chemotherapeutic schedule. Oral administration and the 
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absence of control treatment programs may increase the proportion of patients which do not 
complete the treatment or do a suboptimal compliance of it leading to a high risk of parasite 
resistance emergence (Sundar & Chakravarty, 2013). Miltefosine relapse probability has been 
estimated to be of ca. 21% and it has been associated to low levels of drug exposure (Dorlo et 
al., 2014). Furthermore, only 10 years after its registration, there are increasing evidences of 
treatment failure, possible resistance emergence and reinfection under field conditions (Rijal et 
al., 2013; Ostyn et al., 2014).   
In 2006 paromomycin was the latest drug registered for VL. Paromomycin is a low cost 
compound, classified as “orphan drug” (FDA, EMEA) sponsored by the Institute for One World 
Health (www.iowh.com), after a long time of being used as antimicrobial. Short time course 
parenteral administration, affordable cost, efficacy and low toxicity make it a potential first line 
drug against leishmaniasis. Clinical trials carried out in India have established the efficacy of 
intramuscular route for paromomycin administration. However, there have been regional 
differences in clinical drug efficacy trials (Sundar & Chakravarty, 2013) and induction of 
resistant L. donovani strains in vitro (Maarouf et al., 1998) suggests the possibility of resistance 
emergence if used in monotherapy.  
Amphotericin B deoxycholate is highly efficacious against Leishmania infections 
(particularly L. donovani and L. infantum) presenting excellent cure rates (i.e. 97%). It is the 
treatment of choice in India for refractory VL (Mishra et al., 1992) and recommended for PKDL 
(WHO, 2010). No resistant isolates have been reported even after prolonged therapy in humans 
coinfected with VIH and L. infantum (Durand et al., 1998), although some resistant lines of L. 
donovani and L. mexicana have been obtained in vitro under pharmacological pressure 
(Espuelas et al., 2000; Al-Mohammed et al., 2005). However, high toxicity, adverse effects 
during administration, requiring hospitalization and monitoring, and high cost are the main 
shortcomings of its therapeutic use. To reduce toxicity several lipid formulations have been 
developed and three are commercially available [i.e. liposomal amphotericin B (AmBisome®), 
amphotericin B lipid complex (Abelcet®) and amphotericin B cholesterol dispersion 
(Amphotec™ formerly known as Amphocil™).  
Liposomal amphotericin B (AmBisome®), approved in both USA and Europe is considered 
the best treatment option for VL caused by L.donovani and L.infantum (WHO, 2010) in terms of 
security and efficacy rates (Bern et al., 2006) and is recommended in HIV coinfected patients 
(Croft & Yardley, 2002). Actually it has been considered that preparations of lower toxicity of 
AmB would make this compound an almost ideal treatment of visceral leishmaniasis in humans 
(Alvar et al., 2006). The high price of the treatment with AmBisome® or other lipid-based 
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formulations is unaffordable in low-income areas. Recently there has been an agreement for 
price reduction of the liposomal formulation in developing endemic countries (Olliaro & 
Sundar, 2009). Despite this, high cost of liposomal AmB still restricts its general use in endemic 
areas (Table 2).  
 
 
 
Table 2.  Drugs currently used for the treatment of VL (Griensven et al., 2010). 
 
*Miltefosine treatment failure in the field has been recently documented in India and Nepal (Rijal et al., 2013; Ostyn 
et al., 2014). 
 
 
 
1.7.4.2. Chemotherapy of canine leishmaniasis (CanL) 
Chemotherapy of infected animals, particularly in the Mediterranean, includes the use of the 
same compounds employed in the treatment of the human infection (Oliva et al., 2004; Noli & 
Auxilia, 2005). Chemical structures of the main antileishmanial compounds are illustrated in 
Figure 14. A large body of information has been obtained by veterinary practitioners, especially 
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with pentavalent antimonials and combinations, along their clinical practice. However, this 
experience has hardly been published and the treatment conditions were mostly not controlled, 
thus failing to meet statistical standards and rendering the data difficult to interpret.  
The drugs more frequently employed are pentavalent antimonials, particularly meglumine 
antimoniate, administered as monotherapy or in combination and miltefosine- amphotericin B 
and paromomycin have also been used among other compounds- (Vexenat et al., 1998a; 
Vexenat et al., 1998b; Noli & Auxilia, 2005; Oliva et al., 2010; Podaliri Vulpiani et al., 2011). 
The variability of treatment schedules (number of doses, total dose administered, administration 
route, duration of treatment), sometimes contradictory results (i.e. with AmBisome and others) 
or the use of different systems of post-treatment monitoring have demanded standardized 
treatment protocols. International efforts –particularly from Spain, Italy and Brazil- for 
standardization of diagnosis, management, control and prognosis of CanL have recently 
increased (Baneth, 2013).  
In high endemicity regions it is estimated that 30-70% of infected dogs if untreated will 
develop the disease within the following 2 to 3 years (Roura et al., 2013). None of the drugs 
available for CanL treatment achieves parasite clearance; neither prevents relapses nor 
transmission to sandflies. Although clinicopathological improvement or clinical cure can be 
achieved relapses are frequent as a consequence of parasites’ survival within the host (Noli, 
1999; Baneth & Shaw, 2002). Prognosis of the animals subjected to antileishmanial treatment is 
highly unpredictable and depends on the initial clinicopathological and physiological status of 
the infected dogs, particularly, if present, the degree of renal dysfunction (Roura et al., 2013). 
Accurate classification of the clinical stage of the disease and the presence of intercurrent 
infections are crucial when establishing a therapeutic protocol or anticipating the final outcome 
of the infection (Oliva et al., 2010; Solano-Gallego et al., 2011). Actually it has been stated that 
affected dogs treated with meglumine antimoniate followed by a subsequent treatment at the 
time of recurrences have a 75% probability of living four additional years (Noli, 1999).  
All therapeutic regimens established for CanL must be accompanied by supportive therapy, 
appropriate diet and a monitoring system during chemotherapy (clinical and haematological 
parameters, biochemical profile, serum protein levels, liver and, particularly, renal functionality 
markers and anti-Leishmania antibody levels) (Podaliri Vulpiani et al., 2011). The patient 
should be periodically re-evaluated to detect disease progression or regression (Roura et al., 
2013). Succinctly, there is not only a need for effective treatment schedules with the existing 
chemotherapeutic agents and for adequate surveillance but also for the discovery of new drugs. 
 
Literature review: chemotherapy of leishmaniasis │41 
 
Antileishmanial activity of Allicin: mechanism of action, in vivo efficacy and value in combined therapy with amphotericin B │ María Jesús Corral 
 
 
Figure 14. Chemical structures of some relevant compounds with antileishmanial activity. Main compounds 
employed in the chemotherapy of VL are pentavalent antimonials (i.e. sodium stibogluconate and meglumine 
antimoniate), miltefosine, amphotericin B and paromomycin. Chemical structures were obtained from Pubchem.  
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Pentavalent antimonials 
Pentavalent antimonials (SbV) have been available since the 1920s and for the last 60 years 
have been the first line drug for the treatment of leishmaniasis. The development of this less 
toxic antimonial form is attributed to Brahmachari, Schmidt and Kikuth among others and led to 
the synthesis in 1937 of antimony gluconate (i.e. Solustibosan®) and in 1945, sodium 
stibogluconate (i.e. Pentostam®). Soon after the launch of Pentostam, Aventis developed 
another carbohydrate complex form of SbV, meglumine antimoniate (Glucantime®). 
Nowadays, there are two marketed formulations, N-methylglucamine (meglumine) antimoniate, 
containing  85 mg of SbV/mL (Glucantime®, Aventis, France), and sodium stibogluconate 
(Pentostam® GlaxoSmithKline, UK) with 100 mg of SbV/mL. There are also some cheaper 
generic antimonial formulations undergoing clinical trials (Croft & Yardley, 2002).  
Despite the continued use of antimonials against Leishmania for over 50 years, their 
mechanism of action remains poorly understood and several potential targets have been 
proposed. To date, still is not clear whether the final active form of pentavalent antimonials is 
SbIII or whether both oxidation states (SbV and SbIII) present biological activity (Frezard et al., 
2013). Two main models have been proposed to address pentavalent antimonials mode of 
action: (i) the prodrug model, in which SbV will act as a prodrug and will be further reduced in 
host cells to the more active and toxic trivalent antimonium (SbIII) (Figure 15); and (ii) direct 
antileishmanial activity of SbV (i.e. inhibition of type I topoisomerase) (Frezard et al., 2013). 
Interestingly, dramatic differences have been described in the IC50s for SbV against extracellular 
stages (>64 μg/mL) and intracellular amastigotes (8.8-10.5 μg/mL) of L. donovani (Vermeersch 
et al., 2009). 
Some studies reported that a variable amount of SbIII -the most active and toxic form of the 
antimonial- could be present in the marketed preparations, and this could partially explain the 
toxicity of the drug (Croft & Yardley, 2002). SbV has been suggested to act as a prodrug, being 
converted to the more active antileishmanial and toxic SbIII form in the host. Nevertheless, this 
link between toxicity for the host and antileishmanial activity of SbIII forms has been 
challenged, since only a marginal effect on Leishmania of the residual SbIII in pentavalent 
antimonial drugs administered could be observed in vivo (Dzamitika et al., 2006). 
Leishmanicidal activity of antimonials has been related to the selective inhibition of enzymes 
required for energy metabolism (glycolysis and Krebs cycle) and fatty acids oxidation (Berman 
et al., 1985). However, SbIII killed promastigotes of L.mexicana in vitro, were not affected by 
SbV and neither the antimonial inhibited hexokinase, phosphofructokinase, pyruvate kinase, 
malate dehydrogenase and phosphoenolpyruvate carboxykinase (Mottram & Coombs, 1985). 
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Comparable results were obtained in L.tropica promastigotes without any noticeable effect of 
Glucantime® on the activity of hexokinase and phosphofructokinase (Foulquie et al., 1999). 
Another possible mechanism of action of antimonials (SbV) is the inhibition of type I DNA 
topoisomerase (Chakraborty & Majumder, 1988), but no relationship has been found by Walker 
and Saravia (2004) between leishmanicidal activity of SbIII and inhibition of topoisomerase I in 
L. donovani.  In addition, it has been shown that SbIII interferes with trypanothione metabolism 
by two different mechanisms, namely rapid efflux of intracellular trypanothione and 
glutathione, and inhibition of trypanothione reductase (Wyllie et al., 2004). Most experimental 
work has been carried out in vitro or ex vivo and in some cases with promastigotes. 
Consequently, in the infected host other mechanisms could be involved. 
 
 
 
 
 
 
 
 
 
 
 
Figure 15.  Prodrug model suggested by Frezard et al. (2013) for the mechanism of action of pentavalent 
antimonials. Reduction of SbV to SbIII may be mediated (1) by the thiols Cys or Cys-Gly as reducing agents within 
the phagolysosomes, (1′ ) by T(SH)2 as the predominant thiol within parasite or by the thiol-dependent reductase 1 
(TDR1) or antimoniate reductase 2 (ACR2); (2) formation of complexes between SbIII and thiols (GSH, T(SH)2); (3) 
sequestration by ABC transporter multidrug resistance protein A (MRPA) or possibly pentamidine resistance protein 
1 (PRP1) into intracellular organelles or active extrusion by a non-identified plasma membrane transporter; (4) 
binding of SbIII to the active site and inhibition of trypanothione reductase, increasing intracellular ROS production; 
(5) ejection of Zn(II) from zinc-finger protein by competition with SbIII, resulting in the interference with post-
transcriptional regulation of gene expression; (?) means a mechanism not yet elucidated. GSH, glutathione; YGCS, 
enzyme y-glutamylcysteine synthase; T(SH)2 ,trypanothione; Spd, spermidine; ODC, ornithine decarboxylase; TR, 
trypanothione reductase; AQP1, aquaglyceroporin; TDR1, thiol dependent reductase 1; ACR2, antimoniate 
reductase 2; MRPA, multidrug resistance protein A; Orn, ornithine; ROS, reactive oxygen species. 
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As mentioned earlier in this review resistance emergence against antimonials is of particular 
concern in the state of Bihar, India. Mechanisms underlying development of resistance are not 
completely understood although antimony-resistant lines of Leishmania have shown to have 
increased levels of trypanothione and this likely increases conjugation to the metalloid. This 
conjugate can either be sequestered inside an organelle through a MRPA (multidrug resistance 
protein A) transporter or effluxed outside the cell possibly via another ATP-binding cassette 
(ABC) transporter (Ouellette et al., 2004). 
Both Pentostam® and Glucantime® are usually employed in the control of leishmaniasis 
although N-methylglucamine (meglumine) antimoniate, administered by parenteral or 
intramuscular route, is the SbV formulation most frequently used for treating leishmaniasis in 
humans and dogs, particularly in the Mediterranean basin (Oliva et al., 2010). On occasion, they 
have been recommended to prevent the development of the disease in asymptomatic infected 
dogs. This pre-symptomatic treatment could, in addition, induce an important reduction of the 
available parasites for sandflies (Gradoni et al., 1987; Mancianti et al., 1988) thus diminishing 
the risk of transmission to other dogs or humans. 
The use of antimonials is restricted by the side effects, mainly nephrotoxicity (Veiga et al., 
1990; Baneth & Shaw 2002), reported. However, toxicity of antimonials is a controversial issue, 
since the apparent toxicity disappears when the doses are applied more separately (Valladares et 
al., 1998). Actually, antimonials have a short-half life (21, 42 and 122 min after intravenous, 
intramuscular and subcutaneous administration, respectively) and are quickly eliminated by 
urine and do not accumulate; after 6-9 h the 80-95% of meglumine antimoniate is eliminated 
through the kidneys (Tassi et al., 1994). Possibly the renal toxicity after administration of the 
antimonial reported in some studies is due to previous kidney damage caused by intraglomerular 
deposition of circulating immunocomplexes inducing glomerulonephritis (Mancianti et al., 
1989; Poli et al., 1991). Oliva et al. (2010) concluded that no scientific evidence is presently 
available that supports a genuine nephrotoxicity of antimonials in dogs. Other side effects 
observed after administration include painful local swellings at the site of the injection, 
gastrointestinal disturbances, locomotory problems, joint stiffness, anorexia and fatigue (Noli, 
1999; Baneth & Shaw, 2002; Denerolle & Bourdoiseau, 1999). Apathy has been observed 
during the first days post-treatment (Ferrer & Roura, 2012). 
Meglumine antimoniate induces a rapid improvement of the clinical condition of the infected 
dogs, temporary recovery of cell-mediated immune response (Bourdoiseau et al., 1997) and a 
differential IgG1/IgG2 pattern up to 5-12 months post-treatment (Fernández-Pérez et al., 2003). 
This is observed in 75-90% of the animals treated. However, parasitological cure of the dogs is 
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not achieved and relapses are the rule in ca. 75% of the cases in the following 6 to 8 months 
post-treatment (Slappendel & Teske, 1997; Gramiccia et al., 1992; Ikeda-García et al., 2007). 
As observed in human leishmaniasis, the presence of resistant strains of L. infantum to 
meglumine antimoniate in dogs has sporadically been reported (Gramiccia et al., 1992; Carrió & 
Portús, 2002); this resistance development could be related to inappropriate under-dosage of the 
drug.   
As mentioned, treatment schedules in canine leishmaniasis are variable and this holds also 
true for meglumine antimoniate dosing. Doses from 40-75 mg/Kg, twice a day for 4 weeks or 
75-100 mg/Kg/day administered by subcutaneous injection are currently employed (Tassi et al., 
1994; Denerolle & Bourdoiseau, 1999; Noli, 1999; Manna et al., 2008; Solano-Gallego et al., 
2011). Separation of daily doses is recommended on the basis of the pharmacokinetic properties 
to sustain tissue levels. Treatments are supposed to be repeated after relapses and a prolonged 
treatment (2-3 additional weeks) could be used if no improvement of the animal is observed. 
Meglumine antimoniate is used as monotherapy, although practitioners favour its combination 
with allopurinol and to a lesser extent with miltefosine (see below). The most frequent treatment 
schedule used by veterinary clinicians is meglumine antimoniate (100 mg/Kg/day for 4 weeks) 
plus allopurinol (10 mg/Kg/per os, twice a day, six to twelve months). Dogs treated with the 
combination show a prolonged period of clinical remission (Denerolle & Bourdoiseau, 1999). 
Comparable results have been obtained in naturally infected dogs with L.infantum treated with 
the combination of allopurinol (15 mg/Kg per os twice a day until clinical improvement, 
followed by allopurinol plus sodium stibogluconate, 30 mg/Kg/day, subcutaneously for 1 
month, followed by allopurinol at the same dose up to eight months) (Pasa et al., 2005). 
Adverse effects of the combination are those of the drugs administered in monotherapy.  
Some drug delivery systems (DDS), particularly liposomes, have been employed. These 
formulations have shown promising results as they retain the leishmanicidal ability of this 
compound and reduce its potential toxicity (Valladares et al., 2001). Despite this apparent 
success, Schettini et al. (2005) observed that treatment with liposomal forms could not provoke 
the complete elimination of parasites either. Other formulations of sodium stibogluconate in 
non-ionic surfactant vesicles have been tested on rodent models (mouse and hamster) and dogs. 
In all cases the encapsulated forms increased efficacy with lower toxicity when compared to the 
free form (Nieto et al., 2003). 
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Allopurinol  
Allopurinol is a structural analogue of hypoxanthine that was first used against leishmaniasis 
in the 1980's. This drug (e.g. Zyloric®) is traditionally used in humans for the treatment of gout 
as it reduces serum and urinary uric acid concentrations. Its mechanism of action is based on the 
inhibition of enzymes of purine metabolism such as xanthine oxidase. 
 In vitro efficacy of allopurinol and allopurinol ribonucleoside against Leishmania 
amastigotes was low (ED50 54-96 μM and 86-213 μM, respectively) and studies in CL murine 
models revealed also a moderate to low efficacy of the compound in vivo (Neal et al., 1985). In 
Leishmania, but not in mammals, this compound is also metabolized to various nucleosides and 
nucleotides which exert toxicity via incorporation into RNA (Nelson et al., 1979a; 1979b).  
Allopurinol does usually not generate side effects, and thus is recommended in individuals 
with chronic nephritis due to leishmaniasis (Plevraki et al., 2006) or in locations where first 
choice drugs are not available. Nevertheless, it has been shown that this leishmaniostatic 
compound alone has poor efficacy in terms of parasite elimination (Cavaliero et al., 1999; 
Koutinas et al., 2001; Oliva et al., 2010) and does not prevent infection of healthy individuals 
(Saridomichelakis et al., 2005). In spite of this limitation it has been used in canine 
leishmaniasis both in monotherapy or combined with antimonials.  
Doses are variable ranging from 5-30 mg/Kg/every twelve hours per os. The treatment 
should be maintained for at least six months (Noli, 1999; Oliva et al., 2010) and is 
recommended to be preferably continued for 12 months (Roura et al., 2013). The most 
frequently used dose is 10 mg/Kg/twice a day (Cavaliero et al., 1999; Solano-Gallego et al., 
2011). Side effects are not common but hepatic and renal function must be monitored during 
prolonged treatment since xanthinuria and xanthine urolythiasis can occur particularly in dogs 
with hepatic disease (Saridomichelakis et al., 2005). A moderate clinical improvement of the 
animals treated with allopurinol has been described (Cavaliero et al., 1999; Vercammen et al., 
2002) and 20 mg/Kg/day, one week every month, of this compound were effective to maintain 
clinical remission in naturally infected dogs. Additionally, allopurinol has been reported to 
ameliorate renal function, preventing deterioration of glomerular filtration rate in infected dogs 
with proteinuria, provided that there is no renal insufficiency (Plevraki et al., 2006).  
Since parasitological cure is not achieved (Koutinas et al., 2001), relapses appear once the 
administration of allopurinol is interrupted (Ginel et al., 1998; Cavaliero et al., 1999). The 
comparatively poor efficacy of allopurinol monotherapy demands combination with antimonials 
or miltefosine, except for cases with severe renal injury (Solano-Gallego et al., 2011). 
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Miltefosine and Alkylphosphocholines 
Miltefosine (hexadecylphosphocholine) was originally developed as an antineoplastic by its 
ability to induce apoptosis selectively in tumour cells. The use of the oral formulation for the 
treatment of solid tumours was discontinued due to dose-limiting gastrointestinal side effects in 
cancer patients (Dorlo et al., 2012a).   
First in vitro and in vivo activity of miltefosine against Leishmania was described by Croft et 
al. (1987). Interspecific variability to miltefosine has been demonstrated in Leishmania 
parasites; L.donovani intracellular amastigotes (EC50 3.3-4.6 μM = 1.3-1.9 μg/mL) were more 
susceptible than L.major (EC50 31.6-37.2 μM = 31.6-37.2 μg/mL) and other cutaneous species 
of Leishmania (Escobar et al., 2002). Furthermore, remarkable intraspecific variability of 
miltefosine efficacy was observed in different L.donovani isolates from Nepal (EC50 0.04-8.7 
μg/mL) and Peru (EC50 8.4 and >30 μg/mL) (Yardley et al., 2005). L infantum canine and 
human isolates also displayed variable susceptibility to miltefosine (IC50 for intracellular 
amastigotes from 4.12 to 69.5 μM) (Maia et al., 2013). Some other derivatives of 
alkyllysophospholipids such as edelfosine or ilmofosine have also shown antileishmanial 
activity (in promastigotes and amastigotes) in vitro (Escobar et al., 2002; Azzouz et al., 2005). 
Efficacy of oral miltefosine against VL was first demonstrated in vivo in a murine model of 
L.donovani (Kuhlencord et al., 1992) and Le Fichoux et al. (1998) described that miltefosine 
was also able to reduce by 89% the parasite burden in spleen and liver in BALB/c mice infected 
with L. infantum. 
Miltefosine mechanism of action is not completely known and several potential targets have 
been proposed, probably indicating a multitarget mode of action (Figure 16) (Dorlo et al., 
2012). Activity of hexadecylphosphocholine has been mainly linked to a disturbance of lipid-
dependent cell signalling pathways and an apoptotic-like cell death. Miltefosine altered the ether 
lipid metabolism and the synthesis of some virulence-linked surface molecules of Leishmania 
[i.e. glycosylphosphatidylinositol (GPI) anchor biosynthesis] (Lux et al., 1996). Moreover, 
miltefosine-resitant strains have shown decreased ergosterol levels and modification of fatty-
acids (i.e. length and level of unsaturation) suggesting that fatty-acid and sterol metabolism 
could be also affected by miltefosine treatment (Rakotomanga et al., 2005). Miltefosine treated 
promastigotes (Paris et al., 2004; Marinho et al., 2011) and amastigotes (Verma & Dey, 2004) 
showed phenotypic characteristics of an apoptotic-like cell death similar to that described for 
metazoans. Mitochondrial dysfunction in miltefosine-treated promastigotes has also been 
examined (Santa-Rita et al., 2004). As reviewed by Dorlo et al. (2012a), miltefosine, besides its 
antileishmanial activity, has demonstrated immunomodulatory properties by inducing the 
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release of some cytokines (e.g. IL-12, IFN-γ, TNF-α), NO production in macrophages, and 
enhancement of IFN-γ receptors, therefore, increasing IFN-γ response in infected Mφ promoting 
an IL-12 mediated Th1 response. However, other authors did not observe an up-regulatory 
effect in MHC-II or co-stimulatory molecules or an induction of IL-12, IL-10 and TNF-α in 
L.major infected dendritic cells (Griewank et al., 2010). Selection of miltefosine-resistant 
Leishmania promastigotes (15-fold less susceptible to miltefosine) (Pérez-Victoria et al., 2003b) 
and amastigotes (Hendrickx et al., 2014) under laboratory conditions has been relatively easy. 
Increased drug efflux and defect in drug internalization have been proposed as possible 
mechanisms of resistance (Pérez-Victoria et al., 2003a, 2003b).   
 
 
 
Figure 16. The various proposed mechanisms of action of miltefosine against Leishmania inside the macrophage. 
PC, phosphatidylserine. Image from Dorlo et al., 2012a. 
 
Promising results (i.e. 94 % cure rate) in phase II and phase III clinical trials in India lead to 
the approval of miltefosine in 2002 for the treatment of VL in humans in India (Sundar et al., 
2006). Impavido® is the commercially available oral miltefosine for humans and there is also a 
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marketed veterinary formulation to treat CanL, Milteforan®, registered for its use in European 
countries but not approved by the FDA (Oliva et al., 2010). Gastrointestinal adverse effects (i.e. 
vomiting and diarrhoea) have been described as the main acute toxic effects of miltefosine in 
humans or dogs (Olliaro et al, 2003).Treatment of naturally infected dogs with L. infantum 
using 2 mg/Kg/day miltefosine for 28 consecutive days yielded clinical improvement of the 
animals, recovery of pre-treatment haematologic abnormalities (50%) and seronegativity (IFAT 
test) in ca. 50% of pre-trial seropositive dogs (Woerly et al., 2009). Comparable results were 
obtained by Mateo et al. (2009) using the same treatment schedule. Another study carried out in 
Brazil evaluated miltefosine treatment using three different therapeutic regimens (100 
mg/animal, administered daily over a 28 day period;  200 mg/animal, administered daily over a 
28 day period; and 100 mg/animal, administered daily for 45 days) in naturally infected dogs 
(n=14) during the following 24 months post-treatment. Although clinical improvement and 
recovery was evident, parasitological cure was never achieved; and 6 months after treatment all 
animals presented a significant increase in parasite load. The authors discourage clinicians from 
using miltefosine in the treatment of CanL in endemic areas of Brazil (Andrade et al., 2011). 
Combination of miltefosine with allopurinol (2 mg/Kg/day, oral administration miltefosine 
plus 10 mg allopurinol/Kg/day per os, PO) for 30 days induced a rapid improvement of the 
clinical condition of severely affected dogs (one week after starting the treatment) and recovery 
of normal renal function after two weeks (Manna et al., 2005). Impressive clinical recovery with 
progressive reduction of L. infantum burden in lymph node aspirates and increase of IFN-γ was 
observed during an extended follow-up period after various miltefosine-based treatment 
regimens; however parasitological clearance was not achieved, as evidenced by PCR performed 
24 months after treatment (Manna et al., 2005). In 2009, Manna et al. evaluated in 28 infected 
dogs the efficacy of the combination of miltefosine (2 mg/Kg/day, PO) with allopurinol (10 
mg/Kg/day, PO) for 30 days, followed by allopurinol alone at the same dosage for 12 months. 
Eight dogs received a second miltefosine cycle and 4/8 relapsed, and although clinical 
amelioration was observed, even two miltefosine cycles failed to eliminate the infection.  
The main limitation of miltefosine is the induction of fetal malformations which restricts its 
use to non-fertile individuals or those under contraceptive treatment (Sinderman & Engel, 
2006). In addition, the potential of this compound to generate resistant Leishmania under field 
conditions is high and treatment failure and relapse rates are increasing (Rijal et al., 2013; 
Sundar & Chakravarty, 2013; Ostyn et al., 2014). The ability of miltefosine-exposed 
Leishmania to overexpress a transporter protein expelling the drug from the parasite, the long 
half-life (>150 h) of the compound and the prolonged treatment required, often associated with 
subtherapeutic drug levels, favour rapid emergence of resistances (Pérez-Victoria et al., 2006). 
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Treatment failure has been recently associated to exposure of parasites to low levels of the drug 
(Dorlo et al., 2014). Other risk factors as reinfection, emergence of resistant Leishmania isolates 
or reduced treatment quality should be also assessed as possible relapse sources. Decreased 
efficacy over the years has been highlighted by several authors (Ostyn et al., 2014) with final 
cure rates of 96.7% (Jha et al., 1999), 82% (Bhattacharya et al., 2007) and 72% (Rahman et al., 
2011). Moreover, oral administration of miltefosine, a logistic advantage to treat human 
leishmaniasis in remote regions even with poor sanitary standards, implies lacking control of 
resistance development (Sundar & Chakravarty, 2013). Similar considerations can be made and 
should be evaluated in a veterinary scenario. 
Another alkylphosphocholine analogue, oleylphosphocholine (OlPC, Dafra Pharma Research 
& Development, Belgium) has demonstrated to be equipotent to miltefosine in vitro and orally 
effective and tolerable in a hamster model of VL (Fortin et al., 2012), in a murine model of CL 
(Fortin et al., 2014), delivered intralesionally in tattooed liposomes (Shio et al., 2014) and in 
dogs with CanL (Hernández et al., 2014). No information is available about the teratogenicity, 
pharmacokinetics -in particular regarding the half-life of the compound- and resistance selection 
under laboratorial conditions of this miltefosine analogue.  
 
Amphotericin B 
Amphotericin B (AmB) is a broad spectrum polyene macrolide antibiotic obtained from the 
fermentation of the fungus Streptomyces nodosus.  Its leishmanicidal capacity was discovered in 
the 60s of the past century (Croft et al., 2006). The compound was mainly used as antifungal, 
especially for the treatment of systemic mycoses. Its mechanism of action has been related to 
the ability to bind to sterols, preferentially ergosterol, in cell membranes of Leishmania and 
fungi. The binding of AmB to sterols results in perturbation of the cell membrane structure and 
formation of pores composed of AmB-sterol aggregates causing membrane depolarization and 
leakage of ions as K+ leading to cell death (Brajtburg et al., 1990; Ramos et al., 1996). Actually, 
this primary mechanism of action could explain why clinically significant resistance to AmB is 
so rare (Gray et al., 2012). However, some studies point toward a more complex mode of action 
since pore formation does not necessarily lead to cell death (Baginski & Czub, 2009). AmB can 
produce cellular auto-oxidation and generation of free radicals (Lamy-Freund et al., 1985). 
Thus, cell death could be a result of oxidative stress and ionic membrane permeability 
(Brajtburg et al., 1990b). AmB-resistant Leishmania lines have been obtained in vitro and 
resistance has been correlated to an increased cell membrane fluidity and substitution of 
ergosterol by one of its precursors (mainly, cholesta-5,7,24-trien-3β-ol) which presents lower 
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affinity for AmB (Mbongo et al., 1998). Moreover, an increased expression of MDR1 
(multidrug resistant protein 1 transporter) -an ABC transporter- was evident in resistant 
parasites, suggesting a higher AmB efflux. Antioxidant defence in resistant parasites was also 
modified as shown by the up-regulation of the thiol metabolic pathway (Purkait et al., 2012)   
 
 
Figure 17. Amphotericin B mechanism of action in Leishmania and cellular events conferring amphotericin B 
resistance. AmB binds to ergosterol-containing membranes in Leishmania parasites, causing membrane 
depolarization and ionic leakage leading to cell death. Oxidative stress contributes to cell injury and death of 
Leishmania. In resistant strains ergosterol is replaced by cholesta-5,7,24-trien-3β-ol (with low AmB affinity) in the cell 
membrane. However, it is possible that certain amount of AmB molecules can enter the cell, but some may also be 
pumped out by MDR1. Remaining intracellular AmB auto-oxidizes generating ROS production. ROS production may 
be counteracted by the up-regulated tryparedoxin cascade of the thiol metabolic pathway. GSH, glutathione; Cys, 
cysteine; T(SH)2, trypanothione, SP, spermidine;  ODC, ornithine decarboxylase; TR, trypanothione reductase; TryS, 
trypanothione synthetase; SPS, spermidine synthetase; GCS, glutamylcysteine synthetase; GST, Glutathione S-
transferase; cTXN, tryparedoxin; CTP, cytidine triphosphate; ROS, reactive oxygen species; MDR1, multidrug 
resistant protein 1. Modified from Purkait et al., 2012. 
 
AmB presents excellent in vitro activities against promastigotes and intracellular 
amastigotes of L.donovani (IC50 0.1-0.4 μM) (Vermeersch et al., 2009) and L.infantum 
(IC50 0.04-0.71 μM) (Maia et al., 2013). AmB is marketed in a colloidal suspension of AmB 
deoxycholate to be administered parenterally. A large number of studies have shown the 
leishmanicidal efficacy of this compound, although its high toxicity, adverse effects during 
infusion and cost hamper its general use. Toxicity for mammals has been attributed to the 
similarity between ergosterol from the Leishmania membranes and cholesterol, the major sterol 
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in mammalian cells, causing nonspecific binding and thereby altering potassium permeability. 
AmB affinity for sterols, and therefore toxicity, depends on its state of aggregation: the 
monomeric form of AmB does not interact with ergosterol, whereas its affinity increases with 
aggregation (Gruda & Dussaul, 1988). Moreover, the sterol composition of the membrane also 
influences the selectivity of AmB for ergosterol (Barwicz & Tancrède, 1997), which could 
contribute to differential sensitivity of Leishmania species to AmB. 
Amphotericin has been employed in human medicine as a second choice drug against 
leishmaniasis but its use is increasing due to the emerging resistance to antimonials (Croft & 
Yardley, 2002; Croft et al., 2006). To reduce its adverse effect in the mammalian host many 
drug delivery systems (DDS) have been developed (Sundar & Chakravarty, 2013). The 
leishmanicidal drug reaches the actual intracellular location where Leishmania amastigotes 
multiply. In turn, the AmB trapped in large-size liposomes can no longer interact with 
mammalian sterols and accordingly the toxicity for the host is substantially lowered. The most 
successful has been AmBisome®, a formulation of AmB in sonicated liposomes. Another 
liposomal preparation (Fungisome), developed in India in 2003, indeed yielded most promising 
results in kala-azar patients (100% cure after one month and 90% sustained cure 6 months after 
treatment) with doses of 10 mg/Kg (twice 5mg/Kg) (Mondal et al., 2010). Non-liposomal DDS 
of AmB in clinical use are Amphocil®, a colloidal dispersion of AmB in cholesterol, and 
Abelcet®, a lipid complex which, in fact, was the first lipid formulation of AmB that was 
approved by the FDA for the treatment of fungal infections (Berman et al., 1992; Berman et al., 
1998; Guerin et al., 2002).  
New affordable formulations (e.g. AmB lipid emulsion, ABLE) have shown encouraging 
results in phase II studies. In September 2014 Sundar et al. published a phase III clinical trial in 
India (326/500 patients completed the study) which evaluated the efficacy and safety of single 
dose parenteral infusion of ABLE (15 mg/Kg) versus liposomal AmB. Results showed that 
ABLE was well tolerated [i.e. infusion-related problems were comparable in both groups, 
severe side effects were scarce (ABLE: 0.3%; L-AmB: 1.6%) and hepato-nephrotoxicity was 
not observed in either group] and had favourable efficacy [i.e. clinical improvement was 
comparable (ABLE: 98.9%; L-AmB: 98.4%) and cure was achieved in 85.9% in the ABLE 
treated group compared to 98.4% with L-AmB]. Single-dose administration is a clear asset in 
terms of treatment compliance, access and cost.  
Over the last years alternative DDS of AmB of lower cost and higher stability (i.e. niosomes, 
nanodisks, polymers conjugates, micro/nano-polymeric particles) have been tested against 
experimental leishmaniasis. Nanospheres of poly(ε-caprolactone) with AmB have been 
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employed in vitro against L.donovani amastigotes (Espuelas et al., 2002). These nanospheres, 
coated with poloxamer 188, have also been used to treat fungal infections (Espuelas et al., 
2003). AmB conjugated with arabinogalactan (Golenser et al., 1999) and or associated to 
nanodisks (Nelson et al., 2006) displayed low toxicity and high leishmanicidal activity in mice 
infected with L. major. Using a polysaccharide matrix with anionic lipids, AmB retained the 
leishmanicidal activity against L.donovani infections and was substantially less toxic in a mouse 
model (Loiseau et al., 2002). Similarly, lecithin microemulsions (Moreno et al., 2001) or 
nanospheres of egg albumin (Santhi et al., 1999) had lower toxicity than the free antibiotic. Also 
superaggregated AmB, obtained by heat treatment, has a reduced toxicity (Petit et al., 1999; Bau 
et al., 2003). Human albumin microspheres containing AmB have been tested in vitro and in 
vivo models (hamster) of L.infantum infection. This low cost DDS showed a reduced toxicity 
(10-fold) when compared to AmB deoxycholate and similar leishmanicidal properties (Sánchez-
Brunete et al., 2004; Ordóñez-Gutiérrez et al., 2007).  
Dogs naturally infected with L.infantum have been treated with different dosage regimens of 
AmB (1 to 2-5 mg/Kg, twice per week, slow intravenous infusion in normal saline followed by 
10 mL/Kg mannitol 20%). All animals receiving a total dose over 10 mg/Kg were apparently 
cured after treatment, and 14 out of 17 were PCR-negative (Lamothe, 2001). With the same 
emulsion all dogs were clinically cured and five months post treatment the 38% of the dogs 
were positive by PCR (Cortadellas, 2003). The main side effect of AmB associated to the 
treatment of canine leishmaniasis is nephrotoxicity caused by renal vasoconstriction and 
possibly by its direct action on renal epithelial cells (Baneth & Shaw, 2002). It may also cause 
fever, vomiting, anorexia and periphlebitis (Noli & Auxilia, 2005). AmBisome® (3-5 doses of 
3-3.3 mg/Kg, intravenous injection) administered to naturally infected treated dogs elicited a 
rapid clinical improvement although parasite clearance was only achieved in one dog (Oliva et 
al., 1995). Despite its excellent cure rates in treated dogs it is generally not used due to the 
complexity of preparation and the need of monitoring during administration (Oliva et al., 2010).  
It has often been stated that the use of AmB for the treatment of canine leishmaniasis is not 
recommended, since parasite clearance is not achieved and resistance development appears 
possible (Oliva et al., 2004, 2010; Alvar et al., 2006). Nevertheless, its mechanism of action 
does not likely favours resistance emergence (Gray et al., 2012) and no resistant strains of L. 
infantum, despite the long history of AmB use in human medicine, have ever been identified in 
humans (Durand et al., 1998; Maia et al., 2013) or dogs (Maia et al., 2013). This restriction is 
indeed surprising since AmB was, and still is, the preferred treatment for systemic fungal 
infections in humans and domestic animals including dogs (Vorathavorn et al., 2013) and 
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frequent exposure of L. infantum to this antibiotic must be rated as more than likely over the 
fifty years since its introduction.  
 
Paromomycin (aminosidine) 
Paromomycin (PM) is an aminoglycoside antibiotic produced by Streptomyces spp. This low 
cost compound shows both antibacterial and antiprotozoal activity (Baneth & Shaw, 2002). It is 
the last antileishmanial drug approved for the treatment of VL in India (Sundar et al., 2007) and 
parenteral and intramuscular formulations are available for the treatment of VL and topical 
formulations have been used for CL (Sundar & Chakravarty, 2013). Parenteral formulations 
seem an attractive alternative to antimony treatment in endemic areas. There is a consensus that 
monotherapy with 15 mg/Kg/day for 20 days is well tolerated and efficacious (i.e. cure rates 80-
90%) (Jha et al., 1998). Nonetheless, toxicity, relapses and in vitro selection of resistant strains 
are the main drawbacks for its use in monotherapy (Seifert, 2011; Hendrickx et al., 2014). 
Antileishmanial susceptibility to paromomycin has been proven variable among different 
Leishmania spp. This drug resulted more active against intracellular amastigotes of L.major and 
L.tropica (i.e. ED50s in the range of 1-5 μM) than to L. mexicana (ED50, 39 μM), L.braziliensis 
(ED50, 12 μM) or L.donovani (ED50, 6-18 μM) (Croft et al., 2006). Mechanism of action of 
aminosidine in L.donovani promastigotes has been related to its effect on RNA synthesis and on 
membrane permeability affecting its fluidity and the membranous lipid metabolism (Maarouf et 
al., 1997a). Mitochondrial dysfunction has been also observed in paromomycin exposed 
promastigotes (Maarouf et al., 1997b; Jhingran et al., 2009). Stable and infective resistant 
Leishmania strains have been easily developed under laboratory conditions (Maarouf et al., 
1998). Resistant parasites have shown in vitro decreased drug uptake (Jhingran et al., 2009) and 
more recently Bhandari et al. (2014) confirmed an increase in membrane fluidity and 
paromomycin efflux, accompanied by a decrease in intracellular drug accumulation, and a 
superior tolerance to nitrosative stress at the promastigote and amastigote stages. In addition, an 
increased survival capacity was observed in paromomycin resistant strains in this study.  
Topical paromomycin has shown antileishmanial activity in experimental murine models of 
CL (El-On & Hamburger, 1987) and resulted effective in the treatment of L.major infected 
patients (i.e. 74.2% achieved parasitological cure after 10 days of topical treatment) (El-On et 
al., 1992). A parenteral formulation of this drug reduced the parasite burden in a model infection 
of L. infantum in mice, although the efficacy was lower than that obtained with antimonials 
(Gangneux et al., 1997). Different trials have shown the clinical efficacy of aminosidine for the 
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treatment of CanL (Poli et al., 1997; Oliva et al., 1998; Vexenat et al., 1998a). However, 
aminosidine is not likely suited for monotherapy given the relapses observed 50-100 days after 
treatment with a dose of 20 mg/Kg/day and the casualties associated with higher doses (80 
mg/Kg/day) (Vexenat et al., 1998a). Nephrotoxicity and ototoxicity represent the main adverse 
effects (Oliva et al., 2010). In 2005, Noli & Auxilia proposed a dosage of 5 mg/Kg twice daily 
for 3-4 weeks although they anticipated that relapses should be expected within a few months. 
Lately, two studies carried out in healthy and L. infantum naturally infected dogs evaluated the 
efficacy, safety and pharmacokinetics of aminosidine (15 mg/Kg/day, once daily, subcutaneous 
route, 21 days). Improvement of the clinicopathological status of the animals was observed with 
this regimen although infection persisted in tissues (Athanasiou et al., 2013). Single-dose 
aminosidine was well tolerated, without signs of nephrotoxicity, and resulted in effective serum 
concentrations of the drug.   
A combined therapy of aminosidine and antimonials appears more realistic, since 
interference between these antileishmanial agents has not been observed and renal function was 
not altered after treatment of healthy Beagle dogs (Belloli et al., 1999). Oliva et al. (2010) 
suggested a combination of aminosidine (5 mg/Kg, subcutaneous, daily for 3 weeks) plus 60 mg 
meglumine antimoniate (intramuscular, twice a day for 4 weeks). In murine models of infection, 
the combination of antimonials and aminosidine proved to be more efficacious than the 
individual drugs, but still the parasites persisted in liver and spleen and toxicity was not 
abrogated (Gangneux et al., 1997). Various combinations of paromomycin with other drugs are 
now being explored for the treatment of leishmaniasis in vitro (Morais-Teixeira et al., 2014; PM 
+ miltefosine, Das et al., 2014), in animal models [PM + stearylamine (SA)-bearing 
phosphatidylcholine (PC) liposomes, Banerjee et al., 2011] and in clinical trials (PM + 
gentamicin, Sosa et al., 2013; PM + sodium stibogluconate, Musa et al., 2012). 
 
Pentamidine  
Pentamidine isethionate is an aromatic diamidine used to treat pneumonia caused by 
Pneumocystis carinii, an opportunistic fungal infection frequent in inmunocompromissed 
patients and also described in dogs (Sukura et al., 1996). The drug also has antiparasitic 
properties against Leishmania, Trypanosoma and Plasmodium (Pearson & Hewlett, 1985). 
Currently, pentamidine is still used for the treatment of first stage human African 
trypanosomiasis (HAT) (Babokhov et al, 2013), for some forms of CL, and is considered a 
second-line drug for the treatment of VL (Seifert, 2011). In the 1980s, this drug was used for the 
treatment of refractory VL in India; it has been abandoned due to safety concerns as it has been 
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associated with the induction of insulin-dependent diabetes mellitus and low efficacy (Jha et al., 
1991). A formulation for parenteral use (Pentacarinat®) is available. A closely related 
compound, pentamidine dimetasulfonate (Lomidine®), is also marketed (Baneth & Shaw, 2002; 
Guerin et al., 2002). The mechanism of action of pentamidine is believed comprise induction of 
changes in DNA conformation as a consequence of its double binding to DNA and ubiquitin 
(Nguewa et al., 2005), inhibition of polyamine metabolism and interference with purine 
metabolism (Calonge et al., 1996; Johnson et al., 1998).  
In CanL, an apparently complete clinical and immunologic recovery has been observed after 
pentamidine treatment (Rhalem et al., 1999) but relapses occur. Treatment of dogs with 
pentamidine was carried out during the 80s but was discontinued as a result of adverse side 
effects including irritation at the injection site, vomiting, diarrhoea, hypersalivation, 
tachycardia, hypotension and anaphylactic shock (Baneth & Shaw, 2002; Oliva et al., 2010). As 
with other antileishmanial compounds, various DDS have been investigated (nanospheres of 
polylactic acid and polymethacrylate containing pentamidine), and the results obtained in mouse 
models of L. infantum infections showed a significant increase of efficacy when compared to 
the free compound (Durand et al., 1997a, 1997b). 
 
Domperidone 
Domperidone is a dopamine D2 receptor antagonist used as an antiemetic and prokinetic 
compound. Marketed as Motilium®, oral domperidone has been used since the 1980s in humans 
for the treatment of gastrointestinal disorders (Brogden et al., 1982) and immunomodulatory 
properties have been also ascribed to this molecule. Domperidone transiently increases 
prolactinemia (Rovensky et al., 1995, 1996). Prolactin is known to induce the increase of the 
CD4+ Th1 cellular subpopulation releasing IL-2, IL-12, IFN-γ, TNF-α, and thus, resulting in 
activation of Mφ and natural killer (NK) cells (Sabaté et al., 2014). Cell-mediated immune 
response has been classically related to protection against Leishmania.  
Gómez-Ochoa et al. (2009) reported the development of a Th1-cell mediated immune 
response in naturally L.infantum infected dogs (n=98) after oral treatment with domperidone 
(1mg/Kg, twice daily for 30 days) and its efficacy in controlling and diminishing clinical signs. 
Domperidone, combined with other antileishmanials (e.g. meglumine antimoniate or 
furazolidone), has been used to treat CanL by L.infantum (Lanaro, 2012) and by 
L.(V.)braziliensis (Passos et al., 2014). Although infection was not cleared, relapse rate was 
decreased and improvement of the clinical signs was accelerated. Prophylactic use of 
domperidone (0.5 mg/Kg/day 30 consecutive months, every 4 months) has been explored in 
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healthy dogs (n= 90) during a 21-month follow-up period; results showed a 7-fold reduction of 
the risk of developing an active infection (Sabaté et al., 2014).  
An oral veterinary formulation is available in Spain since 2012, Leishguard® (Esteve), for 
the prevention and control of disease progression in early stages of CanL. Adverse effects 
described are mild and include galactorrhea, gastrointestinal disturbances (diarrhoea, anorexia, 
and abdominal pain) and apathy. Nonetheless, its use in humans has been recently restricted by 
the EMA (European Medicines Agency) (EMA/129231/2014) by its association with heart 
failure (Hondeghem, 2013) this probably leading to a re-evaluation of its use in veterinary 
therapeutics.  
 
Sitamaquine (WR-6026) and 8-aminoquinolines 
The 8-aminoquinolines were the first group of compounds specifically synthesized as 
antiplasmodials. United States military initiated a large-scale research programme, in the 1940s, 
with the aim of synthesizing less toxic and more efficacious antimalarials. This programme 
finally rendered three new compounds: pentaquine, isopentaquine and, the most effective, 
primaquine (Grewal, 1981). Since their discovery, this series of compounds has aroused interest 
in the search for new antileishmanials (e.g. 6-methoxy-8-alkylpiperazinoalkylaminoquinoline 
derivatives: Beveridge et al., 1958; lepidines: Kinnamon et al., 1978; NPC1161B: Nanayakkara 
et al., 2008; tafenoquine: Yardley et al., 2010). 
Sitamaquine (WR-6026), an 8-aminoquinoline analogue, was synthesized at the Walter Reed 
Army Institute (WRAIR) and since 2002 is in clinical development by GlaxoSmithKline (GSK, 
UK) for the oral treatment of VL (Yeates, 2002). Mechanism of action of the molecule remains 
unknown. Sitamaquine accumulates inside acidocalcisomes of Leishmania, yet the 
antileishmanial effect is not related with its accumulation (López-Martín et al., 2008). Loss of 
mitochondrial membrane potential (Vercesi et al., 1992) and oxidative stress (Carvalho et al., 
2011) have also been observed in treated cells. Coimbra et al. (2010) demonstrated that 
sitamaquine has high affinity towards anionic phospholipids and interacts with lipid monolayers 
in L.donovani promastigotes. These authors proposed that sitamaquine diffuses across the cell 
membrane according to an energy-independent electrical gradient and a sterol-dependent 
process. The drug can be effluxed in an energy-dependent manner, suggestive of the existence 
of a still uncharacterized transporter.  
In vitro experiments proved that sitamaquine had activity (ED50, 2.9-19.0 µM) against a 
variety of Leishmania spp. (Garnier et al., 2006). It has been proposed that variable 
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susceptibility can be related to the anionic phospholipid and sterol composition of different 
Leishmania spp plasma membranes (Coimbra et al., 2010). Recently, in an in vitro drug 
combination study carried out on intracellular amastigotes of L. infantum, sitamaquine's  IC50 
resulted of 2.92 ± 0.20 µM (Mesquita et al., 2013). Kinnamon et al. (1978) tested sitamaquine in 
a hamsters infected with L.donovani and results showed that this compound was more active 
than sodium stibogluconate. Conversely, no activity was observed after topical administration in 
a murine model of CL (BALB/c, L.major) (Garnier et al., 2006). 
This compound has completed phase II clinical trials in Kenya (cure rate: 83%: Wasunna et 
al., 2005) and India (cure rate: 87%: Jha et al., 2005). Sitamaquine properties as a drug 
candidate against Leishmania have been reviewed elsewhere (Loiseau et al., 2011). Main side 
effects described in these trials were abdominal pain, headache, vomiting, cyanosis and, more 
concerning, methemoglobinemia (not in Kenya) and renal toxicity with doses ˃ 2.5 mg/Kg. In a 
clinical trial in HIV infected patients methemoglobinemia was dose-limiting (3/6 patients had 
methemoglobine levels ˃20%) (Petty et al., 1999). Nonetheless, another phase II clinical trial 
carried out in Brazil with L. infantum infected patients showed discouraging results as low cure 
rates and lack of increasing efficacy with escalating doses were observed (Dietze et al., 2001). 
Moreover, even though its half-life is short (i.e. 29.1 h in humans) (Yeates, 2002), there is a risk 
of resistance emergence in the field as stable resistant strains of L.donovani can be easily 
obtained under laboratory conditions (Bories et al., 2008) and these cells show a change in drug 
accumulation and lipid metabolism (Imbert et al., 2014). 
Data regarding pharmacokinetics and bioavailability in Beagle dogs defined oral sitamaquine 
as a drug of relatively high systemic clearance, large volume of distribution (100% orally 
available), short half-life and low systemic availability (4%), probably due to pre-systematic 
liver metabolism (Taylor et al., 1991). Toxicity studies in dogs after oral administration of 
sitamaquine revealed a mean of 30% methemoglobine in the treated animals (3 mg/Kg/day for 4 
weeks) (Levine et al., 1997) and of 20.7% after a 4 consecutive day treatment with 0.0116 
mmol/Kg sitamaquine (Anders et al., 1988). Whether or not sitamaquine is a good candidate for 
the treatment of CanL needs further research including metabolites involved and toxicity.  
 
Marbofloxacin and fluoroquinolones 
Fluoroquinolones, which target DNA topoisomerase type II and gyrase, are a group of broad 
spectrum antibiotics extensively used for the treatment of human respiratory and urinary 
infections (e.g. ciprofloxacin). DNA topoisomerases have been proposed as interesting 
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molecular targets in the search for new antikinetoplastid agents. These enzymes play key roles 
in cellular functions and there is evidence that human and parasite topoisomerases are 
sufficiently distinct, therefore making them a potential chemotherapeutic target (Das et al., 
2004). Fluoroquinolones have demonstrated leishmanicidal (Croft & Hogg, 1988) and 
trypanocidal activity by promoting the formation of protein DNA covalent complexes (Nenortas 
et al., 1999).  
Marbofloxacin is a synthetic third generation fluoroquinolone antibiotic approved for 
veterinary use that has shown in vitro antileishmanial activity (Oliva et al., 2010). A trial to 
assess its efficacy was carried out in Greece in naturally infected dogs with L.infantum (n=24) 
and results suggested amelioration of the clinical status in the treated animals (Rougiers et al., 
2008). In 2012, Rougiers et al., reported the results obtained in a field trial with marbofloxacin 
(n=72 dogs) in different endemic areas (i.e. Spain, Italy and France) with a follow-up period of 
12 months. Regimen used in the study was a dose of 2 mg/Kg/day Marbocyl®, orally 
administered for 28 consecutive days. Clinical improvement was evident after 3 months in 61% 
of the treated animals and 10 animals were clinically cured after 3 months. However, none of 
the animals achieved parasite clearance and relapse rates were high (20/38 dogs 5.5 months 
after treatment completion).  
 
Metronidazole and azoles  
Azoles are inhibitors of the ergosterol synthetic pathway. Ergosterol is the main sterol 
existing in Fungi, Leishmania spp. and Trypanosoma spp. (Croft et al., 2006). This similarity 
explains the interest antifungal azoles have raised as potential antileishmanial agents. A number 
of azoles (e.g. ketoconazole, imidazole, itraconazole, metronidazole, fluconazole, posaconazole) 
have been investigated for activity against Leishmania spp. although stage and species 
sensitivity variation have been observed in vitro, in vivo and in clinical trials (Croft & Yardley, 
2002; Paniz Mondolfi et al., 2011; Sundar & Chakravarty, 2013). This disparity of results 
observed between promastigotes and amastigotes has been related to the ability of the latter to 
take up cholesterol from the host cell under drug pressure (Roberts et al., 2003).  
In CanL their efficacy has been lower than that of SbV antimonials (Baneth & Shaw, 2002). 
Metronidazole has also been tested in combination with spiramycin (Pennisi et al., 2005) or 
enrofloxacin (Bianciardi et al., 2004) has been evaluated in the treatment of CanL. None of the 
combined therapies cleared the infection. Moreover, clinical efficacy was moderate and better 
results were obtained in the antimonial treated groups.  
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Recently, fexinidazole, a compound patented by Merial (patent application nº 20140213624), 
has been proposed as a potential oral drug candidate for the treatment of VL (Wyllie et al., 
2012). In fact, currently DNDi is recruiting participants in Sudan for a phase II/III trial to study 
its efficacy against VL caused by L.donovani (clinicalTrial.gov identifier: NCT01980199). 
Results obtained with this nitroimidazole against L.donovani in murine models have shown a 
decrease in parasite burden of 98.4%. The biological activity and pharmacokinetics in dogs 
suggest the interest of this drug as a good candidate for further testing against CanL.  
 
Buparvaquone and derivatives (naphtoquinones) 
Buparvaquone (BPQ) is a hydroxynaphtoquinone currently marketed as Butalex® for the 
treatment of theileriosis in cattle. Theileria is an intracellular Apicomplexa that parasitizes T 
and B lymphocytes. In vitro antileishmanial activity of BPQ and other naphtoquinones was 
described in the early 1990s. In spite of encouraging in vitro activity, limited success was 
observed in a murine model of L donovani infection (62% reduction of parasite burden in liver) 
(Croft et al., 1992). Due to BPQ's physicochemical properties (i.e. low aqueous solubility and 
high lipophilicity) its phosphate prodrugs (i.e. buparvaquone-3-phosphate, 3-
phosphonooxymethyl-buparvaquone) were studied in an attempt to increase bioavailability. 
Strong in vitro inhibitory activities were observed against Leishmania spp. (Mäntylä et al., 
2004). In vivo studies, on cutaneous and visceral mouse models of leishmaniasis, revealed the 
efficacy of different topical formulations of BPQ for CL and that buparvaquone-3-phosphate 
was the most active antileishmanial molecule against L.donovani murine infection (Garnier et 
al., 2007).  
A liposomal BPQ formulation containing phosphatidylserine (BPQ-PS-LP) has recently been 
proved efficacious in vitro against promastigotes and amastigotes of L.chagasi and its 
therapeutic efficacy has also been explored in a hamster model. This formulation (0.33 
mg/Kg/day for eight days) reduced spleen (89.4%) and liver (67.2%) parasite burden and, 
although in vitro efficacy against intracellular Leishmania spp. amastigotes of free BPQ was 
high (IC50=1-4 µM), BPQ (20 mg/Kg/day, 8 days), failed to cure hamsters (Reimão et al., 
2012). Information regarding efficacy of BPQ to treat CanL is scarce. Only one study is 
available and BPQ (5 mg/Kg/day for 12 days) was ineffective (Vexenat et al., 1998b).  
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1.7.5. Current strategies to improve the chemotherapy of VL 
On previous grounds the need for novel and efficacious antileishmanial treatments seems 
evident. In 2005, Pink et al. thoroughly reviewed the current scenario regarding the challenges 
in drug discovery against parasitic neglected diseases. They concluded that the overall cost for 
developing a new antiparasitic or anti-infectious agent is not higher or technically more 
demanding than that of other drugs targeting different pathologies. Certainly, the attrition rate in 
the development of new therapeutic agents is very high (Herper, 2013). However, in the case of 
antiparasitic agents this situation is not so evident. In fact, it has been determined that success 
rate in some cases (i.e. antimalarials) is higher than that of other medications. In spite of the 
high morbidity and mortality rates of these diseases investment has been limited (Figure 18). In 
the time-period corresponding to 1975-1999 more than 1300 new drugs or presentations were 
launched to the market and only 13 of them were indicated for the treatment of neglected 
diseases caused by helminths and protozoa. Malaria, trypanosomiasis, leishmaniasis and 
tuberculosis together are responsible for 5% of the world's disease burden and, in 2000, only 
0.1% of the global health budget was dedicated for the discovery of drugs against these 
diseases. 
 
Figure 18. TDR investment in neglected diseases in relation with disability-adjusted life years (DALY) estimates. The 
DALY estimates determine the level of WHO/TDR funding for research; as a disease has higher prevalence and 
incidence, the higher the budget for its research and development. Image from Handman et al., 2008.  
 
Given the comparatively low research and development (R&D) effort on drug discovery it is 
not surprising that the majority of compounds employed in the treatment of leishmaniasis were 
originally developed for other indications. This opportunistic "piggy-back" strategy (“new 
indications for old drugs”), although less expensive, is a useless tool for the identification of 
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new drug targets (e.g. better use of the genome sequence of Leishmania, distinct metabolic 
pathways and regulation systems) and for the introduction of entirely different chemical 
compounds. In the face of resistance emergence and treatment failure, this trend seems to be 
slowly changing. Some pharmaceutical companies and foundations (e.g. Bill & Melinda Gates 
Foundation) have growing interest in the development of compounds for non-profitable diseases 
(Handman et al., 2008). Moreover, the establishment of some public-private partnerships (e.g. 
Drugs for Neglected Diseases Initiative, DNDi; Institute for One World Health, IOWH) has 
increased the research efforts for rationale antiparasitic chemotherapy development in the last 
years (Pink et al., 2005). Besides, novel academia-industry partnerships as a mean to increase 
innovation in pharmaceutical R&D are becoming more frequent and highly successful if 
adequately funded (e.g. Cancer Research Technology, UK). It is suggested that academia 
together with the biotech industry can form a new “front end” to the early discovery phases of 
drug development; further preclinical, clinical development phases and commercialization can 
be then taken by pharma companies (Tralau-Stewart et al., 2009). An analysis on the actual 
reasons underlying the scarce efficiency of the drug discovery by pharmaceutical companies is 
beyond the purpose of this review. Probably the causes are multiple and besides those described 
previously and the anticipated low returns of antiparasitic drugs, other factors related to their 
R&D structure and internal expenses’ distribution would be involved (Cuatrecasas, 2006).  
In the particular case of leishmaniasis current therapy is insufficient to control disease and 
infection in endemic areas. Present day chemotherapy has serious shortcomings including 
toxicity and side effects induced by some drugs; high cost of the most effective presentations, 
length of treatments and resistance phenomena described in many Leishmania isolates. In the 
absence of efficacious vaccines, novel therapeutic options are compulsory (Sundar & 
Chakravarty, 2013).  
The search for novel, safe, affordable and effective antileishmanial chemotherapies has 
followed different strategies. Approaches can be classified as short-to-medium term (i.e. new 
indications for existing drugs, combination therapy, improvements in known drugs and 
compound classes) or long-term (e.g. discovery of new synthetic or natural agents, 
immunochemotherapy) (Pink et al., 2005; Croft et al. 2006; Seifert, 2011; Mendes-Roatt et al., 
2014). In addition, incorporation of drug delivery systems (DDS) as a complementary strategy 
to develop new formulations of old and novel compounds and combinations represents another 
approach for therapy improvement (Pham et al., 2013). We will focus, in our review, on the 
three most suggestive strategies, namely combination therapy, development of DDS and the 
discovery of new drugs.  
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1.7.5.1. Combination therapy  
In the coming years, even supposing new drugs are being developed, there are fair evidences 
to support that compounds now available for leishmaniasis are going to still constitute the main 
chemotherapeutic arsenal against the disease with its limitations (see Table 2). Thus, already 
miltefosine efficacy has diminished in the field and resistance is a growing concern as in the 
case of antimonials among other drugs (Sundar & Chakravarty, 2013). Combination therapy has 
recently attracted interest in the treatment of neglected diseases (e.g. malaria, tuberculosis, HIV, 
leishmaniasis) as a mean of prolonging life-span of existing drugs (Bryceson, 2001).  
It is assumed that the combination of chemically different entities can reduce needed dosage 
or length of treatment, thus lowering associated toxicity, attaining higher compliance and, 
therefore, decreasing direct and indirect costs ensuing less burden on the health systems 
(Griensven et al., 2010). Moreover, combined therapy may be suitable to diminish resistance 
emergence and increase treatment efficacy (Croft et al., 2006) improving therapy options in 
complicated situations such as HIV coinfection (WHO, 2010) or in solid organ transplants 
(Antinori et al., 2008). From a pharmacologic perspective, distinct mechanisms of action are 
recommended. A similar pharmacokinetic profile would be propitious as development of 
double-resistant parasites is improbable (Griensven et al., 2010). Another advantage would be 
short half-life and a rapid elimination phase, as selection of resistant strains is more probable to 
occur when parasites are exposed to subtherapeutic concentrations of the drugs (Stepniewska & 
White, 2008).  
There are clear cut differences in the exploration of combination therapy in human and 
veterinary medicine. The information on the combined use of effective antileishmanial drugs on 
humans or even in preclinical studies is very scarce although there is a growing number in the 
last years (e.g. Seifert & Croft, 2006; Serrano-Martín et al., 2009; Seifert, 2011). On the 
contrary, in the veterinary arena this strategy has been traditionally used for the treatment of 
CanL as a relatively successful and safe chemotherapeutic approach (e.g. Oliva et al., 2010; 
Solano-Gallego et al., 2011). However, drugs combined, dosage and schedules were generally 
based on empirical observation and not on the knowledge of the drug-drug-host interaction. A 
more thorough development would need a deep understanding on the actual behaviour of the 
drugs combined (e.g. mechanism of action, pharmacokinetics).  
Generally speaking drugs in combination can exert effects greater than, equal to, or less than 
the sum of their individual potencies. Relationships between molecules are therefore classified 
as synergistic, additive or antagonistic. The classic approach to study the nature of the drug-
drug interaction is the "chequerboard" approximation, in which two serial dilutions of the test 
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compounds are used to calculate the fractional inhibitory concentration (FIC) index. This 
parameter will quantify if the effect of combination is synergistic (i.e. FIC ˃ 1) or antagonistic 
(i.e. FIC˂ 1). However, this straightforward and popular method is prone to reproducibility 
errors thus leading to contradictory conclusions (Odds, 2003). To overcome the limitations of 
the chequerboard approaches some models of interaction have been developed (Tallarida, 
2006). Among them, a modified three-dimensional analytical method to characterize drug-drug 
interactions, developed by Prichard et al. (1993), and the combination index (CI) method 
developed by Chou & Talalay (1984). This method is based on the multiple drug effect equation 
derived from the median-effect principle and the mass action law and allows the quantification 
of synergism among other parameters (Chou, 2010). The fine understanding of the interaction 
between drugs administered simultaneously to an infected host would allow the establishment 
of more accurate dosage and schedules. 
 
 
Table 3. Clinical trials on combination therapy for VL (Griensven et al., 2010).  
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Data available from recent human drug combinatory clinical trials are encouraging. Several 
phase II trials have identified combined therapeutic regimens that have resulted efficacious, 
well-tolerated, safe and of shorter duration than those of the equivalent monotherapy regimens. 
Table 3 resumes the completed and on-going studies (in 2010) on combination therapy for VL 
in East Africa and India. Irrational use of antimonials has probably led to the appearance of 
resistance and unresponsiveness particularly in Bihar, India (Croft et al., 2006). Caution should 
be taken as in vitro resistance to drug combinations has been already reported in L.donovani 
promastigotes (García-Hernández et al., 2012). Therefore, in the absence of alternative 
compounds, close and effective monitoring and regulatory policies are essential to avoid misuse 
and guarantee proper implementation of the regimens.  
 
1.7.5.2. Drug Delivery Systems (DDS) 
Drug delivery systems (DDS) were designed to provide an alternative mean of administering 
single or combined compounds -old and new drugs- enhancing drug efficacy while minimizing 
side effects. DDS are therefore used to improve drug solubility; modify ADMET (absorption, 
distribution, metabolism, excretion and toxicity) profile (e.g. improved absorption, increased 
residency time); enhance target localization in cells (e.g. macrophages) or tissues; prevent 
degradation in biological fluids (e.g. gastric degradation) allowing the exploration of new 
administration routes; and reduce toxicity-related adverse effects. Different DDS systems 
developed for the treatment of VL have been recently reviewed elsewhere (Pham et al., 2013). 
Liposomes and nanoparticles are suitable carriers for VL chemotherapeutic agents as these 
particles are phagocytised by Leishmania host cells in target organs (liver and spleen). Figure 19 
illustrates a schematic representation of different DDS.  
The DDS more extensively used in the treatment of VL is Liposomal-amphotericin B (i.e. L-
AmB, AmBisome®) (Sundar & Chakravarty, 2013). As described in previously in this review 
(see AmB section) other lipid based DDS have been used for AmB release. Liposomal-
encapsulated antimonials have also been developed (Alving et al., 1978; Schettini et al., 2005). 
Liposomes were developed by Bangham in 1985 and commercialized for the first time in 1986 
as the liposomal-anti-aging product Capture (Dior) (Müller et al., 2000). They are vesicles 
formed from one or more phospholipid bilayers with an internal aqueous core. Liposomal-based 
formulations have been reported to prolong in vivo the circulation time of the drug, therefore, 
modifying its toxicity and distribution. Liposomes are readily internalized by cells of 
mononuclear phagocytic system (MPS) and this is a clear advantage in the treatment of 
intracellular parasites as Leishmania. Moreover, liposomal surface can be modified to improve 
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macrophage uptake (e.g. mannosilated, fucosylated or phosphatidylserine-coated liposomes) 
(Reimão et al., 2012; Pham et al., 2013). Among limitations it has been indicated the high price 
and toxicity of liposomes, linked to leakage of free drug during administration (Berman, 1997), 
or the possibility of development of accumulation-related side-effects due to prolonged 
concentration of drugs in the liver (Alving, 1983).  
Niosomes as carriers are a good alternative to liposomes. Niosomes are vesicles, similar to 
the latter, composed of non-ionic surfactants and cholesterol, which are cheaper, biodegradable, 
relatively nontoxic, and chemically more stable, therefore, offering a better drug retention. They 
may also release the drugs in a controlled manner (Kazi et al., 2010). Biodegradable polymeric 
nanoparticles (NPs) were developed in the 1970s (Pham et al., 2013). They are more stable than 
liposomes and also offer controlled release properties, can target different organs/tissues and are 
also used in DNA gene therapy. 
 
Figure 19.   Schematic illustration of different drug delivery systems (DDS) (not to scale). Image from Pham et al., 
2013. 
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Moreover, NPs are rapidly internalized by macrophages. NPs (100-1000 nm) can be 
classified into nanospheres or nanocapsules. Different hydrophobic polymers have been used 
for NPs synthesis [e.g. poly (lactic acid), PLA; poly (glycolic acid), PGA; poly (lactide-co-
glycolide), PLGA; poly (cyanocrylate); polyalkylcyanocrylates, PACA] (Soppimath et al., 
2001). Second-generation NPs -included NPs based on chitosan, gelatin, sodium alginate, 
hydrophilic biodegradable polymers- try to slow down macrophage uptake and act as carriers to 
other tissues (e.g. poly (ethylene glycol), PGE; polys(ε-caprolactone)s (Pham et al., 2013). 
Müller et al. (2000) highlighted that the number of marketed NPs containing products is scarce 
mainly due to cytotoxic effects of polymers and the lack of suitable massive scale production. 
Solid lipid NPs, introduced in the 1990s, are a secure alternative to classic NPs and large scale 
production is feasible making them attractive carriers (Müller et al., 2000). This DDS as other 
lipid-based carriers are rapidly cleared from plasma to liver and spleen yet their use has not been 
deeply explored in the treatment of parasitic diseases (Pham et al., 2013). Encouraging results 
were obtained with AmB (Lemke et al., 2005). Critical reviews on the use of DDS against 
Leishmania have been published by Romero & Morilla (2008) and Pham et al. (2013), the latter 
particularly focused on the development of oral drugs.  
 
1.7.5.3. New Drugs 
No ideal drug to control leishmaniasis, human or canine, is presently available. Many of the 
drugs currently used against leishmaniasis are expensive and toxic, and the treatments of choice 
are losing their effectiveness due to the emergence of resistance (Handman et al., 2008). As 
previously stated the geographical distribution of leishmaniasis has not been reduced and even 
re-emergence phenomena related to human migrations (e.g. wars, famine) and bioclimatic 
changes have been described. Therefore the need for new antileishmanial drugs still is a 
challenge for the industrial sector and the academia.  
By both scientific and economic reasons drug discovery processes quickly integrated the 
advances from biomedical sciences, particularly molecular biology, and engineering. It was 
assumed that the use of the powerful techniques developed would reduce costs and the time 
invested to obtain safer drugs, affordable and in a shorter discovery time-line (Koehn & Carter, 
2005) besides providing a rational approach to drug discovery. After the realization that the vast 
majority  of  drug  targets  are  proteins, molecular biology exerted a profound influence on drug  
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discovery, through parasite gene cloning and expression, identification of differential genes of 
hosts and parasites, identification of new targets and the search for small “druggable” molecules 
(Handman et al., 2008). Moreover, these available tools would fit the discrete and iterative 
process prevailing in drug discovery and could be easily adapted, through robotics, to the 
molecular target identification and validation by High Throughput Screening (HTS) (Figure 20). 
It has been assumed that this process together with the criteria for suitable anti-parasite hits, 
leads and drug candidates (Table 4) would offer adequate tools for development of new drugs 
(Pink et al., 2005). 
 
 
Figure 20. Drug discovery process and main stages. Identification and validation of molecular targets. If the target is 
unknown, compounds are tested for activity against the whole parasite. Molecules (actual or potential inhibitors) are 
screened in target or cell-based assays. Hits are defined as compounds that have shown activity against the whole 
parasite and that can be considered for further in vivo testing in animal models. Analyses of the pharmacokinetic and 
pharmacodynamic (PK/PD) properties of the molecule are also initiated at this stage. Compounds that have shown in 
vivo activity without overt toxicity and that have been considered "druggable" are defined as leads. Leads often need 
optimization of efficacy and ADME properties and re-evaluation of toxicity (thick arrows: lead optimization). Once a 
compound reaches the stage for testing in humans is defined as a drug candidate. From now on the drug candidate 
enters in preclinical and clinical studies following the typical drug development pathway. From Pink et al., 2005.    
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HTS allows analysis of massive compound libraries in a short period of time. Its 
combination with the availability of newly synthesized compounds by combinatorial chemistry 
put on the bench millions of molecules to be screened. The high attrition rate of this non-
directed screening could be reduced by selecting focused compound collections (e.g. 
compounds with defined activity against related parasites or biochemical activity against 
enzymes or receptors known as molecular targets of the parasite) or computational filtering 
strategies [e.g. favourable ADME (absorption, distribution, metabolism, and excretion) 
predictions, biochemical profile of the molecule] (Handman et al., 2008).  
Structure-based drug discovery has impressively progressed in the last decade. Availability 
of 3D structure, in theory, should facilitate in silico virtual screens and compound docking, 
predicting structure activity relationships (SARs) and, therefore, enabling the search or 
synthesis of the adequate molecule or analogues. While many suitable "drug-like" (i.e. sharing 
certain characteristics that act as drugs like shape, size, solubility) molecules are produced, 
synthetic chemical compounds sometimes generate compounds likely to be toxic, unstable, 
highly reactive or mutagenic (Pink et al., 2005).  
Despite the intellectually appealing nature of these approaches the success rate has been 
modest. The extraordinary advances in our knowledge of the basic biology of Kinetoplastida, 
particularly in Leishmania (e.g. genomic, proteomic, metabolomics), use of bioinformatics and 
in silico design have not yet resulted in the development of new antileishmanial drugs. 
Steverding (2010), in a critical review on the historical development of chemotherapy against 
infections by Trypanosoma brucei, concluded that the rational design of drugs against this 
disease had only produced a single compound, eflornithine (α-difluoromethyl ornithine, 
DFMO), in fact developed as antiproliferative for human cancer. 
It is expected that refinement of selection criteria of screened libraries, the increasing 
knowledge of drug-target interaction and the growing industry-academia collaborative efforts 
would render this synthetic chemically-based approach a useful system to identify new 
potentially effective drugs. Nevertheless, up to now the control of leishmaniasis still relies on 
“old” drugs and presently no new drugs are foreseen commercially available at the moment. 
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Table 4. Criteria for anti-parasite hits, leads and drug candidates (Pink et al., 2005). 
HIT 
Start of a screening campaign 
• Active in vitro against protozoa IC50 ≤ 1µg/mL* (nM- low μM range)* 
• Selective (minimum of ten times more active against parasite than against mammalian 
cells) 
LEAD 
Start of a screening campaign 
• Active in vivo against parasites ≤ 100 mg/Kg* 
• Not overtly toxic in animals at the efficacious dose 
• Active in vitro against relevant parasite types (e.g. drug-resistant parasites) 
• Chemically tractable (analogues can be obtained) 
 
Candidate for lead optimization: more stringent criteria of selection 
• Active in vitro with activity similar to that of existing drugs 
• Active in vivo against parasites in the relevant animal model (e.g. chronic or late-stage 
disease) when delivered by a relevant route (oral is preferred) in an acceptable 
formulation at a reasonable dose (˂˂ 100 mg/Kg)* 
• Good selectivity against several mammalian cell lines 
DRUG DEVELOPMENT CANDIDATE 
After succeeding lead optimization process compound that seems also to fulfil other essential 
criteria  
• Activity in vivo comparable or exceeding that of standard drugs in the most relevant 
animal models 
• Activity against desired range of parasites (e.g. different spp, drug-resistant strains) 
• Pass early toxicity/mutagenicity (e.g. Ames Test) criteria 
• Acceptable metabolic profile in vitro and in vivo  
• Acceptable pharmacokinetic profile 
• Amenable to cost-effective scale-up 
• Preferably: well understood mode of action 
CLINICAL DEVELOPMENT CANDIDATE 
• Drug development candidate for which additional criteria have been met in studies of 
detailed pharmacology, pharmacokinetics/absorption, distribution, metabolism and 
excretion, mutagenicity and toxicity, formulation, scale-up for production, cost of goods 
 
*Values may vary depending on parasite, assay and compound. 
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1.7.5.3.1. New drugs from natural origin 
Historically, natural products from different origins (e.g. plants, marine organisms), have 
been an importance source of new therapeutic agents and are the basis of traditional medicine in 
the past and also, presently, in large areas where human leishmaniasis is endemic. The 
investigation of natural products for novel therapeutics peaked in the pharmaceutical industry 
between 1970-1980 this leading to the fact that between 1981 and 2002 the 49% of the new 
chemical entities (NCEs) introduced in the market were natural products, semi-synthetic natural 
products analogues or synthetic compounds based on natural products (Koehn & Carter, 2005). 
Despite this success during the past decades the research carried out by the industry on these 
molecules has dropped (Newman, 2008; Li & Vederas, 2009). Several reasons could account 
for this lack of interest, including the complex molecular interactions in natural sources, 
difficult integration of these mixtures in HTS and concerns about the proprietary rights on the 
identified molecules. Figure 21 illustrates the long process for natural product drug discovery 
and the generic scheme for bioassay-guided fractionation required when working with crude 
extracts to obtain a pure compound.  
Nonetheless, the important contribution of drugs from natural sources is still true in the post 
HTS and post-genomic era (Harvey, 2008) since between 2005 and 2007 thirteen natural 
product-derived drugs were approved by the Food and Drug Administration (FDA) and five of 
them were the first members of new classes (Li & Vederas, 2009). Moreover, in the period 
1981-2006, only one NCE obtained by de novo combinatorial chemistry, the kinase inhibitor 
sorafenib for renal carcinoma, got the approval of FDA (Newman, 2008). This low productivity 
output of the so-called “HTS-Combichem” strategy has put under scrutiny the R&D orientation 
of pharmaceutical companies. Rather than stressing the differences (e.g. time length of drug 
development, labour investment, efficacy and efficiency) between both approaches, synthetic 
chemistry versus natural source molecules, a more eclectic strategy should be followed by 
combining their strengths and minimizing the weaknesses.  
The major bottleneck in natural product drug discovery still is the fractionation and 
purification of active molecules from a complex matrix. Today, difficulties inherent to the 
analysis of complex mixtures of natural origin have been lessened by the availability of 
powerful techniques (Figure 21b) (e.g. Mass spectrometry and Nuclear Magnetic Resonance, 
Ion Cyclotron Resonance Mass Spectrometry, Frontal Affinity Chromatography) and natural-
product databases (Koehn & Carter, 2005; Newman, 2008; Li & Verderas, 2009). Another 
difficulty inherent to this drug discovery approach is that often active principles represent ca. 
1% of the total extract; thus, yielding enough quantity of pure compound is a challenge, 
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particularly when the source are marine organisms (Koehn & Carter, 2005). Complementation 
of HTS, in silico design and bioguiding will enhance the efficiency of drug discovery using 
natural products and molecules displaying activity against Leishmania (Tiuman et al., 2011; 
Schmidt et al., 2012a, 2012b; Singh et al., 2014). 
 
 
 
Figure 21. Chemical process of natural product drug discovery and bioguided fractionation scheme for purifying 
compounds from crude extracts. (A and B) A crude extract from the natural source is obtained, concentrated, 
fractioned and purified ideally yielding a single biologically active pure compound. This process (B) requires several 
cycles of fractionation to finally obtain a pure compound. When the pure active compound satisfies selectivity and 
potency requirements, (A) SAR (structure-activity relationship) studies are carried out and the purification process is 
scaled up. Once the feasibility of modulating biological response through synthetic modification is established, the hit 
is declared a lead and proceeds to the lead optimization process by traditional medicinal chemistry. *HPLC, high-
performance liquid chromatography; HP20, a solid phase adsorber; NMR, nuclear magnetic resonance; LC/MS, 
liquid chromatography/mass spectrometry; UV, ultraviolet; IR, infrared spectroscopy. From Koehn & Carter, 2005. 
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1.7.5.3.2. Allicin 
Garlic (Allium sativum), among other plants of the Family Alliaceae, is a rich source of 
organosulfur compounds (1-3%). Historically it has been used as a traditional remedy against 
parasites, fungi, bacteria and viruses (Ankri & Mirelman, 1999; Corzo-Martínez et al., 2007). 
Nevertheless, even though organosulfur compounds had been proposed as the active 
components of crushed garlic cloves (Augusti & Mathew, 1974), it was not until 1944 that 
Cavallito et al. isolated and identified the constituent responsible for the antibacterial activity of 
garlic: allicin.   
The chemistry of garlic is complex and it appears to have been originally developed as a 
potential defence against microorganisms. In intact cloves cysteine-sulfoxides, mainly alliin, is 
enclosed in a separated compartment from alliinase. When a garlic clove is crushed, chopped or 
suffers any other external aggression (e.g. fungal or bacterial invasion), enzyme and substrate 
get into contact. Alliinase catalyses the conversion of alliin into the biologically active allicin, 
that is subsequently transformed into other volatile thiosulphinates. Thiosulphinates are 
responsible for the characteristic odour of garlic which is absent in intact cloves (Ankri & 
Mirelman, 1999). Allicin is extremely reactive and has a short half-life rapidly decomposing 
into other active organosulphur compounds as DAS (diallyl sulfides), DADS (diallyl disulfides), 
DATS (diallyl tri- and tetrasulfides), ajoene and vinyldithiines (Figure 22).   
The absorption and metabolism of allicin and related compounds are poorly understood 
(Lawson & Wang, 2005). Moreover, although allicin has been proven active in vivo, it is 
unknown if allicin or another derived metabolite is actually reaching the target organs. Allicin 
has never been detected in blood, urine, or stool suggesting its rapid metabolism (Lawson, 
1998). Allyl methyl sulphide detection in the breath has been proposed as a potential indicator 
of its bioavailability (Lawson & Wang, 2005). Radiolabelled studies performed in rats after oral 
administration of the closely related molecule DADS revealed that they were absorbed and 
transformed into allyl mercaptan, allyl methyl sulphide, allyl methyl sulphoxide and allyl 
methyl sulphone as these metabolites could be detected in stomach, plasma, urine and liver 
(Germain et al., 2002).  
 
 Allicin (diallyl thiosulfinate = 2-Propene-1-sulfinothioic acid S-2-propenyl ester) has shown 
antibacterial activity against different bacteria including Helicobacter pylori (O’Gara et al. 
2000; Cañizares et al. 2004) and methicillin-resistant Staphylococcus aureus (MRSA) (Cutler & 
Wilson, 2004) besides a full range of medicinal and antimicrobial effects (Lawson 1998; Ankri 
and Mirelman 1999). Some reports on the antifungal (Candida, Aspergillus) (Shadkchan et al., 
2004; Khodavandi et al. 2011) properties in vitro and in vivo of this molecule have been 
Literature review: chemotherapy of leishmaniasis │74 
 
Antileishmanial activity of Allicin: mechanism of action, in vivo efficacy and value in combined therapy with amphotericin B │ María Jesús Corral 
published. The antiproliferative effect of allicin has been also shown in Entamoeba (Ankri et al., 
1997), Plasmodium (Coppi et al., 2006) and Trypanosoma (Waag et al. 2010). McClure et al. 
(1996) observed that allicin, besides other garlic extracts, was effective against the in vitro 
growth of L. mexicana and L.chagasi promastigotes but no further testing was carried out. In 
spite of the recognised therapeutic value of garlic and garlic extracts, research was hampered by 
the instability of allicin and the rapid transformation of the molecule to related compounds (e.g. 
ajoene, vinyldithiins) this precluding more refined experimentation. The recent availability of a 
stable allicin preparation would allow the exploration of the antileishmanial effect of this low 
molecular weight compound.  
 
 
 
 
Figure 22. Proposed metabolism of allicin. From Corzo-Martínez et al., 2007. 
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1.8. Objectives  
 
On the grounds of the above reviewed state of the art in the chemotherapy of leishmaniasis 
our research project had the following objectives: 
 
i. Setting a reliable and affordable phenotypic platform for discrete screening of putative 
antileishmanial drugs in vitro and ex vivo by improving the quantification method in 
promastigotes and the intramacrophage infection rates of Leishmania infantum 
amastigotes. 
 
 
ii. Evaluation of the potential antileishmanial effect of allicin on promastigotes and 
amastigotes of Leishmania. 
 
 
iii. Exploration of the potential synergy of micromolar allicin and Amphotericin B (AmB), 
in vitro and ex vivo, on the inhibition of Leishmania proliferation. 
 
 
iv. Efficacy of allicin and its combination with AmB in the control of experimental visceral 
leishmaniasis in hamster by L.infantum. 
 
 
v. Determination of the mechanism of action of allicin involved in the inhibition of the 
multiplication of Leishmania. 
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CHAPTER 2 
 
Improvement of 96-well microplate assay for 
estimation of cell growth and inhibition of 
Leishmania with Alamar Blue 
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2.1.a. Resumen  
Mejora de método Alamar Blue 96 pocillos para la determinación de la multiplicación e 
inhibición de Leishmania  
En este capítulo se examina el valor del indicador redox Alamar Blue, método basado en la 
reducción de resazurina, en la determinación de la proliferación celular de promastigotes de 
Leishmania en placas de 96 pocillos. Además, el ensayo fue comprobado con anfotericina B 
(AmB) y alicina. El método fue ensayado en promastigotes de L.infantum y L.donovani 
empleando distintas condiciones de cultivo (fase aérea variable, presencia de rojo fenol, 
distintas densidad celular inicial, diferentes tiempo de incubación, tamponado con Hepes). Los 
resultados demostraron que la fase gaseosa en la que se cultivaban los promastigotes era un 
factor crítico. Los mejores resultados se obtuvieron con concentraciones iniciales del inóculo de 
2,5 x 105 promastigotes/pocillo, un periodo de incubación de hasta 72 h y presencia de una 
atmósfera de 5% CO2 o reducción de la fase gaseosa disponible (bolsas plásticas selladas, placas 
con film adhesivo). La fluorometría resultó más sensible que la espectrofotometría y permitió 
detectar densidades celulares menores en los cultivos. El tamponado del medio de cultivo con 
20 mM Hepes mejoró de forma notable los resultados. Los recuentos de promastigotes de ambas 
especies de Leishmania se correlacionaron con los valores de intensidad de fluorescencia. Los 
valores de la concentración inhibitoria (CI50) de AmB y alicina determinados mediante 
recuentos celulares en cámara de Neubauer y fluorometría fueron comparables. Este indicador 
resulta sencillo, puesto que implica un solo paso, su precio es económico y permite su uso en la 
determinación de la sensibilidad diferencial a fármacos de distintos aislados o especies de 
Leishmania en un formato de 96 pocillos.  
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2.1.b. Abstract 
The value of resazurin-based Alamar Blue redox indicator to determine multiplication of 
Leishmania promastigotes in 96-well microtiter plates was examined. In addition, assay was 
validated with amphotericin B (AmB) and allicin. The method was tested on L.donovani and 
L.infantum promastigotes under different culture conditions (variable air-phase, presence of 
phenol red, initial cell density, incubation time, use of Hepes buffer). Results showed that the 
gas-phase of promastigote cultures was critical. The method yielded consistent results with 
initial plating cell densities of 2.5 x 105 promastigotes/well, up to 72 h incubation and 5% CO2 
atmosphere or reduced air availability (sealed plastic bags, film-sealed microplates). Detection 
of low numbers of promastigotes and earlier results could be obtained using fluorimetry instead 
of spectrophotometry. The addition of 20 mM Hepes improved the results. Fluorescence 
intensity correlated to promastigotes number in both Leishmania spp.  Inhibitory concentration 
(IC50) values for AmB and allicin using cell counting and fluorimetry were comparable. Under 
these conditions this one-step, low-cost redox indicator can be used in drug sensitivity assays 
and studies of differential proliferation rates of Leishmania isolates or strains in a 96-well 
format. 
 
Graphical Abstract 
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2.2. Introduction 
Visceral leishmaniasis is a parasitic disease caused by Leishmania donovani and L. infantum 
(= L.chagasi) (Kinetoplastida). The infection affects both humans and dogs in large areas of the 
world (i.e. India, Mediterranean Basin, and South America) and it is fatal unless treated. Current 
first-line chemotherapy of leishmaniasis relies on a rather limited arsenal of drugs, most of 
which have serious side-effects including nephro- and hepatotoxicity and teratogenicity. 
Therefore, the identification of new molecules or formulations is an urgent need and has been 
recognised by WHO as one of the research areas where a sustained effort has to be made (Alvar 
et al., 2006).  
It is assumed that in vivo models have superior predictive value than in vitro models, and that 
screening using intracellular amastigotes are more convenient than axenic amastigotes and 
promastigotes (Sereno et al., 2007; Vermeersch et al., 2009; De Muylder et al., 2011; Gupta and 
Shakya, 201). In spite of the limitations the promastigote stage is currently used and screening 
with this parasitic stage has been exploited as a first-step to identify “hit” and “lead” anti-
leishmanial compounds in undirected massive screening [High Throughput Screening (HTS)] of 
chemical libraries (Sharlow et al., 2009; Siqueira-Neto et al., 2010; Walker et al., 2011).  
There are several in vitro systems available to determine promastigotes proliferation of 
Leishmania spp (i.e. reporter gene assays, enzymatic determinations, H3 -thymidine 
incorporation, colorimetric methods). Among colorimetric methods, resazurin-based Alamar 
Blue entails several advantages. First, it is simple to use as it requires only a one-step procedure. 
Other benefits reported are its low cost, environmentally friendly composition and 
transferability to field sites if necessary (Räz et al., 1997). Unlike other assays, this redox 
indicator is relatively non-toxic to cells and can be used with long incubation periods (up to 72 
h) (Fumarola et al., 2004). This indicator has been extensively used in the related genus 
Trypanosoma (Räz et al., 1997; Rolón et al., 2006; Sykes and Avery, 2009) and in some 
Leishmania spp (Mikus and Steverding, 2000; de Oliveira-Silva et al., 2008; Shimony and Jaffe, 
2008; Kulshrestha et al., 2013). Recently, this method has been adapted using HTS with 
Leishmania and two different platforms and a 384-well format (Sharlow et al., 2009; Siqueira-
Neto et al., 2010). 
Our laboratory has been engaged on the study of the anti-leishmanial antiproliferative effect 
of different molecules. While Alamar Blue could be easily employed to determine the 
cytotoxicity for the murine cell line J774 (Wert et al., 2011), results obtained with Leishmania 
promastigotes were inconsistent, since resazurin reduction did not correlate with cell counts. 
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Given the lack of experimental details given in the available literature dealing with 
Leishmania, our aim was to examine the value of Alamar Blue to determine the multiplication 
and growth inhibition of L. donovani and L. infantum promastigotes under different culture 
conditions (variable air-phase, cell density and incubation time). Results showed that optimal 
conditions of Alamar Blue assay with promastigotes in 96-well microtiter plates included a 5% 
CO2 atmosphere, the presence on 20 mM Hepes in the culture medium and an initial 
concentration of promastigotes of ca. 2.5 x 105 /mL. With these conditions, reduced resazurin 
(resorufin) measured by fluorimetry provided an accurate estimation of promastigotes 
multiplication and could be used for drug screening and IC50 estimation. 
 
2.3. Material and methods 
 
Parasites 
An autochthonous isolate of L. infantum (UCM 9), obtained from affected dogs in the area of 
Madrid (Spain) by the Clinical Service of the Department of Animal Health, Faculty of 
Veterinary Medicine (Universidad Complutense), and Khartoum 1246 isolate from L. donovani, 
provided by Dr. Toraño (Department of Immunology, Instituto de Salud Carlos III, Madrid) 
were routinely maintained as promastigotes in RPMI 1640 medium (Lonza) at 26 °C 
supplemented with heat inactivated (30 min, 56 °C) foetal bovine serum (FBS) (Sera 
Laboratories International) and 100 U/ml penicillin + 100 μg/ml streptomycin (BioWhittaker) in 
25 ml culture flasks.  
 
Chemicals 
Alamar Blue was purchased from AbD Serotec. Allicin (2-Propene-1-sulfinothioic acid S-2-
propenyl ester) was obtained as liquid Allisure® from Allicin International Ltd (Rye, East 
Sussex, UK) at a concentration of 5000 ppm and kept at a temperature of -80˚C until used. 
Amphotericin B (AmB) was obtained as fungizone (Sigma). 
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Promastigote assays 
Depending on the experiment promastigotes were cultured in flat-bottomed 96-well cell 
culture microtiter plates with lid (Costar, Corning), in microtiter plates wrapped with 
Parafilm®, or in plates sealed with Thermal adhesive film for PCR plates (Simport). For 
comparative purposes promastigote cultures were also done in 1.5 mL eppendorf® tubes. 
Cultures were carried out at 26 ºC in aerated culture chamber or incubated in a 95% air/5% CO2 
humidified atmosphere. Culture media (RPMI 1640) with and without additional 20 mM Hepes 
were employed depending on the experiment.  
 
Alamar Blue assay 
Concentration of resorufin, the product of reduction of resazurin, in the Leishmania cultures 
was determined following the manufacturer’s recommendations by reading the absorbance (A) 
at 570 and 600 nm, and fluorescence (550 nm  excitation wavelength, 590 nm  emission 
wavelength) in a FLUOstar Omega (BMG Labtech) fluorimeter. Fluorescence intensity was 
expressed as arbitrary units (A.U.). Briefly, mid-log phase promastigotes were added to the 
wells of microtiter plates or eppendorf tubes up to a volume of 200 µL/well. After 24 h, 20 µL 
Alamar Blue (10% v/v) was added and the cultures were kept for 24, 48 or 72 additional hours. 
Absorbance and fluorescence intensity were determined every 24 h. Promastigote counts were 
carried out in Neubauer improved chambers and cell viability was assessed by trypan blue 
exclusion staining. Untreated cultures, wells without cells and the maximal concentration of the 
drugs, and wells with culture medium and Alamar Blue (10% v/v) were included as controls. 
All experiments were performed at least in triplicate. 
 
Statistical analysis 
Results were expressed as means ± standard deviation. Data were compared by analysis of 
variance (one- and two-ways ANOVA) and GLM analysis using GraphPad Prism5. Differences 
were considered significant when p<0.05. Figures were also prepared with GraphPad Prism5.  
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2.4. Results 
Determination of optimal cell density 
Different concentrations (104, 2.5 x104, 5 x104, 7.5 x 104, 105, 2.5 x105, 5 x105, 7.5 x 105, 
106) of mid-log phase promastigotes of L.donovani and L.infantum were added in a final volume 
of 200 µL/well in 96-microtiter plates. Cultures were carried out at 26 ºC in plates with lid 
under a 5% CO2 atmosphere or in film-sealed plates. After 24 h incubation, Alamar Blue was 
added and the plates were kept for 24, 48 or 72 h. For each time determination a plate was used. 
Resazurin was effectively reduced to resorufin in the medium, evidenced by the higher levels of 
absorbance and, particularly, fluorescence related both to the initial promastigotes density and 
the time of culture. Absorbance determinations, especially with low initial promastigote 
concentration (<105 promastigotes/well) were more variable (not shown). This variability was 
not observed when cultures were kept in the CO2 atmosphere. Results were more consistent 
when resorufin concentration was determined by fluorimetry. Fluorescence was significantly 
higher (ca. 2 times) when cultures were exposed to 5% CO2 (Figure 1A) as compared to those 
performed in film-sealed plates (Figure 1B). Highest levels of fluorescence were obtained with 
initial inoculums of 2.5 to 5 x 105 promastigotes/well from both Leishmania species, after 72 h 
and exposition to CO2.  
 
 
 
 
 
 
 
 
Figure 1: Effect of incubation time with Alamar Blue on the fluorescence curves with promastigotes of L.donovani. 
Increasing initial plating concentrations of promastigotes were incubated with Alamar Blue (10% v/v) and the 
fluorescence intensity determined (arbitrary units, A.U.) (Excitation wavelength: 560 nm, emission wavelength: 590 
nm). Figure 1A: in the presence of 5% CO2. Figure 1B: film-sealed microplates. Results are means ± standard 
deviation. ●: 24 h; : 48 h and ▲: 72 h. Results are means ± standard deviations of 3 determinations. 
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Correlation between Alamar Blue reduction and promastigotes multiplication 
Preliminary results obtained in our laboratory allowed the use of the redox indicator to 
determine the proliferation of Leishmania promastigotes in culture tubes. However, as shown 
above, for a given initial number of promastigotes and time of incubation, significant 
differences (p<0.05) were found in the concentration of resorufin estimated by absorbance and, 
particularly, fluorimetry depending on the exposition to CO2 or to a limited air phase in the 
sealed microtiter plates. To rule out the possibility of resazurin reduction being an inaccurate 
estimation of Leishmania multiplication, promastigotes (2.5 x 105 /well) were cultured in 96-
well plates under a CO2 atmosphere or under air phase. For comparative purposes parallel 
cultures were done in eppendorf tubes. In all cases cell multiplication was estimated by 
fluorimetry and cell counting of viable Leishmania in Neubauer chamber. A set of cultures was 
employed for each time determination (24, 48, 72 and 96 h).  
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Figure 2A: Proliferation of Leishmania 
promastigotes under different culture 
conditions [White bars: CO2  atmosphere; 
grey bars: aerated cultures; solid bars: 
eppendorf tubes].  Promastigotes were 
seeded (2.5 x 105 promastigotes/well) on day 
0. Alamar Blue was added 24 h later. 
Results are means ± standard deviations of 
3 determinations. 
Figure 2B: Relationship between 
fluorescence intensity (A.U.) and 
promastigote counts at different times and 
culture conditions, ○: 5% CO2 atmopshere; 
●: aerated microplates; ▲: eppendorf tubes. 
Results are means ± standard deviations of 
3 determinations.  
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Figure 2 shows that no significant differences (p>0.05) were found between cultures in the 
experiment irrespective of the exposition to 5% CO2 or to an unlimited air phase. After 96 h, all 
cultures reached values ca. 2.7 x 106 promastigotes/mL in both Leishmania spp (Figure 2A). 
However, resazurin concentration determined by fluorimetry was strongly dependent on the 
culture conditions (Figure 2B). Highest levels of fluorescence were seen in cultures exposed to 
CO2 and the lowest values were present using standard culture conditions with air atmosphere. 
Cultures in eppendorf tubes, with a limited amount of air, displayed intermediate values. These 
results were consistent with the absence of colour change in the standard microtiter plates in 
spite of the active multiplication. These results suggested the importance of the air phase of the 
cultures in the usefulness of Alamar Blue method to determine Leishmania proliferation and 
also the need of standardization of the assay.  
 
Effect of atmosphere and buffer on resazurin reduction by promastigotes of 
Leishmania 
Promastigotes of L.infantum and L.donovani were cultured in 96-well standard microtiter 
plates exposed to 5% CO2, in standard microplates, in microplates wrapped with Parafilm, in 
microplates in sealed plastic bags or film-sealed microplates for PCR. Moreover parallel 
cultures were done in eppendorf tubes to monitor cell viability (trypan Blue exclusion dye) and 
multiplication (counting in Neubauer chamber). Cultures with standard RPMI medium and 
medium with 20 mM Hepes were employed. Absorbance and fluorescence were determined 24, 
48 and 72 h after Alamar Blue addition.  
As expected time-dependent fluorescence increases were observed in all culture conditions 
and both Leishmania species earlier than absorbance variations (not shown) in the 
determinations carried out. Figure 3 shows the results obtained with L. infantum and similar 
values were obtained for L.donovani.  
It was found that the presence of 5% CO2 or limited air availability was critical to get the 
highest fluorescence values. Microplates with lid exposed to air had the lowest levels, 
comparable to those found in Parafilm wrapped plates. By its part, 96-well plates cultured in a 
CO2 incubator displayed the highest resorufin concentrations in all time determinations carried 
out. In cultures done in eppendorf tubes, film-sealed microplates and plastic-sealed microplates 
intermediate values of absorbance and intensity of fluorescence were obtained. Moreover, the 
presence of additional 20 mM Hepes improved the resazurin reduction in all culture conditions, 
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particularly when film-sealed microtiter plates and eppendorf tubes were employed (p<0.01- 
p<0.001). 
 
 
 
Value of resazurin reduction measured by fluorimetry for drug screening in 
Leishmania  
Value of resazurin transformation by fluorimetry for drug screening in 96-well microtiter 
plates was tested with two compounds with antileishmanial activity, namely allicin and AmB. In 
all cases 2.5 x 105 promastigotes/well for both species were used. In the case of allicin, 10, 30, 
60 and 120 µM concentrations were used and microplates in CO2 or aerated incubator, and with 
and without additional 20 mM Hepes in the medium, were used. Parallel counts were done in 
Neubauer haemocytometer with cultures in eppendorf tubes exposed to the same allicin 
concentrations.  
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promastigote cultures of L.donovani with 
additional buffer (20 mM Hepes) at different 
times of incubation. All cultures except □ were 
carried out in 96-well microplates. ●: 5% CO2  
atmosphere ;:aerated microplates; ▲: 
Parafilm wrapped plates; ○: plastic bag-sealed 
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Cultures were treated for 24 h with allicin and absorbance and fluorescence were monitored 
at 24, 48 and 72 h after exposure to the drug. A range of AmB (0, 0.001, 0.002, 0.003, 0.004, 
0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.5, 1 
and 10 µM) was tested with the optimal assay conditions  found (5% CO2 , 20 mM Hepes). 
Fluorescence and absorbance were measured 72 h after exposure to the antibiotic. 
Figure 4A shows the relationship between the allicin concentration and the growth inhibition 
of L.donovani promastigotes determined by cell counting and fluorescence of the cultures. 
Addition of 20 mM Hepes improved the detection of fluorescence in aerated microplates 
whereas no correlation between growth inhibition and resorufin levels in the cultures was 
observed without Hepes in this case. Our results clearly showed that Alamar Blue reduction 
closely correlated to microscopic cell counts and viability, in the allicin concentration range 
examined, provided that a 5% CO2 atmosphere and 20 mM Hepes were present  (Figure 4B). 
Comparable results were obtained for L.infantum. Inhibition of multiplication of Leishmania 
promastigotes in the presence of AmB confirmed the value of the resorufin level with 
fluorimetry using the assay conditions described in the screening and IC50 determination of this 
antileishmanial drug. Actually, for the particular L.infantum isolate employed, an approximate 
IC50 of 0.07µM was obtained by cell counting whereas using the best-fit values with 
fluorescence determinations the value obtained was 0.0618 µM (Figure 5). Figure 6 shows a 
representative result of the effect of CO2 and 20 mM Hepes on the reduction of resazurin. 
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Figure 4B: Best-fit representation of the 
effect of allicin on growth inhibition of 
L.donovani promastigotes, determined by 
fluorescence and cell countings. ▲: cell 
counts;  : 5% CO2  atmosphere and 20 mM 
Hepes; □ : 5% CO2  atmosphere; ●: aerated 
microplates and 20 mM Hepes; ○: aerated 
microplates. Results are means ± standard 
deviations of 3 experiments. 
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Figure 6: Representative image of L.infantum and L.donovani promastigote cultures exposed to different 
concentrations of allicin (0, 10, 30, 60 and 120 µM), with and without 20 mM Hepes, in the presence of 5% CO2 
atmosphere (B) or in air exposed 96-well microplates (A). Marginal wells were not used to avoid edge effect.  
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) Figure 5: Determination of IC50 of 
amphotericin B for L.donovani 
promastigotes using Alamar Blue reagent. 
Experimental conditions included an initial 
plating concentration of 2.5 x 105 
promastigotes/well, 5% CO2 atmosphere 
and 20 mM Hepes. Results are the means 
± standard deviations of 3 experiments. 
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2.5. Discussion 
Present results, with the optimal conditions described, show that Alamar Blue, and 
presumably other resazurin-based methods, is an accurate assay to determine the multiplication 
of Leishmania promastigotes and growth inhibition elicited by antileishmanial drugs. Assay 
conditions examined in a checkerboard manner showed that several factors were relevant to 
obtain consistent results, namely an initial plating density of promastigotes ca. 2.5 x 105, besides 
the presence of a 5% CO2 atmosphere and additional buffering of the medium with 20 mM 
Hepes. Our results on the optimal cell density were comparable to the findings by Mikus and 
Steverding (2000) with L.major and Shimony and Jaffe (2008) with L.donovani and support the 
lower reduction rate of Leishmania compared to T. cruzi epimastigotes (Rolón et al., 2006) and 
bloodstream trypanosomes (Räz et al., 1997). A linear fluorescence response was observed with 
lower plating densities of promastigotes and therefore the method could probably be used in 72 
h experiments in the range of 5 x 104 to 105 promastigotes/well. The plateau observed with 
higher cell densities and incubation times are probably related to the conversion of resorufin to 
colorless and non-fluorescent hydroresorufin (O’Brien et al., 2000). 
Alamar Blue method has been successfully employed to monitor the growth of mammalian 
cells (Ansar Ahmed et al., 1994; Nakayama et al., 1997; O’Brien et al., 2000; Sykes and Avery, 
2009). Most of the assays have been performed in a 95 % air / 5 % CO2  atmosphere, including 
those carried out in African trypanosomes (Räz et al., 1997; Sykes and Avery, 2009), or in 
plastic sealed bags (Martin et al., 2003). More than probably the performance of a redox 
indicator added to a culture medium would be affected by the gas-phase although this factor 
apparently has not been considered in the previous contributions on Leishmania (de Oliveira-
Silva et al., 2008; Shimony and Jaffe, 2008; Vermeersch et al., 2009; Kulshrestha et al., 2013) 
and T. cruzi epimastigotes (Rolón et al., 2006) using 96-well microtiter plates or, more recently 
with the HTS with 384-well format, using L.major (Siqueira-Neto et al., 2010). Our results 
showed that, using the 96-well plate format incubation in a 5 % CO2 gas phase yielded accurate 
results of cell growth and inhibition in Leishmania ( r2 = 0.9713). The carbon dioxide dissolved 
in the medium allowed the efficient reduction of resazurin to the fluorescent resorufin. Actually, 
O’Brien et al. (2000) highlighted the need of CO2 in the medium when reduction is occurring in 
order to capture electrons. In the absence of 5% CO2 additional buffering with Hepes could 
circumvent some of the limitations provided that a limited volume of gas phase was present 
(capped eppendorf tubes, film sealed plates, sealed plastic bags). Earlier and more sensitive 
estimation of resorufin was obtained by fluorimetry and thus should be preferred to 
spectrophotometry. The significantly higher sensitivity of fluorimetry allowed the earlier 
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identification of anti-leishmanial activity of allicin. Promastigote multiplication and inhibition 
could be easily detected by fluorescence after 48 h whereas observation of significant 
absorbance variations needed 72 h as observed by Mikus and Steverding (2000).  
Visceral leishmaniasis, both human and animal, caused by L.donovani and L.infantum 
(=L.chagasi) continues being a challenge for medical doctors and veterinary clinicians in many 
regions of the world. Available drugs have important shortcomings (nephrotoxicity, 
hepatotoxicity, gastrointestinal disturbances) and, moreover, in some areas Leishmania strains 
resistant to first line drugs have been described (Croft et al., 2006). Identification of new 
potentially effective drugs or preparations requires robust and reliable screening methods. In 
vivo tests of efficacy must be reduced at a minimum by both ethical and economic reasons and 
therefore in vitro screening of potentially useful compounds is the first step to identify “hits and 
leads”. Obviously, the best in vitro model to test antileishmanial activity of compounds is done 
on the intracellular amastigote within macrophages (Sereno et al., 2007). However, intracellular 
amastigotes screening is only available to some laboratories, species such as L. donovani, and 
specially L.infantum, have a slow rate of division (Gupta and Shakya, 2011) and some 
Leishmania isolates from clinical cases do not infect the macrophage cell lines employed. By its 
part, promastigotes are easy to culture and they share with amastigotes many metabolic 
pathways and thus some of the most commonly used antileishmanial agents, such as AmB or 
miltefosine, are effective against both parasite stages. Therefore, promastigote screening is 
useful (Sharlow et al., 2009) before testing in intracellular amastigotes, and in vivo, and can be 
employed to monitor susceptibility of clinical isolates to some drugs (i.e. Miltefosine, 
Kulshrestha et al., 2013). 
Among the available methods (3H-thymidine incorporation, microscopic counting, 
quantitative PCR, enzymatic and colorimetric methods) to determine proliferation of 
Leishmania promastigotes, resazurin-based assays such as Alamar Blue  can be carried out in a 
single step, are unaffected by the red phenol from the culture medium and have the advantage of 
low cost and negligible toxicity. Validation with L.donovani and L.infantum promastigotes 
showed that this method could be advantageously used in trials of cell proliferation and drug 
screening, including the determination of approximate IC50 values against promastigotes. 
Conditions described for Leishmania included the presence of 5% CO2, or reduced air 
availability, to allow the efficient reduction of resazurin to resorufin, in a promastigote-density 
related manner. The method was improved by fluorimetry although spectrophotometry could 
also be employed. Given the accuracy (fluorescence vs. promastigotes density), the low number 
of promastigotes needed and results obtained in the determination of IC50 for AmB and allicin as 
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compared to the results with microscopic counting (i.e. Corral-Caridad et al., 2012), this 96-well 
microplate could be adapted for a 384-well format. 
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CHAPTER 3 
 
Effect of allicin on promastigotes and 
intracellular amastigotes of Leishmania 
donovani and L.infantum 
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3.1.a. Resumen  
Efecto de alicina sobre promastigotes y amastigotes intracelulares de Leishmania donovani y 
L.infantum  
La actividad anti-Leishmania de alicina (dialil tiosulfinato) ha sido ensayada in vitro frente a 
promastigotes de Leishmania donovani y L.infantum. Asimismo, se han realizado infecciones 
intracelulares de Leishmania in vitro en macrófagos murinos de la línea celular J774 y ex vivo 
en macrófagos peritoneales de BALB/c empleando un método modificado para el aislamiento 
de promastigotes metacíclicos. El compuesto ha demostrado un efecto inhibitorio dosis y tiempo 
dependiente sobre la multiplicación de promastigotes de L.donovani y L.infantum. Por primera 
vez ha sido descrito el efecto inhibitorio de alicina sobre amastigotes intracelulares de 
Leishmania. El valor de la concentración inhibitoria (CI50) del compuesto obtenido por nosotros 
se encontró en la horquilla micromolar (10-30 µM) para ambas Leishmania spp. El efecto anti-
Leishmania de alicina no fue debido a la presencia de ajoeno como producto de su degradación 
como se confirmó mediante espectrometría de masas. La actividad de la molécula frente a 
promastigotes y amastigotes de Leishmania se incrementó cuando se administró en dosis 
repetidas cada 24 h. Dos administraciones consecutivas de 5 µM alicina lograron inhibir ca. 
50% la proliferación de amastigotes intracelulares de Leishmania. La escasa toxicidad que ha 
demostrado este compuesto frente a células de mamífero apunta al interés de esta molécula en 
terapia combinada para el tratamiento de infecciones por Leishmania.  
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3.1.b. Abstract 
Anti-leishmanial activity of allicin (=diallyl thiosulphinate) has been tested in vitro against 
promastigotes and intracellular amastigotes of Leishmania donovani and L. infantum. 
Macrophage infections have been carried out in vitro in the murine cell line J774 and ex vivo 
with peritoneal macrophages from BALB/c mice with a modified method to isolate metacyclic 
promastigotes. The compound has shown a significant in vitro effect on the multiplication of 
promastigotes of L.donovani and L.infantum in a time- and dose-dependent manner. It has been 
shown for the first time the inhibition of multiplication of intracellular amastigotes of 
Leishmania by allicin. Inhibitory concentrations of the compound were in the micromolar range 
(10-30 µM) for both Leishmania species. Antileishmanial effect of allicin apparently was not 
related to products of degradation of the molecule as assessed by mass spectrometry analysis. 
Inhibitory activity of allicin against promastigotes and intracellular amastigotes increased when 
the compound was added to the cultures every 24 h. Two administrations of 5 µM allicin 
inhibited by ca. 50% the proliferation of Leishmania amastigotes. Low toxicity for mammalian 
cells of this compound suggests the interest of exploring the value of allicin in combined 
therapy against leishmanial infections. 
Graphical abstract 
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3.2. Introduction 
Human Leishmania infections are present in all inhabited continents, with around 12 million 
people infected, 2 million new cases every year and 350 million people living in areas at risk 
(WHO, 2000). Leishmaniasis is a spectral infection with a range of clinical presentations, from 
self-healing dermal infections to visceral fatal processes. Visceral leishmaniasis caused by 
L.donovani and L.infantum = L.chagasi is a severe disease whose distribution has expanded 
frequently associated to HIV infection (Desjeux, 2004). In addition to human cases, canine 
leishmaniasis by L.infantum (Mediterranean Basin) and L.chagasi (South America) constitute a 
first order pathology in veterinary clinics besides its zoonotical importance as reservoirs. The 
main control system of leishmaniasis in both humans and dogs is chemotherapy. Liposomal 
amphotericin (AmB), paromomycin and miltefosine were considered the most promising drug 
for chemotherapy of leishmaniasis (www.who.int/tdr/diseases/leish). However, these drugs have 
some important shortcomings, including high toxicity and teratogenicity of some of them, 
absence of parasitological cure in most cases and unaffordable prices for some of the 
compounds (Sundar and Chatterjee, 2006). Moreover, in some areas resistant Leishmania 
strains to commonly used drugs have emerged (Croft and Coombs, 2003; Croft et al., 2006). 
Therefore, new drugs or combinations are needed (Alvar et al., 2006; Chappuis et al., 2007; 
Mishra et al., 2007).  
This scenario favours the exploration of alternative drugs. Among them, allicin (diallyl 
thiosulfinate = 2-Propene-1-sulfinothioic acid S-2-propenyl ester), a natural product present in 
plants of the Family Alliaceae, including garlic, has shown antibacterial activity against 
Helicobacter pylori (O’Gara et al., 2000; Cañizares et al., 2004) and methicillin-resistant 
Staphylococcus aureus (MRSA) (Cutler and Wilson, 2004) besides a full range of medicinal 
and antimicrobial effects (Lawson, 1998; Ankri and Mirelman, 1999). Reports on the antifungal 
(Candida) (i.e. Khodavandi et al., 2011) and antiprotozoal (Mirelman et al., 1987: Entamoeba; 
Coppi et al., 2006: Plasmodium; Waag et al,. 2010: Plasmodium and Trypanosoma) activity of 
this molecule have been published. Ankri and Mirelman (1999) referred to unpublished results 
on the inhibition of Leishmania major growth by 30 μM allicin. Moreover, McClure et al. 
(1996) observed that allicin, besides other garlic extracts, was effective against the in vitro 
growth of L. mexicana and L. chagasi promastigotes but no further testing was carried out. On 
these grounds we have tested the potential antiproliferative effect of allicin on promastigotes 
and amastigotes of the two major causative agents of visceral leishmaniasis, L. donovani and L. 
infantum. Our results showed that micromolar concentrations of allicin are able to inhibit the 
proliferation of both stages and species. 
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3.3. Material and methods 
Parasites 
An autochthonous isolate of L. infantum (UCM 9), obtained from affected dogs in the area of 
Madrid (Spain) by the Clinical Service of the Department of Animal Health, Faculty of 
Veterinary Medicine (UCM), and “Khartoum 1246” isolate from L. donovani, provided by the 
Department of Immunology, Instituto de Salud Carlos III, Madrid, were routinely maintained as 
promastigotes in RPMI 1640 medium (Lonza) at 26 °C supplemented with heat inactivated (30 
min at 56 °C) foetal bovine serum (FBS) (Sera Laboratories International), 100 U/mL penicillin 
+ 100 μg/mL streptomycin (BioWhittaker) and 1% L-glutamine in 25 ml culture flasks. 
 
Promastigote assay 
Promastigotes were cultured in 10 ml sterile polystyrene tubes. Allicin was obtained as 
liquid Allisure® from Allicin International Ltd (Rye, East Sussex, UK). Dilutions of the 
compound were added up to 2 mL final volume. After 24, 48 and 72 h at 26 °C, live 
promastigotes were counted in an improved Neubauer chamber. Results from treated cultures 
were expressed as % of the multiplication obtained in untreated control cultures. Cultures were 
performed at least in triplicate and cultures treated with 0.1 µM amphotericin B (AmB) were 
included as control. 
 
Cell cytotoxicity assay: MTT assay 
MTT assay was employed to determine the toxicity of allicin for both J774 cells and mouse 
peritoneal macrophages. Peritoneal macrophages were isolated from female BALB/c mice. Cell 
suspension with RPMI-1640 medium (supplemented with 10% heat-inactivated FCS, 1% 
penicillin/streptomycin, 1% L-Glutamine) were seeded in 96 well flat-bottomed cell culture 
plates (Corning). Plates were incubated overnight in a humidified atmosphere 5% CO2/air 
atmosphere at 37 °C to ensure cell adherence. After 24 h, cells (4 x 106 peritoneal 
macrophages/mL; 5 x 103/mL J774 cells) were treated with increasing concentrations of allicin 
(1-120µM). Non-treated cells were included as a negative control. At the end of the drug 
exposure period (24 h), the medium from all the wells was removed and the cells were fed with 
200 µL of fresh medium, and plates were incubated for another 24 h. The viability of cells was 
determined by the MTT reduction assay as described before (Plumb, 2004). Briefly, 200 µL of 
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fresh medium and 50µL of the MTT (Sigma) solution (5mg/mL in PBS) were added to all 
wells; plates were incubated for 4 h protected from light in a humidified atmosphere at 37ºC. 
The remaining formazan crystals were dissolved by adding 200 µL of DMSO (Sigma) and 25 
µL/well of Sorensen’s glycine buffer were added to stop the reaction. Absorbance was read at 
570 nm. The approximate IC50 concentration was determined as the allicin concentration 
required to reduce the absorbance to half that of the untreated control wells (considered as 100% 
viable). Three independent experiments, with eight replicates, were carried out for assessing the 
cytotoxicity of allicin with this method.  
 
Amastigote assay 
In the amastigote assay, infection was carried out using a modification of the methods 
developed by us (Méndez et al. 1996, Wert et al. 2011) and the procedure described by Yao et 
al. (2008) to isolate metacyclic promastigotes. Depending on the experiment, infections with 
Leishmania were carried out in vitro, using the murine macrophage cell line J774, and ex vivo, 
with peritoneal macrophages from BALB/c mice. Stationary phase Leishmania promastigotes 
(day 7) were centrifuged without brake (365 xg, 10 min) through a Ficoll gradient (0, 10% in 
Medium 199, and 30% in sterile PBS). Parasites recovered from the interphase between 0% and 
10% Ficoll were washed with fresh medium and opsonised with 15% normal mouse serum in a 
solution 1:1(v/v) RPMI medium and HBSS, 0.15 mM CaCl2 and 1 mM MgCl2 for 30 min at 37 
ºC. Murine J774 cells (2.5 x104 cells/well) were cultured in 8-well Lab-Tek chambers (Nunc), 
for 16 h with mitomycin C (Calbiochem) at 1 μg/mL was to avoid cell proliferation. The 
washed parasites were added to the macrophage cultures (parasite: macrophage ratio 10:1) and 
maintained at 33 °C in 5% CO2 overnight without mitomycin. Non-internalized promastigotes 
were eliminated by thorough washing three times with fresh medium. Compounds were added 
at appropriate concentrations and maintained for 24 or 48 h depending on the experiment carried 
out.  
In the ex vivo experiments, peritoneal macrophages were obtained from female BALB/c 
mice and cultured as described above except for the absence of mitomycin treatment. 
Macrophage concentration was adjusted to 2.5 x 105/well up to a final volume of 200 µL/well. 
Metacyclic promastigotes were isolated and opsonised as previously described and parasite: 
macrophage ratio was 5:1. After a contact period overnight, Labtek plates were washed with 
RPMI 1640 and the compounds were added at different concentrations and times, and kept at 37 
ºC for 24, 48 or 72 h depending on the experiment. Slides were fixed and stained (May- 
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Grünwald-Giemsa, Merck Darmstadt) and the number of amastigotes/100 cells and % of 
infected cells was determined. Cultures were performed at least in triplicate. 
 
Solid phase microextraction (SPME) and Gas Chromatography/Mass Spectrometry 
(GC/MS) 
The SPME technique was carried out using an 85 μm Light Blue Carboxen/PDMS fibre 
coated with polydimethylsiloxane. Samples (100 μL) from the experimental cultures were 
prepared in extraction vial of 20 mL. RPMI, PBS and internal standards (1μL) were included as 
control samples. Extraction was performed at 40 ºC during 60 min under agitation (250 rpm) 
using an automatic injector Multifibre Change CTC Analysis model Mps2xl. Thermal 
desorption of analytes from the fibre was carried out in the chromatograph injector port at 
220ºC in splitless mode. GC was performed with an Agilent Technologies model 5975C gas 
chromatograph, at a constant flow of 1 mL/min for 5 min using a VA624 column (60 m x 0.25 
mm; 1.4 μm). Oven temperature programme employed included an initial isothermal time at 35 
ºC for 5 min, followed by a 5ºC/min ramp up to 240 ºC setting during 30 min in isothermal 
mode. MS was performed with Agilent Technologies model 7890A mass analyser without 
solvent delay in scan mode and in the 35-650 m/z mass range. Analysis was performed at the 
MS Unit- UCM. 
 
Transmission electron microscopy (TEM) 
The specimens were fixed for 3 h in a solution of glutaraldehyde 2.5% + paraformaldehyde 
4% in PBS at 4ºC followed by 2% osmium tetroxide + 3% potassium ferrocyanide for 1 h, room 
temperature, darkness. Samples were dehydrated with increasing concentrations of acetone in 
water and soaked in resin SPURR (Fedelco Madrid). The resin was polymerized at 70°C for 72 
h. Thin slices, 0.5 µm thick, were dyed with Richardson’s methylene blue and observed by light 
microscopy. Ultra-thin slices, 70 nm thick, were treated with 2% uranyl acetate, as well as 
Reynold’s lead citrate solution and examined with a Zeiss EM 902, transmission electron 
microscope (Carl Zeiss) at the SME-UCM. 
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Statistical analysis  
Statistical significance of differences between mean values obtained in the different groups 
was performed by one-way and two-way ANOVA, repeated measures analysis and Bonferroni 
test. Differences were considered significant when p<0.05. 
 
3.4. Results 
Allicin inhibits the multiplication of Leishmania promastigotes  
Micromolar concentrations of allicin effectively inhibited the growth of promastigotes of 
L.infantum and L.donovani in a dose- and time-dependent manner (p<0.0001) (Figure 1A and 
1b). Only a moderate anti-leishmanial activity (ca. 30-40% reduction as compared to control) 
was observed with the lowest concentration (30 µM) whereas 60 µM and 120 µM provoked a 
reduction over 80% of the initial population of promastigotes after 24 h (p<0.05). Addition of 
120 µM allicin completely eliminated the promastigotes after 72 h. There was a certain recovery 
of Leishmania cultures treated with 30 µM allicin from day 1 onwards. Microscopical 
observation showed active cell division with this concentration (not shown) and the motility of 
promastigotes was higher after 72 h than in similarly treated cells during 48 h.  
 
Figure 1. Effect of allicin on the proliferation of Leishmania infantum (Figure 1A) and L.donovani promastigotes 
(Figure 1B). Compounds were added at time 0. ●: 30 µM; ■: 60 µM; ▲: 120 µM; ▼: amphotericin (0.1 µM). 
Results are the means of three experiments ± standard deviation. 
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As expected, 0.1 µM amphotericin provoked a reduction between 80 and 90% of the 
promastigote number after 24 h. Treatment with allicin (60 and 120 µM) provoked important 
ultrastructural alterations of Leishmania promastigotes (Figure 2). Cellular swelling with 
reduction of electrodense material in the cell cytoplasm and generalized vacuolisation were 
observed. In addition, there was deformation and loss of integrity of membranes from both 
mitochondrion and kinetoplast, and chromatin condensation in the nucleus and kDNA. 
 
 
Figure 2. Transmission electron micrographs of promastigotes of Leishmania infantum treated with 60 µM (B and 
B’), 90 µM (D) and 120 µM (C, C’, C’’) as compared to untreated control cultures (A and A’). Treated promastigotes 
showed generalized vacuolization, reduction of electrodense material in the cytoplasm, cellular swelling (C’’), loss of 
integrity of mitochondrial and kinetoplast membranes (B and C), and chromatin condensation in the nucleus (C’) and 
kDNA (C). n: nucleus, k: kinetoplast, fp: flagellar pocket, f: flagellum, m: mitochondrion. Magnifications are given on 
each micrograph. 
 
Toxicity of allicin for mammalian cells 
Toxicity of a range of allicin concentrations on the murine macrophage cell line J774 and 
mouse peritoneal macrophages was examined (Figure 3) with MTT method. Apparently, all 
concentrations of allicin affected cell viability (p<0.0001) and 10 µM almost completely 
arrested cell proliferation of J774 after 24 h (Figure 3A). However, results obtained with MTT 
did not correlate with the microscopical examination of May-Grünwald-Giemsa stained 
cultures. Cultures treated up to 60 µM allicin did not show significant microscopic alterations as 
can be observed in Figure 4 (C and C’). The apparent discrepancy could be related to the lack of 
discrimination between cytotoxic and cytostatic effects from these colorimetric methods. On 
these grounds toxicity was tested in non-dividing primary cells, mouse peritoneal macrophages 
(Figure 3B). Results showed that allicin did not induce any significant (p<0.0001) toxicity up to 
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a concentration of 60 µM and the cell viability was reduced only by 10% after exposition of 
macrophages to this concentration. 
 
 
 
Figure 3: Effect of different concentrations of allicin on the viability of J774 cells (Figure 3A) and BALB/c mice 
peritoneal macrophages (Figure 3B). Cytotoxicity was determined by MTT assay. Results are means of eight 
determinations. 
 
 
Allicin also inhibits the multiplication of intracellular amastigotes of Leishmania 
The apparent low toxicity prompted us to examine the anti-leishmanial activity of allicin on 
intracellular amastigotes of Leishmania. Given our initial experimental design, the effect of 
allicin was tested on previously infected J774 cells. The modification of the infection procedure 
developed was highly successful since ca. 70% of the J774 cells were infected with Leishmania 
amastigotes. Results obtained showed that the compound was effective against Leishmania 
amastigotes multiplication after 24 h incubation. This anti-leishmanial effect was observed in 
both L.donovani and L.infantum in spite of the higher amastigote burden in L.donovani 
infections (Figure 4). Apparently the compound behaved as leishmaniostatic since no notable 
reduction in the infection rate was appreciated in any of the species tested whereas a significant 
(p<0.05) reduction in the amastigote burden was induced. Antileishmanial effect of allicin was 
dose-dependent (Figure 5) and dose-response curves yielded an approximate IC50 value of 10 
µM for both species. 
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Figure 4. Effect of allicin on the infection of J774 macrophages with Leishmania donovani (upper row) and 
L.infantum (lower row): a and a’: infected and untreated control cultures; b and b’: cultures treated with 30 µM allicin; 
c and c’: cultures treated with 60 µM allicin. Micrographs are representative images stained with May-Grünwald-
Giemsa of the triplicate cultures. Bar: 50 µm. 
 
 
 
 
 
 
 
Figure 5. Effect of the single administration 
of different concentrations of allicin on the 
intracellular amastigote burden of J774 
cells infected with Leishmania donovani 
(empty circles) and L. infantum (filled 
circles). Results are the mean ± standard 
deviation of three experiments. 
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Thermal degradation of allicin 
The apparent recovery of promastigotes cultures of L. donovani and L. infantum treated with 
30 µM allicin (see Figure 1) suggested the possibility of degradation of the compound in the 
experimental conditions established. Mass spectrometry analysis of allicin in RPMI 1640 
medium, exposed for 24 h at the culture temperatures for promastigotes and amastigotes, 26 ºC 
and 37 ºC respectively, showed that the molecule was degraded at both temperatures (Figure 6). 
Our technique did allow us to detect 19 peaks in fresh untreated allicin preparation (Figure 6a) 
whereas only 12 peaks were found after treatment at 37 ºC for 24 h (not shown). Thermal 
degradation products included diallyl sulphides (DAS), diallyl disulphides (DADS) and a 
vinyldithiin although no evidence of allicin or ajoene was obtained. Significantly simpler 
chromatograms were observed in cultures containing allicin (120 µM) treated at 26 ºC. Only 
DADS (Figure 6b) and 2-Butoxyethyl acetate and Benzaldehyde, 3-5 dimethyl were found; the 
last two compounds corresponded to the culture medium, RPMI 1640 (Figure 1c).  
Consistently with the degradation of allicin, anti-leishmanial activity of the preparation was 
greatly improved when this product was freshly added every 24 h. Figure 7 shows the results 
obtained with L.donovani and comparable results were obtained with L.infantum (not shown). 
All concentrations induced a reduction in the number of promastigotes, after 24 h exposition to 
the drug, in a concentration related manner (p<0.05) and no recovery of the cultures could be 
appreciated along the experiment. A different pattern of inhibition was observed onwards (48 h 
and 72 h) depending on the concentration of allicin. Cultures with the lower concentrations 
tested (1 µM, 5 µM and 10 µM) did not multiply for the duration of the experiment. By its part, 
the antileishmanial effect of 30 µM and 60 µM, added every 24 h, provoked a strong reduction 
of the promastigote number and, eventually, promastigote clearance with the highest 
concentration tested after 48 h. These results suggested a leishmaniostatic effect of allicin at low 
concentrations whereas concentrations over 30 µM behaved as leishmanicidal for promastigotes 
under our conditions. 
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Figure 6. Mass spectrometry representative chromatograms of 120 µM allicin + RPMI 1640 medium treated for 24 h 
at 26ºC (b). For comparative purposes fresh untreated allicin (5000 ppm) (a) and RPMI 1640 medium treated for 24 h 
at 26 ºC (c) chromatograms are included.  
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The effect of the addition of allicin every 24 h on the actual stage causing the leishmanial 
infection in mammals, amastigotes, was evaluated in an ex vivo assay with mouse peritoneal 
macrophages infected with L.donovani (Table 1).The modification of the infection procedure 
was very efficient since over 90% of the macrophages were infected with amastigotes after 24 h. 
Infection rate was only slightly affected by both treatment with allicin, and time. The effect of 
the compound on the number of macrophages infected was moderate and actually with the 
highest concentration used (30 µM), after 72 h infection rate was 60 ± 6.5% as compared to 86 
± 2.6 % in the untreated cultures (p<0.05). More relevant was the effect of allicin on the 
intracellular amastigote burden. Untreated control cultures displayed active multiplication along 
the experiment, reaching 965.7 ± 59.9 amastigotes/100 macrophages from the initial burden of 
489 ± 24.2 after 24 h. Antiproliferative effect of allicin was concentration and time dependent 
(p<0.0001, F=12.64). Both amastigote burden (number of amastigotes/ 100 macrophages) and 
relative parasite growth inhibition were significantly reduced with all concentrations of allicin 
(p<0.05 to p<0.01). After 24 h, 10 µM allicin reduced by ca. 40% the number of amastigotes as 
compared to the untreated control cultures and over 67% after 72 h (p<0.05), with three 
administrations of allicin. More importantly, 5 µM allicin significantly (p=0.0014) reduced by 
ca. 50% the number of intracellular Leishmania amastigotes after 48 h.  
 
 
 
Figure 7. Effect of different concentrations 
of allicin added every 24 h on the 
multiplication of Leishmania donovani 
promastigotes. Arrows: days of treatment 
with allicin. ●: untreated control cultures; 
■: 1 µM; ▲: 5 µM; ▼: 10 µM; ♦: 30 µM; 
○: 60 µM. Results are means ± standard 
deviation of three experiments. 
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Table 1. Effect of allicin replaced every 24 h on the multiplication of intracellular amastigotes 
of Leishmania donovani in peritoneal macrophages. Values are means ± standard deviation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Asterisks (*) represent values significantly different (p<0.05) to the untreated control cultures. Different superscripts 
within a column for each time (24h, 48h, 72h) represent differences (p<0.05 to p<0.01) between cultures treated with 
allicin. 
 
 
 
 
Allicin 
(µM) 
 
Amastigotes/ 
100 Mφ 
 
% of 
infection 
 
% Parasite 
growth 
inhibition 
24h 
   0(a) 489.0 (24.2)bcde 91.7 (3.5) 0.00 
1(b) 418.7 (28.5)ed 91.0 (5.5) 14.38(5.84)cde 
5(c) 346.7 (32.5)ae 81.7 (2.5)* 29.11(6.65)bde 
10(d) 292.0 (16.7)ab 74.0 (4.0)* 40.29(3.41)bce 
30(e) 177.3 (6.8)abc 70.0 (1.0)* 63.74(1.39)bcd 
48h 
0 (a) 781.0 (64.9)bcde 79.0 (7.5) 0.00 
1(b) 632.0 (58.5)acde 77.0 (6.0) 19.08(7.49)cde 
5(c) 402.0 (21.3)abe 70.0 (4.5) 48.53(2.73)be 
10(d) 373.3 (61.2)abe 79.3 (3.7) 52.20(7.84)be 
30(e) 228.3 (22.0)abcd 70.7 (2.5) 70.76(2.81)bcd 
72h 
0(a) 965.7 (59.9)bcde 86.0 (2.6) 0.00 
1(b) 670.7 (56.7)acde 82.7 (4.0) 30.55(5.87)cde 
5(c) 436.3 (39.5)abde 72.0 (5.5)* 54.82(4.09)bde 
10(d) 317.7 (7.5)abc 65.0 (1.0)* 67.10(0.77)bc 
30(e) 267.7 (29.6)abc 60.0 (6.5)* 72.28(3.07)bc 
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3.5. Discussion 
A significant inhibitory effect of allicin on the multiplication of both L. donovani and 
L.infantum has been found by us. Inhibition was time- and dose-dependent against 
promastigotes and intracellular amastigotes in vitro (J774 cells) and ex vivo (mouse peritoneal 
macrophages). Very few reports have been published on the effect of allicin against Leishmania 
promastigotes. The approximate IC50 value obtained  (10- 30 µM, 24 h exposition) by us for 
promastigotes from both species is in the line of the value indicated by Ankri and Mirelman 
(1999) (30 µg.mL-1) for promastigotes of L. major and slightly higher than that reported by 
McClure et al. (1996) for L.chagasi and L.mexicana. Allicin, in the micromolar range, 
effectively inhibited the multiplication of amastigotes within J774 murine line cells and 
peritoneal macrophages. As far as we know this is the first report on the inhibitory effect of 
allicin against intracellular amastigotes.  
Mechanism of action of allicin has been related to the rapid reaction with thiol groups 
(Rabinkov et al., 1998) but the actual intracellular targets responsible of the cytostatic / 
cytocidal effects are largely unknown. It has been reported that allicin induces apoptosis 
(Oomen et al., 2004) and our TEM results showed condensation of nuclear chromatin and 
kDNA and loss of integrity of mitochondrial and kinetoplast membrane. Ledezma et al. (2002) 
also observed nuclear alterations in L.amazonensis promastigotes treated with the related 
compound ajoene. Antioxidant systems of glutathione and trypanothione/ trypanothione 
reductase participate in the protection of Leishmania against the toxic effect of nitrogen-derived 
reactive species from macrophages (Romão et al. 2006). Interference of allicin with these thiol-
redox proteins could lead to amastigote destruction and this possibility should be explored. 
Besides this interaction other cell targets (i.e. other thiol-dependent enzymatic systems, cysteine 
proteinases, microtubule disruption) (Ankri and Mirelman,  1999, Prager-Khoutorsky et al., 
2007, Miron et al., 2010, Waag et al., 2010) should be involved since comparable IC50 values 
for allicin, administered as a single dose, were found by us in intracellular amastigotes in J774 
cells and extracellular promastigotes.  
The modified method employed in the macrophage infection with L.infantum metacyclic  
promastigotes (Ficoll gradient + opsonisation with 15% mouse serum) allowed to obtain higher 
yields than those achieved with previously used methods (Méndez et al., 1996, Wert et al., 
2011). Comparative advantage of the methodology was particularly evident in the ex vivo 
experiments with mouse peritoneal macrophages and provides us with a valuable tool for in 
vitro drug screening against intracellular amastigotes of this species.  
Antileishmanial in vitro effect of Allicin│139 
 
 Antileishmanial activity of Allicin: mechanism of action, in vivo efficacy and value in combined therapy with amphotericin B │ María Jesús Corral 
Under our conditions, toxicity of allicin in the concentration range used was low and no 
significant effect on mouse macrophages was observed up to 40 µM as estimated by MTT 
method. Moreover, the absence of substantial toxicity of the compound was confirmed by 
microscopical examination without any noticeable cell alteration up to 60 µM in both J774 cells 
and BALB/c peritoneal macrophages. A lack of correlation between the results of toxicity 
obtained with the colorimetric method in J774 cells and the findings in peritoneal macrophages 
was found. This apparent inconsistency could be related to the limitations of colorimetric 
methods to distinguish between cytostatic and cytotoxic effects of a drug (Plumb, 2004). Our 
results showed that allicin is a potent cytostatic agent but of scarce toxicity for mammalian cells 
as confirmed by the results obtained in non-dividing peritoneal macrophages. In addition it 
stresses the need of performing direct microscopic observation of the cells besides indirect 
methods when testing potentially useful drugs against intracellular parasites.  
Administration of allicin every 24 h greatly increased the anti-leishmanial activity of the 
compound. This finding suggested the degradation of the diallyl thiosulfinate at 26º and 37 ºC 
and is consistent with the reported thermo-sensitivity of the molecule (McClure et al., 1996; 
Cañizares et al., 2004). The degradation of the allicin preparation employed by us after 24 h at 
26º C and 37 ºC was confirmed by mass spectrometry. Allicin is a highly reactive thiosulfinate 
which is rapidly transformed to other types of organosulfur compounds, particularly diallyl 
disulfides (DADS), diallyl sulphides (DAS), ajoene and vinyldithiins (Amagase, 2006). Our 
results showed the presence of sulphides and vinyldithiins but not ajoene (E or Z) and allicin 
were found in any of the analysis. Simpler chromatograms of culture samples are probably 
related to the lower concentrations of allicin (<120 µM) as compared to the standard sample. 
The absence of allicin and ajoene could be due to their short half-life at the culture temperatures 
(26 ºC and 37 ºC) (i.e. ajoene, less than 1 min) and the analytical method employed. It is 
possible that less stringent analysis (HPLC) (Lanzotti, 2006) would allow the detection of these 
compounds. It is noteworthy to indicate that most studies on the degradation of allicin have 
been carried out with free allicin whereas our experiments were performed with a stabilized 
form of this molecule. Whether or not the actual antileishmanial agent in our studies is allicin or 
some other degradation product requires further experimentation. It has been indicated that 
thermal sensitivity of allicin at physiological temperature as well as its rapid transformation to 
other types of organosulphur compounds (Amagase, 2006) could rule out its therapeutic use. 
However, it has been shown that decline of allicin is accompanied by its transformation into 
other compounds (i.e. ajoene) (Fujisawa et al., 2008) with strong anti-leishmanial activity 
(Ledezma et al., 2002). Moreover, the metabolism of allicin, and therefore its bioavailability, is 
unknown for the most part. Recently, oral and peritoneal administration of methanolic extracts 
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of garlic significantly reduced the L.donovani burden in spleens of hamster infected with 
L.donovani (Wabwoba et al., 2010).  
Chemotherapy of leishmaniasis is far from ideal (Alvar et al., 2006; Chappuis et al., 2007) 
and new drugs and combinations are required. Value of IC50 found by us in vitro and ex vivo (5-
10 µM) against intracellular amastigotes possibly excludes allicin as monotherapy against 
leishmanial infections. However, low cost and scarce toxicity of this compound would allow its 
use in combined therapy with other well established anti-leishmanial drugs. 
In conclusion, allicin (=diallyl thiosulphinate) has shown a significant in vitro effect on the 
multiplication of promastigotes of L.donovani and L.infantum. Allicin exhibited a scarce 
toxicity for J774 cells and mouse macrophages. Moreover, it has been shown for the first time 
the inhibition of multiplication of intracellular amastigotes of Leishmania. Consistent infections 
of macrophages (J774 cells, mouse peritoneal) with L.infantum have been obtained with a 
modified method to isolate metacyclic promastigotes. Inhibitory concentrations of allicin were 
in the micromolar range for both Leishmania species and stages. More stable galenic 
preparations are probably needed. However, low toxicity for mammalian cells of this compound 
suggests the interest of testing this molecule in vivo in combined therapy against leishmanial 
infections. 
 
 
 
3.6. Acknowledgements 
MJCC has a PhD studentship from the Spanish Ministry of Economy and Innovation 
(MICINN). Excellent technical help by Beatriz Rojas is acknowledged. Dr. Pedro Girón helped 
us with the statistical analysis. Research was funded by CICYT project AGL2009-13009. 
 
3.7. References 
Alvar J., Croft S.L., Olliaro P., 2006. Chemotherapy in the treatment and control of leishmaniasis. Adv. 
Parasitol. 61: 224-274. 
Amagase H., 2006. Clarifying the real bioactive constituents of garlic. J. Nutr. 136: 716S-725S. 
Ankri S., Mirelman D., 1999. Antimicrobial properties of allicin from garlic. Microb. Infect. 2: 125-129. 
Antileishmanial in vitro effect of Allicin│141 
 
 Antileishmanial activity of Allicin: mechanism of action, in vivo efficacy and value in combined therapy with amphotericin B │ María Jesús Corral 
Cañizares P., Gracia I., Gómez L.A., García A., Martín de Argila C., Boixeda D., de Rafael L., 2004. 
Thermal degradation of allicin in garlic extracts and its implication of the inhibition of the in vitro 
growth of Helicobacter pylori. Biotechnol. Progr. 20: 32-37 
Chappuis F., Sundar S., Hailu A., Ghalib H., Rijal S., Peeling R.W., Alvar J., Boelaert M., 2007. Visceral 
leishmaniasis: what are the needs for diagnosis, treatment and control? Nature Rev. Microbiol. 5: 873-
882. 
Coppi A., Cabinian M., Mirelman D., Sinnis P., 2006. Antimalarial activity of allicin, a biologically 
active compound from garlic clove. Antimicrob. Agents Chemother. 50: 1731-1737. 
Croft S.L., Coombs G.H., 2003. Leishmaniasis-current chemotherapy and recent advances in the search 
for novel drugs. Trends Parasitol. 19: 502-508. 
Croft S.L., Sundar S., Fairlamb A.H., 2006. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19: 
11-126. 
Cutler R.R.,Wilson P., 2004. Antibacterial activity of a new, stable, aqueous extract of allicin against 
methicillan-resistant Staphylococcus aureus. Brit. J. Biomed. Sci. 61: 71–74.  
Desjeux P., 2004. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. 
Infect. Dis. 27: 305-318. 
Fujisawa H., Suma K., Origuchi K., Seki T., Ariga T., 2008. Thermostability of allicin determined by 
chemical and biological assays. Biosci. Biotechnol. Biochem. 72: 2877-2883. 
Khodavandi A., Alizadeh F., Ramal N.S., Sidik S.M., Toman F., Sekawi Z., Jahromi  M.A., Ng K.P., 
Chong P.P., 2011. Comparison between efficacy of allicin and fluconazole against Candida albicans 
in vitro and in a systemic candidiasis mouse model. FEMS Microbiol. Lett. 315: 87-93. 
Lanzotti V., 2006. The analysis of onion and garlic. J. Chromatogr. A 1112: 3-22. 
Lawson L.D., 1998. Garlic: a review of its medicinal effects and indicated active compounds, in: L.D. 
Lawson, R. Bauer (Eds.), Phytomedicines of Europe: Their chemistry and biological activity, 
American Chemical Society, Washington, pp.176-209. 
Ledezma  E., Jonquera A., Bendezú H., Vivas J., Pérez G., 2002. Antiproliferative and leishmanicidal 
effect of ajoene on various Leishmania species: ultrastructural study. Parasitol. Res. 88: 748-753. 
McClure D.C., Noland L.L., Zatyrka S.A., 1996. Antileishmanial properties of Allium sativum extracts 
and derivatives. Acta Hortic. 426:183-191. 
Méndez, S., Nell, M., Alunda, J.M., 1996. Leishmania infantum: infection of macrophages in vitro with 
promastigotes. Int. J. Parasitol. 26: 619-622. 
Mirelman D., Monheit D., Varon S., 1987. Inhibition of Entamoeba histolytica by allicin, the active 
principle of garlic (Allium sativum). J. Infect. Dis. 156: 243-244. 
Miron T., Listowsky I., Wilchek M., 2010. Reaction mechanisms of allicin and allyl-mixed disulfides 
with proteins and small thiol molecules. Europ. J. Med. Chem. 45: 1912-1918. 
Mishra J., Saxena A., Singh S., 2007. Chemotherapy of leishmaniasis: past, present and future. Curr.  
Med. Chem. 14: 1153-1169. 
Antileishmanial in vitro effect of Allicin│142 
 
 Antileishmanial activity of Allicin: mechanism of action, in vivo efficacy and value in combined therapy with amphotericin B │ María Jesús Corral 
O’Gara E.A., Hill D.J., Maslin D.J., 2000. Activities of garlic oil, garlic powder, and their diallyl 
constituents against Helicobacter pylori. Appl. Environ. Microbiol. 66: 2269-2273. 
Oomen S., Anto R.J., Srinivas G., Karunagaran D., 2004. Allicin (from garlic) induces caspase-mediated 
apoptosis in cancer cells. Europ. J. Pharmacol. 485: 97-103. 
Plumb J.A., 2004. Cell sensitivity assays: the MTT assay. Methods Mol. Med. 88: 165-169.  
Prager-Khoutorsky M., Goncharov I., Rabinkov A., Mirelman D., Geiger B., Bershadsky A.D., 2007. 
Allicin inhibits cell polarization, migration and division via its direct effect on microtubules. Cell 
Motil. Cytoskel. 64: 321-337. 
Rabinkov A., Miron T., Konstantinovski L., Wilchek M., Mirelman D., Weiner I., 1998. The mode of 
action of allicin: trapping of radicals and interaction with thiol containing proteins. Biochim. Biophys. 
Acta 1379: 233-244. 
Romão P.R.T., Tovar J., Fonseca S.G., Moraes R.H., Cruz A.K., Hothersall J.S., Noronha-Dutra A.A., 
Ferreira S.H., Cunha F.Q. 2006. Glutathione and the redox control system trypanotione/trypanothione 
reductase are involved in the protection of Leishmania spp against nitrosothiol-induced cytoxicity. 
Braz. J. Med. Biol. Res. 39: 353-363. 
Sundar S., Chaterjee M., 2006. Visceral leishmaniasis- current therapeutic modalities.  Indian J. Med. 
Res. 123: 345-352.  
Waag T., Gelhaus C., Rath J., Stich A., Leippe M., Schirmeister T., 2010. Allicin and derivates are 
cysteine protease inhibitors with antiparasitic activity. Bioorg. Med. Chem. Lett. 20: 5541-5543. 
Wabwoba B.W., Anjili C.O., Ngeiywa M.M., Ngure P.K., Kigondu E.M., Ingonga J., Makwali J., 2010. 
Experimental chemotherapy with Allium sativum (Liliaceae) methanolic extract in rodents infected 
with Leishmania major and Leishmania donovani. J Vector Borne Dis. 47: 160-167. 
Wert L., Alakurtti S., Corral M.J., Sánchez-Fortún S., Yli-Kauhaluoma J., Alunda J.M., 2011. Toxicity of 
betulin derivatives and in vitro effect on promastigotes and amastigotes of Leishmania infantum and 
L.donovani. J Antibiot. (Tokyo) 64: 475-481. 
World Health Organization, WHO, 2000. <who.int/health-topics/leishmaniasis.htm>.  
Yao C., Chen Y., Sudan B., Donelson J.E., Wilson M.E., 2008. Leishmania chagasi: homogeneous 
metacyclic promastigotes isolated by buoyant density are highly virulent in a mouse model. Exp. 
Parasitol. 118, 129-133. 
 
 
 
 
 
 
This chapter has been published in Experimental Parasitology 132(4): 475-482. DOI: 
10.1016/j.exppara.2012.08.016. Corral et al., 2012. 
In vitro interaction of Amphotericin B and Allicin on Leishmania│143 
 
Antileishmanial activity of Allicin: mechanism of action, in vivo efficacy and value in combined therapy with amphotericin B │ María Jesús Corral 
 
CHAPTER 4 
 
In vitro synergistic effect of Amphotericin B 
and Allicin on Leishmania donovani and 
L.infantum  
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4.1.a. Resumen  
Efecto sinérgico de anfotericina B y alicina sobre L.infantum y L.donovani 
La monoterapia actual para el tratamiento de la leishmaniosis presenta importantes efectos 
adversos y se han identificado resistencias frente a los compuestos de primera línea. La 
anfotericina B (AmB) ha mostrado una excelente eficacia frente a Leishmania y hasta la fecha 
no se han detectado resistencias frente al antibiótico. No obstante, su toxicidad ha limitado su 
uso generalizado. Los resultados obtenidos han demostrado que la combinación de alicina y 
AmB ha resultado de moderadamente sinérgica a sinérgica con concentraciones bajas (0,07 µM 
AmB + 35,45 µM alicina indujo una inhibición del crecimiento del 95%). Ninguno de los 
tratamientos ensayados demostró citotoxicidad sobre macrófagos murinos en la horquilla de 
concentraciones ensayada. Alicina, AmB o la combinación de ambos no modificaron los 
porcentajes de infección de los macrófagos infectados por Leishmania spp. Alicina mejoró la 
actividad de AmB sobre amastigotes intracelulares de L.donovani y L.infantum. La combinación 
de 0,05 µM AmB +10 µM alicina indujo una reducción de ca. 45% en el número de amastigotes 
intracelulares, permitiendo reducir a la mitad la dosis necesaria del antibiótico para alcanzar la 
concentración inhibitoria 50 (IC50) de AmB en monoterapia. Estos resultados apuntan al interés 
de explorar esta combinación in vivo y reducir, por tanto, la toxicidad asociada a la AmB 
empleada en monoterapia.  
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4.1.b. Abstract 
Current monotherapy against visceral leishmaniasis has serious side effects and resistant 
Leishmania strains have been identified. Amphotericin B (AmB) has shown an extraordinary 
anti-leishmanial efficacy without emergence of resistance; however toxicity has limited its 
general use. Results obtained showed, using a fixed ratio analysis, that the combination of 
diallyl thiosulfinate (allicin) and AmB ranged from moderately synergic to synergic at low 
concentrations (0.07 µM AmB + 35.45 µM allicin induced a 95% growth inhibition). None of 
the treatments, alone or in combination, had noticeable adverse effect on macrophages (Mφ) in 
the concentration range examined (Allicin: 0.5, 1, 5 and 10 µM; AmB: 0.05, 0.075, 0.1 µM). 
Allicin, AmB or the combination did not affect the infection rate (% of infected Mφ) of 
Leishmania. Allicin enhanced the activity of AmB on intracellular amastigotes of L.donovani 
and L.infantum (ca. 45% reduction on amastigote burden with 0.05 µM  AmB +10 µM allicin) 
this representing near a twofold reduction in the IC50 value of the antibiotic added alone. Results 
point towards the interest of testing this combination in vivo thus reducing the toxicity 
associated to the monotherapy with AmB. 
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4.2. Introduction 
Human Leishmania infections are present in all inhabited continents, with around 12 million 
people infected, 2 million new cases every year, and estimates of around 350 million people 
living in areas at risk (http://who.int/health-topics/leishmaniasis.htm). Leishmaniasis is a 
spectral infection with a range of clinical presentations, from self-healing dermal infections to 
deadly processes. Cutaneous leishmaniasis is by large the most common disease, but visceral 
leishmaniasis [caused by Leishmania donovani and L. infantum (=L. chagasi)] is also present in 
all continents, and the infections produce severe disease. The distribution of these infections has 
greatly expanded, and coinfection of Leishmania and HIV is very frequent (Desjeux, 2004). In 
addition to human cases, canine leishmaniasis caused by L. infantum (Mediterranean Basin) and 
L. chagasi (South America) constitutes a first-order pathology in veterinary clinics besides the 
zoonotical importance of dogs as reservoirs. The main control system of leishmaniasis in both 
humans and dogs is chemotherapy. However, antileishmanial drugs have some important 
shortcomings, including high toxicity and teratogenicity in some cases, absence of 
parasitological cure in most cases, and unaffordable prices for some of the compounds and 
presentations. Moreover, in some areas, Leishmania strains resistant to commonly used drugs, 
particularly antimonials, have emerged (Croft et al., 2006). Liposomal amphotericin (AmB), 
paromomycin, and miltefosine were considered the most promising drugs for chemotherapy of 
leishmaniasis (http://www.who.int/tdr/diseases/leish). However, for the large part, these drugs 
were introduced over 40 years ago, and new active compounds or combinations against 
Leishmania are needed (Alvar et al., 2006; Chappuis et al., 2007).  
The pharmaceutical industry has experienced a contraction during recent years, resulting in 
very few companies being present in the market. It is anticipated that investment and 
intercompany competition and consequently the launch of new antiparasitic agents will be 
reduced (Woods & Knauer, 2010). One of the alternative chemotherapeutic approaches is the 
use of combinations of effective existing drugs whose toxicity precluded them from being 
widely used with chemically unrelated compounds of reduced toxicity. The antibiotic AmB, 
besides being the standard treatment for systemic fungal infections, has shown an extraordinary 
antileishmanial efficacy. Its main mechanism of action, binding to ergosterol-containing 
membranes of Leishmania (Seifert, 2011), probably explains the lack of significant emergence 
of resistance to the compound. However, toxicity has limited its general use, and different low 
toxicity preparations have been developed (i.e., liposomes), but their high price limits their 
standard use (Sundar & Chatterjee, 2006). Some low-cost vehicles for the antibiotic have been 
tested in vitro and in vivo [i.e., albumin microspheres (Sánchez-Brunete et al., 2005) and 
polylactic-co-glycolic acid (PLGA) (Ordóñez-Gutiérrez et al., 2007; Van de Ven et al., 2012), 
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although without further development. For its part, allicin (diallyl thiosulfinate = 2-propene-1 
sulfinothioic acid S-2-propenyl ester), a natural product present in plants of the family 
Alliaceae, with antibacterial (Cutler & Wilson, 2004), antifungal (Candida) (Khodavandi et al., 
2011), and antiprotozoal (Plasmodium and Leishmania promastigotes) (McClure et al., 1996; 
Waag et al., 2010) activities, has been found to exhibit a notable antileishmanial effect on the 
intracellular stages of L. donovani and L. infantum without substantial cytotoxicity for 
mammalian cells (Corral-Caridad et al., 2012).  
On these grounds, our approach was the exploration of the potential synergistic or additive 
antileishmanial effect of the combination of AmB and allicin (low micromolar concentrations of 
AmB plus micromolar allicin), thus avoiding the toxic concentrations needed with AmB in 
monotherapy. Results obtained in vitro against both promastigotes and intracellular amastigotes 
of L. donovani and L. infantum showed that allicin significantly enhanced the leishmanicidal 
activity of AmB and therefore reduced the required amount of AmB to eliminate intracellular 
infection of Mφ by Leishmania.  
 
4.3 Material and methods 
Parasites 
L. infantum (MCAN/ES/2001/UCM-9) is an autochthonous isolate obtained at the Clinical 
Service of the Department of Animal Health, Faculty of Veterinary Medicine (UCM), from a 
naturally infected dog (Madrid, Spain). L. donovani isolate Khartoum 1246 
(MHOM/SD/43/124) was provided by A. Toraño (Department of Immunology, Instituto de 
Salud Carlos III, Madrid, Spain). Both species were routinely maintained as promastigotes in 
25-ml culture flasks at 26°C in RPMI 1640 medium (Lonza Group) supplemented with 10% 
heat-inactivated (30 min at 56°C) fetal bovine serum (FBS; Sera Laboratories International) and 
100 U/ml of penicillin plus 100 μg/ml of streptomycin (BioWhittaker).  
 
Drugs  
Fungizone (deoxycholate-dispersed amphotericin B) was a gift from Bristol-Myers Squibb. 
Stabilized allicin was obtained as liquid Allisure (5,000 ppm) from Allicin International Ltd. 
(Rye, East Sussex, UK). For the in vitro experiments, 10 mM stock, solutions of amphotericin B 
deoxycholate (AmB) in dimethyl sulfoxide (DMSO; Sigma) were prepared. Further dilutions 
were freshly made in RPMI 1640 medium. The final DMSO concentration never exceeded 0.5% 
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in the culture medium and had no effect on cell growth. Dilutions of allicin were directly 
performed in culture medium.  
 
Promastigote assay 
Cell counts  
Preliminary tests to determine the 50% inhibitory concentrations (IC50s) of the individual 
drugs were performed. For the combination assay, the IC50s of the single drugs, previously 
determined by cell counts, were combined. Leishmania log-phase promastigotes were cultured 
in 10-ml sterile polystyrene tubes (initial concentration, 106 parasites/ml; 2 ml/tube) and treated 
with 0.07 μM AmB or 30 μM allicin or the combination of both (0.07 μM AmB plus 30 μM 
allicin). Cultures were counted 24, 48, and 72 h post-treatment in a Neubauer chamber, and the 
viability was determined with trypan blue exclusion dye [0.4% in phosphate-buffered saline 
(PBS)]. Experiments were performed in triplicate. 
Alamar Blue assay for promastigote proliferation and synergism of the drug 
combination  
Mid-log-phase promastigotes were seeded in 96-well culture plates (Corning) at an initial 
plating density of 2.5 x 105 cells/well (200 μl/well). Cultures were exposed for 24 h to various 
concentrations of the drugs and their combinations. Promastigote proliferation and inhibition 
were determined with Alamar Blue reagent (AbDSerotec Ltd.) (10%, v/v) by following the 
manufacturer’s recommendations by reading fluorescence intensity (550-nm excitation 
wavelength and 590-nm emission wavelength) in a FLUOstar Omega (BMG Labtech) 
fluorimeter after 72 h of incubation with the dye. Untreated cultures, wells without cells and the 
maximal concentration from each compound and their combinations, and wells with culture 
medium and Alamar Blue (10%, v/v) were included as controls. Results for growth inhibition 
were expressed as percentage of growth in untreated control cultures. Cultures were performed 
at least in triplicate.  
Alamar Blue assays with increasing concentrations of the single drugs were performed first, 
and appropriate drug combination ratios were tested according to the results obtained. Drugs 
were combined at constant ratios [0.01:5, 0.01:10, and 0.01:20 (μM AmB/ μM allicin)] by 
following a modified fixed-ratio method (Seifert & Croft, 2006), and their dose-effect 
relationships were assessed by the Chou-Talalay combination index (CI) method using 
CalcuSyn software (Chou & Hayball, 1996; Chou, 2008). This method is based on the multiple-
drug effect equation derived from the median-effect principle and the mass action law. Results 
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provide a quantitative determination for synergism (CI < 1), additivity (CI = 1), and antagonism 
(CI > 1). The software allows the calculation of the dose reduction index (DRI), a parameter 
which indicates the fold dose reduction allowed in a drug combination to reach a given degree 
of inhibition compared to the drug as a single agent. It provides other dose-effect-related 
parameters such as the potency (Dm) of the drugs alone or in combination, this representing the 
concentration which inhibits cell growth by 50%, and the shape of the dose-effect curve (m), 
where m of 1, > 1, and < 1 indicate hyperbolic, sigmoidal, and flat sigmoidal curves, 
respectively. The linear correlation coefficient (r) of the median-effect plot represents the 
conformity of the data to the mass action law.  
 
Cytotoxicity assay for mammalian cells 
Toxicity for mammalian cells was determined ex vivo in murine (female BALB/c mice; 
Harlan) peritoneal Mφ isolated by peritoneal lavage, resuspended in RPMI 1640 medium 
supplemented with 10% FBS, and seeded in 96-well culture plates (4 x 106 cells/ml; 200 
μl/well). Plates were incubated overnight to allow cell adherence at 37°C in a 5% CO2–95% air 
mixture. Different concentrations of allicin (10, 30, and 40 μM) plus AmB (0.1 and 0.5 μM) 
were added to the cultures. At the end of the drug exposure period (24 h), the medium was 
removed; wells were replenished with fresh medium and incubated for another 24 h. The 
viability of cells was determined by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) reduction assay as described previously (Plumb, 2004). Briefly, 50 
μl of MTT (Sigma) solution (5 mg/ml in sterile PBS) was added to the wells, and the plates 
were kept for 4 h at 37°C in a humidified atmosphere protected from light. Formazan crystals 
were dissolved with 200 μl of DMSO and 25μl/well of Sorensen’s glycine buffer (0.1 M glycine 
and 0.1 M NaCl, adjusted to pH 10.5 with 1 M NaOH) and added to stop the reaction. 
Absorbance was read at 570 nm in a microplate reader. Untreated cells and wells without cells 
and the maximal concentration from each compound were included. Three independent 
experiments were carried out. 
 
Amastigote assay and determination of the synergism of the drug combination  
Infection of Mφ was carried out with the modification developed by us (Méndez et al., 1996; 
Corral-Caridad et al., 2012). In brief, 2.5 x 104 J774 cells/well (200 μl/well) were cultured in 8-
well Lab-Tek chambers (Nunc) for 16 h to ensure adherence. Stationary-phase Leishmania 
promastigotes (day 7 to 10) were centrifuged (370 xg, 10 min, without brake) in a 5810R 
centrifuge (Eppendorf) through a Ficoll gradient (0, 10% in medium 199, and 30% in sterile 
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PBS). Metacyclic parasites recovered were washed and opsonized with 15% normal mouse 
serum (Jackson ImmunoResearch) in a solution (1/1, v/v) of RPMI medium and Hanks’ 
balanced salt solution (HBSS; Sigma), 0.15 mM CaCl2, and 1 mM MgCl2 for 30 min at 37°C 
and 5% CO2. Infection was carried out overnight at 33°C at a parasite/Mφ ratio of 10:1 in 5% 
CO2. Non-internalized promastigotes were removed by thorough washing, and fresh media 
containing the appropriate compounds dilutions were added to the wells. Cultures were treated 
with AmB (0.05, 0.075, and 0.1 μM) and allicin (0.05, 1, 5, and 10 μM) administered alone and 
in combination for 48 h. Unless otherwise stated, mitomycin C (Calbiochem) at 1 μg/ml was 
added to avoid cell line proliferation. Untreated cultures, cultures treated with mitomycin C, and 
cultures treated with 0.5% DMSO were included as negative controls. Slides were fixed and 
stained (May-Grünwald Giemsa; Merck Darmstadt), and the number of amastigotes/100 cells 
and % of infected cells were determined. Drug activity was expressed as percentage of growth 
inhibition compared to that in untreated cultures. Three independent experiments were 
performed at least in triplicate.  
 
Statistical analysis   
Graphs were generated and statistical analysis was performed using GraphPad Prism 5. 
Statistical significance of differences between mean values obtained in the different groups was 
determined by repeated-measures generalized linear model analysis, one-way analysis of 
variance (ANOVA), and Bonferroni test. Differences were considered significant at a p value of 
< 0.05. 
 
4.4. Results 
Figure 1 shows the results obtained by cell counting in the preliminary test on the effect of 
the combination of AmB and allicin. Similar results were obtained with both species, L. 
donovani (Figure 1A) and L. infantum (Figure 1B). Both compounds, AmB (0.07 μM) and 
allicin (30 μM), reduced by more than 50% the Leishmania growth after 24 h of exposure, 
although a certain recovery of cell multiplication was observed on the 48 h and 72 h samplings. 
Combination of AmB (0.07 μM) and allicin (30 μM), however, provoked the cell death of the 
majority of the leishmanial population, and actually, after 72 h, L. infantum counts reached a 
mere 3 x 103/ml, this representing a reduction of more than 99% compared to the untreated 
cultures. These results were suggestive of a positive interaction (additive or synergic) between 
the compounds.  
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Figure 1. Effect of 30 μM allicin ( ■), 0.07 μM AmB ( ▲) and the combination (30 μM allicin + 0.07 μM AmB) (○) on 
the multiplication of L.donovani (Figure 1A) and L.infantum (Figure 1B) promastigotes after 24, 48 and 72 hours. 
(●): Untreated control cultures. Data are means ± standard deviation of an experiment in triplicate. 
 
 
To determine the effect of the combination, drugs were tested at constant micromolar ratios 
(0.01:5, 0.01:10, and 0.01:20) (AmB/allicin); growth inhibition was estimated with the Alamar 
Blue fluorimetric method. The two Leishmania species behaved similarly; Table 1 shows the 
results obtained for L. infantum promastigotes. In all cases, data obtained agreed with mass law 
action (r) and inhibition followed a sigmoid curve (m > 1). Dm values, corresponding to IC50s, 
obtained for the individual drugs tested were in the range of the previously estimated 
concentrations (22.1 μM for allicin and 0.09 μM for AmB). Growth inhibition results showed 
the significantly higher effect of the combination with allicin even with 0.01 μM AmB. Thus, 
whereas AmB administered alone did not induce at this concentration any inhibition of 
promastigotes’ multiplication, the combination with 20 μM allicin provoked a 37.5% growth 
reduction. This effect of allicin was more evident with 0.02 μM AmB, since when the antibiotic 
was combined with 20 μM allicin, 50% inhibition was reached (IC50), and with 40 μM allicin, 
89% (IC90) of the multiplication was stopped. Similarly, an AmB concentration of 0.08 μM, 
close to the IC50 of this compound, with 40 μM allicin reduced almost completely the 
multiplication of the promastigotes. It is noteworthy that microscopic examination of the 
promastigotes subjected to the combinations showed that they were not viable and that no 
recovery of the cultures was found (data not shown). 
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Table 1. Effect of AmB and allicin and their combination on promastigotes of Leishmania 
infantum determined by Alamar Blue assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drugs were combined at constant ratios (0.01:5, 0.01:10, and 0.01:20) and their dose-effect parameters were 
assessed by the Chou-Talalay method (Chou & Hayball, 1996) using CalcuSyn software. Dm (median-effect dose) 
signifies the potency and it is the concentration which inhibits cell growth by 50%; m is the shape of the dose-effect 
curve, where m values of 1, > 1, and < 1 indicate hyperbolic, sigmoidal, and flat sigmoidal curves, respectively; r 
represents the linear correlation coefficient of the median-effect plot (conformity of the data to the mass action law 
principle). The m, Dm (μM), and r values for AmB (drug 1 [D1]) were 1.451, 0.09, and 0.86, respectively, and those 
for allicin (D2) were 2.066, 22.13, and 0.90, respectively. Results are expressed as the means ± standard deviations 
of three independent experiments. 
 
The combined effect of the two compounds in terms of synergism-antagonism was complex, 
as shown at Table 2. Generally speaking, all combinations allowed reduction of the 
concentrations required for AmB (DRI), and synergism (CI < 1) was evident only with the fixed 
ratio (0.01 μM AmB plus 5 μM allicin) (Figure 2). Combination allowed a 7- to 10-fold 
reduction of the AmB dose required to provoke a 90 to 95% reduction in the promastigotes’ 
multiplication.  
 
Combination 
Ratio 
D1-D2  
 
AmB 
(µM)  
 
Allicin 
(µM)  
 
Growth 
Inhibition 
 (%) 
  
 
Parameters 
m Dm  
(µM) 
r 
 (0.01:5) 0.0025 1.25 3.5 ± 0.59    
0.005 2.5 3.4 ± 0.98    
 0.01 5 3.5 ± 0.45    
 0.02 10 3.6 ± 2.84    
 0.04 20 15.0 ± 1.32    
 0.08 40 99.0 ± 0.03    
 0.16 80 99.0 ± 0.02 2.655 11.71 0.90 
(0.01:10) 
 
0.0025 2.5 3.1 ± 1.54    
0.005 5 3.3 ± 1.49    
0.01 10 4.0 ± 2.02    
 0.02 20 52.0 ± 2.22    
 0.04 40 97.0 ± 1.65    
 0.08 80 99.0 ± 0.11    
 0.16 160 99.0 ± 0.12 1.998 21.96 0.91 
(0.01:20) 0.0025 5 1.42 ± 1.05    
0.005 10 2.09 ± 1.13    
 
 
0.01 20 37.5 ± 1.52    
0.02 40 89.0 ± 2.31    
 
 
0.04 80 99.0 ± 0.07    
0.08 160 99.0 ± 0.04    
 0.16 320 99.0 ± 0.02 2.478 26.30 0.94 
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Table 2. Dose-effect relationships of the combination of AmB and allicin on Leishmania 
infantum promastigotes. 
 
Drugs were combined at constant ratios (0.01:5, 0.01:10, and 0.01:20), and their dose-effect relationships were 
assessed by the Chou-Talalay method (Chou & Hayball, 1996) using CalcuSyn software. CI was calculated by the 
combination index equation. CI of < 1, = 1, and > 1 indicate synergism, additive effect, and antagonism, respectively, 
at different effective doses (ED50, ED75, ED90, and ED95). Synergistic effects (CI < 1) are in bold. DRI indicates the 
fold dose reduction allowed in a drug combination to reach a given degree of inhibition compared to the drug as a 
single agent. Computer-simulated dose-required values of each drug in combination to reach a given effect level are 
included. 
 
 
Figure 2. Representative normalized isobolograms of the interaction of AmB with allicin at a fixed ratio (0.01 μM 
AmB to 5 μM allicin). Lines intersect at the x and y axes at the normalized concentrations corresponding to the EC50 
(●) (A), EC75 (■) (B), and EC90 (▲) (C) when the compounds were administered alone. The same symbols are used 
for the concentrations found with the AmB-plus-allicin combination to elicit the same effect as the drugs added alone 
(EC50, EC75, and EC90). Dr, dose required (μM AmB + μM allicin); EC, effective concentration.  
 
Drug 
combination 
ratio 
D1+D2 
 
% Growth 
Inhibition  
 
(EDn) 
CI values  
DRI value 
Dose required  
(µM) 
AmB Allicin AmB Allicin 
(0.01:5) 50 0.79 (moderate synergism) 3.89 1.89 0.023 11.69 
 75 0.65 (synergism) 5.48 2.13 0.035 17.69 
 90 0.54 (synergism) 7.73 2.39 0.053 26.75 
 95 0.49 (synergism) 11.52 2.74 0.071 35.45 
(0.01:10) 50 1.23 (moderate antagonism) 4.14 1.01 0.022 21.94 
 75 1.16 (slight antagonism) 5.31 1.03 0.037 36.49 
 90 1.09 (nearly additive) 6.81 1.05 0.061 60.71 
 95 1.05 (nearly additive) 8.06 1.07 0.085 85.82 
(0.01:20) 50 1.33 (moderate antagonism) 6.92 0.84 0.015 31.22 
 75 1.19 (slight antagonism) 9.47 0.91 0.023 47.48 
 90 1.07 (nearly additive) 12.96 1.01 0.036 72.23 
 95 0.99 (nearly additive) 16.05 1.06 0.048 96.07 
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Given the results obtained with the extracellular stage of Leishmania, interaction was tested 
on intracellular amastigotes. Toxicity of the combination of AmB plus allicin was assayed on 
peritoneal Mφ from BALB/c mice. None of the concentrations of allicin employed (10 through 
40 μM) in the combination induced any significant toxicity as assessed by MTT assay (Figure 
3). However, 0.5 μM AmB, irrespective of the allicin concentration used, significantly (p < 
0.001) inhibited the viability of Mφ, more than 60%. As expected, no toxicity for mammalian 
cells was found with 0.1 μM AmB. This value is in the range of reported IC50s for Leishmania 
and supported the exploration of the combined treatment with allicin on the multiplication of 
intracellular amastigotes of Leishmania given the apparent absence of toxicity of the 
dialylsulfide up to 40 μM.  
 
Only concentrations below 0.1 μM AmB and 10 μM allicin were tested (Table 3). For 
comparative purposes, the effect of both compounds administered alone was also included. 
Since antileishmanial effect was determined by cell counting, drugs were combined at a non-
constant ratio in a checkerboard manner. As expected, AmB alone showed an approximate IC50 
of 0.1 μM, and the maximal concentration of allicin (10 μM) reduced by ca. 30% the 
multiplication of amastigotes. Tested concentrations of the drugs, added alone or in 
combination, did not significantly affect the viability and infection rate of Mφ under our 
experimental conditions; infection rates ranged from 47.3% ± 3.8% to 67.0% ± 3.5%, and the 
results obtained with the two Leishmania species (L. infantum and L. donovani) were similar 
(data not shown). An interaction between the compounds was found from moderately 
synergistic with the lowest concentrations to antagonistic with the highest concentration used  
(0.1 μM AmB plus 10 μM allicin) (Figure 4A). In spite of this deduced interaction (CI), the 
most significant finding of the experiment was that 10 μM allicin could induce ca. 50% 
reduction of amastigotes’ multiplication when administered with 0.05 μM AmB. It should be 
Figure 3. Effect of the combination of AmB 
and allicin on the ex vivo survival of mouse 
peritoneal macrophages (Mφ). Numbers on 
the x axis represent the concentration (μM) of 
AmB plus concentration (μM) of allicin. Solid 
bar, untreated control Mφ; gray bars, Mφ 
cultures treated with 0.1 μM AmB; white bars, 
Mφ cultures treated with 0.5 μM AmB. 
Results are the means ± standard deviations 
of three independent experiments. 
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pointed out that for the particular L. infantum isolate employed, this AmB concentration 
administered alone had almost no effect (7.3%  ± 5.5% growth inhibition) on the multiplication 
of intracellular amastigotes. This represents a 2-fold reduction in the dose required for the 
antibiotic. 
 
Table 3 Effects of AmB, allicin, and their combination on the multiplication of intracellular 
amastigotes of Leishmania infantum in J774 cells. 
 
Drugs were combined at a non-constant ratio and their dose-effect relationships assessed by the Chou-Talalay 
method (Chou & Hayball, 1996) using CalcuSyn software. CI was calculated by the combination index equation. CI of 
< 1, = 1, and > 1 indicate synergism, additive effect, and antagonism, respectively, at the different drug combination 
doses. Synergistic effects (CI < 1) are in bold. DRI indicates the fold dose reduction allowed in a drug combination at 
the different data points compared with each drug alone. Statistical differences between the effects of AmB alone 
and the combination of AmB plus allicin are indicated as follows: *, p < 0.05; **, p < 0.001; and ***, p < 0.0001. 
Values are means ± standard deviations. 
 
 
Drug combination 
non-constant ratio  
(µM) 
% of 
Infection 
 
% Growth 
Inhibition  
 
CI value  DRI value 
AmB Allicin    AmB Allicin 
0 0 64.7 ± 2.5 0    
0.05  67.0 ± 3.5 7.3 ± 5.5    
0.075  64.7 ± 4.5 25.8 ± 5.1    
0.1  58.3 ± 2.1 50.1 ± 5.5     
 
0.05 60.3 ± 2.1 1.3 ± 4.2    
1 61.7 ± 5.7 15.7 ± 4.6    
5 56.7 ± 3.1 24.9 ± 1.8    
10 63.0 ± 4.4 32.8 ± 3.9    
0.05 
0.05 62.7 ± 3.1 26.1 ± 3.1 ** 0.75 (moderate synergism)  1.51 11.28 
1 60.0 ± 4.0 28.5 ± 4.4 ** 0.80 (moderate synergism) 1.55 6.04 
5 56.7 ± 1.5 34.2 ± 6.3 *** 1.30 (moderate antagonism) 1.67 1.42 
10 56.3 ± 1.5 45.6 ± 8.5 *** 1.58 (antagonism) 1.91 0.94 
0.075 
0.05 56.0 ± 9.5 47.4 ± 4.5 *** 0.82 (moderate synergism) 1.29 19.68 
1 54.0 ± 8.2 55.8 ± 10.9 *** 0.79 (moderate synergism) 1.42 11.96 
5 59.0 ± 4.4 54.8 ± 2.0 *** 1.13 (nearly additive) 1.41 2.34 
10 59.0 ± 2.6 54.0 ± 3.6 *** 1.58 (antagonism) 1.39 1.15 
0.1 
0.05 47.3 ± 3.8 61.4 ± 3.8 * 0.90 (slight synergism) 1.13 27.58 
1 53.3 ± 3.8 61.5 ± 3.3 * 0.95 (nearly additive) 1.13 13.86 
5 53.0 ± 3.6 64.5 ± 5.0 ** 1.18 (slight antagonism) 1.17 3.00 
10 47.7 ± 1.5 64.9 ± 0.9 ** 1.50 (antagonism) 1.18 1.51 
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Figure 4. Representative isobolograms of the in vitro interaction between AmB and allicin on intracellular 
amastigotes of L. donovani. Results correspond to the non-constant ratio experiments using 0.05 μM (A), 0.075 μM 
(B), and 0.1 μM (C) AmB and 0.05, 1, 5, and 10 μM allicin. Black circles indicate the IC50 of the combination at the 
concentrations on the x and y axes. 
 
4.5. Discussion 
The aim of this work was the evaluation of the in vitro antileishmanial effect of the 
combination of AmB and allicin with the final purpose of reducing the required doses of the 
antibiotic and therefore the toxicity associated with its use. Results showed, using a fixed-ratio 
analysis with the extracellular stage (Chou & Hayball, 1996; Chou, 2008) and a checkerboard 
analysis with amastigotes, that the combination of the two compounds was from moderately 
synergic to synergic at low concentrations against both promastigotes (0.07 μM AmB plus 
35.45 μM allicin induced 95% growth inhibition) and amastigotes (ca. 45% reduction with 0.05 
μM AmB plus 10 μM allicin); this represents nearly a 2-fold reduction in the IC50 of the 
antibiotic added alone (Corral-Caridad et al., 2012; Vermeersch et al., 2009). The differences 
observed between promastigotes, with a 7- to 11-fold reduction of AmB, and amastigotes, with 
a ca. 2-fold reduction, support an interest in using intracellular amastigotes in drug screening 
(Ordóñez-Gutiérrez et al., 2007; Sereno et al., 2007; Vermeersch et al., 2009).  
It is clear that in vitro and ex vivo tests measure only the antiparasitic effect and that no 
direct prediction of the effect in vivo can be drawn from the results (Seifert et al., 2011). 
Analysis showed that some drug combinations were classified as antagonist in spite of reaching 
a highly inhibitory effect in amastigotes and particularly promastigotes. This finding, previously 
observed in anti-Plasmodium screening (Wiesner et al., 2002; Fivelman et al., 2004), suggests 
that even drugs associated with an indifferent effect in vitro could be useful therapeutic partners 
in vivo.  
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In addition, differential interaction between AmB and allicin found in promastigotes and 
amastigotes of Leishmania could give us some clues on the mechanism of action of the drugs 
used. The main mechanism of action of AmB against Leishmania is related to the preferential 
binding to ergosterol (Seifert, 2011), which impairs the permeability of membranes, resulting in 
loss of small cations and causing cell death (Berman et al., 1998; Larabi et al., 2003). This 
mechanism is also responsible for the fungicidal activity of the antibiotic.  
The mechanistic basis of the antiproliferative, and in particular the antileishmanial, activity 
of allicin (Corral-Caridad et al., 2012; Plumb, 2004) is not clearly understood, although several 
cellular targets have been incriminated (Rabinkov et al., 1998). Apparently allicin produces an 
enhancement of fungicidal activity of AmB by inhibiting ergosterol trafficking from the plasma 
membrane to the vacuole membrane in Candida (a member of the Fungi) (Ogita et al., 2009). 
Leishmania also has considerable amounts of ergosterol on the plasma membrane. Resistance to 
AmB in clinical isolates of L. donovani has been associated, besides the presence of cholesta-
5,7, 24-trien-3β-ol instead of ergosterol, with the upregulation of the thiol metabolic pathway 
(Purkait et al., 2012). No thiol contents have been yet determined by us in allicin-treated 
Leishmania, but interference with thiols has been considered the main mechanism of action for 
allicin (Rabinkov et al., 1998; Miron et al., 2010). The synergy observed could be related to the 
impairment of the thiol metabolic pathway provoked by allicin, thus enhancing the effect of 
AmB. Whether or not this enhancement of AmB effect in the presence of allicin is responsible 
for the synergism found by us in amastigotes and, particularly, promastigotes of Leishmania 
needs further experimentation, which is under way.  
Chemotherapy of leishmaniasis, both human and animal, is not yet solved in spite of the 
substantial efforts made on basic aspects of Leishmania biology. An alternative approach to 
monotherapy is the combination of drugs using well-established chemotherapeutic agents (i.e., 
miltefosine plus amphotericin B or antimonials plus amphotericin B) (Olliaro, 2010); in 
addition, these drug combinations have been common in veterinary clinical practice.  
Our results showed the apparently synergistic effect of allicin and AmB in the micromolar 
range. Data obtained with drug combinations in vitro have many limitations in spite of the dose-
effect relationship analysis carried out (i.e., unforeseen interactions and pharmacokinetics) 
(Chou. 2008). However, the 2-fold reduction in the required dose of AmB against intracellular 
amastigotes and the possibility of using higher non-toxic doses of allicin (> 10 μM) suggest 
exploration of this combination in vivo. 
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CHAPTER 5 
 
Efficacy of low doses of amphotericin B plus 
allicin against experimental visceral 
leishmaniasis 
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5.1.a. Resumen 
Eficacia de dosis bajas de Alicina y Anfotericina B en el tratamiento de la leishmaniosis 
visceral experimental 
Objetivos: Valorar la eficacia de la combinación de alicina y desoxicolato de anfotericina 
(AmB) en la quimioterapia de las infecciones por Leishmania infantum con el objetivo final de 
reducir la dosis de AmB en el tratamiento de la leishmaniosis visceral. 
Métodos: Los cricetos fueron infectados por vía intraperitoneal (ip) con L.infantum (107 
promastigotes en fase estacionaria). A partir del día 45 postinfección los animales fueron 
tratados (ip) con AmB (1 o 5 mg/kg/día), alicina (5 mg/kg/día) o con una combinación de AmB 
(1 mg/kg/día) + alicina (5 mg/kg/día) durante 5 días. Se determinaron las alteraciones clínicas y 
fisiológicas, y se valoró la respuesta de anticuerpos (IgG, IgG1, IgG2). La carga parasitaria de 
estimó mediante dilución límite y los niveles de AmB en plasma, riñón, bazo e hígado se 
valoraron mediante HPLC. 
Resultados: No se apreciaron signos clínicos ni alteraciones hepatorrenales. AmB, a la dosis 
de 1 mg/kg/día, no eliminó la infección mientras que en dos de los animales tratados con 5 
mg/kg/día de alicina no se pudo aislar L.infantum. La combinación (5 mg/kg/día alicina + 1 
mg/kg/día AmB) redujo la carga parasitaria en >95%. La actividad de la combinación frente a la 
infección por L.infantum fue comparable (p<0,05) al tratamiento estándar con AmB (5 
mg/kg/día). 
Conclusiones: Alicina (5 mg/kg/día durante 5 días) redujo de forma significativa la carga de 
Leishmania en el bazo e hígado de los cricetos infectados. La administración conjunta de alicina 
(5 mg/kg/día durante 5 días) y AmB (1 mg/kg/día durante 5 días) mostró un efecto aditivo 
parcial en la reducción de carga parasitaria en los dos órganos. 
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5.1.b. Abstract 
Objectives: To evaluate the efficacy of the combination of allicin and amphotericin 
deoxycholate (AmB) in the chemotherapy of Leishmania infantum infection with the final aim 
of reducing the dose of AmB in the chemotherapy of visceral leishmaniasis. 
Methods: Hamsters were intraperitoneally (ip) infected with L.infantum (107 stationary 
phase promastigotes). On day 45 post-infection animals were treated ip with AmB (1 or 5 
mg/kg/day), allicin (5 mg/kg/day) or a combination of AmB (1 mg/kg/day) + allicin (5 
mg/kg/day) for 5 days. Animals were clinically and biopathologically monitored and the 
antibody response (IgG, IgG1, IgG2) was determined. Parasite burdens were estimated by 
limiting dilution and AmB biodistribution was determined by HPLC in plasma, kidney, spleen 
and liver. 
Results: No clinical signs or liver and kidney alterations were observed. AmB (1 mg/kg/day) 
did not clear the Leishmania infection and no parasites were detected in two animals treated 
with 5 mg/kg/day allicin. Combination therapy (5 mg/kg allicin + 1 mg/kg AmB) reduced 
the L.infantum burden by > 95%. Antileishmanial activity of the combination was comparable 
(p< 0.05) to the standard AmB treatment (5 mg/kg). 
Conclusions: Allicin alone (5 mg/kg/day for 5 days) significantly reduced the  Leishmania 
burden in spleen and liver of infected hamsters. Co-administration of allicin (5 mg/kg/day for 5 
days) and AmB (1 mg/kg/day for 5 days) showed a partial additive effect on the reduction of 
leishmanial burden in both target organs. 
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5.2. Introduction 
Visceral leishmaniasis, a disease that is fatal unless treated, is caused by Leishmania 
donovani and Leishmania infantum (= L.chagasi) and is responsible for ~40 000 human deaths 
per year (http://www.who.int/leishmaniasis/). As such, this infection is second only to malaria 
among human parasitic diseases. Moreover, L.infantum infection is a first-order pathology in 
veterinary medicine since in endemic regions infection reaches a prevalence sometimes 
exceeding 25% of the total dog population, besides its role as a reservoir for the human 
population. Visceral leishmaniasis is among the frequent co-infections found in 
immunodepressed patients (e.g. HIV+ or solid organ transplant recipients). No available vaccine 
for humans has been developed and the present immunoprophylaxis of dog infections has 
important drawbacks (e.g. annual revaccination, adverse effects). Chemotherapy, both of 
humans and dogs, is imperfect and relies on the use of drugs discovered >50 years ago. In 
addition, important resistances have been described against some of the first-line drugs (i.e. 
antimonials) employed in endemic areas (Croft et al., 2006). The long half-life of some of the 
alternative treatments (e.g. miltefosine) and easy selection of resistant lines of L.donovani to 
others (e.g. paromomycin) (Maarouf et al., 1998) suggests that emergence of resistance has to 
be expected when used in monotherapy. 
Amphotericin B (AmB) has been extensively used against systemic fungal infections and as 
a second-line treatment against leishmaniasis. It is a very effective antileishmanial drug and the 
main mechanism of action that has been described, binding to ergosterol-containing Leishmania 
membranes, does not favour the appearance of resistance (Seifert, 2011; Gray et al., 2013). The 
main inconvenience of this drug has been the toxicity associated with its use as the 
deoxycholate (Laniado-Laborín and Cabrales-Vargas, 2009; Hamill, 2013), but this limitation 
has been partially circumvented by the use of low-toxicity vehicles (e.g. lipid carriers) (Alvar et 
al., 2006). However, the high price of liposomal preparations makes the treatment unaffordable 
in most endemic areas for human use and simply irrelevant for veterinary purposes. Among the 
possible strategies to manage the problems with the currently available antileishmanial 
compounds -inefficacy, price, toxicity and induction of resistance- combination therapy and the 
use of new molecules have been indicated as research areas worth of exploration (Chappuis et 
al., 2007).  
Allicin (2-propene-1-sulfinothioic acid S-2-penyl ester; dialylsulphur) has shown activity 
against some protozoa, including Leishmania (McClure et al., 1996; Waag et al., 2010). The 
main mechanism of action of allicin is related to its high permeability through cell membranes 
and interaction with thiols (Miron et al., 2000). Stabilized allicin has shown a significant 
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antiproliferative effect, in the micromolar range, against amastigotes (the stage present in the 
infected hosts) of L.donovani and L.infantum without evidence of toxicity for mammalian cells 
(Corral-Caridad et al., 2012). Apparently allicin enhances the antifungal (Candida) activity of 
AmB by inhibiting ergosterol trafficking (Borhijan et al., 2009). Recently, a synergistic effect of 
low concentrations of allicin and AmB has been reported against these species using an 
intracellular ex vivo model (mouse macrophages and amastigotes). We have tested the effect of 
the combination of AmB at a 5-fold reduced dose with allicin on experimental infections of 
hamsters with L.infantum. The final aim of the research is the reduction of the required dose of 
AmB and therefore the toxicity associated with the antibiotic if used in monotherapy of 
leishmaniasis. 
 
5.3. Material and methods 
Leishmania culture media and drugs 
L.infantum (MCAN/ES/97/10.445) zymodeme MON-1 was obtained from a naturally 
infected dog and has been routinely maintained by subpassage in hamsters and as promastigotes 
in RPMI 1640 medium (Lonza) in 25 mL culture flasks at 26°C supplemented with 10% heat-
inactivated (30 min, 56°C) fetal bovine serum (FBS; TDI), 1% L-glutamine (Lonza) and 100 
U/mL penicillin  + 100 μg/mL streptomycin (Lonza). Fungizone® (deoxycholate-dispersed 
amphotericin B) was from Bristol-Myers Squibb and stabilized allicin was obtained as liquid 
Allisure® (15 000 ppm) from Allicin International Ltd. 
 
Experimental infection of hamsters and follow-up 
Female hamsters were purchased from Janvier SAS. At the time of their arrival their weight 
ranged from 80 to 90 g. After a quarantine period of 30 days, animals were randomly allocated 
to six matched groups of six hamsters each except group 1 (five animals). Group 1 was the 
uninfected control group; group 2 was infected but untreated; group 3 was treated with 5 
mg/kg/day AmB for 5 days; group 4 was treated with 1 mg/kg/day AmB for 5 days; group 5 
was treated with 5 mg/kg/day allicin for 5 days; and group 6 was treated with 1 mg/kg/day AmB 
plus 5 mg/kg/day allicin for 5 days.  
Dilutions of the compounds were made with 5% dextrose solution to a final volume of 500 
μL. All treatments were administered by the intraperitoneal (ip) route. Animals, except those in 
group 1, were infected with 107 stationary phase promastigotes in 500 μL by ip injection on day 
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0 of the experiment. From day 45 post-infection (p.i.) onwards, the hamsters were treated with 
the appropriate drug or drug combination. The uninfected control group received the same 
volume (200 μL) of dextrose 5% solution. On day 30 p.i. one of the animals in the infected, 
untreated group (group 2) was euthanized to assess the infection. Ten days after the last 
treatment animals were anaesthetized with isoflurane, bled by intracardiac puncture and 
sacrificed by anaesthetic overdose.  
Experimental animals were dissected and the liver, kidneys and spleen were removed, 
weighed and used to estimate the parasite burden (liver and spleen) and to perform the 
pharmacological determinations. During the entire experiment the animals were housed at the 
facilities of the Instituto de Salud Carlos III, Majadahonda, Madrid (ISCIII) with a 12 h 
light/dark cycle, fed with pellets and given water ad libitum. Animals were observed daily for 
undesired reactions to the infection and treatments and body weight was determined weekly. 
Blood samples (serum and plasma) were obtained at the end of the experiment to determine the 
levels of renal and liver function markers [urea, creatinine, glutamic oxaloacetic transaminase 
(GOT), glutamic pyruvic transaminase (GPT) and alkaline phosphatase (ALP)] by standard 
clinical laboratory techniques (DLV Laboratorio Veterinario, Madrid). Experimental design and 
procedures were approved by the ethics committee of the ISCIII and followed the 
recommendations of EC Directive 2010/63/EU. 
 
ELISA 
The peripheral specific antileishmanial antibody response (IgG, IgG1 and IgG2) was 
determined by ELISA using serum samples from all experimental animals. Microtitre 96-well 
plates (Nunc) were coated with 25 μg/mL (50 μL/well) of soluble L.infantum extract or fixed 
promastigotes (108 promastigotes/mL; 50 μL/well) overnight at 4°C. For the latter, mid-log-
phase promastigotes were fixed with 0.025% formaldehyde solution (Panreac) for 2 h at room 
temperature (RT) and washed three times with PBS. To ensure cell adhesion, prior to blocking, 
promastigote-coated plates were centrifuged (500 g, 10 min, RT).  
Plates were blocked with 2% BSA (100 μL/well) at 37°C for 1 h. Animal sera were used at 
dilution 1/50 (50 μL/well), as established by prior ELISA chequerboard titrations (not shown), 
and incubated for 2 h at 37°C. After washing, secondary antibodies (50 μL/well) were added 
and the plates were incubated for 1 h at RT. Antibodies were diluted in PBS-Tween at 1/2000 
dilution for total IgG [Goat Anti-Hamster IgG(H+L)-HRP, Southern Biotech] and at 1/1000 
dilution for biotinylated mouse anti-Armenian hamster IgG1 (Abcam) and mouse anti-Armenian 
hamster IgG2 (Abcam), both of which react with heavy chains of Syrian hamster IgG isotypes. 
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After washing, IgG1 and IgG2 plates were further incubated with 50 μL/well HRP-conjugated 
streptavidin (Southern Biotech) at a dilution of 1/2000 and incubated for 30 min at RT. Finally, 
a 1 mg/mL solution of O-phenylenediamine (Sigma) and H2O2 (1/1000) were added (100 
μL/well). The reaction was stopped with 50μL of 3N H2SO4 and absorbance was read at 492nm. 
 
Efficacy of treatments 
Besides clinical observation of the experimental hamsters, at the end of the experiment the 
antileishmanial efficacy of drugs and combinations was estimated by determining the parasite 
burden by limiting dilution assay as previously described (Castro et al., 2011). Briefly, livers 
and spleens were removed, weighed and homogenized in Schneider's medium (Sigma) 
supplemented with 20% heat-inactivated FBS, 2% sterile human urine, 20 mM HEPES (Lonza), 
1% L-glutamine (Lonza) and 100 U/mL penicillin + 100 μg/mL streptomycin (Lonza). Organ 
homogenates were filtered through a cell strainer to ensure a single-cell suspension. Further 
dilutions of the homogenate were done in the same medium to a final concentration of 10 
mg/mL; 200 μL/well of this cell suspension was added to the first well of a 96-well culture plate 
(Corning) and serial 4-fold dilutions were made across the plate. Plates were incubated for 2 
weeks at 26°C and the presence of parasites was assessed by microscopy. The parasite burden 
(number of parasites/g of organ) was calculated as described by Buffet et al. (1995).  
 
Amphotericin B biodistribution in treated hamsters 
Blood samples were obtained at the end of the experiment from group 3 (hamsters treated 
with 5 mg/kg AmB), group 4 (treated with 1 mg/kg AmB) and group 6 (treated with 1 mg/kg 
AmB  +  5 mg/kg allicin). Plasma was obtained and samples were stored at –20°C until analyses 
were performed.  
Plasma samples (100 μL) were spiked with meloxicam (Fagrón SL) as internal standard at a 
final concentration of 10 μg/mL. Two extractions were carried out with methanol (300 μL each) 
and a third extraction with acetonitrile (300 μL). After every extraction, the mixture was 
vortexed and centrifuged at 9000 rpm, 10 min, 4°C. The supernatants were collected (300 
μL × 3) and evaporated off in a concentrator (Savant, SpeedVac®) at 35°C. Samples were 
reconstituted with 200 μL of a 1: 1 mixture of methanol : mobile phase (acetonitrile : acetic 
acid : water) (52 : 4.3 : 43.7, v/v/v). The reconstituted samples were centrifuged (9000 rpm, 5 min) 
and the supernatants were analysed by the validated HPLC method described below.  
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HPLC was equipped with a Jasco PU-1580 pump, a Jasco AS-2050 Plus autosampler and a 
Jasco UV-1575 UV–visible detector. Integration of the peaks was performed with the program 
Borwin 1.5 for PC (JMBS Developments). AmB was isocratically eluted using a Thermo 
Hypersil BDS C18 reverse-phase column (200 × 4.6 mm, 5 μm) and a mobile phase as above 
with a flow rate of 1 mL/min. Absorbance was monitored at 406 nm and the injection volume 
was set at 100 μL. Under these conditions, the relative retention times of AmB and the internal 
standard were 7.9 and 5.1 min, respectively. Plasma AmB concentrations were calculated from 
linear regression calibration curves of the AmB/internal standard peak height ratio. The linear 
range in plasma was 0.01 to 10 μg/mL (y = 0.2191x − 0.0026; r2 = 0.9986). 
Liver samples (0.5 g) were spiked with meloxicam (10 μL at 200 μg/mL) as internal 
standard. Samples were homogenized with PBS (pH 7.4, 0.25 mL). Then, AmB was extracted 
with methanol (1 mL). The mixture was vortexed and then centrifuged (5000 rpm, 20 min). The 
supernatants were filtered through a 0.45 μm filter (Millipore® Millex PVDF) and then 
analyzed by the HPLC method previously described. Liver AmB concentrations were calculated 
from linear regression calibration curves of the AmB/internal standard peak height ratio. 
Similarly, kidney samples (0.15 g) and spleen samples (0.075 g) were analysed. Spleen samples 
were pooled (three animals/group) to obtain the required amount of tissue. 
Statistical analysis 
Graphs and statistical analysis were performed using GraphPad Prism 5. The statistical 
significance of differences between mean values obtained in the different groups was 
determined by one-way analysis of variance followed by Tukey's test. In all cases a p value 
of p < 0.05 was considered significant. 
 
5.4. Results 
Clinical follow-up 
No clinical signs were noted during the experiment as a consequence of either infection 
with L.infantum alone (group 2) or infection and treatments administered. Similarly, no 
important alterations were found in any of the biochemical parameters determined in the 
experimental hamsters (Figure 1) since renal (urea, creatinine) and liver function markers (ALP 
and GOT/GPT ratio) were comparable in all experimental groups irrespective of infection and 
the treatments administered.  
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The only exception was the blood urea nitrogen level in infected, untreated hamsters (group 
2), which was significantly higher than levels in uninfected control animals and animals 
receiving AmB (5 mg/kg), allicin (5 mg/kg) or the allicin + AmB combination. However, 
creatinine values were in all cases <0.2 mg/dL. ALP levels were in the range of 214-251 U/L 
and the GOT/GPT index was <1.0 in all groups. These results suggest that allicin, AmB or the 
combination (allicin + mB) with the doses and treatment schedule followed in our experiment 
did not induce any significant toxicity in the infected animals. 
 
 
 
 
 
 
Figure 1. Values of renal and kidney function markers at the end of the experiment. G1, uninfected control; G2, 
infected with Leishmania infantum; G3, infected and treated with 5 mg/kg/day AmB; G4, infected and treated with 1 
mg/kg/day AmB; G5, infected and treated with 5 mg/kg/day allicin; G6, infected and treated with 1 mg/kg/day AmB + 
5 mg/kg/day allicin. ALP, alkaline phosphatase; GPT, serum glutamate pyruvate transaminase; GOT, serum glutamic 
oxaloacetic transaminase. Data are means + SEM. 
 
Antibody response 
Comparable results were obtained with the two antigens, although higher OD values were 
obtained with the cell-based assay. L.infantum infection elicited a significant rise in anti-
Leishmania IgG against the soluble extract of the parasite (Figure 2) and fixed promastigotes 
(Figure 3) as assessed by the results observed in infected  +  untreated hamsters (group 2).  
Using fixed promastigotes of Leishmania, animals treated with the lowest AmB dose (group 
4) displayed values not significantly different from those found in infected, untreated hamsters 
(group 2) (Figure 3A). However, animals treated with allicin alone (group 5) or together with a 
low dose of AmB (group 6) showed significantly lower antibody values (p < 0.05). Values in 
animals treated with the combination were not different from those in animals treated with 
standard dosage of AmB (group 3; 5 mg/kg/day, 5 days) (p > 0.05) or the uninfected control 
group (group 1).  
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The pattern found for the specific IgG2 response was more complex (Figures 2B and 3B). 
Excluding the uninfected control hamsters, the lowest antibody values were found in animals 
receiving 5 mg/kg/day AmB (group 3) and the highest IgG2 levels in hamsters treated with 
allicin alone (group 5). Moreover, group 3 hamsters were significantly different (p < 0.05) from 
the group treated with allicin alone (group 5) but not from the infected control group (group 2) 
or those treated with the lowest AmB dose (group 4) or the combination of allicin + AmB (group 
6). The IgG1 response was very low in all groups and no significant differences between them 
were found (Figures 2C and 3C). 
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Figure 2. Serum specific antibody responses 
against soluble Leishmania infantum antigen 
(SLA) estimated by ELISA on day 60 of the 
experiment. (A) Total IgG (H + L). (B) IgG2. 
(C) IgG1. G1–G6, experimental groups as in 
Figure 1. ΔOD, increase in OD.  
Values are means  ±  SEM. 
 
Figure 3. Serum specific antibody response 
to fixed promastigotes of Leishmania 
infantum estimated by ELISA on day 60 of 
the experiment. (A) Total IgG (H + L). (B) 
IgG2. (C) IgG1. G1–G6, experimental groups 
as in Figure 1. ΔOD, increase in OD.  
Values are means  ±  SEM. 
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Liver and spleen Leishmania burden 
Figure 4 shows the results obtained in the determination of L.infantum burden in liver and 
spleen. The infection procedure (ip administration) was efficient and all infected control 
hamsters (group 2) had detectable infections. Spleen burdens of Leishmania (~ 6.0 log10 units) 
were, in general, significantly higher than those found in the liver (~ 3.0 log10 units). The 
negative control group (group 1) did not show any parasites.  
The curative effect of AmB was dependent on the dose administered. With the highest dose 
(5 mg/kg AmB; group 3) no parasites were detected in two animals and the average reduction 
of L.infantum burden was 94.5% in the spleen and 90.6% in the liver. However, none of the 
hamsters treated with 1 mg/kg AmB (group 4) was free of infection, although the parasite 
burden was reduced by ~ 70% in the spleen and a similar reduction was found in the liver. 
Allicin, administered alone (group 5), cleared Leishmania infection in two of the hamsters 
and both liver and spleen parasite burdens were significantly lower than those found in the 
infected, untreated group (p< 0.05). Results with the combination of 1 mg/kg AmB and 5 mg/kg 
allicin) (group 6) showed a partially additive effect. The reduction in Leishmania burden was 
significantly (p < 0.05) higher than that obtained with 1 mg/kg AmB and slightly better than that 
obtained with the higher dose of allicin (5 mg/kg). In three out of six hamsters in group 6 
no Leishmania were recovered from the liver and in two out of six no parasites were detected in 
the spleen. Results in terms of organ clearance were similar to those found with the standard 
AmB treatment (5 mg/kg AmB). 
 
 
 
 
 
 
 
 
Figure 4. Leishmania infantum burden (parasite burden, PB) determined by limiting dilution. G1–G6, experimental 
groups as in Figure 1. White bars, spleen burden; grey bars, liver burden. Values are means ± SEM. 
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Amphotericin B pharmacokinetics 
Very low AmB plasma concentrations were found in all experimental animals (Figure 5). 
However, AmB was detected in all organs analysed (kidney, liver and spleen). Animals in group 
3 (5 mg/kg AmB) exhibited significantly higher AmB levels in liver, kidney and spleen than 
animals in groups 4 (1 mg/kg AmB) and 6 (1 mg/kg AmB + 5 mg/kg allicin) but no differences 
were observed in plasma among groups. AmB levels in group 6 hamsters were higher than those 
in group 4, although the difference was not statistically significant. 
 
 
Figure 5. Amphotericin B (AmB) concentrations in plasma, liver, kidney and spleen of hamsters infected and treated 
with 5 mg/kg/day AmB (black bars) (group 3), 1 mg/kg/day AmB (grey bars) (group 4) and 1 mg/kg/day AmB + 5 
mg/kg/day allicin (white bars) (group 6). Values are means ± standard deviation. Statistically significant differences 
(p<0.0001) were found between groups 3 and 4 (*) and between groups 3 and 6 (#). 
 
 
5.5. Discussion 
Successful chemotherapy of leishmaniasis remains a challenge in spite of the research that 
has been done on the fundamental biology of the aetiological agents. In practice only a handful 
drugs are currently used and clinical isolates of L. donovani have shown notable resistance to 
the pentavalent antimonials (Chakravarty and Sundar, 2010). Moreover, given the relatively 
easy selection of resistant Leishmania lines to paromomycin (Maarouf et al., 1998) and 
miltefosine (Seifert, 2011), together with the oral administration of the latter and risks 
associated with self-medication, clinical resistance after monotherapy with these drugs will 
probably appear (Maltezou, 2010).  
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AmB is probably the best existing drug against leishmaniasis, with cure rates exceeding 95% 
(Chappuis et al., 2007; Paila et al., 2010) and negligible levels of resistance after being 
employed as the reference drug against systemic fungal infections for >50 years (Gray et al., 
2013). The main mechanism of action of AmB is still controversial (Ramos et al., 1996; 
Pucadyil et al., 2004; Chattopaddhyay and Jarufulla, 2011), although it is generally considered 
that binding of AmB to ergosterol in the Leishmania membrane is the first or the unique event 
(Gray et al., 2013) causing cell destruction. The few reports of clinical resistance in 
Leishmania are related to a modification of ergosterol to the closely related lipid cholesta-
5,7,24-trien-3β-ol (Purkait et al., 2012).  
To cope with the shortage of available drugs against leishmaniasis, combination therapy with 
a variety of drugs and schedules (Chunge et al., 1985; Murray and Hariprashad, 1996) has some 
potential advantages, such as delaying or preventing the development of resistance and 
shortening of treatment regimens (Seifert and Croft, 2006). Since the main shortcoming of AmB 
is toxicity (Laniado-Laborín and Cabrales-Vargas, 2009; Hamill, 2013), our approach used a 
combination of allicin with the antibiotic AmB with the aim of reducing the amount of AmB 
required and therefore the potential toxicity of the antibiotic.  
The experimental model employed (L.infantum and hamster) produced consistent infections 
with significantly higher parasite burdens in the spleen than in the liver, thus confirming its 
value (Binzahim et al., 1993; Requena et al., 2000; Melby et al., 2001; Dea-Ayuela et al., 2007; 
Moreira et al., 2012) and its suitability for in vivo testing of antileishmanial agents. Moreover, 
the limiting dilution assay allowed the detection of the parasite 2 months after infection in both 
the spleen and the comparatively less parasitized liver. 
No clinical signs or biopathological alterations were observed in any of the infected or 
infected +treated animals, indicating the lack of toxicity of AmB and allicin at the doses 
administered. The levels of ALP found in our experiment were higher than the reference range 
of 50–186 U/L. This could be related to the age of the hamsters, since immature animals have 
higher ALP levels than adults due to release of the enzyme from growing bone (Washington and 
van Hoosier, 2012). The alteration in blood urea nitrogen level in group 2 hamsters provided 
evidence of renal compromise in infected animals. Moreover, higher values of urea, observed in 
all groups compared with the reference range (12–26 mg/dL), were probably due to diet (i.e. 
high protein content) and sex (i.e. female) (Washington and van Hoosier, 2012). 
In our experiment, 5 mg/kg allicin administered by the ip route, to avoid the potential 
degradation induced by the conditions in the stomach, elicited a clear antileishmanial effect in 
hamsters since two out of six animals were cleared of L.infantum in both spleen and liver. As far 
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as we know this is the first evidence of the antileishmanial activity of allicin in vivo without 
apparent toxicity in infected, treated animals. The combination of allicin + AmB significantly 
improved the efficacy of low-dose AmB (group 4), and was slightly more efficacious than 
allicin at 5 mg/kg. The low-dose combination of AmB + allicin (group 6) cleared the leishmanial 
infection in three out of six hamsters. Moreover, the reduction in the Leishmania spleen burden 
was almost as great as that obtained with standard AmB chemotherapy in this model (5 mg/kg, 
5 days, ip) (96.57% versus 94.5%) (Manandhar et al., 2008). These results suggest a partial 
additive antileishmanial effect of the combination in vivo. Results obtained with either drug 
administered alone to hamsters support the predictive value of the in vitro and ex vivo model 
(Leishmania-infected macrophages) for drug screening of antileishmanial molecules (Sereno et 
al., 2007).  
No information on the mechanism of action of the combination against Leishmania is 
available. However, in fungi (e.g. Candida albicans) the enhanced fungicidal activity of this 
combination (Kim et al., 2012) has been related to the inhibition of ergosterol trafficking by 
allicin in the presence of non-lethal concentrations of AmB (Borhijan et al., 2009; Ogita et al., 
2009). AmB levels in treated hamsters suggested, but did not demonstrate conclusively, that 
allicin improves the accumulation of the antibiotic in the target organs, and this should be 
explored.  
Resolution of Leishmania infection after vaccination or successful therapy seems to be 
associated with a Th2-to-Th1 switch with a dominant IgG2 response (Melby et al., 2001; Murray 
et al., 2003; Rama Íñiguez et al., 2006; Samant et al., 2009; Gupta et al., 2012). Our results 
showed a degree of correlation between total IgG (H + L) and Leishmania burden (Requena et 
al., 2000). However, hamsters treated with 5 mg/kg AmB (group 3) had lower levels of specific 
IgG2 than animals treated with 1 mg/kg AmB. This suggests that the relationship of the 
IgG1 and IgG2 pattern to the outcome of leishmanial infections in hamsters is not clear. In fact, 
hamsters treated with AmB showed antibody levels comparable to those of infected, untreated 
hamsters (Asthana et al., 2013). In addition, slightly different patterns were obtained with fixed 
promastigotes and soluble extracts of Leishmania. These variations are probably related to the 
different sets of antigens recognized by the sera of infected hamsters. Allicin apparently 
enhances proinflammatory responses (IFN-γ, TNF and IL-12p70) in mice (Feng et al., 
2012), which could explain the relatively high IgG2 response in animals treated with allicin or 
allicin + AmB. Whether or not the role of these cytokines is similar in mice and hamsters or, 
alternatively, allicin has immunostimulating properties should be clarified. More research is 
needed (refining of the dosage and time schedule), but our results point to the interest of this 
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combination as a means of reducing the dose of AmB needed in the chemotherapy of 
leishmaniasis. 
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CHAPTER 6 
 
Antileishmanial activity of allicin: a 
mechanistic approach 
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6.1.a. Resumen 
Mecanismo de acción de alicina frente a Leishmania 
La actividad antimicrobiana y antiparasitaria de alicina ha sido ampliamente estudiada 
aunque los mecanismos de acción implicados en su actividad frente a Leishmania no han sido 
explorados. En esta contribución presentamos las alteraciones ultraestructurales y bioquímicas 
provocadas por esta molécula sobre los promastigotes de Leishmania infantum. Los estudios de 
microscopía electrónica de transmisión mostraron que alicina indujo importantes 
modificaciones que incluyeron el aumento de tamaño de la mitocondria, invaginaciones de la 
membrana mitocondrial interna y pérdida de integridad. Se observaron asimismo dilatación de 
la membrana nuclear y vacuolización citoplasmática generalizada. La exposición de los 
promastigotes a alicina causó la producción de niveles elevados de especies reactivas de 
oxígeno (ROS), tanto en citoplasma como en mitocondria, no controladas por tioles 
intracelulares; colapso del potencial de membrana mitocondrial, disminución de la producción 
de ATP y elevación de calcio citosólico. La incubación de los promastigotes con SYTOX Green 
mostró que la disminución de ATP no estaba asociada al  incremento de la permeabilidad de la 
membrana celular. La tinción con Anexina V y yoduro de propidio (PI) demostró que alicina no 
indujo la externalización de fosfatidilserina en la membrana. Además, el análisis TUNEL 
permitió observar que alicina no provocó fragmentación de ADN. Estos resultados indicaban 
que alicina indujo necrosis celular en Leishmania. El análisis del ciclo celular, mediante tinción 
con PI, mostró que alicina detenía el ciclo celular en la fase G2/M. Se concluye que la diana 
primaria de alicina es la mitocondria e induce estrés oxidativo, no controlado por la defensa 
antioxidante, que provoca una disfunción mitocondrial, incremento de los niveles 
citoplasmáticos de calcio y una catástrofe bioenergética que conduce a la necrosis celular y 
detención del ciclo celular en fase premitótica. 
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6.1.b. Abstract 
Antimicrobial activity of allicin has been extensively studied although the precise 
mechanism of action underlying its antileishmanial effect has been virtually unexplored. Here 
we report the ultrastructural and biochemical alterations caused by diallyl thiosulphinate in 
Leishmania infantum promastigotes. Transmission electron microscopy showed that allicin 
induced relevant morphological changes, including mitochondrial swelling, invaginations in the 
inner mitochondrial membrane and loss of internal integrity. Other important alterations 
observed involved swelling of the nuclear membrane and an intense vacuolization of the 
cytoplasm. Exposure of the parasites to allicin led to high production of intracellular and 
mitochondrial reactive oxygen species (ROS) which was not controlled by thiol homeostasis, 
collapse of the mitochondrial membrane potential, reduced production of ATP and elevation of 
cytosolic calcium. The incubation of the promastigotes with SYTOX Green revealed that 
decrease of ATP was not associated with plasma membrane permeabilization. Annexin V and 
propidium iodide (PI) staining indicated that allicin did not induce phosphatidylserine exposure 
on the plasma membrane. Moreover, TUNEL analysis demonstrated that allicin did not provoke 
DNA fragmentation. These results point towards a necrotic type of cell death in Leishmania 
after exposure to diallyl thiosulphinate. In addition, analysis of the cell cycle with PI staining 
showed that allicin induced cell cycle arrest in the G2/M phase. We conclude that allicin 
primarily targets mitochondria and induces oxidative stress, uncontrolled by the antioxidant 
defense of the cell, which leads to mitochondrial dysfunction, increase of cytosolic calcium 
levels and a bioenergetic catastrophe leading to cell necrosis and cell cycle arrest in the 
premitotic phase. 
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6.2. Introduction 
Leishmaniases are vectorial parasitic diseases of mammals, including humans, caused by 
species of the genus Leishmania (Protista). Infections are present in all inhabited continents and 
their prevalence has been estimated around 12 million people infected, with an annual incidence 
of 2 million and 350 million people living in areas at risk (WHO, 2010). Leishmaniases are, for 
the most part, transmitted by some species of sandflies (Insecta, Psychodidae) and therefore 
their epidemiology is highly dependent on the environmental conditions regulating the presence, 
abundance and dynamics of vector populations. Leishmaniasis presents a range of clinical 
forms, from cutaneous self-healing infections to fatal unless treated visceral processes, mainly 
related to the Leishmania species involved and the immune status of hosts (WHO, 2010). 
Presently, it is considered the second most lethal parasitic disease, after malaria, visceralizing 
species being responsible of 20,000 to 40,000 human deaths per year (Alvar et al., 2012). In the 
last years a rise in human prevalence has been found and it has been related to the changing 
epidemiological patterns (e.g. non-vectorial transmission, lower investments in public health, 
climate change, and human migrations). Recent estimates based on databases and statistical 
modelling rise the current human population to 1.71 billion and 1.69 billion individuals living in 
areas suitable for cutaneous leishmaniasis and visceral leishmaniasis respectively (Piggot et al., 
2014).  
Control of leishmaniasis relies mainly on chemotherapy using antimonials, amphotericin B, 
miltefosine and paromomycin (Sundar & Chatterjee, 2006). However, these drugs have several 
shortcomings including high price, long treatments and side effects such as toxicity and 
teratogenicity (Sundar & Chakravarty, 2013) and this research area is hardly attractive for 
industry (low returns, long development required, high costs). In addition, in some of the most 
affected areas of the world (i.e. northeastern India), resistance to the treatment of choice 
(antimonials) is widespread (Croft et al., 2006); therefore there is an urgent need of new 
molecules, both synthetic and natural (Croft & Olliaro, 2011).  
Allicin (diallyl thiosulfinate) and related compounds have been shown to inhibit the 
multiplication of several neoplastic cell lines and the viability and growth of different tumors 
(Knowles & Milner, 2001; Arunkumar et al., 2006; Chu et al., 2012). In addition it has shown 
antibacterial (O’Gara et al., 2000; Cañizares et al., 2004; Cutler & Wilson, 2004), antifungal 
(Khodavandi et al., 2011a; Lemar et al., 2005) and antiprotozoal activity (Mirelman et al., 1987; 
McClure et al. 1996; Coppi et al., 2006; Waag et al., 2010). More recently, antiproliferative 
activity of allicin has been shown against intracellular amastigotes of Leishmania (Corral et al., 
2012) and in vivo experimental infections with L.infantum (Corral et al., 2014). Allicin easily 
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diffuses across cell membranes and it has been described to react with thiol groups (Rabinkov et 
al., 1998) and some other intracellular targets have also been incriminated (e.g. cysteine 
proteases, microtubules disruption) (Ankri and Mirelman, 1999; Prager-Khoutorsky et al., 2007; 
Miron et al., 2010; Waag et al., 2010) but the actual mechanism of action of allicin and the type 
of death induced are for the most part unknown. It has been reported that allicin induces p53-
mediated autophagy of Hep G2 human liver cancer cells (Chu et al., 2012) and apoptosis 
through caspase activation (Oomen et al., 2004) and via Nrf2 (Zhang et al., 2010). Nevertheless, 
the closely related compound diallyl disulfide causes cell cycle arrest in the G2/M checkpoint in 
HCT-15 (Knowles & Milner, 2001) and PC-3 (Arunkumar et al., 2006) cell lines.  
Information in unicellular eukaryotes is scarce although allicin seems to inhibit the 
expression of silent information regulator 2 (SIR2) gene (ortholog to mammalian SIRT1) 
(Khodavandi et al., 2011b) thus inhibiting the hyphae formation in Candida (Low et al., 2008). 
In addition, one of the metabolites of allicin, allyl alcohol, induces oxidative stress in this 
fungus. On these grounds our aim was to explore the mechanistic basis of its antileishmanial 
activity. Preliminary transmission electron microscopy (TEM) studies of Leishmania 
promastigotes exposed to sublethal concentrations of allicin showed that the most altered 
organelle was the unique mitochondrion from this kinetoplastid (Corral et al., 2012). Present 
results indicate that allicin induces in Leishmania promastigotes ROS generation with 
mitochondrial dysfunction with a collapse of the mitochondrial membrane potential (∆Ψm) and 
rapid elevation of cytosolic Ca2+ levels. These events lead to a bioenergetic catastrophe with fall 
of mitochondrial ATP production and cell necrosis with no evidence of apoptotic-like markers. 
  
6.3. Material and Methods 
Drugs 
Allicin (2-Propene-1-sulfinothioic acid S-2-propenyl ester) was purchased as liquid 
Allisure® from Allicin International Ltd. (Rye, East Sussex, UK) at a concentration of 5000 
ppm and stored at -80˚C until used.  
 
Parasite culture and maintenance  
The canine isolate of L.infantum (MCAN/ES/2001/UCM9) was employed in all the 
experimental procedures. Promastigotes were routinely cultured in 25 mL culture flasks at 27ºC 
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in RPMI 1640 modified medium (Lonza) supplemented with 10% heat-inactivated (30 min at 
56°C) fetal bovine serum (TDI laboratories) and 100 U/mL of penicillin plus 100 μg/mL of 
streptomycin (BioWhittaker).  
 
Ultrastructural study by Transmission Electron Microscopy (TEM) 
Leishmania untreated and allicin treated cultures (27ºC, 24 h allicin exposure) were 
centrifuged (3000xg, 10 min, 4ºC) and the resulting cell pellet was fixed for 90 min at 4ºC in 
2% glutaraldehyde (Sigma) in 0.1 M sodium cacodylate buffer (pH 7.4). Cells were washed in 
the same buffer containing 4.5% sucrose. Parasites were post-fixed for 1 h in the dark at 4ºC in 
a solution containing 1% osmium tetroxide in 0.1 M cacodylate buffer and washed in the same 
buffer. Samples were dehydrated with increasing concentrations of ethanol in Milli-Q water (10 
min incubations in 50% and 70% EtOH at 4ºC and 90% and 100% EtOH at room temperature 
(RT). To enhance contrast, en-bloc staining was carried out as an intermediate step with 1% 
uranyl acetate solution in 70% EtOH for 45 min at 4ºC in the dark. Samples were embedded in 
Epon 12 resin and polymerized (24 h at 45ºC and 48 h at 60ºC). After polymerization, Epon 
blocks were sectioned with an ultramicrotome (Leica EM UC6). Ultrathin sections, 50-60 nm 
thick, were mounted on 300-mesh grids, stained with 1 % uranyl acetate aqueous solution and 
lead citrate and observed using a TEM/STEM Philips Tecnai 12 electron microscope at the 
Instituto de Salud Carlos III facilities (Majadahonda, Madrid). 
 
Measurement of Reactive Oxygen Species (ROS) generation 
Intracellular ROS levels were measured using the cell permeable probe H2DCFDA (2',7'-
dichlorodihydrofluorescein diacetate, Molecular Probes). This non-fluorescent compound 
passively diffuses into cells where is retained upon intracellular hydrolization by esterases. 
Oxidation of the compound by ROS results in the formation of the fluorescent product 
dichlorofluorescein (DCF). This probe can be oxidized in the presence of different ROS species 
such as hydrogen peroxide (H2O2), hydroxyl radicals (OH˙) and peroxynitrites among others.  
Experiments were carried out in triplicate following a modified protocol described by 
Fonseca-Silva et al. (2011). Briefly, 2 x 106/mL mid-log phase promastigotes were incubated at 
27ºC for 3h in the absence or presence of increasing concentrations of allicin (15-120 µM). 
Parasites were washed in phosphate saline buffer (PBS) (Lonza) and resuspended in 1 mL of 
PBS (2 x 106/mL) and incubated with 20 µM H2DCFDA for 20 min at 37ºC, 5% CO2. Aliquots 
of 200 µL/well were transferred to a 96-well solid flat bottomed black microtiter plate (Costar, 
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Corning) and fluorescence intensity was measured in a FLUOstar OPTIMA microplate reader 
(BMG Labtech) using excitation/emission wavelength of 500 nm/490 nm. Antimycin A (5 µM) 
(Sigma) was used as a positive control of ROS generation. 
 
Measurement of mitochondrial ROS generation  
Superoxide anion (O2-) production was assayed fluorimetrically using the mitochondrial 
targeted probe MitoSox Red (Molecular probes) as described previously by Carvalho et al. 
(2010) with some modifications. This cell-permeable dye is positively charged and reacts in the 
presence of O2- rendering a red-fluorescent product when oxidized.  
Cells (107 promastigotes/mL) were loaded with 1 µM MitoSox Red for 30 min at 27 ºC in 
HBSS (Ca/Mg) (Hank's Balanced Salt Solution with calcium and magnesium, Gibco). Parasites 
were washed in HBSS and then treated with allicin (15-120 µM) for 3h at 27ºC. After treatment 
cells were washed and resuspended in HBSS (107 promastigotes/mL). Aliquots of 200 µL/well 
were transferred to a 96-well solid black microtiter plate (Costar, Corning) and fluorescence 
intensity was recorded in a FLUOstar OPTIMA microplate reader (BMG Labtech) with an 
excitation wavelength of 510 nm and emission of 580 nm. Untreated cultures and cultures 
treated with 5 µM antimycin A (Sigma) were included as controls. Three experiments were 
carried out in triplicate.  
 
Measurement of free cytosolic calcium  
Cytosolic Ca2+ in promastigotes was monitored using Fluo 4AM dye (Molecular Probes) 
using a modified protocol previously described by Serrano-Martín et al. (2009). Exponentially 
growing cultures were washed twice with the following loading buffer: 137 mM NaCl, 4 mM 
KCl, 1.5 mM KH2PO4, 8.5 mM Na2HPO4, 11 mM glucose, 2 mM CaCl2, 0.8 mM MgSO4 and 
20 mM HEPES-NaOH, pH 7.4 (Sigma).  
A total of 107 cells/mL were preloaded with 5 µM Fluo 4AM for 60 min at 27ºC in the same 
loading buffer. Pluronic F-127 (0.02%, Molecular Probes) was added to facilitate the dispersion 
of the nonpolar AM ester as recommended by the manufacturer. Parasites were washed twice 
with loading buffer to allow complete intracellular de-esterification of the AM esters and cells 
were further incubated for 15 min at 27ºC. Fluorescence was excited using a 485 nm filter and 
read through a 520 nm long-pass emission filter in a microplate reader (FLUOstar OPTIMA, 
BMG Labtech). To measure intracellular Ca2+ responses, baseline fluorescence was monitored 
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before the addition of the different stimuli. Cells were treated with increasing concentrations of 
allicin (15-120 µM) and fluorescence intensity was recorded for 1 h every 5 min. Fluorescence 
intensity measurements were normalized according to Takahashi et al. (1999). Maximal 
fluorescence values were obtained by permealizing cells with 0.5% Triton X-100 under the 
saturating Ca2+ environment. Minimal fluorescence was measured after chelation of Ca2+ with 8 
mM EGTA. Two independent experiments were carried out in triplicate.  
 
Measurement of mitochondrial transmembrane potential (∆Ψm) 
Changes in the ∆Ψm were analyzed by flow cytometry using the cationic lipophilic dye 
5,5_,6,6_-tetrachloro-1,1_,3,3_-tetraethylbenzimidazole carbocyanide iodide (JC-1) according 
to manufacturer’s instructions (Molecular Probes). As a positive charged molecule, this dye 
selectively accumulates in mitochondria in inverse proportion to ∆Ψm according to the Nernst 
equation (Perry et al., 2011).  Healthy cells, with functional mitochondrial electron transport, are 
negatively charged and will accumulate more dye. When the ∆Ψm collapses JC-1 dye will be 
accumulated in its monomeric form within the cytosol of the cells. The JC-1 monomer, which 
predominates in cells with depolarized ∆Ψm, emits green fluorescence (530 nm or in FL-1 in 
FACS analysis), whereas the J-aggregates, which are formed in mitochondria with high 
potentials ≥140 mV, emit red fluorescence (590 nm or in FL-2). The ratio between red/green 
fluorescence intensities (FL-2/FL-1; 590 nm/530 nm) allows assessment of ∆Ψm fluctuations 
(Keil et al., 2011). 
After 3 h of treatment with allicin (15-120 µM, 27ºC) promastigotes were washed in PBS 
and resuspended (2 x 106/mL) in 1 mL of PBS containing JC-1 dye at a final concentration of 6 
µM. Parasites were incubated in the dark for 20 min at RT. After incubation, parasites were 
washed twice in PBS to eliminate the non-internalized dye. Non-treated cells and cells treated 
with 100 µM of the mitochondrial uncoupler carbonyl cyanide 3-chlorophenylhydrazone 
(CCCP, Sigma) were included as controls. Measurements were performed using a FACScan 
flow cytometer and analyzed with CellQuest software (Becton Dickinson). 
 
Measurement of cellular ATP levels 
Quantification of ATP levels was carried out using the CellTiter-Glo luminescent assay 
(Promega) as previously described by Manzano et al. (2011). This assay generates a 
luminescent signal which is directly proportional to the amount of ATP present. Briefly, mid-
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log phase promastigotes (2 x 106/mL) were incubated at 27ºC in RPMI supplemented medium 
in the presence of 15, 30, 60, 90 and 120 µM allicin for 3 h. Untreated cultures and cultures 
treated with 20 mM sodium azide (Sigma) which inhibits mitochondrial oxidative ATP 
generation were included as controls. After the drug exposure period, a 30 µL aliquot of the 
parasite suspension was transferred to a 96-well solid white flat bottomed microtiter plates 
(Costar, Corning) and an equal volume of CellTiter-Glo was added to each well. Plates were 
incubated in the dark for 10 min at room temperature (RT) and luminescence was measured 
using a FLUOstar Omega microplate reader (BMG Labtech). Three independent experiments 
were carried out in triplicate.  
 
Determination of plasma membrane integrity 
Cell membrane permeabilization was determined using the SYTOX Green nucleic acid stain 
(Molecular Probes) as described previously (Lynn et al., 2011) with modifications. Intact cells 
are impermeable to SYTOX Green dye which penetrates compromised membranes and binds to 
nucleic acids. Mid-log phase promastigotes were washed twice in HBSS and parasites (2 x 106 
promastigotes/mL) were incubated (15 min, 27ºC) in the dark with 2 µM SYTOX Green. Cells 
were washed in HBSS and incubated in the presence of increasing concentrations of allicin (0, 
15, 30, 60, 90 and 120 µM) for 3 h at 27ºC. An aliquot of the parasite suspension (200 µL/well) 
was transferred to a 96-well solid black microtiter plate (Costar, Corning) and fluorescence 
intensity was measured in a FLUOstar OPTIMA microplate reader (BMG Labtech) with 
excitation and emission wavelengths of 520 nm and 500 nm, respectively. Control for maximum 
fluorescence (100% membrane permeabilization) was obtained by the addition of 0.5% Triton 
X-100. Three independent experiments were carried out in triplicate. 
 
Determination of Trypanothione reductase (TryR) activity in parasite lysates 
Assessment of TryR activity was carried out using the colorimetric method described by van 
den Bogaart et al. (2014). TryR is a NADPH-dependent oxidoreductase which reduces 
trypanothione (T[S]2) to dihydrotrypanothione (T[SH]2). Within the cells, trypanothione is re-
oxidized when inactivating free radicals and other reactive oxygen species thus playing a critical 
role in the parasite antioxidant defense. Measurement of TryR activity was monitored by 
coupling the regeneration of T[S]2 to the reduction of 5,5′-dithiobis-2-nitrobenzoic acid (DTNB, 
Sigma). One molecule of DTNB re-oxidizes T[SH]2 forming two molecules of yellow 
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thionitrobenzoate ion (TNB2-) which can be quantified spectrophotometrically (Hamilton et al., 
2003). Figure 1 shows a scheme of the reaction: 
 
 
Figure 1. TryR activity assay principle: regeneration of T[S]2 by DTNB-coupled reaction (Modified from van den 
Bogaart et al., 2014). 
 
 
Leishmania logarithmic promastigotes (2 x 106/mL; 50 mL) were grown in 75 cm2 culture 
flasks and exposed to different allicin concentrations (30, 60 and 120 µM) for 3 h at 27ºC. 
Untreated cultures were included as negative controls. The tricyclic neuroleptic drug 
clomipramine HCl (Sigma) has previously been reported to selectively inhibit TryR (Ondarza et 
al., 2000). Positive controls consisting in cultures treated with 10 µM clomipramine HCl (3h, 
27ºC) were also included in the experiment. After the drug exposure period, cells were washed 
twice in PBS and cultures were concentrated (2 x 107/mL; 1mL/eppendorf). Samples were 
centrifuged (10000 rpm, 5 min, RT) and supernatants were discarded. Pellets were incubated for 
15 min at RT with 1 mL of lysis buffer consisting of 1 mM EDTA, 40 mM HEPES, 50 mM 
Tris-HCl (pH 7.5), and 2% v/v Triton X-100 (Sigma). Prior to lysis, buffer was supplemented 
with 1 mM protease inhibitor phenylmethanesulfonyl fluoride (PMSF, Sigma). Stock solutions 
and further dilutions of NADPH (Sigma), T[S]2 (Bachem) and DTNB (Sigma) were stored and 
prepared as described by van den Bogaart et al. (2014). 
To determine TryR activity, an aliquot (375 µL) of the parasite lysate was transferred into a 
new microcentrifuge tube, followed by the sequential addition of NADPH (125 µL/sample), 
T[S]2 (375 µL/sample) and DTNB (125 µL/sample) yielding final concentrations of 200, 75 and 
100 µM, respectively. A blank was included for each sample consisting of the same reaction 
mixture without the substrate. T[S]2 was replaced by an equal volume of 0.05M Tris buffer (pH 
7.5). Samples were incubated at 27ºC protected from light and absorbance (λ= 412 nm) was 
determined for 90 min every 15 min in a UV Mini 1240 spectrophotometer (Shimadzu). Blank 
values were subtracted from all the samples. TNB ion formation is equivalent to TryR activity.  
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Determination of non-protein thiol levels: GSH, T[SH]2 and Cys 
Reagents and materials 
L-cysteine (Cys) (97%), glutathione (GSH) (99%), 2,3-dimercapto-1-propanol (DMP) 
(98%), methanesulfonic acid (MSA) (99.5%), tris (2-carboxyethyl)phosphine hydrochloride 
(TCEP-HCl) (98%), diethylenetriaminepentaacetic acid (DTPA) (99%) were purchased from 
Sigma. Trypanothione (T[SH]2)  (>99%) was obtained from Bachem AG, monobromobimane 
(mBBr) was from Toronto Research Chemicals.  
Acetonitrile (MeCN) and methanol (MeOH) (HPLC-grade) were provided by Scharlab and 
trifluoroacetic acid (TFA) (HPLC-grade, 99.5%) was from Apollo Scientific. Analytical grade 
reagents: 3-[4-(2-hydroxyethyl)-1-piperazinyl) propane sulfonic acid (HEPPS) (99%) was from 
AppliChem and sodium hydroxide (NaOH) was from Thermo-Fisher Scientific. Water was 
purified with a Milli-Q system from Millipore. All solutions used in the HPLC were passed 
through a 0.45 μm nylon filter before use. 
Experimental procedure 
Exponentially growing promastigotes (2 x 106/mL; 50-100 mL) were harvested in triplicate 
and treated for 24 h with increasing allicin concentrations at 27ºC. Cell suspensions were 
washed twice in PBS and frozen (2 x 107 cells; 50 µL PBS) at -80ºC until the time of analyses.  
Standards and stock solutions were prepared as described below. Briefly, GSH, Cys, and 
T[SH]2 stock solutions were prepared in Milli-Q water at a concentration of 8mM, 8 mM and 
15 mM, respectively. DMP stock solution was prepared in Milli-Q water at a concentration of 8 
mM. A stock solution of mBBr was prepared in acetonitrile at a concentration of 50 mM and 20 
mM TCEP solution was made in 200 mM HEPPS buffer (pH 8.2). All solutions were aliquoted 
and stored at -20 ºC in the dark until the time of analysis. Appropriate aliquots of Cys, GSH and 
T(SH)2 stocks were mixed and diluted with extraction solution (6.3 mM DTPA with 0.1% TFA) 
to construct a calibration curve of each thiol with concentration ranging between 0.05 and 6.2 
nmol/mL. The internal standard, DMP, was prepared at a final concentration of 0.75 nmol/mL.  
The extraction of thiols was performed in acid media using as extraction solvent 50 μL of 6.3 
mM DTPA (0.1% TFA) that was added to microcentrifuge tubes containing the pellets 
resuspended in PBS. After vortex mixing, Leishmania extracts were immediately frozen in 
liquid N2 and thawed three times to fully release cellular content. The supernatant was collected 
by centrifugation (13,000 rpm, 10 min) and subsequently derivatized. 
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The derivatization procedure followed was based on the method described by Minocha et al. 
(2008). Firstly, 10 μL of 20 mM TCEP and 246 μL of 200 mM HEPPS buffer (6.3 mM DTPA, 
pH 8.2) were mixed to obtain a sulfur reducing solution that was subsequently added to 100 μL 
aliquots of Leishmania sample extracts or standards; 4 μL of 75 μmol/L DMP was also added as 
an internal standard. Then, the mixtures were incubated at 45 ºC in a water bath for 10 min to 
guarantee the reduced state of thiols before mBBr derivatization. For derivatization of thiols, 10 
μL of 50 mM of mBBr was added to the vials containing samples or standards and incubated in 
the dark for 30 min at 45 ºC in a water bath. Finally, 100 μL of 1 M MSA were added to stop 
reaction and derivatized samples were analyzed by HPLC-DAD/FLD [High-performance liquid 
chromatography (HPLC) equipped with both diode-array detector (DAD) and a fluorescence 
detector (FLD)].  
Chromatographic separation of the thiols was performed on a SynergiTM Hydro-RP (250 
mm × 4.6 mm, 4 μm) HPLC column from Phenomenex (Torrance, CA, USA). A gradient 
program was used with the mobile phase, combining solvent A (Milli-Q water with 0.1% TFA) 
and solvent B (MeCN with 0.1% TFA) as follows: 10% B (5 min), 20.6% B (6.7 min), 31.1% B 
(13.6 min) and 100% B (5 min). The column was equilibrated with 10% of solvent B for a total 
of 8 min before next injection. Analyses were performed at a flow rate of 1.0 mL/min and the 
column temperature was kept at 40 ºC. The injection volume was 100 μL and all the compounds 
elute within 30 min. The DAD detector was set at both 290 and 380 nm and the excitation and 
emission wavelengths of the FLD detector were set at 380 nm and 470 nm, respectively. 
Quantification was performed using internal calibration and peak area measurements. Multiple 
analyses were performed using blanks and standards to determine detection limits, response 
linearity and reproducibility of the protocol. 
 
Annexin V and Propidium Iodide staining 
Externalization of phosphatidylserine (PS) upon the outer leaflet of the plasma membrane 
has been considered a common marker of apoptosis in eukaryotic cells. This calcium regulated 
process takes place as an early event in the apoptotic dying cascade. PS translocation in the cell 
surface serves as a specific signal for phagocytic clearance without triggering an inflammatory 
response (Balasubramanian et al., 2007). Annexin V, a Ca2+-dependent phosphatidil-binding 
protein with high affinity for PS, was used for PS labeling. Evaluation of plasma membrane 
integrity with propidium iodide (PI) staining allowed the discrimination between necrosis and 
apoptosis.  
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PS exposure in Leishmania promastigotes was analyzed using the Annexin V-FLUOS 
Staining kit (Roche) according to manufacturer's instructions. Briefly, cells (2 x 106/mL) were 
incubated at 27ºC in the presence of allicin (30-120 µM) for 3, 12, 24 and 48 h. Cells were 
washed twice in cold PBS and the resulting pellet resuspended in 100 µL of HEPES buffer 
containing Annexin-V and PI (2 µL of each). Samples were incubated at RT in the dark for 15 
min and analyzed by flow cytometry (FACScan, Becton Dickinson) with CellQUEST software. 
Cultures incubated at 45ºC overnight were used as positive death controls.  
 
In situ DNA fragmentation detection and cell cycle analysis 
A biochemical hallmark of late apoptosis stages is internucleosomal DNA fragmentation. 
Chromatin cleavage by endonucleases originates nucleosomal DNA fragments that can be 
labeled in situ by the terminal deoxynucleotidyl transferase (TdT) mediated dUTP nick-end 
labelling (TUNEL) method. TUNEL was performed using an APO-BrdU™ TUNEL Assay Kit 
(Invitrogen) following manufacturer's recommendations. Bromodeoxyuridine (BrdU) is a 
synthetic thymidine analog. This assay is based on the ability of TdT enzyme to incorporate 
labeled-dUTP (BrdU) to 3'-hydroxyl ends of DNA breaks (Gavrieli et al., 1992). BrDU 
incorporation can be labeled and quantified by flow cytometry measuring fluorescence intensity 
emitted by a conjugated anti-BrdU antibody.  
Briefly, promastigotes (2 x 106/mL) were treated with allicin for 48 and 72 h and washed 
twice with cold PBS. Parasites were fixed in 1% paraformaldehyde (4ºC, 15 min), washed and 
incubated at -20ºC overnight in 70% ethanol. After washing, cells were incubated (60 min, 
37ºC, darkness) in DNA-labeling solution to allow TdT-mediated DNA-BrdU binding. Cells 
were washed twice in rinsing buffer and incubated (30 min, RT, darkness) with Alexa Fluor 488 
conjugated anti-BrdU antibody. Prior to flow cytometric analyses (FACScan, CellQUEST 
software). PI/RNase A staining solution was added to examine cellular DNA content and study 
cell cycle progression.  
 
Statistical analysis  
Statistical analysis and graphs were performed with GraphPad Prism 5 software. Statistical 
significance of differences was determined by one-way analysis of variance (ANOVA) and 
Bonferroni post-test. Differences were considered significant at a p value of < 0.05. 
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6.4. Results 
Transmission Electron Microscopy (TEM) studies of allicin treated Leishmania 
promastigotes 
Normal morphology and structural organization of Leishmania promastigotes is shown in 
untreated controls (Figure 2A, 2A’ and 2A’’). Promastigotes incubated in the presence of 
different concentrations of allicin for 24 h showed important morphological and subcellular 
alterations (Figure 2B-2J). 
Electron micrographs of treated parasites revealed significant ultrastructural changes in the 
mitochondrion and kinetoplast (Figure 2B, 2C, 2E, 2F and 2I). Allicin treated promastigotes 
presented intense mitochondrial swelling and loss of electron dense material in the 
mitochondrial matrix, particularly evident in Figures 2B and 2I. In some images, mitochondrial 
cristae could be recognized (Figure 2B and 2F). Indeed, a complete loss of internal integrity of 
this structure was observed with high allicin concentrations (Figures 2B and 2I). Moreover, 
invaginations of the inner mitochondrial membrane could be seen in some micrographs (Figures 
2B and 2I).  
A second relevant morphological change took place in the nucleus. Swelling of the nuclear 
membrane was evident in all drug-treated cells (Figures 2B, 2D, 2E, 2G, 2H and 2J). Peripheral 
chromatin condensation in the nucleus was found in some micrographs (Figures 2B, 2G and 
2H). Extensive alterations in the structure and organization of the cytosol were found after 
treatment with allicin. Cytoplasm vacuolization (Figures 2B, 2C, 2D, 2F, 2H, 2I and 2J), 
dramatic changes in cytosolic density (loss of electron dense material) (e.g. Figures 2G, 2H and 
2J) and an increase in the number of cytoplasmic vesicles, probably autophagosomal structures, 
were observed in allicin exposed parasites (Figures 2B, 2C, 2D, 2F, 2I and 2J). Glycosomes, 
megasomes and acidocalcisomes could be observed in untreated controls (Figure 2A’’). 
Presence of glycosomes or other electrodense vesicles was remarkably reduced in treated 
parasites. However, acidocalcisomes persisted in treated promastigotes (Figures 2H, 2I and 2J).  
No significant alteration could be observed in the flagellum or flagellar pocket (not shown). 
Ultrastructural internal changes and cell swelling were evident after allicin exposure; 
nevertheless, cellular membrane integrity seemed to be conserved in treated cells (Figures 2G 
and 2H).  
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Figure 2. Electron micrographs of untreated (2A, 2A’ and 2A’’) and treated (24 h exposure to allicin) Leishmania 
promastigotes. Allicin treated parasites (24 h drug exposition): 60 μM (2D, 2E, 2F and 2H), 90 μM (2B, 2C and 2I), 
120 μM (2G and 2J). m: mitochondrion; k: kinetoplast; n: nucleus; Nm: nuclear membrane; gly: glycosomes; *: 
acidocalcisomes; ▲▲: inner mitochondrial membrane invaginations.  
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ROS production of promastigotes in the presence of allicin 
Experimental approach only included the exposition to different concentrations of allicin in 
the micromolar range. The molecule triggered the elevation of intracellular fluorescence, after 
3h treatment with allicin, as assessed by the synthesis of dichlorofluorescein (DCF) this 
evidencing the presence of high levels of hydroxyl radicals, hydrogen peroxide and 
peroxynitrites (Figure 3A). Intracellular ROS generation was concentration dependent and 
reached over 5-fold production in the presence of 90 µM allicin. It is noteworthy to indicate that 
the exposition of promastigotes to the estimated EC50 value (30 µM) elicited a ROS production 
similar to the value reached by the positive control (5 µM antimycin A). 
  
 
 
Figure 3. Allicin induces ROS 
generation in Leishmania 
promastigotes in a concentration-
dependent manner. Figure 3A, 
intracellular generation of ROS 
estimated by H2DCFDA in 
promastigotes treated for 3h with 15-
120 µM allicin, untreated control 
cultures and positive control exposed 
to 5 µM antimycin A.  
 
 
 
Figure 3B, effect of allicin on 
mitochondrial ROS generation by 
MitoSox Red in promastigotes 
treated for 3 h. Figure shows the 
results in Relative Fluorescence 
Units (RFU) and folds relative to 
untreated control cultures. Results 
shown correspond to means ± 
standard deviation (S.D.) of three 
experiments in triplicate and asteriks 
represent significant differences 
related to untreated cultures (***: 
p<0.0001). 
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Availability of a mitochondrial targeted probe (MitoSox Red) allowed the estimation of 
superoxide anion production. Similarly to the ROS production determined by the H2DCFDA 
probe, allicin effectively induced a strong elevation of superoxide production in mitochondria of 
treated cells (Figure 3B). This induction was very notable even with moderate allicin 
concentrations and a 6-fold increase was found with a concentration of 30 µM. It should be 
indicated that this increase, in the region of the levels reached by the positively treated 
promastigotes (5 µM antimycin), was maintained with higher allicin concentrations (60-120 
µM). 
 
Effect of allicin on the levels of cytosolic Ca2+ in Leishmania promastigotes 
It has been shown that oxidative stress causes mitochondrial depolarization in Leishmania 
(e.g. L.donovani) by increasing cytosolic Ca2+ levels. Moreover, the role of this cation and the 
fine regulation of its cellular concentration are critical. On these grounds, the cytosolic levels of 
calcium in L.infantum promastigotes treated with increasing concentrations of allicin (15-120 
µM) were determined at different times (0-60 min). For comparative purposes results obtained 
were normalized using as baseline the fluorescence before adding stimuli.  
 
 
 
 
 
 
 
 
 
Addition of allicin induced a rapid increase of cytosolic Ca2+ in a dose-dependent manner for 
a given post treatment time. Figure 4 shows the results obtained after 20 min. Chelation with 8 
mM EGTA inhibited this increase whereas the permeabilization of the cell membrane of 
Leishmania with 0.5% Triton X-100, in a saturated Ca2+ environment, showed the maximal 
Figure 4. Intracellular Ca2+ increases in response to 
allicin stress. Leishmania promastigotes were 
treated with allicin (15-120 µM) for 20 min. Calcium 
levels were determined by Fluo 4AM preloading of 
cells (60 min) in loading buffer with 0.02% Pluronic 
F-127. Maximal fluorescence was obtained with 
cells treated with 0.5% Triton X-100 and minimal 
after chelation with 8 mM EGTA. Data presented 
corresponds to the average increase of normalized 
fluorescence intensity of two independent 
experiments in triplicate (mean ± S.D.). Asterisks 
represent significant differences compared to 
untreated control promastigotes (*: p<0.05; ***: 
p<0.001). 
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cytosolic concentration. The increase of calcium was very rapid and after 20 min cells treated 
with the EC50 concentration (30 µM allicin) reached ca. 43% of the maximal value obtained 
with the positive control. 
 
Mitochondrial membrane potential of allicin-treated promastigotes 
Evaluation of mitochondrial transmembrane potential (∆Ψm) of L.infantum promastigotes 
treated with allicin was carried out using the cationic dye JC-1 and its selective accumulation in 
mitochondria inversely related to ∆Ψm. A net negative charge of mitochondrial membrane is a 
characteristic of healthy cells thus allowing the concentration of the cationic dye. JC-1 
aggregates emit red fluorescence at higher potential whereas with membrane potentials below 
140 mV remains as a monomer within the cytoplasm emitting green fluorescence.  
The potential can be altered by some intracellular events (e.g. ROS production) in 
Leishmania and our results showed an increase in mitochondrial ROS production in the 
presence of allicin, even at low micromolar concentrations. To asses changes in the ∆Ψm in the 
presence of allicin it was considered relevant to determine the ratio between red fluorescence 
(590 nm or FL-2) and green fluorescence (530 nm or FL-1). Fluorescence intensity as 
determined by FACS analysis (Figure 5A) showed that the FL-2/FL-1 ratio (red/green 
fluorescence ratio) was significantly affected, in our experimental conditions, in a dose-related 
manner since only 15-30 µM allicin induced a 23-30% reduction of the ratio and this value was 
below 90% with allicin concentrations >90 µM.  
 
 
 
 
 
 
 
Figure 5. Allicin provokes the loss of ∆Ψm in 
L.infantum promastigotes. Cells were exposed for 3 h 
to 15-120 µM allicin and fluctuations of ∆Ψm were 
determined by flow cytometry of cells preloaded with 
JC-1. Fluorescence intensity was determined by 
FACS analysis (green, FL-1 and red, FL-2). 
Untreated and positive (100 µM CCCP treated cells, 
3 h) cultures were included. Figure 5A: Effect of 
allicin on FL-2/FL-1 ratio. Fluorescence intensity was 
determined by FACS analysis. (FL-2: J-aggregates  
and in FL-1: JC-1 monomers). Untreated control cells 
and promastigotes exposed to the mitochondrial 
membrane uncoupler CCCP were included as 
controls. Data represents the mean ± S.D of three 
determinations. Asterisks represent significant 
differences to the untreated control cultures (*: 
p<0.05; **: p<0.005; ***: p<0.001). 
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Actually, the reduction with 60 µM was higher than that found with the CCCP treated 
control. Furthermore, the depolarization of the mitochondria evidenced by the ∆Ψm fall was 
supported by the shift of the Leishmania population towards the right in the FL-1 channel (green 
fluorescence) as observed by FACS analysis (Figure 5B). 
 
Figure 5B. Representative FACS analysis of monomeric JC-1 (green fluorescence intensity, FL-1) levels in 
promastigotes of L.infantum treated with allicin, untreated or subjected to the mitochondrial uncoupler CCCP (100 
µM). 
 
Cellular ATP levels of Leishmania promastigotes treated with allicin  
Allicin induced a dose-dependent notable fall of ATP levels in Leishmania, since exposure 
to 30 µM allicin (3 h) reduced ATP levels over 40% (2.59 ± 0.16 Relative Luminescence Units, 
RLU, in 30 µM allicin-treated promastigotes versus 4.55 ± 0.27 RLU in untreated control 
cultures). The decrease of ATP levels caused by 60 µM allicin was significantly higher 
(p<0.001) than the fall provoked by 20 mM sodium cyanide (Figure 6A).  
To ascertain that this fall of ATP was not due to membrane leakage, cellular membrane 
permeability of treated promastigotes was evaluated with SYTOX Green. Exposition to allicin 
(≥ 90 µM) induced altered permeability of plasma membrane of promastigotes of Leishmania 
(p<0.001); 120 µM allicin yielded ca. 50% increased permeability from that obtained with the 
positive control (0.5% Triton X-100) at least as assessed by SYTOX Green internalization 
(Figure 6B). Interestingly, low concentrations of diallyl thiosulfinate, and in particular in the 
range of EC50 values for this parasite stage (ca. 30 µM), did not result in any significant 
alteration of the cell membrane. These results point towards the fact that the diminished 
intracellular ATP generation observed in treated cells (<60 µM; i.e. drug concentrations that did 
not induce a notable damage of the plasma membrane) was probably due to a direct action of 
allicin on mitochondria. 
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Figure 6A. Allicin induces the fall of ATP production by Leishmania. Effect of allicin (15-120 µM, 3 h) on ATP levels 
of L.infantum promastigotes determined by the CellTiter-Glo luminescent assay. Untreated control cells and cells 
treated with 20 mM sodium azide as inhibitor of mitochondrial oxidative generation of ATP were included. Data 
presented corresponds to one representative experiment of the three independent experiments in triplicate carried 
out. Figure 6B.  Effect of allicin on membrane permeabilization. Promastigotes of Leishmania were incubated with 
allicin (15-120 µM) for 3 h and the permeability to SYTOX Green nucleic acid stain determined. Untreated and 
positive samples exposed to 0.5% Triton X-100 were included. Data represents means ± S.D. of three independent 
experiments carried out in triplicate. Asterisks represent significant differences to the untreated control cultures (***: 
p<0.001). 
 
 
Effect of allicin on trypanothione reductase (TryR) activity and non-protein thiol 
levels in Leishmania 
Trypanothione reductase (TryR) plays a fundamental role in the antioxidant defense of the 
cells through the reduction of trypanothione, the unique thiol present in Kinetoplastida including 
Leishmania. Given the strong induction on ROS production by allicin treated promastigotes (see 
above), it was considered relevant to know whether the enzymatic activity was affected by the 
diallylsulphide and also its possible impact on the intracellular levels of non-protein thiols. 
Exposure of Leishmania promastigotes to allicin for 3 h provoked a dose-dependent reduction 
of TryR activity in parasite lysates of treated cells. Residual activity in the presence of the 
lowest allicin concentration (30 µM) only reached a 66.67% of that found in untreated control 
cultures; 120 µM allicin reduced the TryR activity by a 80%, inhibition higher than that induced 
by the specific inhibitor clomipramine. Remaining TryR present in the leishmanial lysates 
displayed standard enzymatic kinetics (Figure 7). 
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Figure 7. Inhibition of TryR activity of Leishmania by allicin. Promastigotes treated for 3 h with varying concentrations 
of allicin (30, 60 and 120 µM) were lysed and the enzyme activity was determined by the sequential addition of 
200µM NADPH, 75 µM trypanothione and 100 µM DTNB. Thionitrobenzoate ion (TNB2-) produced was proportional 
to TryR activity and was quantified spectrophotometrically (412 nm) at different time points. Untreated control 
cultures and cultures treated with the TryR inhibitor clomipramine (100 µM) were included. Data shown correspond 
to the mean values of a representative experiment, from the two executed, carried out in duplicate. 
 
No clear figure emerged, in the three experiments carried out, when the levels of GSH, 
T[SH]2 and Cys from Leishmania promastigotes exposed to allicin were analyzed, variability 
was high among the experiments. However, the tendency suggests that non-protein thiol levels 
increased with allicin treatment (≤ 60 μM) (Table 1). Higher allicin concentrations induced a 
reduction of the analyzed thiols. T[SH]2 levels remained ca. 1.0 and 2.0 nmol/108 cells 
irrespective of the allicin concentration; only with 100 and 120 µM allicin, when TryR activity 
was reduced over 80% (see above), the levels of the thiol fell. By its part, the levels of GSH 
showed a pattern of increased levels with low allicin concentrations (< 30-50 µM), up to 2.5-3.0 
nmol/108 cells, followed by reduced levels with higher concentrations of the drug. Levels of 
cysteine were more variable between experiments although in all determinations there was a 
steady increase with higher drug concentrations. 
 
Table 1. Levels of non-protein thiols (cysteine, trypanothione and glutathione) in promastigotes 
of L.infantum promastigotes treated with allicin (10-120 µM). 
Allicin 
(µM) 
nmol/108 cells 
Cys GSH T[SH]2  
mean S.D. mean S.D. mean S.D. 
0 0.723 0.194 0.723 0.126 1.162 0.130 
10 0.914 0.214 0.914 0.146 1.591 0.192 
20 1.179 0.684 1.179 0.211 1.998 0.231 
30 1.448 0.801 1.448 0.194 2.235 0.135 
40 1.371 0.962 1.371 0.154 2.162 0.173 
50 1.561 0.711 1.561 0.184 2.365 0.112 
60 1.869 0.909 1.869 0.173 2.217 0.206 
80 1.675 0.849 1.675 0.166 3.076 0.255 
100 1.656 1.079 1.656 0.138 0.655 0.069 
120 1.771 0.762 1.771 0.100 0.216 0.012 
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Non-protein cellular thiols of Leishmania were separated, identified and quantified using 
HPLC-DAD-FLD. This approach was modified to improve reproducibility and sensitivity. 
Several isocratic and gradient elution conditions were evaluated using different 
acetonitrile/water mixtures containing TFA. Experimental parameters such as peak weight, 
resolution (Rs) and retention times (rt) have been compared to select the adequate separation 
procedure.  
The optimized separation was performed in gradient elution mode that yields Rs higher than 
2.0 and rt of 6.70, 11.94, 15.90 and 26.43 min for Cys, GSH, T[SH]2 and DMP, respectively. 
The RTs were reproducible between runs. Figure 8 shows a representative chromatogram of a 
standard mixture of the thiols. Thiols were quantified using an internal standard (DMP) 
calibration model using an eight-point calibration curve, which covered three-log concentration 
range (0.05 – 6.2 nmol/mL) for the three monothiols Cys, GSH and T(SH)2. The r2 value for 
standard curves was >0.999 for all thiol compounds tested. 
 
 
 
 
 
Figure 8. HPLC elution profile of MBBr derivatized thiols. Standard solution of Cys, GSH and T[SH]2 prepared at 3 
nmol/mL; 0.075 nmol/L of DMP was added as an internal standard. 
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Externalization of phosphatidylserine in allicin-treated Leishmania promastigotes 
Results obtained in the TEM study showed some alterations in the nuclear structure of the 
treated cells, these including the chromatin condensation in the periphery of the nucleus. 
Therefore it was considered relevant to evaluate the possibility of allicin inducing apoptosis in 
Leishmania. One of the most frequently used early markers of apoptosis is the externalization of 
phosphatidylserine (PS) by apoptotic cells. Figure 9 shows the results obtained, by FACS, after 
48 h treatment with 30, 60 and 120 µM allicin. Results obtained in the first three determinations 
(3, 12 and 24 h) did not yield significant results.  
 
 
 
Figure 9. PS externalization in Leishmania promastigotes is not detected with Annexin V and PI (propidium iodide) 
after treatment of promastigotes with allicin. L.infantum promastigotes were exposed to allicin (30, 60 and 120 µM) 
for 3, 12, 24 and 48 h and subsequently stained with Annexin V-FITC + PI and analyzed by flow cytometry. Data 
correspond to the samples exposed for 48 h. Lower row shows the allicin-treated cultures and the upper row includes 
unstained cells, untreated control cells and cells exposed overnight at 45 ºC. Percentages are shown in each 
quadrant. (-/-): healthy cells; Annexin+: apoptotic cells; Annexin+/PI+: late apoptotic or early necrotic cells; PI+: 
necrotic cells.  
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Using the EC50 concentration of the compound (30 µM) a shift of the cell population from 
the bottom left quadrant (Annexin V or PS-/PI-), characteristic of untreated healthy control 
cells, towards the upper left (PI+) and upper right quadrants (PS+/PI+) was observed. This shift 
was increased with higher concentrations of allicin and only a residual population remained 
double negative even with 120 µM. It is noteworthy to indicate that no annexin single positive 
(PS+) population was found with any of the concentrations and times of treatment. These results 
point towards the absence of apoptotic cell death in Leishmania as a consequence of allicin 
treatment. In our case, cell distribution with the drug showed a necrotic cell death pattern 
similar to that found in Leishmania subjected to thermal treatment (45ºC, overnight).  
 
Effect of allicin on in situ DNA fragmentation of Leishmania 
Intranucleosomal DNA fragmentation is characteristic of late apoptosis and this 
fragmentation remains stable. Using the dUTP nick-end labelling (TUNEL) method, FACS 
analysis of cultures of Leishmania promastigotes treated for 48 and 72 h with allicin (30, 60 and 
120 µM) showed that no DNA fragmentation was evident in our treated cells (Figure 10A and 
10B). There was a shift in the FL1-H axis but this shift was present in all cultures irrespective of 
the treatment and the concentration of allicin. A small and possibly non-significant apoptotic 
population was observed after 48 h in the cultures with the highest allicin concentration (>60 
µM). In the 72h sample a significant fraction of the population displayed an apparent 
phenotypic fragmentation pattern. However cellular distribution was similar in both treated and 
untreated control cultures. These results obtained with the marker of late apoptosis reinforce the 
lack of evidence of apoptotic-like death in Leishmania after treatment allicin.  
 
Allicin induces G2/M phase cell cycle arrest of Leishmania infantum promastigotes 
In order to determine the effect of allicin on the progression of the cell cycle of L.infantum 
promastigotes, cells were treated with different concentrations of the antileishmanial (30, 60 and 
120 µM) at different exposure times (48 and 72 h) and analyzed by flow cytometry using PI 
staining. Allicin induced notable changes in the distribution of cell cycle phases of synchronized 
cultures. These alterations were time and dose dependent as shown in Figure 10C. FACS 
analysis of untreated control cultures showed 1.3% of cells in Sub-G1 phase in 48 h cultures and 
0.17% in 72h cultures. Allicin treatment did not induce the appearance of the Sub-G1 peak, 
characteristic of apoptotic cells, as the highest concentration produced a minimal change in the 
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G0/G1 phase % (i.e. 48 h: 1.24% and 72 h: 1.20%). Untreated controls presented a large 
population in the G0/G1 phase (i.e. 48 h: 72.42% and 72 h: 62.48%) whereas the allicin treated 
cells showed a dose dependent increase in the G2/M phase cell population and a reduction of the 
cells in G0/G1 phase. Allicin 120 μM (3h) induced a marked shift in the G2/M gate (i.e. 48 h: 
23.83% and 72 h: 48.90%). Figure 10D illustrates the cell cycle phases and their analysis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Allicin does not provoke oligonucleosomal DNA fragmentation but it induces cell cycle arrest at G2/M 
phase in Leishmania. 10A, Apoptotic control cells of APO-BrdU™ TUNEL Assay Kit. 10B, analysis of DNA 
fragmentation in Leishmania. Promastigotes of L.infantum treated with allicin (30, 60 and 120 µM) for 48 and 72h 
and the incorporation of bromodeoxyridine (BrUD) (TUNEL) analyzed by flow cytometry with Alexa Fluor 488 
conjugated anti-BrDU antibody. Untreated cell cultures, positive and negative controls were included.  
A 
 
B 
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Figure 10C, Cultures of L.infantum promastigotes treated with allicin (30, 60, 120 µM) (48 and 72h) from the TUNEL 
assay were incubated with PI/RNAse staining solution and DNA contents and cell cycle progression determined. 
Untreated promastigotes were included as controls. 10D, Cell cycle analysis: phases and interpretation. 
 
C 
D 
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6.5. Discussion 
Our experiments showed that allicin induced morphological alterations in vital cellular 
organelles. Significant ultrastructural TEM changes were observed compared to normal 
morphology and organization of Leishmania (e.g. Pimienta & de Souza, 1985; de Souza, 2008). 
This is relevant since microscopy is a golden standard to determine intracellular targets of toxic 
agents and the type of cell death.  
Micromolar concentrations of the molecule did not provoke detectable lesions in the plasma 
membrane of promastigotes treated for 24 h (even with the higher concentration employed 120 
µM). The absence of morphological alterations in the cell membrane was in agreement with the 
scarce permeability to SYTOX Green found, with values below 5%, after 3 h treatment with 30 
µM allicin and only significant increases in membrane permeability with concentrations ≥ 90 
µM allicin, concentrations well above the cytostatic concentration found (30 µM) (Corral et al., 
2012). There was intense cytoplasmic vacuolization, with loss of electron dense material and 
neoformation of cytosolic vesicles, comparable to that described by Ledezma et al. (2002) in 
L.amazonensis promastigotes treated with the related compound ajoene. Similar vesicular 
formations were described as autophagosomes in Trypanosoma cruzi epimastigotes treated with 
cysteine protease inhibitors (Engel et al., 1998), in Leishmania spp promastigotes exposed to 
monoterpenic aldehydes (Machado et al., 2012) and in L.amazonensis promastigotes and 
amastigotes treated with 22,26-Azasterol (Rodrigues et al., 2002). The latter study (i.e. 
Rodrigues et al., 2002) linked the presence of autophagosomes to an intensive remodeling 
process of intracellular organelles irreversibly damaged by the drug.  
Another significant alteration observed in the TEM analysis was the swelling of the nuclear 
membrane. The same type of nuclear alteration was described in Leishmania by Machado et al., 
(2012) after treatment with citral (a compound present in essential oil of Cymbopogon citratus), 
by Ledezma et al. (2002) with ajoene and in T.cruzi by Engel et al. (1998) after the exposition to 
cysteine protease inhibitors. Allicin has been also described to inhibit cysteine proteases (Waag 
et al., 2010) thus suggesting that this mode of action could also be contributing to Leishmania 
cell death. Changes in nuclear chromatin organization with accumulation in the periphery was 
suggestive of an apoptotic-like cell death process although, as it will further be discussed, no 
other phenotypic characteristics of apoptosis were found by us in Leishmania promastigotes 
after allicin exposure. 
Most outstanding morphological changes took place within the mitochondrion. In allicin 
treated promastigotes this organelle presented a less electrodense matrix and a significant 
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swelling, with loss of cristae integrity. Comparable alterations have been described in 
L.amazonensis and T.cruzi after treatment with antifungal compounds such as ketoconazole and 
terbinafine (Lazardi et al., 1990; Vannier-Santos et al., 1995) and after exposition to 2,2-
Dipyridyl (Mesquita-Rodrigues et al., 2013). Mitochondrial swelling was also identified in other 
previous studies (El-On & Messer, 1986; Ledezma et al., 2002; Rodrigues et al., 2002; Machado 
et al., 2012). It is recognized that mitochondrial dysfunction precedes both programmed cell 
death and necrosis (Kroemer et al., 1998). The importance of this organelle in the energetic 
machinery of eukaryotic cells is critical in trypanosomatids such as Leishmania promastigotes 
given the scarce ability of this stage to survive and multiply in anaerobic environments 
(Hellemond et al., 1997). Moreover, these Protista only have one large mitochondrion, 
representing ca. 12% of cellular volume containing near one third of the total cell DNA and 
therefore is the target of many antileishmanial drugs (Monzote-Fidalgo & Gille, 2011).  
Our results showed that allicin consistently induced high ROS generation in the cytosolic 
and mitochondrial compartments, a collapse of mitochondrial membrane potential, diminished 
levels of ATP, and elevation of intracellular Ca2+. Cells living in aerobic environments generate 
physiologic levels of ROS these serving to regulate transcription and as endogenous signaling 
messengers (Zhang et al., 2006). However, excessive ROS production leads to oxidative stress, 
damage of intracellular organelles, mitochondrial dysfunction and cell death (Duchen, 2000; 
Zong & Thompson, 2006). In our experiments we found that 30 µM allicin induced an elevation 
of ROS production similar to that produced by the inhibitor of electron transport antimycin (5 
µM). Interestingly there was a dose-dependent production of intracellular ROS as determined by 
H2DCFDA up to 90 µM allicin, whereas mitochondrial superoxide anion levels reached a 
plateau with allicin concentrations ≥ 30 μM. Results were obtained after exposition of 3 h to the 
compound but high levels of ROS induction observed and the reported easy diffusion across 
membranes of allicin (Miron et al., 2010) suggest that this event probably occurs very early 
after exposition to the molecule. These results indicate a prooxidant activity of allicin at the 
concentrations used.  
Superoxide dismutase, several peroxidases and peroxyredoxins have been found in 
Leishmania for detoxication of ROS (Dolai et al., 2009). Trypanosomatids are devoid of 
catalase and classical selenium containing GSH peroxidase. Leishmania and other 
Kinetoplastida lack glutathione reductase (Fairlamb et al., 1985) and therefore the major 
mechanism to avoid oxidative stress relies on the unique thiol trypanothione (bis-glutathionyl 
spermidine, T[SH]2) (Fairlamb & Cerami, 1992). Actually, the enzyme reducing trypanothione, 
TryR, has been shown to be critical for survival of L.donovani (Muller et al., 2003). Given the 
ROS elevation induced by allicin it was relevant to determine the levels of non-protein thiols 
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and one of the key enzymes involved in Leishmania antioxidant defense: TryR. Additionally, it 
has been reported that allicin interacts rapidly with thiols (Rabinkov et al., 1998). Our results 
showed that allicin inhibited TryR activity in cell lysates of L.infantum promastigotes in a 
concentration dependent manner. Allicin (30 µM) reduced by 25% the basal activity compared 
to untreated cells, near 50% of the inhibition induced by clomipramine, a well-known 
irreversible inhibitor of TryR (Benson et al, 1992). Even though allicin had an effect on TryR 
activity, the biological significance of this inhibition is not known since our experiments were 
carried out with parasite lysates and not with the purified enzyme.  
Levels of non-protein thiols found were higher than those previously found in wild type but 
comparable to those determined in arsenic-resistant strains of L.tarentolae  (Mukhopadhyay et 
al., 1996) and lower than those reported in antimonium sensitive clones from L.donovani 
(Decuypere et al., 2012). Allicin induced a dose-related intracellular elevation of total non-
protein thiols and levels of Cys, GSH and T[SH]2 doubled the basal cellular store when allicin 
was used at concentrations between 30 and 60 µM. This homeostatic intracellular thiol response 
has been also found in resistant isolates of Leishmania to ROS generated by trivalent antimony 
(Mandal et al., 2007). At these concentrations of the drug the activity of TryR was diminished in 
our conditions by 25-50%. Nevertheless, additional experimentation with the purified enzyme to 
evaluate the effect of allicin in the kinetics of TryR would be necessary to verify the percentage 
of inhibition and to determine whether it was a reversible or an irreversible process. The related 
compound ajoene has been described to be an irreversible covalent inhibitor of TryR in T.cruzi 
(Gallwitz et al., 1999), thus, suggesting a probable effect of allicin on TryR enzyme kinetics. In 
our case, it seems that the allicin-elicited ROS generation did not provoke a collapse of the 
trypanothione reducing system of Leishmania and therefore cell death was not primarily due to 
this mechanism of action. Moreover, whereas it is recognized that the glutathione/trypanothione 
system plays a fundamental role to protect kinetoplastids from ROS or other toxic compounds 
(Fairlamb & Cerami, 1992; Krauth-Siegel & Comini, 2008) no strict correlation has been found 
between peroxide resistance and the elevation of reduced thiols (trypanothione and glutathione) 
or increased activity of ornithine decarboxylase, rate-limiting enzyme in trypanothione synthesis 
(Miller et al., 2000). Additionally, over 90% loss of activity of TryR is required for 
trypanosomal death (Krieger et al., 2000) most likely because trypanosomatids have redundant 
mechanisms against oxidative stress.  
There is a strong connection between the oxidative stress and the levels of intracellular Ca2+ 
in normal and transformed cells from pluricellular organisms (e.g. Richter, 1993; Camello-
Almaraz et al., 2006; Zhang et al., 2006; Zhong & Thompson, 2006) and also in Leishmania 
(e.g. Mukherjee et al., 2002; Das et al., 2008; Dolai et al., 2011). It has been proposed that the 
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oxidative stress diminishes the intracellular systems of translocation of Ca2+ this leading to the 
uncontrolled elevation of Ca2+ in the cytosol (Jewel et al., 1982; Orrenius et al., 1989). Fine 
tuning of intracellular Ca2+ levels is critical for living cells, as Ca2+ is an important regulator of 
many enzyme systems and a paramount cell messenger in all eukaryotic cells including 
Leishmania (Richter, 1993; Benaim & García, 2011). Consequently, the disruption of Ca2+ 
homeostasis in any cell usually drives to lethal effects (Zhivotovsky & Orrenius, 2011).   
Ca2+ homeostasis is carried out by the regulatory transport from intracellular organelles and 
from the surrounding medium. In the case of trypanosomatids, including Leishmania, normal 
cytosolic Ca2+ concentrations are in the range of 20-50 nM whereas [Ca2+ ] in the blood are of 
ca. 2 mM (Benaim & García, 2011) and of ca. 200 nM in the cytosol of mammalian cells. 
Considering the different stages in the life cycle of Leishmania this is indicative of a highly 
efficient regulatory mechanism. Balance of Ca2+ uptake/efflux through the plasma membrane 
involves a Ca2+-ATPase identified in trypanosomatids capable of pumping out, under normal 
circumstances, this cation without restriction (Benaim & García, 2011). In addition, intracellular 
calcium stores include: acidocalcisomes, characteristic organelles of some Protista, including 
trypanomatids, where the transport is mediated by a Ca2+-ATPase and a Ca2+/H+ exchanger 
mechanism (Docampo & Moreno, 1999; Serrano-Martín et al., 2009); the endoplasmic 
reticulum (ER), for Ca2+ long-term storage (Orrenius et al., 2003); and mitochondria, which play 
a short-term fundamental role in the cellular physiology in rapid increases in cytoplasmic 
calcium, thus preventing fatal effects for the cell. Mitochondria are able to transiently store large 
amounts of Ca2+ provided the mitochondrial membrane integrity, as the driving force for Ca2+ 
entry is the electrochemical gradient formed at the inner mitochondrial membrane (Richter, 
1993; Benaim & García, 2011). This physiological role is played by energy-dependent Ca2+ 
uptake from the cytosol through a uniporter transporter and cation release by several routes 
(Orrenius et al, 2003).  
In our experiments allicin induced a rapid elevation of cytosolic Ca2+, probably from 
intracellular stores and particularly mitochondrion. The possibility of extracellular uptake 
cannot be ruled out since the culture medium contained available Ca2+. By its part the influx of 
the cation through non-selective cation channels activated under oxidative stress has been 
proposed as novel mechanism of apoptotic-like death in L.donovani promastigotes (Mukherjee 
et al., 2002). Additional experiments are needed to determine the calcium channels involved and 
thus the possible effect of ROS on gate opening for the cation in the plasma membrane. 
However, at the concentrations of allicin causing Ca2+ elevation (besides ROS generation) no 
variations in the plasma membrane permeability were found at least as assessed by SYTOX 
Green internalization.  
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Promastigotes of L.infantum, exposed to sublethal concentrations of allicin, showed (i) high 
ROS generation and (ii) increase of cytosolic Ca2+. These alterations were accompanied by (iii) 
fall of mitochondrial membrane potential (∆Ψm) and (iv) reduced ATP production. The first 
three alterations are comparable to the observed effects on Leishmania of chemical agents 
inducing oxidative stress (e.g. H2O2: Mukherjee et al., 2002; curcumin: Das et al., 2008; 3,3’ –
Diindoylmethane: Roy et al., 2008; tunicamycin: Dolai et al., 2011). However, the precise 
sequence of these events is variable depending on the drug and the experimental approaches. 
Thus, cell death of Leishmania induced by some antimicrobial peptides has been related to the 
direct toxicity of cytosolic Ca2+ and its toxic effect on the mitochondrial membrane (e.g. 
Kulkarni et al., 2009). In our work the high levels of ROS inside the mitochondrion and its 
apparent saturation (> 30 µM allicin) besides the extensive morphological alterations observed 
in TEM suggest that this organelle was the primary target of allicin. Thus, allicin-induced ROS 
generation, not regulated by thiols, provoked the mitochondrial membrane depolarization with 
fall of ∆Ψm, this leading to the decreased ability of the mitochondrion to retain (and regulate) 
intracellular Ca2+ levels and an impaired mitochondrial synthesis of ATP. 
It is well-known that ROS can induce mitochondrial dysfunction and ∆Ψm dissipation in 
Leishmania (e.g. Fonseca-Silva et al., 2011) and in mammalian cells (e.g. Malik et al., 2007; Lu 
& Gong, 2009). The maintenance of the ∆Ψm is vital for oxidative phosphorylation and 
subsequent production of ATP. As electrons move through the respiratory chain a proton 
gradient is generated in the inner mitochondrial membrane that the ATP-synthase uses to power 
the synthesis of ATP. Moreover in mammals, ROS, intracellular Ca2+ levels, ∆Ψm 
depolarization, and a fall in ATP levels can induce mitochondrial permeability transition pore 
(MPTP) opening (Zorov et al., 2000; Halestrap et al., 2004) that allows the entrance of water 
and solutes leading to matrix swelling, leakage of mitochondrial proteins into the cytosol and 
total ∆Ψm collapse (Ly et al., 2003). If confirmed, it could explain the mitochondrial 
ultrastructural alterations observed by TEM (i.e. mitochondrial swelling). 
Energy metabolism in trypanosomatids is highly variable in terms of relative importance of 
organelles (mitochondrion + glycosomes) for ATP production, substrates (amino acids, 
carbohydrates) and intermediary metabolic products (Tielens & van Hellemond, 2009). 
Contrary to procyclic trypanosomes (i.e. Trypanosoma brucei) the large part of internalized 
glucose by Leishmania promastigotes is fully catabolized to CO2 in a complete TCA cycle 
(Saunders et al., 2011). In fact it is estimated that ca. 70% energy requirements of Leishmania 
are provided by oxidative phosphorylation in mitochondria (Manzano et al., 2011).With the 
exception of Ca2+ all other parameters were determined at 3 h; this limitation makes necessary 
further research. Furthermore, a crosstalk between Ca2+ -both intramitochondrial and cytosolic-, 
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oxidative stress and mitochondrial dysfunction by membrane depolarization (∆Ψm) is 
recognized (e.g. Richter, 1993, Gordeeva et al., 2003) with more than probable feed-back loops 
(Kroemer et al., 1998). Research to determine the upstream vs. downstream location of events 
have included the use of inhibitors of oxidative stress, such as N-acetylcysteine –NAC- (e.g. 
Dolai et al., 2011) although the value of these assays should be carefully taken. Actually NAC, 
widely used in metazoan cells and Leishmania, behaves as a regulator of redox balance and not 
as antioxidant since many of its effects are related, via membrane-permeant cysteine precursor, 
to the thiol levels of the cells (Murphy et al., 2011).  
Mitochondrial membrane collapse (MMC), and consequently the lack of functionality of 
mitochondria is an irreversible cellular dysfunction leading depending on the relative weight of 
bioenergetic catastrophe or protease and endonuclease activation to cell necrosis or apoptosis 
respectively (Kroemer et al., 1998; Lemasters et al., 1998). It has been shown that allicin is able 
to induce apoptosis in some cancer cell lines (PC-3, Hep G2) (Arunkumar et al., 2006; Chu et 
al., 2012). ATP availability, after mitochondrial membrane depolarization, determines the 
switch from apoptosis (no fall of ATP) to cell necrosis (low ATP) (Richter et al., 1996; Leist et 
al., 1997; Eguchi et al., 1997; Kim et al., 2003). Apoptosis is an ATP-requiring form of 
programmed cell death relatively well characterized in cells from metazoans.  
The presence of true apoptosis in Protista, such as trypanosomatids, remains a controversial 
issue on mechanistic (i.e. caspases absence) and evolutionary bases (e.g. selective value of 
individual programmed cell death in unicellular organisms). Perhaps the use of a term such as 
apoptosis, as the only form of programmed cell death, should be abandoned since many forms 
of cell death (autophagy, programmed cell necrosis) cross the strict boundaries of such division 
and, on occasion, they have been considered a continuum (Zong & Thompson, 2006). In 
Leishmania there are many reports on apoptotic-like death, after the MMC, by the presence of 
some phenotypic features of metazoan apoptotic cells, namely DNA fragmentation, caspase-like 
activation, externalization of phosphatidylserine, cell cycle arrest at Sub-G0/G1 phase (e.g. Lee 
et al., 2002; Zangger et al., 2002; Das et al., 2008; Roy et al., 2008; Dolai et al., 2009, 2011; 
Kulkarni et al., 2009; Mukherjee et al., 2009). For the most part, these programmed cell deaths 
reported in Leishmania present wide variations and hardly exhibit all characteristic markers of 
apoptosis in cells from pluricellular organisms; probably a reconsideration of death paths in 
parasitic protozoa should be reevaluated (Proto et al., 2013). Our results did not show any 
conclusive evidence of apoptotic-like death since DNA fragmentation was not observed, no 
phosphatidylserine exposure was detected and there was a cell cycle arrest at the G2/M phase. 
Consequently, the cell death found in Leishmania after treatment with allicin is compatible with 
cell necrosis.   
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Taking together our experiments showed that allicin induced high ROS generation, not 
controlled by intracellular thiols. This impairment of the intra-promastigote redox balance 
induced the mitochondrial membrane depolarization (∆Ψm) with dysfunction of the TCA and 
therefore reduction of ATP production, and elevation of intracellular Ca2+. These events, 
possibly through a feed-back process, provoked the collapse of mitochondrion with loss of 
integrity and finally a cellular energetic catastrophe leading to the necrotic death of Leishmania 
promastigotes with cell cycle arrest at the premitotic phase (G2/M) (Figure 11).  
 
 
Figure 11. Proposed mechanism of action of allicin in Leishmania. Allicin induced oxidative stress not controlled by 
intracellular thiol homeostasis. Impairment of the redox balance induced ∆Ψm depolarization with dysfunction of 
oxidative phosphorylation and subsequent reduction of ATP synthesis and an increase in cytosolic Ca2+ levels. 
These interconnected events induce –probably through a feed-back process- a mitochondrial collapse with 
mitochondrial swelling and loss of organelle integrity and, finally, a cellular energetic catastrophe leading to a necrotic 
cell death of Leishmania promastigotes with cell cycle arrest at the premitotic phase (G2/M). ROS: reactive oxygen 
species; O2-: superoxide anion; ∆Ψm: mitochondrial transmembrane potential; Ca2+: calcium cation; ATP: adenosine 
triphosphate; TCA: tricarboxylic acid cycle or citrate cycle. 
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7.1. Current scenario of chemotherapy of leishmaniasis 
The number of entries in the web gives an approximate estimation of the interest on 
leishmaniasis. Thus “leishmaniasis” and “dog leishmaniasis” are popular items and in a non- 
selective web engine (i.e. Google) the search for “treatment of leishmaniasis” yields over 
840,000 documents and “treatment of canine leishmaniasis” around 200,000 entries. This 
popularity is not only related to lay contributions (e.g. patients’ associations, pet owners, 
publicity) since using selective data banks widely used by the scientific community (e.g. 
Pubmed) the term “leishmaniasis” gives back more than 20,000 scientific publications and “dog 
leishmaniasis” over 2100. With all limitations of these figures it is clear that leishmaniasis and, 
in particular, treatment of leishmaniasis both in humans and dogs, is an appealing field for the 
society and also an active area of research for the scientific community.  
Be correct this conclusion, it is hardly understandable the scarcity of adequate tools to 
control the disease (e.g. diagnosis, chemotherapy) and the reported lack of clear criteria for the 
use of the currently available: “Prevalence and incidence data for assessing the full impact of 
(human) leishmaniasis are unreliable. No objective data are available because: i) transmission 
of the disease occurs in remote rural areas; ii) many cases are not diagnosed because patients 
do not receive medical care; and (iii) leishmaniasis is notifiable in only 33 of the 88 countries in 
which it is endemic. Leishmaniasis (human) is one of the most neglected tropical diseases, in 
terms of the few tools available for control and the lack of clear criteria for methods of control. 
The most pressing research needs for leishmaniasis control are the search for alternative and 
cheap medicines for oral, parenteral or topical administration in shorter treatment cycles, and 
identification of mechanisms to facilitate access to existing control measures, including health-
sector reform in some developing countries”. These quotes correspond to the Secretariat Report 
from the 60th World Health Assembly (WHO) on Control of leishmaniasis (Report A60/10) (22 
March 2007). Seven years later leishmaniasis has been declared endemic in 98 countries (Alvar 
et al., 2012) and, in spite of the worldwide research effort and the intensive labor and resources 
invested, the pursued goals are essentially the same (WHO, 2010). In the veterinary arena, and 
particularly in the endemic areas for ZVL by L.infantum (=L.chagasi), several of the above 
mentioned needs are also applicable.  
Regardless of the continued work on the development of vaccines and the apparent 
feasibility of antileishmanial vaccine development given the reported resistant status to 
homologous priming infection in humans; the traditional leishmanization protecting against 
cutaneous leishmaniasis in the Old World; and the partial protection against the infection 
elicited in CanL by the recently marketed preparations (e.g. CaniLeish®), no available vaccine 
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exists for human leishmaniasis and, the existing version for CanL has several drawbacks (e.g. 
side effects, partial protection). In the absence of efficacious vaccines the main control system 
of leishmaniasis is chemotherapy.  
Unfortunately, current control of leishmaniasis, both human and canine, is inadequate. 
Presently, liposomal amphotericin b (AmB), paromomycin and miltefosine are considered by 
WHO (www.who.int/tdr/diseases/leish) as the most promising drugs and, together with 
antimonials (SbV), constitute the main arsenal for leishmaniasis treatments. Shortcomings from 
these drugs include the emergence of resistance to the first line treatment SbV (e.g. India, 
Nepal) (Croft et al., 2006), high toxicity and teratogenicity of some of them, absence of 
parasitological cure in most cases and unaffordable prices of the less toxic and more efficacious 
preparations (Sundar & Chaterjee, 2006). Novel short course and highly efficient therapies are 
needed in the field to face leishmaniasis (Sundar & Chakravarty, 2013).  
 
7.2. Antileishmanial drug discovery requires reliable experimental 
models 
Promastigote cultures as a first step drug screening 
Drug discovery process requires the validation of the synthetic or natural products aimed for 
therapeutic use. A variety of surrogate experimental models have been depicted to test the 
potential value of a given molecule in the treatment of leishmaniasis. In the first steps of the 
drug pipeline development, when “go-no go” decisions are taken, no animals models are used 
but rather non-cellular systems and parasites cultures. Since most targets of currently used drugs 
(antileishmanial and others) are enzymes the inhibitory activity of the potential drugs on the 
enzyme target has been employed as a selective criterion. Moreover this strategy can be easily 
adapted to High Throughput Systems (HTS) of screening. Obviously there is a wide gap 
between biochemistry, pharmacology and, finally, therapeutics and despite shortcomings 
phenotypic screening using parasites still is preferred and has been successfully adapted to HTS. 
In the case of Leishmania the vast majority of screenings to identify hits and leads, even in 
massive analyses, have been performed using cultured promastigotes (e.g. Siqueira-Neto et al., 
2010; Walker et al., 2011). This cultured stage, comparable to the dividing cells within the 
sandfly vectors, differs (e.g. morphology, biochemistry) from the actual parasitic stage, 
amastigote, present in the infected host and is not an ideal model for checking potentially useful 
drugs. However, cultures of intracellular amastigotes are not available to many labs, 
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promastigotes and amastigotes share many metabolic pathways –promastigotes have been used 
to monitor clinical emergence of resistance to miltefosine (Kulshrestha et al., 2013)-, and some 
Leishmania spp such as L.donovani and, particularly, L.infantum have slow multiplication rates. 
Furthermore, with some exceptions (e.g. prodrugs as SbV), compounds effective against 
amastigotes exhibit also antiproliferative effect on promastigotes (e.g. AmB, miltefosine) 
(Sharlow et al., 2009).  
Phenotypic screening of drug inhibitory effect on promastigotes by microscopy is time 
consuming and to circumvent this limitation several indirect methods have been developed such 
as nephelometry, colorimetry, reporter genes, RT-PCR, 3H-thymidine incorporation, or 
software development. Among them, cell growth monitoring by the determination of 
extracellular levels of resorufin, the product of reduction of resazurin, and in particular Alamar 
Blue, is a single-step, low cost and of negligible toxicity to the cells. Alamar Blue has been 
extensively used to monitor the multiplication of normal and transformed mammalian cells 
(O‘Brien et al., 2000; Sykes & Avery, 2009).  
Preliminary tests carried out in our laboratory, with this method and colorimetry or 
fluorimetry, yielded inconsistent results when monitoring cell multiplication of L.infantum and 
L.donovani promastigotes using standard culture conditions (26ºC, air phase) in different culture 
media (e.g. RPMI 1640, Schneider). Since more than probably the performance of a redox 
indicator would be affected by the gas-phase of cultures, particularly oxygen, the possible effect 
of the promastigotes’ atmosphere was explored. Results obtained using a 5% CO2 /95% air and 
additional buffering with 20 mM Hepes greatly improved the results (linearity, correlation 
between cell counts and resorufin level) with initial plating cell densities of 2.5x105  
promastigotes/mL for both Leishmania spp and using spectrophotometry or, better, fluorimetry 
(Chapter 2). This finding agrees well with the use of a partial CO2 atmosphere for Alamar Blue 
in the majority of assays with mammalian cells (expected) and in those with blood stream 
trypanosomes (Räz et al., 1997; Sykes & Avery, 2009). No adequate explanation, unless it was 
not stated, for the absence of inconveniences in the previous experiments on Leishmania carried 
out with aerated cultures (de Oliveira-Silva et al., 2008; Shimony & Jaffe, 2008; Vermeersch et 
al., 2009; Kulshrestha et al., 2013) or in HTS with a 384-well format (Siqueira-Neto et al., 
2010). On experiential store it is known that different growth curves, cell density and apparent 
efficacy of some drugs on Leishmania promastigotes can be obtained, depending on the culture 
media and additives employed. It is thus possible that slight variations in culture conditions 
could allow them to overcome the inconvenient found by us using aerated atmosphere and 
Alamar Blue. In any case, experimental conditions described in our contribution showed high 
repeatability, applicability to both Leishmania spp tested, no interference with red phenol, and 
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resazurin reduction and cell numbers were highly correlated (r2 =0.9713). This made the 
modification developed a good tool to screen potential antileishmanial drugs in 96-well format 
and probably adaptable to HTS. In addition, it stressed the need of standardization of culture 
conditions and monitoring. 
 
Antileishmanial drug screening with intracellular amastigotes 
It is generally assumed that in vivo models have superior predictive value than in vitro or ex 
vivo models to test antileishmanial drugs and that intracellular amastigotes are more convenient 
than axenic amastigotes and promastigotes for this purpose (Sereno et al., 2007). However, the 
systematic use of intracellular amastigotes is hampered by the unavailability of the technique to 
many laboratories, slow multiplication rates of some leishmanias (see above) and the species-
dependent culture requirements. Clearly there are interspecies differences even in those closely 
related and, actually, the first modified method of infection of macrophages (mouse peritoneal 
and J774 cell line) with promastigotes of L.infantum was published less than 20 years ago 
(Méndez et al., 1996) when routine culture of L.donovani intracellular amastigotes was carried 
out in many laboratories. Method developed included an overnight low temperature (33 ºC) 
treatment of macrophages (Mφ) prior to the promastigote-macrophage contact. That infection 
procedure has been used since then (e.g. Ordóñez-Gutiérrez et al., 2007, 2009; Wert et al., 
2011), although infection rate (% of infected Mφ) and amastigote burden (number of 
intracellular amastigotes/infected Mφ) values were lower than those obtained with L.donovani. 
On these grounds the exploration of a more reliable screening tool for potential antileishmanial 
drugs on intracellular amastigotes (higher infection rate and parasites’ multiplication) was 
considered by us a necessity to become a routine procedure for the screening of antileishmanial 
drugs.  
An improvement of the available technique for L.infantum infection has been developed  by 
combining the previously established method in  our laboratory (Méndez et al., 1996), the 
isolation of metacyclics with a discontinuous Ficoll gradient (Yao et al., 2008), and 
opsonization with 15% normal mouse serum (Chapter 3). The modification of the infection 
method was successful increasing the infection rate with both Leishmania spp (L.infantum: 65-
70% of J774 cells, ca. 80% of mouse peritoneal macrophages; L.donovani: 70-75% of J774 
cells, ca. 95% of mouse peritoneal macrophages) (Figure 1) and intracellular multiplication. The 
modification performed was useful for the culture of both Leishmania spp tested and provide us 
with a valuable tool for in vitro and ex vivo drug screening against this more predictive parasite 
stage. We have not tested the fluorimetric method to determine the viability of intracellular 
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amastigotes of Leishmania (Bilbao-Ramos et al., 2012). Combination of the infection 
improvement and determination of amastigotes multiplication inside Mφ with fluorimetry 
would provide us with a powerful protocol to test potentially useful drugs against leishmaniasis. 
 
 
Figure 1. Ex vivo L. donovani infection: BALB/c peritoneal macrophages with intracellular amastigotes. Cells were 
stained with May-Grünwald-Giemsa 24 h after infection. Bar: 100 µm. 
 
 
7.3. Micromolar concentrations of allicin (diallyl thiosulfinate) inhibit 
the multiplication of promastigotes and intracellular amastigotes of 
Leishmania 
As previously stated the low number of available antileishmanial drugs and the shortcomings 
from most of them, including the resistance emergence, make the discovery and development of 
alternative chemotherapeutic agents an urgent need. Strategies to develop new treatments can be 
grossly  divided in short-to-medium term [e.g. new indications for old drugs –a large proportion 
of present antileishmanial drugs-, combination therapy, incorporation to drug delivery systems 
(DDS)] and long-term (e.g. discovery of new synthetic or natural agents, immunotherapy) (Pink 
et al., 2005; Pham et al., 2013). 
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Allicin (diallyl thiosulfinate = 2-Propene- 1-sulfinothioic acid S-2-propenyl ester), a natural 
product present in plants of the Family Alliaceae, including garlic, has shown antibacterial 
activity against bacteria [e.g. Helicobacter pylori, methicillin-resistant Staphylococcus aureus 
(MRSA)] (O’Gara et al., 2000; Cutler & Wilson, 2004), antifungal (e.g. Candida, Aspergillus) 
(Khodavandi et al., 2011; Cañizares et al., 2004) and different Protista (e.g. Trypanosoma, 
Leishmania, Entamoeba, Plasmodium) (Mirelman et al., 1987; Coppi et al. 2006; Waag et al., 
2010). Previous studies involving Leishmania were carried out using promastigotes and the 
information provided was very limited. The absence of information, our experience with of 
methods for promastigote and amastigote screening, and the availability of stabilized allicin 
prompted us to test the potential antiproliferative effect of allicin on the two major causative 
agents of visceral leishmaniasis, L. donovani and L. infantum (Chapter 3). 
A significant inhibitory effect of allicin in the micromolar range on the multiplication of 
L.donovani and L.infantum has been found by us. Inhibition was time- and dose-dependent 
against promastigotes and intracellular amastigotes in vitro (J774 cells) and ex vivo (BALB/c 
mouse peritoneal Mφ). The approximate IC50 value obtained  (10- 30 µM, 24 h exposition) for 
promastigotes from both species was in the line of the value indicated by Ankri and Mirelman 
(1999) (30 µg.mL-1) for L.major and slightly higher than that reported by McClure et al. (1996) 
for L.chagasi and L.mexicana. More importantly, allicin, at these concentrations, effectively 
inhibited the multiplication of amastigotes. As far as we know this was the first report on the 
inhibitory effect of allicin against Leishmania intracellular amastigotes. In addition, toxicity of 
allicin in the concentration range used was low and no significant effect on mouse Mφ was 
observed up to 40 µM as estimated by MTT method and the absence of morphological alteration 
of macrophages up to 60 µM in both J774 cells and BALB/c peritoneal Mφ. 
Administration of allicin every 24 h greatly increased the anti-leishmanial activity of the 
compound. This finding suggested the degradation of the diallyl thiosulfinate at 26º and 37 ºC 
(McClure et al. 1996; Cañizares et al. 2004). Allicin is a highly reactive thiosulfinate which is 
rapidly transformed to other types of organosulfur compounds, particularly diallyl disulfides 
(DADS), diallyl sulphides (DAS), ajoene and vinyldithiins (Amagase, 2006). The degradation 
of the allicin preparation employed was confirmed by mass spectrometry (MS) since sulphides 
and vinyldithiins were present but neither ajoene (E or Z) nor allicin were found in any of the 
analysis. The absence of allicin and ajoene could be due to their short half-life at the culture 
temperatures (26 ºC and 37 ºC) (i.e. ajoene, less than 1 min) and the analytical method 
employed. It has been indicated that thermal sensitivity of allicin at physiological temperature 
as well as its rapid transformation to other types of organosulphur compounds (Amagase, 2006) 
could rule out its therapeutic use. However, it has been shown that decline of allicin is 
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accompanied by its transformation into other compounds (i.e. ajoene) (Fujisawa et al. 2008) 
with strong anti-leishmanial activity (Ledezma et al. 2002). Whether or not the actual 
antileishmanial agent in our studies is allicin or some other degradation product requires further 
experimentation.  Moreover, the metabolism of allicin, and therefore its bioavailability, is 
unknown for the most part. Value of IC50 found by us in vitro and ex vivo (5-10 µM) against 
intracellular amastigotes possibly excludes allicin as monotherapy against leishmanial 
infections. Nonetheless, low cost and scarce toxicity of this compound would allow its use in 
combined therapy with other well established anti-leishmanial drugs. 
 
7.4. Synergistic combination of allicin and amphotericin B in the 
micromolar range on Leishmania promastigotes and intracellular 
amastigotes 
To increase the lifespan of existing antileishmanials and face the reported resistance or 
unresponsiveness to some currently used drugs (e.g. miltefosine, SbV) an alternative approach 
to monotherapy is drug combination using well established chemotherapeutic agents (Olliaro, 
2010). The notable activity of allicin and its low toxicity for mammalian cells (J774, peritoneal 
mouse Mφ) prompted us to explore the possibility of using this molecule in combination with 
amphotericin B (AmB). This antibiotic, once a second line antileishmanial treatment, has 
transformed, after the emergence of resistance to SbV in some areas (Croft & Coombs, 2003; 
Croft et al., 2006) particularly formulated in liposomes, as the choice drug for (human) 
leishmaniasis control. Moreover, no significant resistance against this molecule has been 
reported in Leishmania in spite of its long time (over 50 years) of use in clinical practice 
(Durand et al., 1998; Gray et al., 2012). The use of this antibiotic with extraordinary 
antileishmanial efficacy has been restricted by the side effects induced and long periods of 
treatment with clinical monitorization.  
On these grounds our approach was the exploration of the potential synergistic or additive 
antileishmanial effect of the combination (low micromolar concentrations of AmB + 
micromolar allicin) thus avoiding the toxic concentrations needed with AmB in monotherapy. 
Data obtained in many combination studies using checkerboard approaches with two-fold 
dilutions of two drugs lack in significance due to the absence of further analysis. Therefore, for 
promastigotes screening, combinations of allicin and AmB at a non-constant ratio were used 
following the robust Chou-Talalay method (Chou, 2006; Chou, 2008; Chou & Hayball, 1996) 
for drug combination analysis. Results obtained showed that the combination of both molecules 
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ranged from moderately synergic to synergic at low concentrations against both promastigotes 
(0.07 µM AmB + 35.45 µM allicin induced a 95% growth inhibition) and amastigotes (ca. 45% 
reduction with 0.05 µM AmB +10 µM allicin); this represented near a two-fold reduction in the 
IC50 value of the antibiotic added alone (Vermeersch et al., 2009). The observed differences 
between promastigotes, with a 7 to 11-fold reduction of AmB, and amastigotes, with ca. two-
fold reduction, support the interest of using intracellular amastigotes in drug screening (Sereno 
et al., 2007; Seifert et al., 2011) (Chapter 4). 
Leishmania has considerable amounts of ergosterol on the plasma membrane. Apparently 
allicin produces an enhancement of fungicidal activity of AmB by inhibiting the ergosterol 
trafficking from plasma membrane to vacuole membrane in Candida (Fungi) (Ogita et al., 
2009). Whether or not this enhancement of AmB effect in the presence of allicin is responsible 
of the synergism found by us in amastigotes and particularly promastigotes of Leishmania needs 
further experimentation. Data obtained with drug combinations in vitro and ex vivo have many 
limitations in spite of the dose-effect relationship analysis carried out (i.e. unforeseen 
interactions, pharmacokinetics) (Chou, 2008). However, the two-fold reduction in the required 
dose of AmB against intracellular amastigotes and the possibility of using higher non-toxic 
doses of allicin (>10 µM) suggested the interest of the exploration of this combination in vivo.  
 
7.5. Allicin is effective against experimental leishmaniasis in hamster 
and reduces the required amphotericin effective dose 
In face of the shortage of effective and affordable treatments for leishmaniasis, combination 
therapy has emerged as one of the most favored and readily implemented strategies. A variety of 
drugs and schedules have been tested (Chunge et al., 1985; Murray et al., 2003; Sundar & 
Chakravarty, 2013). The rationale behind this approach relates to the potential advantages of the 
combinations (e.g. delay or prevention of the development of resistance; shortening of treatment 
regimens) (Seifert & Croft, 2006; Griensven et al., 2010) although resistance can also develop at 
least under laboratory conditions (García-Hernández et al., 2012).  
In our case we tested the combination of the newly recognized antileishmanial molecule 
allicin in vitro and ex vivo, and AmB. This antibiotic probably is the best existing drug against 
leishmanias with cure rates exceeding 95% (Alvar et al., 2006; Paila et al., 2010) and negligible 
levels of resistance after being employed as the reference drug against systemic fungal 
infections for more than 50 years (Durand et al., 1998; Gray et al., 2012). It is generally 
considered that AmB binding to ergosterol from Leishmania membrane is the main event 
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causing the cell destruction. The differential affinity of AmB by cholesterol (in mammalian 
cells) and ergosterol (in Leishmania membranes) would account for the differential toxicity for 
hosts and parasites. Actually the residual toxicity, by unspecific binding to cholesterol, is the 
main shortcoming from AmB (Laniado-Laborín & Cabrales-Vargas, 2009; Hamill, 2013).  
Our results showed that (i) allicin exhibited a very low toxicity for mammalian cells besides 
significantly inhibiting the multiplication of Leishmania inside Mφ (Chapter 3), and (ii) a 
synergistic antileishmanial activity of AmB and allicin in vitro and ex vivo, on intracellular 
amastigotes of Leishmania (Chapter 4). Unfortunately, although intracellular amastigotes from 
Leishmania are a good in vitro or ex vivo model to test potentially useful antileishmanial drugs 
(Sereno et al., 2007), there is a wide gap between biochemistry, pharmacology and therapeutics. 
Therefore we planned to evaluate the efficacy of allicin and also its combination with low 
concentrations of AmB in a recognized experimental model of visceral leishmaniasis: hamster 
infections.  
The final aim of the combination strategy would be the reduction (below toxic levels) of the 
necessary AmB doses to effectively control the infection in hamsters (Chapter 5).  As expected 
the experimental model employed (L.infantum and hamster) produced consistent infections with 
significantly higher parasite burdens in the spleen and altered blood urea nitrogen thus 
confirming its suitability for in vivo testing of antileishmanial agents (Binzahim et al., 1993; 
Requena et al., 2000; Melby et al., 2001; Dea-Ayuela et al., 2007; Moreira et al., 2012). Groups 
of infected hamsters were treated from day 45th post infection onwards [AmB (1 or 5 
mg/Kg/day), allicin (5 mg/Kg/day) or a combination of AmB (1 mg/Kg/day) + allicin (5 
mg/Kg/day) for 5 days] and no clinical signs or biopathological alterations were observed; 
therefore, indicating the lack of toxicity of AmB and allicin or their combination at the doses 
administered.  
Treatment, in vivo follow up and Leishmania burden determined by the limiting dilution 
assay, showed that allicin (5 mg/Kg/day, 5 days) had a clear antileishmanial effect in hamsters 
since 2 out of 6 animals were cleared of L.infantum in both spleen and liver. As far as we know 
this is the first evidence of the antileishmanial activity of allicin in vivo without apparent 
toxicity for infected and treated animals. By its part the combination of the lower dose of AmB 
+ allicin reduced over 95% the L.infantum burden, this level of efficacy being actually 
comparable (p<0.05) to the standard AmB treatment (5 mg/Kg/day).These results confirmed in 
vivo the synergistic effect reported in vitro and ex vivo for this combination (Chapter 4) and 
suggests the possibility of reducing 5 times the required dose of AmB in monotherapy without 
loss of efficacy. 
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Actual basis of the antileishmanial activity of the combination is not known and should be 
explored since, apparently, allicin improved the accumulation of the antibiotic in the target 
organs and in the treated hamsters a comparatively higher specific IgG2 response was observed 
perhaps related to the enhancement of a pro-inflammatory response induced by allicin (Feng et 
al., 2012). More research is needed in this predictive model of human and canine leishmaniasis 
(e.g. refined dosage, time schedule, administration via) but our results point towards the interest 
of this combination, reducing the needed dose of AmB and thus its toxicity, in the 
chemotherapy of leishmaniasis.  
 
7.6. Mechanistic basis of the antileishmanial activity of allicin: 
bioenergetic catastrophe and cell necrosis 
Despite the reported value of allicin and related compounds to inhibit the multiplication of 
unicellular eukaryotic organisms (e.g. Candida, Trypanosoma, and Leishmania) and 
transformed cells from metazoans (Chapters 1 & 3) its mechanism of action is virtually an 
unexplored research field. It has been indicated that, given its highly reactive nature, allicin 
rapidly interacts with thiols, thiol-dependent enzymatic systems, cysteine proteinases, 
microtubules (Ankri & Mirelman, 1999; Prager-Khoutorsky et al., 2007; Miron et al., 2010; 
Waag et al., 2010). Additionally, it has been reported to induce cell apoptosis (Oomen et al., 
2004). Nevertheless, the actual intracellular targets responsible of the cytocidal/cytostatic effect 
of the molecule are largely unknown. Availability of a stabilized allicin formulation and the 
suggestive results obtained in vitro, ex vivo and in vivo against Leishmania prompted us to 
investigate its possible antileishmanial mechanism of action.  
Transmission electron microscopy (TEM) studies carried out showed that the most 
prominent alteration observed in promastigotes of L.infantum and L.donovani treated with this 
molecule was the loss of integrity of mitochondrial and kinetoplast membrane (Chapter 1 & 
3).This finding was most indicative of the involvement of energetic cell machinery on the 
activity of allicin. Primarily, because microscopy is a golden standard to determine intracellular 
targets of toxic agents and also the type of cell death; and in second place, because 
trypanosomatids, including Leishmania, only have a large mitochondrion representing ca. 12% 
of cellular volume (Monzote-Fidalgo & Gille, 2011). Kinetoplastids strongly rely on this 
organelle given their scarce capacity to survive and multiply in anaerobic environments 
(Hellemond et al., 1997; Manzano et al., 2012). 
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Our results showed that allicin, at sublethal concentrations, induced an elevation of the 
production of reactive oxygen species (ROS). Although ROS are present in normal cells playing 
a significant role as signaling messengers (Zhang et al., 2006) the overproduction is linked to 
oxidative stress, mitochondrial dysfunction and cell death (Duchen, 2000; Zong & Thompson, 
2006). Since allicin can easily cross cell membranes (Miron et al., 2010) this event should take 
place very rapidly after exposition to the molecule. To cope with the damaging oxidative stress 
Leishmania relies mainly on trypanothione (=bis glutathionyl spermidine) (Fairlamb & Cerami, 
1992) since these Kinetoplastida are devoid of catalase and classical selenium containing GSH 
peroxidase and no glutathione reductase is present (Fairlamb et al., 1985). Our results showed 
that trypanothione reductase (TryR) activity was only moderately inhibited and, expectedly, 
thiols (cysteine, glutathione and trypanothione) levels increased. These findings, besides 
confirming the interaction of allicin with thiols (Rabinkov et al., 1998), suggested that the 
molecule did not provoke a collapse of the trypanothione reducing system and therefore cell 
death of allicin-treated Leishmania was not primarily related to this mechanism of action. 
There is a tight connection between oxidative stress and intracellular Ca2+ in all organisms 
including Leishmania (Mukherjee et al., 2002; Das et al., 2008; Dolai et al., 2011). The fine 
tuning of intracellular Ca2+ level is critical for cell homeostasis (Richter, 1993) and oxidative 
stress can disrupt the intracellular calcium translocation (Orrenius et al., 1989) among calcium 
stores (e.g. mitochondrion, acidocalcisomes, endoplasmic reticulum). Our experiments showed 
that allicin induced a rapid elevation of intracellular Ca2+, probably from intracellular stores and 
particularly mitochondrion, since no variations in the plasma membrane permeability were 
found at least as assessed by SYTOX Green internalization. ROS generation and increase of 
cytosolic Ca2+ in Leishmania exposed to sublethal allicin concentrations were accompanied by 
the fall of mitochondrial membrane potential (∆Ψm) and reduced ATP production. The high 
levels of superoxide anion (O2-) inside the mitochondrion and its apparent saturation (> 30 µM 
allicin) besides the extensive morphological alterations observed in TEM (Chapter 1 & 3) 
suggested that this organelle was the primary target of allicin. Thus, we propose that allicin-
induced ROS generation, not regulated by thiols, provoked the mitochondrial membrane 
depolarization with fall of ∆Ψm, this leading to the decreased ability of the mitochondrion to 
retain (and regulate) intracellular Ca2+ levels and therefore causing uncoupling and impairment 
of mitochondrial ATP synthesis. This is critical since an estimated 70% of all energy 
requirements in Leishmania are fulfilled by oxidative phosphorylation in mitochondria 
(Manzano et al., 2012). Nonetheless, there are still open questions and further investigation is 
needed to validate this proposed mechanism of action. Increase in cytosolic Ca2+ can be due 
either to the transport from the extracellular milieu or can be extruded from intracellular calcium 
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stores (i.e. acidocalcisomes, mitochondrion, endoplasmic reticulum). Calcium origin should be 
addressed. Additionally, it is difficult to assess if calcium elevation or ROS generation is the 
initial event triggering Leishmania cell death. Further experimentation using calcium chelating 
agents and antioxidants prior to or in conjunction with the allicin treatment is needed. Other 
important energetic organelles in Leishmania are glycosomes. Evaluation of the role of this 
organelle in the mechanism of action of allicin should also be considered.  
Mitochondrial membrane collapse (MMC), and consequently the lack of functionality of 
mitochondria, is an irreversible cellular dysfunction leading, depending on the relative weight of 
bioenergetic catastrophe/protease and endonuclease activation, to cell necrosis or apoptosis 
respectively (Kroemer et al., 1998). Apparently allicin is able to induce apoptosis in some 
cancer cell lines (PC-3, Hep G2) (Arunkumar et al., 2006; Chu et al., 2012). ATP availability, 
after mitochondrial membrane depolarization, determines the switch from apoptosis (no fall of 
ATP) to cell necrosis (low ATP) (Leist et al., 1997; Eguchi et al., 1997; Kim et al., 2003). In our 
case there was a net fall of ATP production. Despite the variations found in programmed cell 
death our results did not show any conclusive evidence of apoptotic-like death since DNA 
fragmentation was not observed (TUNEL assay), no phosphatidylserine (Annexin V/PI staining) 
was exposed and there was a cell cycle arrest at G2/M phase (PI staining). On these grounds, the 
death type found in Leishmania treated with allicin is compatible with cell necrosis.  
Additional experiments would be required to precisely know the downstream-upstream 
sequence of events but available data point towards the early induction of high ROS generation 
in Leishmania by exposure to allicin. The impairment of the intra-promastigote redox balance 
induced the mitochondrial membrane depolarization (∆Ψm) with dysfunction of the TCA and 
therefore reduction of ATP production, and elevation of intracellular Ca2+. These events, 
possibly through a feed-back process, lead to the collapse of mitochondrion with loss of 
integrity and finally a cellular energetic catastrophe leading to the necrotic death of Leishmania 
promastigotes with cell arrest at the premitotic phase (G2/M). 
 
7.7. Concluding remarks 
Current chemotherapy of leishmaniasis is not satisfactory in terms of administration via and 
length of treatments, high price of the most effective and safe drugs (e.g. liposomal AmB), 
serious side effects (e.g. teratogenicity of miltefosine) and toxicity. Nevertheless, as stated by 
WHO (2010) and the routine human and veterinary chemotherapeutic indications, the most 
effective drugs against this infection have, on average, more than 50 years and no new chemical 
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entities (NEC) are presently foreseen. Moreover no obvious reasons can be invoked for this low 
efficacy in antileishmanial drug discovery (Pink et al., 2005). Generally speaking this 
unexpected crisis of innovation in the pharmaceutical research is not restricted to leishmaniasis 
or even parasitic diseases and perhaps is related to the internal structure and expense distribution 
of pharmaceutical companies, with strict division between financial and R&D departments 
(Cuatrecasas, 2006) and the anachronism of patent system (e.g. panda’s thumb: a long history of 
evolution but not suitable for present times) (Moon et al., 2012). In the particular case of 
leishmaniasis, besides these components, drug development has followed opportunistic 
strategies (e.g. piggy-back development) and low returns are expected from potential users.  
The analysis of this situation transcends the purpose of our present work although it deserves 
a deep evaluation. The enormous advances in basic biology of Leishmania and the available 
technologies (e.g. molecular biology, genomic, proteomics, transcriptomics, metabolomics, 
robotics, miniaturization, and bioinformatics) have not resulted in a substantial improvement of 
the development of antileishmanial drugs (Koehn & Carter, 2005). Drug discovery processes 
quickly integrated the advances from biomedical sciences, particularly molecular biology and 
engineering in the 1980s. It was assumed that the use of the powerful techniques (target 
selection, HTS screening) would reduce costs and time invested to obtain drugs safer, 
affordable, in a shorter discovery time-line (Koehn & Carter, 2005) and profitable besides 
providing a rational approach to drug discovery. Combinatorial chemistry (directed through 
molecular docking and in silico design) or undirected, with favorable ADMET properties 
(absorption, distribution, metabolism, excretion, toxicity) would put on the bench an 
unprecedented number of potentially useful drugs. Innovation is linked to the inherent risk of 
failure, and failure in companies is synonym of expensive. Pharma industry under the mantra 
“fail fast, fail cheap” tried to increase success rates but results point towards that maybe they are 
asking the wrong questions. Up to date attrition rate is very high and although many molecules 
are being tested, in laboratory and field conditions, no new antileishmanial drug has been 
developed. Certainly there are no single solutions to these problems although some comments 
could be made on the prevailing drug development system. Since the end of the 1980s many 
pharmaceutical companies stopped the work on natural products in spite of the high rate of 
success with that source of molecules (Newman, 2008). It was assumed that the HTS-
CombiChem tandem would produce a full range of drugs. To date this approach, while labor-
saving, has not yielded the expected results after checking large chemical libraries for hit and 
lead identification and subsequent lead optimization to produce new drug candidates.  
Chemical synthesis has followed in many cases the feasibility of chemical reactions using a 
limited handful of structures. On the contrary, scaffolds identified from natural sources have an 
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unsurpassed variety and complexity, much higher than those obtained in synthetic products (Lee 
& Schneider, 2001; Feher & Schmidt, 2003). With the present shortage of new drugs, the high 
attrition rate of the synthetic chemistry-based drug development and the innovation crisis, the 
role of natural or natural-derived molecules as an importance source of potentially effective 
drugs against leishmaniasis (and other, particularly parasitic diseases) in  our opinion should be 
reevaluated. Present technological tools, including molecular biology, molecular docking and 
HTS, and the improvements in chemical synthesis by mimicking natural molecules (Feher & 
Schmidt, 2003) could overcome the traditional drawbacks from natural molecules (e.g. low 
yield, limited supply, complex structures). Moreover, bioguiding of the process with well-
established and predictive models in vitro, ex vivo and in vivo could result in more efficient way 
of developing new drugs or combinations.  
Our experimental work showed that a natural molecule, allicin, displayed a significant 
antileishmanial effect in vitro and in vivo and, perhaps more importantly, its concurrent 
administration in the micromolar range allowed to reduce the needed amount of AmB to 
effectively control experimental leishmaniasis in hamsters. These results are encouraging and 
support the interest of exploring molecules from natural sources and take advantage of the 
technologies presently available. 
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7.8. Conclusions 
 
i. The modification developed for the Alamar Blue assay, with promastigote cultures with 
5% CO2 atmosphere, 20 mM Hepes buffer and fluorimetry readings, increased 
reproducibility and sensitivity of the method and allows its routine use in drug 
screening for the identification of potential antileishmanial molecules.   
 
ii. The combination of the thermal pretreatment and isolation of an enriched population of 
metacyclic promastigotes of Leishmania infantum and L.donovani increased 
internalization and intracellular multiplication in macrophages. High infection rates (% 
of infected Mφ), number of intracellular amastigotes and reproducibility of the results 
make the modified infection procedure a good tool for drug screening and 
characterization of virulence in Leishmania isolates.  
 
iii. The antiproliferative effect of diallyl thiosulphinate (=allicin), in the micromolar range, 
on promastigotes and intracellular amastigotes of L.donovani and L.infantum has been 
demonstrated for the first time. The IC50 determined for the intracellular stage (10-30 
μM) probably excludes this molecule for the monotherapy of leishmaniasis.  
 
iv. The robust methodology employed for the analysis of the interaction between allicin 
and amphotericin B (AmB) showed from moderate synergy to synergy between both 
molecules against both stages of Leishmania, allowing a 50% reduction of the required 
dose of AmB. These results point towards the interest of this combination for the 
treatment of leishmaniasis.   
 
v. Allicin, administered intraperitoneally to hamsters (Mesocricetus auratus) 
experimentally infected with L.infantum (5 mg/Kg/day, 5 days), exhibited an important 
antiparasitic activity without toxicity as shown by the absence of clinical signs or 
physiological abnormalities. 
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vi. The combination of allicin (5 mg/Kg/day, 5 days) and AmB (1 mg/Kg/day, 5 days) 
showed antiparasitic efficacy in vivo (reduction > 95% of the parasite burden) 
comparable to that shown by the standard AmB dose (5 mg/Kg/day, 5 days). The 
reduction of the AmB dose required points towards the interest of this combination for 
the treatment of leishmaniasis.   
 
vii. The differences observed in the IC50 values between promastigotes and amastigotes for 
the combination allicin + AmB and the apparent synergistic effect found with 
intracellular amastigotes, confirmed by in vivo studies, suggest the need of using 
intracellular amastigotes of Leishmania for drug screening for their higher predictive 
value.  
 
viii. Apparently, allicin targets the mitochondrion of Leishmania. Diallyl thiosulphinate 
induces increased ROS generation in the cytosol and mitochondrion. The redox 
imbalance provokes the mitochondrial membrane depolarization, rise of cytoplasmic 
calcium without alteration of permeability of the plasma membrane and fall of ATP 
production. These events induce a mitochondrial collapse with loss of integrity, 
energetic cellular catastrophe and necrotic cell death with cell cycle arrest in the 
premitotic phase (G2/M). 
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Summary 
 
Antileishmanial activity of diallyl thiosulphinate (=allicin), alone or in combination with 
amphotericin B (AmB), has been tested in vitro, ex vivo and in vivo on Leishmania 
promastigotes and intracellular amastigotes. In addition, a resazurin-based fluorimetric method 
to estimate the promastigotes’ proliferation has been improved and the mechanism of action of 
allicin on Leishmania has been explored. 
The value of resazurin-based Alamar Blue redox indicator to determine multiplication of 
Leishmania promastigotes in 96-well microtiter plates was examined. In addition, assay was 
validated with AmB and allicin. The method was tested on L.donovani and L.infantum 
promastigotes under different culture conditions (variable air-phase, presence of phenol red, 
initial cell density, incubation time, use of Hepes buffer). Results showed that the gas-phase of 
promastigote cultures was critical. The method yielded consistent results with initial plating cell 
densities of 2.5 x 105 promastigotes/well, up to 72 h incubation and 5% CO2 atmosphere or 
reduced air availability (sealed plastic bags, film-sealed microplates). Detection of low numbers 
of promastigotes and earlier results could be obtained using fluorimetry instead of 
spectrophotometry. The addition of 20 mM Hepes improved the results. Fluorescence intensity 
correlated to promastigotes number in both Leishmania spp.  Inhibitory concentration (IC50) 
values for AmB and allicin using cell counting and fluorimetry were comparable. Under these 
conditions this one-step, low-cost redox indicator can be used in drug sensitivity assays and 
studies of differential proliferation rates of Leishmania isolates or strains in a 96-well format. 
Anti-leishmanial activity of allicin has been tested in vitro against promastigotes and 
intracellular amastigotes of L.donovani and L.infantum. Macrophage infections have been 
carried out in vitro in the murine cell line J774 and ex vivo with peritoneal macrophages (Mφ) 
from BALB/c mice with a modified method to isolate metacyclic promastigotes. The compound 
has shown a significant in vitro effect on the multiplication of promastigotes of L.donovani and 
L.infantum in a time- and dose-dependent manner. It has been shown for the first time the 
inhibition of multiplication of intracellular amastigotes of Leishmania by allicin. Inhibitory 
concentrations of the compound were in the micromolar range (10-30 µM) for both Leishmania 
species. Antileishmanial effect of allicin apparently was not related to products of degradation 
of the molecule as assessed by mass spectrometry analysis. Inhibitory activity of allicin against 
promastigotes and intracellular amastigotes increased when the compound was added to the 
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cultures every 24 h. Two administrations of 5 µM allicin inhibited by ca. 50% the proliferation 
of Leishmania amastigotes. Low toxicity for mammalian cells of this compound suggests the 
interest of exploring the value of allicin in combined therapy against leishmanial infections. 
Current monotherapy against visceral leishmaniasis has serious side effects and resistant 
Leishmania strains have been identified. The antibiotic AmB has shown an extraordinary anti-
leishmanial efficacy without emergence of resistance; however toxicity has limited its general 
use. Results obtained showed, using a  non-fixed ratio analysis, that the combination of diallyl 
thiosulfinate (allicin) and AmB ranged from moderately synergic to synergic at low 
concentrations (0.07 µM AmB + 35.45 µM allicin induced a 95% growth inhibition). None of 
the treatments, alone or in combination, had noticeable adverse effect on Mφ in the 
concentration range examined (Allicin: 0.5, 1, 5 and 10 µM; AmB: 0.05, 0.075, 0.1 µM). 
Allicin, AmB or the combination did not affect the infection rate (% of infected Mφ) of 
Leishmania. Allicin enhanced the activity of AmB on intracellular amastigotes of L.donovani 
and L.infantum (ca. 45% reduction on amastigote burden with 0.05 µM  AmB +10 µM allicin) 
this representing near a twofold reduction in the IC50 value of the antibiotic added alone. Results 
point towards the interest of testing this combination in vivo thus reducing the toxicity 
associated to the monotherapy with AmB. 
Results obtained in vitro and ex vivo with the combination of AmB and allicin prompted us 
to evaluate the efficacy of the combination of allicin and amphotericin deoxycholate (AmB) in 
the chemotherapy of L.infantum infection with the final aim of reducing the dose of AmB in the 
chemotherapy of visceral leishmaniasis. For this purpose hamsters were infected 
intraperitoneally (ip) with L.infantum (107 stationary phase promastigotes). On day 45 post-
infection animals were treated ip with AmB (1 or 5 mg/kg/day), allicin (5 mg/kg/day) or a 
combination of AmB (1 mg/kg/day) + allicin (5 mg/kg/day) for 5 days. Animals were clinically 
and biopathologically monitored and the antibody response (IgG, IgG1, IgG2) was determined. 
Parasite burdens were estimated by limiting dilution and AmB biodistribution was determined 
by HPLC in plasma, kidney, spleen and liver. No clinical signs or liver and kidney alterations 
were observed. AmB (1 mg/kg/day) did not clear the Leishmania infection and no parasites 
were detected in two animals treated with 5 mg/kg/day allicin. Combination therapy (5 mg/kg 
allicin + 1 mg/kg AmB) reduced the L.infantum burden by >95%. Antileishmanial activity of the 
combination was comparable (p< 0.05) to the standard AmB treatment (5 mg/kg/day). 
Antimicrobial activity of allicin has been extensively studied although the precise 
mechanism of action underlying its antileishmanial effect has been virtually unexplored. 
Transmission electron microscopy showed that allicin induced relevant morphological changes, 
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including mitochondrial swelling, invaginations in the inner mitochondrial membrane and loss 
of internal integrity. Other important alterations observed involved swelling of the nuclear 
membrane and an intense vacuolization of the cytoplasm. Exposure of the parasites to allicin led 
to high production of intracellular and mitochondrial reactive oxygen species (ROS) which was 
not controlled by thiol homeostasis, collapse of the mitochondrial membrane potential, reduced 
production of ATP and elevation of cytosolic calcium. The incubation of the promastigotes with 
SYTOX Green revealed that decrease of ATP was not associated with plasma membrane 
permeabilization. Annexin V and propidium iodide (PI) staining indicated that allicin did not 
induce phosphatidylserine exposure on the plasma membrane. Moreover, TUNEL analysis 
demonstrated that allicin did not provoke DNA fragmentation. These results point towards a 
necrotic type of cell death in Leishmania after exposure to diallyl thiosulphinate. In addition, 
analysis of the cell cycle with PI staining showed that allicin induced cell cycle arrest in the 
G2/M phase. We conclude that allicin primarily targets mitochondria and induces oxidative 
stress, uncontrolled by the antioxidant defence of the cell, which leads to mitochondrial 
dysfunction, increase of cytosolic calcium levels and a bioenergetic catastrophe leading to cell 
necrosis and cell cycle arrest in the premitotic phase. 
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Resumen 
 
Escenario actual de la quimioterapia de la leishmaniosis  
El informe de la 60ª Asamblea Mundial de la Salud (OMS) para el Control de la 
leishmaniosis (Informe A60/10) (22 de marzo de 2007) concluyó que, en el ámbito de la 
medicina humana, los datos disponibles sobre la prevalencia e incidencia de la leishmaniosis no 
eran fiables debido al carácter rural de muchos de los procesos, falta de diagnóstico y 
notificación al no ser una enfermedad de declaración obligatoria (EDO) en todos los países en 
los que estaba presente. Asimismo se señaló, entre las necesidades de investigación más 
urgentes para el control de la enfermedad, la exploración de nuevos fármacos económicos 
alternativos y con ciclos de tratamiento más cortos y, por ello, de más fácil implementación. En 
2014, la situación, a pesar de los esfuerzos de investigación y desarrollo (I+D) es similar. En el 
ámbito veterinario, y en particular en las áreas endémicas para ZVL por L.infantum (= 
L.chagasi), varias de las necesidades mencionadas anteriormente también son aplicables.  
El desarrollo de una respuesta protectora en el hombre frente a una reinfección homóloga por 
Leishmania así como la inmunización tradicional frente a la leishmaniosis cutánea, mediante 
leishmanización, sugiere que el desarrollo de una vacuna eficaz frente a la leishmaniosis es 
factible. Sin embargo, a pesar del profundo conocimiento de la biología, bioquímica y biología 
molecular de Leishmania spp, y de la inmunología de las leishmaniosis, no existe ninguna 
vacuna registrada frente a la leishmaniosis humana. La protección lograda con algunas de las 
preparaciones comerciales frente a la leishmaniosis canina (e.g. CaniLeish®) es solo parcial (no 
impide la infección aunque mejora el cuadro clínico del paciente), de escasa duración 
(revacunación anual) además de provocar efectos secundarios de consideración. 
 En estas circunstancias el principal sistema de control de la leishmaniosis es la 
quimioterapia. La anfotericina B liposomada (AmB), paromomicina y la miltefosina han sido 
considerados por la OMS (www.who.int/tdr/diseases/leish) como los fármacos más 
prometedores y, junto con los antimoniales (SbV), constituyen el principal arsenal para el 
control terapéutica de la leishmaniosis. Estos fármacos, sin embargo, presentan importantes 
inconvenientes. Así, existen resistencias de L.donovani a algunos de ellos (e.g. SbV, 
miltefosina) (Croft et al., 2006), otros son muy tóxicos o teratogénicos, ninguno de ellos logra 
una curación parasitológica y las preparaciones menos tóxicas y eficaces (e.g. AmB 
liposomada) tienen un precio elevado que las hace inaccesibles a la población humana de las 
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áreas endémicas (Sundar & Chaterjee, 2006; Sundar & Chakravarty, 2013) e irrelevantes en un 
contexto veterinario.  
 
El descubrimiento de fármacos frente a Leishmania requiere modelos 
experimentales fiables. Cribado de fármacos con promastigotes.  
Se han empleado diferentes modelos experimentales para evaluar el potencial terapéutico de 
una molécula o combinación frente a la leishmaniosis. En las primeras fases de la exploración 
de una molécula de potencial interés se emplean modelos celulares. Teniendo en cuenta que la 
mayoría de los compuestos empleados en la terapéutica (frente a la leishmaniosis y otros 
procesos) tienen un mecanismo de acción basado en la inhibición de enzimas, la actividad de 
estos ha sido empleada como criterio selectivo de fácil adaptación al cribado (dirigido o no) 
mediante sistemas de cribado de alto rendimiento (“High Throughput Systems”, HTS). Sin 
embargo, la distancia existente entre bioquímica (inhibición de un enzima), farmacología y 
terapéutica (farmacocinética, farmacodinamia) hace que sean preferibles el empleo de cribados 
fenotípicos empleando cultivos de Leishmania. Además, algunos de ellos han sido adaptados 
con éxito a cribados HTS. Con el objetivo de alcanzar un mayor éxito en el cribado y que este 
sea además menos costoso deben favorecerse los cribados selectivos o dirigidos (e.g. familia de 
compuestos de estructura o acción similar, compuestos con dianas terapéuticas conocidas, 
propiedades farmacocinéticas favorables). 
La gran mayoría de cribados, incluso en los análisis masivos, se han realizado utilizando 
promastigotes cultivados (e.g. Siqueira-Neto et al, 2010; Walker et al, 2011). Esta fase, 
comparable a las células que se dividen dentro de los vectores (Diptera, Psychodidae), difiere 
(por ejemplo, en su morfología y su bioquímica) de la fase parasitaria, el amastigote, presente en 
los vertebrados infectados. Al no ser la fase responsable de la infección, el promastigote no es 
un modelo ideal para la identificación de fármacos potencialmente útiles. No obstante, 
promastigotes y amastigotes comparten muchas rutas metabólicas y por lo tanto, con algunas 
excepciones (e.g. profármacos como SbV), las moléculas eficaces frente a promastigotes lo son 
también frente a amastigotes (e.g. AmB, miltefosina) (Sharlow et al., 2009). El estadio 
extracelular también ha sido empleado para determinar la resistencia clínica frente a algunos 
fármacos, como la miltefosina (Kulshrestha et al, 2013). Por otra parte, los ensayos con 
amastigotes intracelulares –a pesar de su mayor interés- son más laboriosos y no están presentes 
en todos los laboratorios.  
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El cribado fenotípico en promastigotes de fármacos leishmanicidas/leishmaniostáticos 
mediante microscopía requiere una gran inversión de tiempo y personal por lo que se han 
desarrollado métodos indirectos tales como la nefelometría, colorimetría, PCR cuantitativa, 
citometría de flujo, incorporación de 3H-timidina o tratamiento de imágenes (e.g. ensayos con 
“reporter genes”) entre otros. Un método de cuantificación colorimétrica, Alamar Blue, es de 
bajo coste, fácil ejecución y toxicidad insignificante para las células. Este método, basado en la 
determinación de resorrufina, producto de la reducción de resazurina, se ha empleado con 
frecuencia para determinar la multiplicación de células de mamífero, normales y transformadas 
(O'Brien et al., 2000; Sykes & Avery, 2009).  
Las pruebas preliminares realizadas en nuestro laboratorio mostraron resultados 
inconsistentes en el seguimiento de la multiplicación de promastigotes de L.infantum y 
L.donovani, en condiciones estándar (26ºC, aireación) y con diferentes medios de cultivo (e.g. 
RPMI 1640, Schneider). Ya que probablemente el rendimiento de un indicador redox se vería 
afectado por la fase gaseosa de los cultivos, en particular por el oxígeno y el dióxido de 
carbono, se exploró y cuantificó su posible efecto en el ensayo de Alamar Blue. Los resultados 
obtenidos con una atmósfera de 5% CO2/95% aire sobre cultivos tamponados con 20 mM 
HEPES mejoraron de forma notable los resultados (linealidad y correlación entre el recuento de 
células y el nivel de resorrufina detectado) cuando los cultivos se iniciaron con un inóculo de 
2,5 x 105 promastigotes de Leishmania spp y la reducción de resazurina fue valorada mediante 
fluorometría (Capítulo 2). Nuestros resultados fueron consistentes con el empleo de una 
atmósfera de CO2 habitual en la mayoría de los ensayos con células de mamíferos, los 
efectuados sobre tripanosomas de torrente circulatorio y aquellos realizados en amastigotes 
axénicos de Leishmania (Räz et al., 1997; Sykes & Avery, 2009). No disponemos de 
explicación adecuada a la ausencia de inconvenientes en experimentos anteriores con 
Leishmania spp sin CO2 (de Oliveira-Silva et al, 2008; Shimony & Jaffe, 2008; Vermeersch et 
al, 2009; Kulshrestha et al, 2013) o en HTS con un formato de 384 pocillos (Siqueira-Neto et 
al., 2010) salvo que no fuera explícitamente indicado o debido al diferente comportamiento de 
los promastigotes de Leishmania relacionado con modificaciones de los medios de cultivo (e.g. 
aditivos, concentración, suero fetal bovino).  
Las condiciones experimentales descritas en nuestro trabajo han permitido obtener una alta 
repetibilidad y reproducibilidad de los resultados con las dos especies ensayadas (L.infantum y 
L.donovani). Además no existió interferencia con el rojo fenol presente en el medio de cultivo y 
la reducción de resazurina estuvo estrechamente relacionada con el nº de células (determinado 
mediante recuento en cámara de Neubauer) (r2= 0,9713). La modificación desarrollada, además 
de constituir una herramienta adecuada para el cribado de fármacos de interés frente a la 
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leishmaniosis de posible empleo en formatos adaptables a HTS, apunta a la necesidad de 
estandarización de las condiciones de cultivo de Leishmania y la cuantificación de la 
multiplicación de promastigotes. 
 
Evaluación de fármacos frente a amastigotes intracelulares de Leishmania  
De forma  general se considera que los modelos in vivo de cribado de fármacos tienen un 
valor predictivo superior que los modelos in vitro o ex vivo, y que los amastigotes intracelulares 
son más convenientes para este propósito que los promastigotes o los amastigotes axénicos 
(Sereno et al., 2007). Sin embargo, el uso sistemático de amastigotes intracelulares está menos 
extendido debido a los requerimientos técnicos superiores –respecto a promastigotes-, tasa de 
multiplicación lenta en algunas especies de Leishmania (e.g. L.infantum vs L.donovani), así 
como los requerimientos específicos de algunas especies. Estos requerimientos singulares 
explican la diferente eficacia de las infecciones en dependencia de la especie de Leishmania 
implicada, incluso cuando están estrechamente emparentadas. De hecho, en el caso de 
L.infantum el primer método de infección de macrófagos (Mφ) peritoneales de ratón (y la línea 
celular murina J774) con promastigotes fue publicado hace menos de 20 años (Méndez et al., 
1996), mucho después que dichos cultivos fuesen rutinarios con L.donovani. Dicho método 
modificado incluía que la temperatura en el periodo de contacto (incubación overnight) de los 
Mφ con los promastigotes de L.infantum fuera de 33°C, temperatura es más cercana a la de la 
piel donde se produce la infección. 
Este procedimiento ha sido utilizado desde entonces (e.g. Ordóñez-Gutiérrez et al, 2007, 
2009; Wert et al, 2011) aunque la tasa de infección (% de Mφ infectados) y la carga parasitaria 
(número de amastigotes intracelulares/Mφ infectado) eran inferiores a los valores obtenidos en 
infecciones paralelas con L.donovani. Consideramos, por ello, explorar la posibilidad obtener 
infecciones más eficaces (superior carga parasitaria, mayor % de infección) y consistentes con 
L.infantum como paso previo a su utilización en el cribado de moléculas de potencial interés. Se 
ha desarrollado una modificación del método de infección mediante la combinación del método 
establecido previamente en nuestro laboratorio (Méndez et al., 1996), el aislamiento de 
metacíclicos con un gradiente de Ficoll discontinuo (Yao et al., 2008), y la opsonización de los 
promastigotes con 15% de suero de ratón (Capítulo 3). La modificación del método de infección 
ha permitido obtener elevaciones notables de la tasa de infección de ambas especies 
(L.infantum: 65-70% en células J774, ca. 80% en Mφ peritoneales de BALB/c; L. donovani: 70-
75% en J774, ca. 95% en Mφ peritoneales de ratón) y de la multiplicación intracelular, 
particularmente de L.infantum. El empleo conjunto del método de infección mejorado y el 
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método fluorométrico para determinar la viabilidad de amastigotes intracelulares de Leishmania 
(Bilbao-Ramos et al., 2012), no ensayado por nosotros, podría constituir una potente plataforma 
para el ensayo de fármacos leishmanicidas/leishmaniostáticos y ser adaptado a HTS. 
 
Dialil tiosulfinato (alicina) inhibe a concentraciones micromolares (µM) la 
multiplicación de promastigotes y amastigotes de Leishmania. 
Las deficiencias actuales del control quimioterápico de la leishmaniosis (reducido arsenal 
terapéutico, resistencias, toxicidad, ausencia de curación parasitológica) hacen del I+D de 
nuevos agentes una necesidad urgente. Las estrategias a seguir para lograr este objetivo pueden 
ser a corto-medio plazo [e.g. nuevas indicaciones para fármacos antiguos –muchos de los 
tratamientos actuales de la leishmaniosis-, terapia combinada, incorporación de sistemas de 
administración de fármacos (DDS)] o a largo plazo (e.g. inmunoterapia, identificación de 
nuevas moléculas sintéticas o naturales) (Pink et al., 2005; Pham et al, 2013).  
La alicina (dialil tiosulfinato), producto natural presente en plantas de la familia Alliaceae, 
ha mostrado actividad antibacteriana [e.g. Helicobacter pylori, cepas de Staphylococcus aureus 
resistentes a la meticilina (MRSA)] (O'Gara et al., 2000; Cutler & Wilson, 2004), antifúngica 
(i.e. Candida) (Cañizares et al., 2004; Khodavandi et al, 2011) y actividad antiproliferativa 
frente a distintos Protista (e.g. Trypanosoma, Leishmania, Entamoeba, Plasmodium) (Mirelman 
et al, 1987; Coppi et al 2006; Waag et al, 2010). La información existente sobre la actividad de 
esta molécula sobre Leishmania era muy reducida y solo basada en los estudios efectuados 
sobre promastigotes. Esta falta de información, el desarrollo del modelo de infección de Mφ con 
promastigotes de Leishmania y la disponibilidad de alicina estabilizada nos llevó a probar el 
potencial efecto antiproliferativo de alicina frente a los dos principales agentes causantes de la 
leishmaniosis visceral, L.donovani y L.infantum (Capítulo 3).  
Los resultados obtenidos han mostrado un efecto inhibitorio significativo de alicina a 
concentraciones micromolares sobre la multiplicación de L.donovani y L.infantum. La 
inhibición fue tiempo y dosis dependiente y tanto frente a promastigotes como amastigotes 
intracelulares in vitro (células J774) y ex vivo (Mφ peritoneales de ratón BALB/c). La IC50 
obtenida (ca. 10-30 µM, 24 h de exposición) para los promastigotes de ambas especies estaba en 
la línea del valor indicado por Ankri & Mirelman (1999) (30 µg/mL) para L.major y 
ligeramente superior que la señalada por McClure et al. (1996) para L.chagasi y L.mexicana. 
Más relevante fue la observación de que, la alicina, a estas concentraciones, inhibió la 
multiplicación de amastigotes, hecho no señalado anteriormente. Además, la toxicidad de 
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alicina a las concentraciones empleadas fue baja y no mostró toxicidad en células de mamífero 
(método MTT, ausencia de alteraciones morfológicas en células J774 y  Mφ  murinos).  
La administración de alicina en dosis repetidas cada 24 h incrementó significativamente su 
eficacia antiproliferativa. Este hallazgo sugería la degradación del dialil tiosulfinato a 26ºC y 
37ºC (McClure et al 1996; Cañizares et al., 2004). Esta molécula es altamente reactiva y es  
rápidamente transformada a otros tipos de compuestos orgánicos de azufre, en particular 
dialitrisulfuro (DATS), dialildisulfuro (DADS), dialilsulfuro (DAS), ajoeno y vinilditinas 
(Amagase, 2006). 
La degradación de la preparación de alicina utilizada tras una exposición de 24 h a dichas 
temperaturas se confirmó mediante microextracción en fase sólida, cromatografía de gases y 
espectrometría de masas (SPME/GC/MS). Las muestras tratadas mostraron sulfuros y 
vinilditinas pero no ajoeno (E o Z) o alicina. La ausencia de alicina y ajoeno podría ser debida a 
su corta vida media a las temperaturas de cultivo (26ºC y 37ºC) (ajoeno < 1 min) o bien al 
método analítico empleado. En este sentido se ha indicado que la sensibilidad térmica de alicina 
a temperatura fisiológica, así como su rápida transformación en otros tipos de compuestos 
orgánicos de azufre (Amagase, 2006) podrían descartar su uso terapéutico. Sin embargo, se ha 
demostrado que la disminución de la alicina es acompañada por su transformación en otros 
compuestos (i.e. ajoeno) (Fujisawa et al. 2008) que presenta una importante actividad anti-
Leishmania (Ledezma et al. 2002). Además, otros subproductos de la degradación de alicina 
(e.g. DATS, DADS, DAS) han demostrado tener también potente actividad antimicrobiana (e.g. 
DAS y DADS frente a Helicobacter pylori; DATS comercializados en China frente a Giardia; 
DADS y ajoeno han demostrado actividad antiviral) (Corzo-García et al., 2007) y no debe 
descartarse su posible efecto frente a Leishmania. La determinación de la molécula responsable 
de la actividad frente a Leishmania observada en nuestro estudio, alicina o algún producto de 
degradación, requiere experimentación adicional. Por otra parte el metabolismo de la alicina, y 
por lo tanto su biodisponibilidad, son en su mayor parte desconocidos (Lawson, 1998; Lawson 
& Wang, 2005).  
El valor de IC50 determinado in vitro y ex vivo (ca. 5-10 µM en dosis repetidas) frente a 
amastigotes intracelulares posiblemente excluye a la alicina como monoterapia frente a las 
leishmaniosis. Sin embargo, su coste reducido y su escasa toxicidad podrían permitir el uso de 
alicina en terapia combinada con otros fármacos anti-Leishmania bien establecidos.  
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Interacción de alicina y anfotericina B, a concentraciones micromolares, frente a 
promastigotes y amastigotes intracelulares de Leishmania 
Entre las estrategias empleadas para hacer frente a la aparición de resistencias y a la 
reducción de la eficacia de algunos de los fármacos empleados en la monoterapia de la 
leishmaniosis (e.g. SbV, miltefosina) se encuentra la utilización de combinaciones de fármacos 
de conocida actividad leishmanicida/ leishmaniostática (Olliaro, 2010; Sundar & Chakravarty, 
2013). La notable actividad anti-Leishmania de alicina y la reducida toxicidad para células de 
mamífero encontradas, impulsaron la exploración de la combinación de esta molécula con 
Anfotericina B (AmB).  
Este compuesto, de ser un tratamiento de segunda línea para la leishmaniosis, se ha 
convertido, como consecuencia de la aparición de resistencias, en el fármaco de elección en 
muchas zonas endémicas de la enfermedad (Croft & Coombs, 2003; Croft et al, 2006; Sundar & 
Chakravarty, 2013). En la actualidad la AmB, especialmente la formulada en liposomas, es la 
primera línea terapéutica para el control en el hombre de esta enfermedad, en particular de las 
leishmaniosis viscerales (OMS, 2010). Además, a pesar de su utilización en la práctica clínica 
(leishmaniosis, micosis sistémicas) durante más de 50 años, la aparición de resistencias es 
anecdótica (Durand et al., 1998; Gray et al., 2012; Purkait et al., 2012). Las restricciones al uso 
de este antibiótico han estado relacionadas con los efectos secundarios (toxicidad) y larga 
duración de los tratamientos con monitorización clínica necesaria. Nuestra experimentación 
pretendía conocer el posible efecto sinérgico, aditivo o antagónico de alicina y AmB a 
concentraciones micromolares (atóxica), in vitro y ex vivo, con el objetivo de reducir la dosis 
necesaria de AmB en monoterapia y, por ello, minimizar su toxicidad.  
La mayor parte de los estudios experimentales llevados a cabo sobre combinación de 
fármacos frente a Leishmania han empleado combinaciones de diluciones de dos moléculas sin 
análisis ulterior. Sin embargo, existen metodologías de mayor significación que la aproximación 
“checkerboard” para determinar la interacción real de dos compuestos (e.g. anergia, sinergia, 
antagonismo) (Odds, 2003). Por ello, en nuestro estudio sobre el efecto anti-Leishmania de la 
combinación AmB + alicina se utilizó la robusta metodología de Chou-Talalay y el software 
CalcuSyn desarrollado por dichos autores (Chou, 2006; Chou, 2008; Chou & Hayball, 1996). 
Los resultados mostraron que la combinación de ambas moléculas fue de moderadamente 
sinérgica a sinérgica con concentraciones bajas de ambos compuestos tanto frente a 
promastigotes (i.e. la combinación de 0,07 µM AmB + 35,45 µM alicina indujo una inhibición 
del crecimiento del 95%) como amastigotes (i.e. reducción del ~ 45% con 0,05 µM AmB + 10 
µM alicina). Estas concentraciones representaban una reducción cercana al 50% en el valor de 
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la IC50 del antibiótico cuando era empleado como único fármaco (Vermeersch et al., 2009; Maia 
et al., 2013). Por otra parte las diferencias observadas entre los resultados obtenidos con 
promastigotes (con una reducción de 7-11 veces de la concentración necesaria de AmB) y 
amastigotes (con una reducción próxima al 50%) subrayan la necesidad de utilizar amastigotes 
intracelulares en la identificación de moléculas de interés frente a Leishmania (Sereno et al, 
2007; Seifert et al., 2011) (Capítulo 4).  
Al igual que ocurre en hongos, el principal esterol presente en la membrana plasmática de 
Leishmania es el ergosterol. Aparentemente, alicina es capaz de incrementar la actividad 
fungicida de la AmB mediante la inhibición del tráfico de ergosterol desde la membrana celular 
a la membrana de las vacuolas originadas por AmB en Candida albicans (Fungi) (Ogita et al., 
2009). En nuestro caso, la base de esta acción sinérgica frente a Leishmania requiere 
experimentación adicional. Los datos obtenidos con combinaciones de fármacos in vitro y ex 
vivo presentan limitaciones (e.g. interacciones imprevistas, modificaciones en los perfiles de 
PK/PD) a pesar del análisis de relación dosis-efecto llevado a cabo (Chou, 2008). A todos los 
efectos, una combinación de los fármacos A+B puede comportarse como un tercer fármaco, C. 
No obstante, la reducción en la dosis necesaria de AmB frente a amastigotes intracelulares de 
Leishmania y la posibilidad de utilizar dosis no tóxicas de alicina (>10 µM) sugirieron el interés 
de la exploración de esta combinación in vivo. 
 
Alicina es eficaz contra la leishmaniosis visceral experimental en hámster y reduce 
la dosis efectiva requerida de anfotericina B 
 La terapia combinatoria ha sido una de las estrategias empleadas, fomentada por la OMS 
(2010), para hacer frente a la aparición de fallos terapéuticos y resistencias en Leishmania 
(Chunge et al., 1985; Murray et al., 2003). Experimentalmente se ha logrado generar resistencia 
frente a combinaciones en L.donovani (García-Hernández et al., 2012), por lo que se debe tener 
cautela en su implementación. No obstante, el empleo de fármacos en combinación para el 
tratamiento de la LV presenta importantes ventajas entre las que se incluyen el aumento de la 
eficacia y la tolerancia del tratamiento, la reducción de la toxicidad, duración y coste del mismo, 
y la limitación o prevención de la aparición de resistencias aumentando así la vida útil de los 
medicamentos que tenemos a nuestra disposición (Seifert & Croft, 2006; Griensven et al., 
2010).  
AmB probablemente es el mejor medicamento existente frente a la leishmaniosis con tasas 
de curación superiores al 95% (Alvar et al., 2006; Paila et al., 2010; Sundar & Chakravarty, 
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2013) y niveles insignificantes de resistencia después de ser empleado como fármaco de 
referencia contra las infecciones fúngicas sistémicas durante más de 50 años (Durand et al, 
1998; Gray et al, 2012).  
En general se considera que la unión de AmB al ergosterol de la membrana celular de 
Leishmania es la principal causa de su actividad leishmanicida (Purkait et al., 2012). La afinidad 
diferencial de AmB por el colesterol (abundante en células de mamífero) y ergosterol (en las 
membranas de Leishmania) explicaría la toxicidad diferencial para los hospedadores y los 
agentes parasitarios. En realidad, la toxicidad residual de AmB, por unión inespecífica al 
colesterol, se considera el principal inconveniente para su uso (Laniado-Laborín  & Cabrales-
Vargas, 2009; Hamill, 2013).  
Nuestros resultados mostraron que (i) alicina exhibió una toxicidad muy baja para células de 
mamífero además de ser capaz de inhibir significativamente la multiplicación de amastigotes 
intracelulares de Leishmania (Capítulo 3), y (ii) la actividad in vitro y ex vivo frente al parásito 
resultante de la interacción de AmB + alicina en combinación resultó sinérgica (Capítulo 4). Los 
amastigotes intracelulares de Leishmania son un buen modelo para evaluar fármacos de 
potencial valor (Sereno et al., 2007) pero no permiten anticipar el valor terapéutico del fármaco 
o combinación. Por ello, se evaluó la eficacia terapéutica de la alicina, así como de su 
combinación con AmB a bajas dosis, en un modelo experimental de leishmaniosis visceral.  
El objetivo final de la estrategia de combinación sería la reducción (por debajo de los niveles 
tóxicos) de las dosis de AmB necesarias para controlar eficazmente la infección crónica por 
L.infantum en criceto (Mesocricetus auratus) (Capítulo 5). El modelo experimental permitió 
obtener infecciones consistentes, con cargas parasitarias significativamente más altas en bazo    
–respecto a hígado- y una alteración de los niveles hemáticos de urea, confirmando así su 
idoneidad para los ensayos in vivo de moléculas leishmanicidas/leishmaniostáticas (Binzahim et 
al., 1993; Requena et al, 2000; Melby et al., 2001; Dea-Ayuela et al., 2007; Moreira et al, 2012). 
Los grupos de cricetos infectados fueron tratados desde el día 45 post-infección mediante 
administración intraperitoneal de los compuestos [AmB (1 o 5 mg/Kg/día), alicina (5 
mg/Kg/día) o una combinación de AmB (1 mg/Kg/día) + alicina (5 mg/Kg/día) durante 5 días 
consecutivos]. Ninguno de los compuestos ni la combinación indujeron signos clínicos en los 
animales o alteraciones fisiológicas lo que confirmó la ausencia de toxicidad de AmB, alicina o 
la combinación con la pauta terapéutica empleada. El tratamiento con alicina (5 mg/Kg/día, 5 
días) eliminó la infección por L.infantum en 2 de los 6 animales tratados, tanto en bazo como en 
hígado. Estos resultados han supuesto la primera evidencia de la actividad de alicina in vivo 
frente a las infecciones por Leishmania. 
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La combinación de AmB (1 mg/Kg/día) + alicina (5 mg/Kg/día) redujo más del 95% de la 
carga parasitaria de L. infantum, nivel de eficacia comparable (p<0,05) con los resultados 
obtenidos con la dosificación estándar de AmB (5 mg/Kg/día). Dichos resultados confirman in 
vivo la sinergia observada in vitro y ex vivo (Capítulo 4) y sugiere la posibilidad de reducir 
cinco veces la dosis requerida de AmB en monoterapia sin pérdida de eficacia. El mecanismo 
responsable de la interacción sinérgica o aditiva hallada no es conocido y debe ser explorado. 
Aparentemente, alicina mejoró la acumulación del antibiótico en los órganos diana y en los 
hámsteres tratados se observó una respuesta específica IgG2 comparativamente mayor, quizás 
relacionada con la respuesta proinflamatoria inducida por alicina (Feng et al., 2012). Se necesita 
más investigación en este modelo predictivo de leishmaniosis humana y canina (e.g. posología, 
vía de administración, naturaleza de la interacción) pero nuestros resultados apuntan hacia el 
interés de esta combinación, con la posibilidad de reducir la dosis necesaria de AmB, y por lo 
tanto su potencial toxicidad, en la quimioterapia de leishmaniosis. 
 
Mecanismo de acción de alicina: catástrofe bioenergética y necrosis celular en 
Leishmania 
A pesar de la eficacia de alicina y compuestos relacionados para inhibir la multiplicación de 
organismos eucariotas unicelulares (e.g. Candida, Trypanosoma, Leishmania) y de células 
cancerosas (Capítulos 1 y 3) su mecanismo de acción es en su mayor parte desconocido. Se ha 
indicado que, dada su naturaleza altamente reactiva, probablemente reacciona rápidamente con 
tioles, sistemas enzimáticos tiol-dependientes, cisteín preoteasas y microtúbulos (Ankri & 
Mirelman, 1999; Prager-Khoutorsky et al., 2007; Miron et al., 2010; Waag et al., 2010). 
Además, se ha descrito su capacidad para inducir apoptosis en células tumorales (Oomen et al., 
2004). Sin embargo, las dianas intracelulares responsables del efecto citocida/citostático de la 
molécula son en gran parte desconocidas. La disponibilidad de una formulación estabilizada de 
alicina y los resultados obtenidos in vitro, ex vivo e in vivo frente a Leishmania nos llevaron a 
investigar su posible mecanismo de acción leishmanicida/leishmaniostático.  
 Mediante microscopía electrónica de transmisión (MET) la alteración más notable 
observada en promastigotes de L. infantum y L.donovani tratados con alicina fue la pérdida de 
integridad de la membrana mitocondrial y la alteración a nivel del kinetoplasto (Capítulo 3 & 
5). La microscopía es una notable herramienta para determinar las dianas intracelulares así 
como el tipo de muerte celular. Por otra parte, los Trypanosomatidae, incluyendo Leishmania, 
solo tienen una gran mitocondria que representa ca. 12% del volumen celular (Monzote-Fidalgo 
& Gille, 2011) y dependen en gran medida de esta organela dada su escasa capacidad para 
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sobrevivir y multiplicarse en ambientes anaeróbicos (Hellemond et al., 1997; Manzano et al, 
2012).  
Nuestros resultados mostraron que alicina, a concentraciones subletales, indujo una 
elevación de la producción de especies reactivas de oxígeno (ROS). Aunque ROS están 
presentes en células normales y desempeñan un papel significativo como mensajeros (Zhang et 
al, 2006) la elevación de sus niveles está relacionada con el estrés oxidativo, la disfunción 
mitocondrial y la muerte celular (Duchen, 2000; Zong & Thompson, 2006). Ya que la alicina 
atraviesa membranas celulares con facilidad (Miron et al., 2010), dicha elevación debe 
producirse muy rápidamente. La principal defensa antioxidante de Leishmania depende 
principalmente de tripanotion (=bis-glutationil espermidina) (Fairlamb & Cerami, 1992), debido 
a que los Kinetoplastida carecen de catalasa, glutation peroxidasa y de glutation reductasa 
(Fairlamb et al., 1985). Nuestros resultados mostraron que alicina solo inhibió de forma 
moderada la actividad de la tripanotion reductasa y existió una elevación de los niveles totales 
de tioles (i.e. cisteína, glutation y tripanotion) en las células tratadas. Estos resultados, además 
de confirmar la interacción de alicina con tioles (Rabinkov et al., 1998), sugerían  que la muerte 
celular de Leishmania no estaba relacionada principalmente con este mecanismo de acción de 
alicina.  
Existe una estrecha relación entre el estrés oxidativo y el Ca2+ intracelular en todos los 
organismos, incluyendo Leishmania (Mukherjee et al, 2002; Das et al, 2008; Dolai et al, 2011). 
Una fina regulación de los niveles de Ca2+ intracelulares resulta crítica para la homeostasis y 
supervivencia celular (Richter, 1993). Se ha demostrado que el estrés oxidativo puede 
interrumpir la translocación de calcio intracelular (Orrenius et al., 1989) en las diferentes 
reservas celulares de calcio (e.g. mitocondria, acidocalcisomas, retículo endoplasmático). 
Nuestros experimentos mostraron que la alicina indujo una rápida elevación del Ca2+ 
citoplasmático. Este incremento probablemente esté relacionado con el transporte desde los 
depósitos intracelulares y, en particular desde la mitocondria, ya que no se encontraron 
variaciones en la permeabilidad de la membrana plasmática. No obstante, se requiere 
experimentación adicional para comprobar el origen extracelular (i.e. apertura de canales 
iónicos en la membrana plasmática) o intracelular (i.e. movilización de depósitos) del catión. La 
generación de ROS y el aumento de Ca2+ citosólico en Leishmania expuestas a concentraciones 
subletales de alicina fueron acompañados por la caída del potencial transmembrana 
mitocondrial (ΔΨm) y por la reducción de la producción de ATP. Los elevados niveles de ROS 
intramitocondriales y su aparente saturación (> 30 µM alicina) además de las alteraciones 
morfológicas observadas en MET (Capítulo 3 & 5) apuntan a la mitocondria como diana 
primaria de alicina en Leishmania.  
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Así, la generación de ROS inducida por alicina, no compensada por tioles, provocaría la 
despolarización de la membrana mitocondrial con caída del ΔΨm; ello reduciría la capacidad de 
la mitocondria para retener (y regular) los niveles intracelulares de Ca2+  junto con la disfunción 
de la fosforilación oxidativa y derivada caída de la producción de ATP. Esta caída es crítica ya 
que se estima que el 70% de todas las necesidades energéticas de Leishmania dependen de la 
fosforilación oxidativa en mitocondria (Manzano et al., 2012).  
El colapso de la membrana mitocondrial (CMM) y, por consiguiente, la disfuncionalidad de 
la mitocondria, es un proceso irreversible que culmina con la muerte celular ya sea por necrosis 
o bien por apoptosis (Kroemer et al., 1998). Aparentemente alicina es capaz de inducir 
apoptosis en algunas líneas celulares cancerosas (PC-3, Hep G2) (Arunkumar et al, 2006; Chu 
et al., 2012.). La disponibilidad de ATP, tras la despolarización de la membrana mitocondrial, 
determina si la muerte se producirá mediante apoptosis (sin caída de ATP) o necrosis (bajos 
niveles de ATP) (Leist et al., 1997; Eguchi et al., 1997; Kim et al., 2003). En nuestro caso 
existió una caída neta de la producción de ATP. A pesar de las variaciones encontradas en los 
tipos de muerte celular programada nuestros resultados no mostraron ninguna evidencia 
concluyente de muerte apoptótica ya que no se observó fragmentación de ADN (mediante 
TUNEL), no se halló exposición de fosfatidilserina [mediante tinción con Anexina V y yoduro 
de propidio (IP)] y el ciclo celular se detuvo en la fase G2/M (análisis con IP). Por tanto, 
nuestros resultados apuntan a que alicina induce la muerte de Leishmania mediante un proceso 
de necrosis celular.  
Serían necesarios más experimentos para determinar la secuencia precisa de eventos pero los 
datos disponibles apuntan hacia la rápida generación de ROS –intracelular e intramitocondrial- 
en Leishmania como consecuencia de la exposición a alicina. El desequilibrio redox provocaría 
la despolarización de la membrana mitocondrial (ΔΨm) con disfunción del ciclo del ácido 
tricarboxílico (CAT) y, por lo tanto, la reducción de la producción de ATP acompañada de una 
elevación del Ca2+ citosólico. Estos procesos, posiblemente a través de un proceso de 
retroalimentación, llevarían al colapso de la mitocondria con pérdida de su integridad y, 
finalmente, a una catástrofe energética celular que de forma irreversible conduciría a la muerte, 
por necrosis, de los promastigotes de Leishmania con detención del ciclo celular en la fase 
premitótica (G2/M). 
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Observaciones finales y conclusiones  
La quimioterapia actual de la leishmaniosis no es satisfactoria teniendo en cuenta vía de 
administración y la duración de los tratamientos, el precio de los fármacos más eficaces y 
seguros (e.g. AmB liposomada), los efectos secundarios (e.g. teratogenicidad de miltefosina) y 
la toxicidad de la mayoría de compuestos. Sin embargo, los medicamentos más eficaces contra 
esta infección tienen, en general, más de 50 años y no se anticipa el lanzamiento de nuevas 
moléculas eficaces. La falta de alternativas terapéuticas para el control de la leishmaniosis y 
otras enfermedades parasitarias no tiene razones obvias derivadas de una dificultad específica 
inherente a estos agentes etiológicos (Pink et al., 2005). Se ha señalado que esta crisis de 
innovación por parte de la industria farmacéutica –no solo restringida a este grupo de 
enfermedades- está más relacionada con factores como la estructura interna de la industria, con 
separación estricta de los departamentos financieros y de I+D (Cuatrecasas, 2006) y al 
anacronismo del actual sistema de patentes (Moon et al., 2012). A estos factores, en el caso 
particular de la leishmaniosis, habría que añadir los escasos retornos esperables en términos 
económicos y el uso de estrategias oportunistas seguidas en numerosas ocasiones para la 
identificación de nuevas moléculas con actividad antiparasitaria frente a esta enfermedad (e.g. 
indicaciones nuevas para fármacos antiguos; nuevas presentaciones).  
Es relevante señalar que los enormes progresos de la biología básica de Leishmania y las 
tecnologías disponibles (e.g. genómica, proteómica, transcriptómica, metabolómica, robótica, 
miniaturización, bioinformática) no han dado lugar a una mejora sustancial del desarrollo de 
fármacos leishmanicidas/leishmaniostáticos. En la década de los 80 del siglo pasado se anticipó 
que los avances de la biología molecular, además de poder ser integrados con facilidad en el 
descubrimiento de fármacos (e.g. identificación de dianas, sistemas de cribado de alta 
capacidad), reducirían los tiempos de desarrollo de fármacos seguros y asequibles permitiendo 
reducir costes, humanos y materiales (Koehn &  Carter, 2005). En efecto, el cribado sistemático, 
dirigido o no, de bibliotecas químicas permitiría identificar moléculas con potencial terapéutico 
en cortos periodos de tiempo. Por otra parte, el tándem “cribado de alta capacidad/química 
combinatoria” pondría a disposición de la comunidad científica un número de moléculas sin 
precedentes. Sin embargo, la tasa de fracaso ha sido muy alta y, aunque existen numerosas 
moléculas en evaluación en condiciones de laboratorio y de campo, no se ha desarrollado 
ningún nuevo fármaco frente a Leishmania.  
La escasez actual de fármacos eficaces frente a la leishmaniosis junto con la escasa 
eficiencia del desarrollo de moléculas de interés obtenidas mediante la síntesis química y la 
crisis de innovación de la industria farmacéutica aconsejan, en nuestra opinión, una 
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reevaluación del potencial terapéutico de moléculas de origen natural o sus derivados (). La 
investigación sobre productos naturales fue abandonada por la industria de forma simultánea a 
la utilización sistemática de la síntesis química, a pesar de los éxitos obtenidos a partir de 
productos naturales (Newman, 1980) y su papel en la terapéutica actual de numerosas 
enfermedades. Las moléculas naturales presentan una extraordinaria variedad y complejidad 
estructural muy superior a las sintéticas (Lee & Schneider, 2001; Feher & Schmidt, 2003) 
mientras que en la química de síntesis solo se utiliza un número reducido de estructuras.  
La riqueza y complejidad en término de número de moléculas presentes en un extracto de 
origen natural constituyó una importante limitación para el estudio de nuevos principios activos 
derivados de plantas u otros organismos (e.g. hongos, organismos marinos). En particular, la 
mayor dificultad era lograr identificar, aislar y conseguir cantidades suficientes de la molécula 
con actividad biológica presente en una mezcla compleja como es un extracto. En la actualidad 
se dispone de potentes herramientas (e.g. espectrometría de masas, resonancia magnética 
nulcaer, diversas técnicas cromatográficas, técnicas de biología molecular, sistemas de cribado 
de alta capacidad) y más información (e.g. relación estructura-función) que podrían subsanar los 
inconvenientes inherentes al estudio de productos naturales (Feher & Schmidt, 2003; Koehn & 
Carter, 2005). Además, el análisis “bioguiado” del proceso de identificación, con modelos bien 
establecidos y predictivos in vitro, ex vivo e in vivo puede resultar en una forma más eficiente de 
desarrollar nuevos fármacos y combinaciones.  
Nuestro trabajo experimental ha mostrado que una molécula natural, alicina, exhibe un 
efecto significativo frente a Leishmania in vitro e in vivo y, quizás de forma más notable, su 
administración a concentraciones micromolares atóxicas ha permitido reducir la dosis necesaria 
de AmB para controlar eficazmente la leishmaniosis experimental. Estos resultados sugieren el 
interés de la exploración de nuevas moléculas de origen natural con las tecnologías disponibles 
en la actualidad. 
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Conclusiones 
 
i. La modificación desarrollada del método Alamar Blue, en cultivos con atmósfera de 5% 
CO2, tamponado adicional (20 mM Hepes) y fluorimetría, incrementó la sensibilidad y 
precisión de la técnica y permite su empleo rutinario en el cribado de moléculas con 
potencial actividad leishmanicida/leishmaniostática. 
 
ii. La combinación de tratamiento térmico y separación de promastigotes metacíclicos de 
Leishmania infantum y L. donovani incrementó la internalización y multiplicación 
intracelular en macrófagos. Los elevados niveles de infección (% Mφ infectados), 
número de amastigotes producidos y repetibilidad de los resultados convierten a este 
método en una buena herramienta tanto para el cribado de fármacos como para la 
caracterización de la virulencia de aislados de Leishmania.  
 
iii. Se ha demostrado, por vez primera, la inhibición de la multiplicación de promastigotes 
y amastigotes intracelulares de L.donovani y L.infantum por dialil tiosulfinato (=alicina) 
a concentraciones micromolares. El valor IC50 hallado para la forma intracelular (10-30 
µM) probablemente excluye a esta molécula como monoterapia en el tratamiento de la 
leishmaniosis. 
 
iv. El empleo de un método robusto de análisis de la interacción entre alicina y anfotericina 
B (AmB) mostró la existencia de sinergia moderada a sinergia entre ambas moléculas 
frente a los dos estadios de desarrollo de Leishmania permitiendo reducir un 50% la 
concentración requerida del antibiótico. Estos resultados apuntan al interés de esta 
combinación en el tratamiento de la leishmaniosis. 
 
v. Alicina, administrada a cricetos (Mesocricetus auratus) infectados experimentalmente 
con L.infantum (5 mg/Kg/día, 5 días) mostró una notable actividad antiparasitaria y 
ausencia de toxicidad, evidenciada por la ausencia de signos clínicos o alteraciones 
fisiológicas.  
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vi. La combinación de alicina (5 mg/Kg/día, 5 días) y AmB (1 mg/Kg/día, 5 días) mostró in 
vivo una eficacia antiparasitaria (reducción > 95% de la carga parasitaria) comparable a 
la medicación estándar con AmB (5 mg/Kg/día, 5 días). La reducción de las dosis de 
AmB necesarias, en presencia de alicina, apunta al interés de esta combinación en la 
terapéutica de la leishmaniosis. 
 
vii. La diferencia en los valores de IC50 hallados para la combinación alicina + AmB en 
promastigotes y amastigotes, así como la aparente sinergia observada en el modelo de 
amastigotes intracelulares, confirmada in vivo, sugieren la necesidad de realizar 
cribados de fármacos frente a Leishmania en amastigotes, por su superior valor 
predictivo. 
 
viii. La mitocondria de Leishmania aparentemente es la organela diana de alicina. Dialil 
tiosulfinato induciría la generación de niveles elevados de ROS en el citosol y la 
mitocondria. La alteración del equilibrio redox provoca la despolarización de la 
membrana mitocondrial, elevación de calcio citosólico sin alteración de la 
permeabilidad de la membrana plasmática y caída de la producción de ATP. Estos 
eventos provocarían un colapso de la mitocondria con pérdida de su integridad, 
catástrofe bionergética y muerte por necrosis con detención del ciclo celular en fase 
premitótica (G2/M). 
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ResazurinThe value of resazurin-based Alamar Blue redox indicator to determinemultiplication of Leishmania promastigotes
in 96-well microtiter plates was examined. In addition, assaywas validatedwith amphotericin B (AmB) and allicin.
The method was tested on L.donovani and L.infantum promastigotes under different culture conditions (variable
air-phase, presence of phenol red, initial cell density, incubation time, use of Hepes buffer). Results showed that
the gas-phase of promastigote cultures was critical. The method yielded consistent results with initial plating cell
densities of 2.5 × 105 promastigotes/well, up to 72 h incubation and 5% CO2 atmosphere or reduced air availability
(sealed plastic bags, film-sealed microplates). Detection of low numbers of promastigotes and earlier results could
be obtained using fluorimetry instead of spectrophotometry. The addition of 20 mM Hepes improved the results.
Fluorescence intensity correlated to promastigotes number in both Leishmania spp. Inhibitory concentration
(IC50) values for AmB and allicin using cell counting and fluorimetry were comparable. Under these conditions
this one-step, low-cost redox indicator can be used in drug sensitivity assays and studies of differential proliferation
rates of Leishmania isolates or strains in a 96-well format.
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Visceral leishmaniasis is a parasitic disease caused by Leishmania
donovani and L. infantum (= L.chagasi) (Kinetoplastida). The infection
affects both humans and dogs in large areas of the world (i.e. India,
Mediterranean Basin, and South America) and it is fatal unless treated.
Current first-line chemotherapy of leishmaniasis relies on a rather lim-
ited arsenal of drugs, most of which have serious side-effects including
nephro- and hepatotoxicity and teratogenicity. Therefore, the identifi-
cation of new molecules or formulations is an urgent need and has
been recognised byWHOas one of the research areaswhere a sustained
effort has to be made (Alvar et al., 2006).
It is assumed that in vivomodels have superior predictive value than
in vitro models, and that screening using intracellular amastigotes are
more convenient than axenic amastigotes and promastigotes (Sereno
et al., 2007; Vermeersch et al., 2009; De Muylder et al., 2011; Gupta
and Shakya, 2011). In spite of the limitations the promastigote stage is
currently used and screeningwith this parasitic stage has been exploited
as a first-step to identify “hit” and “lead” anti-leishmanial compounds in
undirected massive screening [High Throughput Screening (HTS)] of
chemical libraries (Sharlowet al., 2009; Siqueira-Neto et al., 2010;Walker
et al., 2011).culty of Veterinary Medicine,
Spain. Tel.: +34 91 3943701;
rights reserved.There are several in vitro systems available to determine
promastigotes proliferation of Leishmania spp (i.e. reporter gene
assays, enzymatic determinations, H3 -thymidine incorporation, colori-
metric methods). Among colorimetric methods, resazurin-based Alamar
Blue entails several advantages. First, it is simple to use as it requires only
a one-step procedure. Other benefits reported are its low cost, environ-
mentally friendly composition and transferability to field sites if neces-
sary (Räz et al., 1997). Unlike other assays, this redox indicator is
relatively non-toxic to cells and can be usedwith long incubation periods
(up to 72 h) (Fumarola et al., 2004). This indicator has been extensively
used in the related genus Trypanosoma (Räz et al., 1997; Rolón et al.,
2006; Sykes and Avery, 2009) and in some Leishmania spp (Mikus and
Steverding, 2000; de Oliveira-Silva et al., 2008; Shimony and Jaffe,
2008; Kulshrestha et al., 2013). Recently, this method has been adapted
using HTS with Leishmania and two different platforms and a 384-well
format (Sharlow et al., 2009; Siqueira-Neto et al., 2010).
Our laboratory has been engaged on the study of the anti-leishmanial
antiproliferative effect of differentmolecules.While Alamar Blue could be
easily employed to determine the cytotoxicity for the murine cell line
J774 (Wert et al., 2011), results obtained with Leishmania promastigotes
were inconsistent, since resazurin reduction did not correlate with cell
counts. Given the lack of experimental details given in the available liter-
ature dealing with Leishmania, our aim was to examine the value of
Alamar Blue to determine the multiplication and growth inhibition of
L. donovani and L. infantum promastigotes under different culture condi-
tions (variable air-phase, cell density and incubation time). Results
showed that optimal conditions of Alamar Blue assaywith promastigotes
in 96-well microtiter plates included a 5% CO2 atmosphere, the presence
112 M.J. Corral et al. / Journal of Microbiological Methods 94 (2013) 111–116on 20 mM Hepes in the culture medium and an initial concentration
of promastigotes of ca. 2.5 × 105/mL. With these conditions, reduced
resazurin (resorufin) measured by fluorimetry provided an accurate
estimation of promastigotes multiplication and could be used for drug
screening and IC50 estimation.
2. Material and methods
2.1. Parasites
An autochthonous isolate of L. infantum (UCM 9), obtained from
affected dogs in the area of Madrid (Spain) by the Clinical Service
of the Department of Animal Health, Faculty of Veterinary Medicine
(Universidad Complutense), and Khartoum 1246 isolate from
L. donovani, provided by Dr. Toraño (Department of Immunology,
Instituto de Salud Carlos III, Madrid) were routinely maintained as
promastigotes in RPMI 1640 medium (Lonza Group, Basel, Switzerland)
at 26 °C supplemented with heat inactivated (30 min, 56 °C) foetal
bovine serum (FBS) (Sera Laboratories International, Horsted Keynes,
UK) and 100 U/mL penicillin + 100 μg/mL streptomycin (BioWhittaker,
Verviers, Belgium) in 25 mL culture flasks.
2.2. Chemicals
Alamar Blue was purchased from AbD Serotec (Oxford, UK). Allicin
(2-Propene-1-sulfinothioic acid S-2-propenyl ester) was obtained as
liquid Allisure® from Allicin International Ltd (Rye, East Sussex, UK)
at a concentration of 5000 ppm and kept at a temperature of −80 °C
until used. Amphotericin B (AmB) was obtained as fungizone (Sigma,
St. Louis, USA).
2.3. Promastigote assays
Depending on the experiment promastigotes were cultured in
flat-bottomed 96-well cell culture microtiter plates with lid (Costar,
Corning, NY, USA), in microtiter plates wrapped with Parafilm®, or
in plates sealed with Thermal adhesive film for PCR plates (Simport,
Beloeil, Canada). For comparative purposes promastigote cultures were
also done in 1.5 mL eppendorf ® tubes. Cultures were carried out at
26 °C in aerated culture chamber or incubated in a 95% air/5% CO2
humidified atmosphere. Culture media (RPMI 1640) with and without
additional 20 mMHepes were employed depending on the experiment.
2.4. Alamar Blue assay
Concentration of resorufin, the product of reduction of resazurin, in
the Leishmania cultures was determined following the manufacturer's
recommendations by reading the absorbance (A) at 570 and 600 nm,
and fluorescence (550 nm excitation wavelength, 590 nm emission
wavelength) in a FLUOstar Omega (BMG Labtech, Ortenberg, Germany)
fluorimeter. Fluorescence intensity was expressed as arbitrary units
(A.U.). Briefly, mid-log phase promastigotes were added to the wells
of microtiter plates or eppendorf tubes up to a volume of 200 μL/well.
After 24 h, 20 μL Alamar Blue (10% v/v) was added and the cultures
were kept for 24, 48 or 72 additional hours. Absorbance and fluores-
cence intensity were determined every 24 h. Promastigote counts
were carried out in Neubauer improved chambers and cell viability
was assessed by trypan blue exclusion staining. Untreated cultures,
wells without cells and the maximal concentration of the drugs, and
wells with culture medium and Alamar Blue (10% v/v) were included
as controls. All experiments were performed at least in triplicate.
2.5. Statistical analysis
Results were expressed as means ± standard deviation. Data were
compared by analysis of variance (one- and two-ways ANOVA) andGLManalysis using GraphPad Prism5. Differenceswere considered signif-
icant when p b 0.05. Figures were also prepared with GraphPad Prism5.
3. Results
3.1. Determination of optimal cell density
Different concentrations (104, 2.5 x104, 5 × 104, 7.5 × 104, 105,
2.5 × 105, 5 × 105, 7.5 × 105, 106) of mid-log phase promastigotes of
L.donovani and L.infantumwere added in a final volume of 200 μL/well
in 96-microtiter plates. Cultures were carried out at 26 °C in plates
with lid under a 5% CO2 atmosphere or in film-sealed plates. After
24 h incubation, Alamar Blue was added and the plates were kept for
24, 48 or 72 h. For each time determination a plate was used. Resazurin
was effectively reduced to resorufin in the medium, evidenced by the
higher levels of absorbance and, particularly, fluorescence related both
to the initial promastigotes density and the time of culture. Absorbance
determinations, especially with low initial promastigote concentration
(b105 promastigotes/well) were more variable (not shown). This vari-
ability was not observed when cultures were kept in the CO2 atmo-
sphere. Results were more consistent when resorufin concentration
was determined by fluorimetry. Fluorescence was significantly higher
(ca. 2 times) when cultures were exposed to 5% CO2 (Fig. 1A) as com-
pared to those performed in film-sealed plates (Fig. 1B). Highest levels
of fluorescence were obtained with initial inoculums of 2.5 to 5 × 105
promastigotes/well from both Leishmania species, after 72 h and expo-
sition to CO2.
3.2. Correlation between Alamar Blue reduction and
promastigotes multiplication
Preliminary results obtained in our laboratory allowed the use of
the redox indicator to determine the proliferation of Leishmania
promastigotes in culture tubes. However, as shown above, for a given ini-
tial number of promastigotes and time of incubation, significant differ-
ences (p b 0.05) were found in the concentration of resorufin estimated
by absorbance and, particularly, fluorimetry depending on the exposition
to CO2 or to a limited air phase in the sealedmicrotiter plates. To rule out
the possibility of resazurin reduction being an inaccurate estimation of
Leishmaniamultiplication, promastigotes (2.5 × 105/well) were cultured
in 96-well plates under a CO2 atmosphere or under air phase. For compar-
ative purposes parallel cultureswere done in eppendorf tubes. In all cases
cell multiplicationwas estimated by fluorimetry and cell counting of via-
ble Leishmania in Neubauer chamber. A set of cultures was employed for
each time determination (24, 48, 72 and 96 h).
Fig. 2 shows that no significant differences (p > 0.05) were found
between cultures in the experiment irrespective of the exposition to
5% CO2 or to an unlimited air phase. After 96 h, all cultures reached
values ca. 2.7 × 106 promastigotes/mL in both Leishmania spp (Fig. 2A).
However, resazurin concentrationdeterminedbyfluorimetrywas strong-
ly dependent on the culture conditions (Fig. 2B). Highest levels of fluores-
cence were seen in cultures exposed to CO2 and the lowest values were
present using standard culture conditions with air atmosphere. Cultures
in eppendorf tubes, with a limited amount of air, displayed intermediate
values. These results were consistent with the absence of colour change
in the standard microtiter plates in spite of the active multiplication.
These results suggested the importance of the air phase of the cultures
in the usefulness of Alamar Blue method to determine Leishmania prolif-
eration and also the need of standardization of the assay.
3.3. Effect of atmosphere and buffer on resazurin reduction by
promastigotes of Leishmania
Promastigotes of L.infantum and L.donovaniwere cultured in 96-well
standard microtiter plates exposed to 5% CO2, in standard microplates,
in microplates wrapped with Parafilm, in microplates in sealed plastic
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Fig. 1. Effect of incubation time with Alamar Blue on the fluorescence curves with promastigotes of L.donovani. Increasing initial plating concentrations of promastigotes were incubated
with Alamar Blue (10% v/v) and the fluorescence intensity determined (arbitrary units, A.U.) (excitationwavelength 560 nm, emissionwavelength 590 nm). A: In the presence of 5% CO2.
B: Film-sealed microplates. ●: 24 h; ■: 48 h and ▲: 72 h. Results are means ± standard deviations of 3 determinations.
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were done in eppendorf tubes to monitor cell viability (trypan Blue ex-
clusion dye) and multiplication (counting in Neubauer chamber). Cul-
tures with standard RPMI medium and medium with 20 mM Hepes
were employed. Absorbance and fluorescence were determined 24, 48
and 72 h after Alamar Blue addition.
As expected time-dependent fluorescence increases were observed in
all culture conditions and both Leishmania species earlier than absorbance
variations (not shown) in the determinations carried out. Fig. 3 shows the
results obtained with L. infantum and similar values were obtained for
L.donovani. It was found that the presence of 5% CO2 or limited air avail-
ability was critical to get the highest fluorescence values. Microplates
with lid exposed to air had the lowest levels, comparable to those found
in Parafilm wrapped plates. By its part, 96-well plates cultured in a CO2
incubator displayed the highest resorufin concentrations in all timedeter-
minations carried out. In cultures done in eppendorf tubes, film-sealed
microplates and plastic-sealed microplates intermediate values of ab-
sorbance and intensity of fluorescence were obtained. Moreover, the
presence of additional 20 mMHepes improved the resazurin reduction
in all culture conditions, particularly when film-sealedmicrotiter plates
and eppendorf tubes were employed (p b 0.01 – p b 0.001).
3.4. Value of resazurin reduction measured by fluorimetry for drug
screening in Leishmania
Value of resazurin transformation by fluorimetry for drug screen-
ing in 96-well microtiter plates was tested with two compounds with40
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Fig. 2. A: Proliferation of Leishmania promastigotes under different culture conditions [W
Promastigotes were seeded (2.5 × 105 promastigotes/well) on day 0. Alamar Blue was added 2
at different times and culture conditions ○: 5% CO2 atmopshere;●:aerated microplates; ▲:epantileishmanial activity, namely allicin and AmB. In all cases 2.5 × 105
promastigotes/well for both species were used. In the case of allicin,
10, 30, 60 and 120 μM concentrations were used and microplates in
CO2 or aerated incubator, and with and without additional 20 mM
Hepes in themedium, were used. Parallel counts were done in Neubauer
haemocytometer with cultures in eppendorf tubes exposed to the same
allicin concentrations. Cultures were treated for 24 h with allicin and
absorbance and fluorescence were monitored at 24, 48 and 72 h after
exposure to the drug. A range of AmB (0, 0.001, 0.002, 0.003, 0.004,
0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07,
0.08, 0.09, 0.1, 0.5, 1 and 10 μM) was tested with the optimal assay con-
ditions found (5% CO2, 20 mM Hepes). Fluorescence and absorbance
were measured 72 h after exposure to the antibiotic.
Fig. 4A shows the relationship between the allicin concentration
and the growth inhibition of L.donovani promastigotes determined by
cell counting and fluorescence of the cultures. Addition of 20 mM
Hepes improved the detection of fluorescence in aerated microplates
whereas no correlation between growth inhibition and resorufin levels
in the cultureswas observedwithoutHepes in this case. Our results clear-
ly showed that Alamar Blue reduction closely correlated to microscopic
cell counts and viability, in the allicin concentration range examined,
provided that a 5% CO2 atmosphere and 20 mM Hepes were present
(Fig. 4B). Comparable results were obtained for L.infantum. Inhibition of
multiplication of Leishmania promastigotes in the presence of AmB
confirmed the value of the resorufin level with fluorimetry using the
assay conditions described in the screening and IC50 determination of
this antileishmanial drug. Actually, for the particular L.infantum isolate60000
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Fig. 5. Determination of IC50 of amphotericin B for L.donovani promastigotes using
Alamar Blue reagent. Experimental conditions included an initial plating concentration
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counting>whereas using the best-fit valueswithfluorescence determi-
nations the value obtainedwas 0.0618 μM(Fig. 5). Fig. 6 shows a repre-
sentative result of the effect of CO2 and 20 mMHepes on the reduction
of resazurin.4. Discussion
Present results, with the optimal conditions described, show that
Alamar Blue, and presumably other resazurin-basedmethods, is an accu-
rate assay to determine the multiplication of Leishmania promastigotes
and growth inhibition elicited by antileishmanial drugs. Assay conditions
examined in a checkerboard manner showed that several factors were
relevant to obtain consistent results, namely an initial plating density of
promastigotes ca. 2.5 × 105, besides the presence of a 5% CO2 atmosphere
and additional buffering of the medium with 20 mM Hepes. Our results
on the optimal cell density were comparable to the findings by Mikus
and Steverding (2000) with L.major and Shimony and Jaffe (2008) with
L.donovani and support the lower reduction rate of Leishmania compared
to T. cruzi epimastigotes (Rolón et al., 2006) and bloodstream trypano-
somes (Räz et al., 1997). A linear fluorescence response was observed
with lower plating densities of promastigotes and therefore the method
could probably be used in 72 h experiments in the range of 5 × 104 to
105 promastigotes/well. The plateau observed with higher cell densities100
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Fig. 4. A: Growth inhibition of L.donovani promastigotes in the presence of allicin (24 h) est
sphere and 20 mM Hepes; □: 5% CO2 atmosphere; ●: aerated microplates and 20 mM Hep
inhibition of L.donovani promastigotes, determined by fluorescence and cell countings. ▲: ce
microplates and 20 mM Hepes; ○: aerated microplates. Results are means ± standard devand incubation time are probably related to the conversion of resorufin
to colourless and non-fluorescent hydroresorufin (O’Brien et al., 2000).
Alamar Bluemethod has been successfully employed tomonitor the
growth of mammalian cells (Ansar Ahmed et al., 1994; Nakayama et al.,
1997; O’Brien et al., 2000; Sykes and Avery, 2009). Most of the assays
have been performed in a 95 % air/5 % CO2 atmosphere, including
those carried out in African trypanosomes (Räz et al., 1997; Sykes and
Avery, 2009), or in plastic sealed bags (Martin et al., 2003). More than
probably the performance of a redox indicator added to a culture medi-
umwould be affected by the gas-phase although this factor apparently
has not been considered in the previous contributions on Leishmania
(de Oliveira-Silva et al., 2008; Shimony and Jaffe, 2008; Vermeersch
et al., 2009; Kulshrestha et al., 2013) and T. cruzi epimastigotes (Rolón
et al., 2006) using 96-well microtiter plates or, more recently with the
HTS with 384-well format, using L.major (Siqueira-Neto et al., 2010).
Our results showed that, using the 96-well plate format incubation in
a 5 % CO2 gas phase yielded accurate results of cell growth and inhibi-
tion in Leishmania (r2 = 0.9713). The carbon dioxide dissolved in the
medium allowed the efficient reduction of resazurin to the fluorescent
resorufin. Actually, O’Brien et al. (2000) highlighted the need of CO2 in
the medium when reduction is occurring in order to capture electrons.
In the absence of 5% CO2 additional buffering with Hepes could circum-
vent some of the limitations provided that a limited volume of gas
phase was present (capped eppendorf tubes, film sealed plates, sealed
plastic bags). Earlier and more sensitive estimation of resorufin was
obtained by fluorimetry and thus should be preferred to spectropho-
tometry. The significantly higher sensitivity of fluorimetry allowed the100
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Fig. 6. Representative image of L.infantum and L.donovani promastigote cultures
exposed to different concentrations of allicin (0, 10, 30, 60 and 120 μM),with andwithout
20 mM Hepes, in the presence of 5% CO2 atmosphere (B) or in air exposed 96-well
microplates (A). Marginal wells were not used to avoid edge effect.
115M.J. Corral et al. / Journal of Microbiological Methods 94 (2013) 111–116earlier identification of anti-leishmanial activity of allicin. Promastigote
multiplication and inhibition could be easily detected by fluorescence
after 48 h whereas observation of significant absorbance variations
needed 72 h as observed by Mikus and Steverding (2000).
Visceral leishmaniasis, both human and animal, caused by L.donovani
and L.infantum (=L.chagasi) continues being a challenge formedical doc-
tors and veterinary clinicians in many regions of the world. Available
drugs have important shortcomings (nephrotoxicity, hepatotoxicity, gas-
trointestinal disturbances) and, moreover, in some areas Leishmania
strains resistant to first line drugs have been described (Croft et al.,
2006). Identification of new potentially effective drugs or preparations
requires robust and reliable screening methods. In vivo tests of efficacy
must be reduced at a minimum by both ethical and economic reasons
and therefore in vitro screening of potentially useful compounds is
the first step to identify “hits and leads”. Obviously, the best in vitro
model to test antileishmanial activity of compounds is done on the intra-
cellular amastigote within macrophages (Sereno et al., 2007). However,
intracellular amastigotes screening is only available to some laboratories,
species such as L. donovani, and specially L.infantum, have a slow rate of
division (Gupta and Shakya, 2011) and some Leishmania isolates from
clinical cases do not infect the macrophage cell lines employed. By its
part, promastigotes are easy to culture and they share with amastigotes
many metabolic pathways and thus some of the most commonly
used antileishmanial agents, such as AmB or miltefosine, are effective
against both parasite stages. Therefore, promastigote screening is use-
ful (Sharlow et al., 2009) before testing in intracellular amastigotes,
and in vivo, and can be employed to monitor susceptibility of clinical
isolates to some drugs (i.e. Miltefosine, Kulshrestha et al., 2013).
Among the available methods (3H-thymidine incorporation, mi-
croscopic counting, quantitative PCR, enzymatic and colorimetric
methods) to determine proliferation of Leishmania promastigotes,
resazurin-based assays such as Alamar Blue can be carried out in a
single step, are unaffected by the red phenol from the culture medium
and have the advantage of low cost and negligible toxicity. Validation
with L.donovani and L.infantum promastigotes showed that this method
could be advantageously used in trials of cell proliferation and drugscreening, including the determination of approximate IC50 values
against promastigotes. Conditions described for Leishmania included
the presence of 5% CO2, or reduced air availability, to allow the efficient
reduction of resazurin to resorufin, in a promastigote-density related
manner. The method was improved by fluorimetry although spectro-
photometry could also be employed. Given the accuracy (fluorescence
vs. promastigotes density), the low number of promastigotes needed
and results obtained in the determination of IC50 for AmB and allicin as
compared to the results with microscopic counting (i.e. Corral-Caridad
et al., 2012), this 96-well microplate could be adapted for a 384-well
format.
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" Allicin inhibits in vitro the
proliferation of promastigotes of
Leishmania.
" No significant toxicity for
mammalian cells was found up to
40 lM allicin.
" Low micromolar allicin (10 lM)
reduced the multiplication of
Leishmania amastigotes.
" Serial treatment every 24 h with the
compound improved its
antileishmanial effect.
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a b s t r a c t
Anti-leishmanial activity of allicin (=diallyl thiosulphinate) has been tested in vitro against promastigotes
and intracellular amastigotes of Leishmania donovani and Leishmania infantum. Macrophage infections
have been carried out in vitro in the murine cell line J774 and ex vivo with peritoneal macrophages from
BALB/c mice with a modified method to isolate metacyclic promastigotes. The compound has shown a
significant in vitro effect on the multiplication of promastigotes of L. donovani and L. infantum in a time-
and dose-dependent manner. It has been shown for the first time the inhibition of multiplication of intra-
cellular amastigotes of Leishmania by allicin. Inhibitory concentrations of the compound were in the
micromolar range (10–30 lM) for both Leishmania species. Antileishmanial effect of allicin apparently
was not related to products of degradation of the molecule as assessed by mass spectrometry analysis.
Inhibitory activity of allicin against promastigotes and intracellular amastigotes increased when the com-
pound was added to the cultures every 24 h. Two administrations of 5 lM allicin inhibited by ca. 50% the
proliferation of Leishmania amastigotes. Low toxicity for mammalian cells of this compound suggests the
interest of exploring the value of allicin in combined therapy against leishmanial infections.
 2012 Elsevier Inc. All rights reserved.
1. Introduction
Human Leishmania infections are present in all inhabited conti-
nents, with around 12 million people infected, 2 million new cases
every year and 350 million people living in areas at risk (WHO,
2000). Leishmaniasis is a spectral infection with a range of clinical
presentations, from self healing dermal infections to visceral fatal
processes. Visceral leishmaniasis caused by Leishmania donovani
and Leishmania infantum = Leishmania chagasi is a severe disease
whose distribution has expanded frequently associated to HIV
infection (Desjeux, 2004). In addition to human cases, canine
leishmaniasis by L. infantum (Mediterranean Basin) and L. chagasi
(South America) constitutes a first order pathology in veterinary
clinics besides its zoonotical importance as reservoirs. The main
control system of leishmaniasis in both humans and dogs is
chemotherapy. Liposomal amphotericin (AmB), paromomycin and
miltefosine were considered the most promising drug for
0014-4894/$ - see front matter  2012 Elsevier Inc. All rights reserved.
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chemotherapy of leishmaniasis (www.who.int/tdr/diseases/leish).
However, these drugshave some important shortcomings, including
high toxicity and teratogenicity of some of them, absence of parasi-
tological cure in most cases and unaffordable prices for some of the
compounds (Sundar and Chaterjee, 2006). Moreover, in some areas
resistant Leishmania strains to commonly used drugs have emerged
(Croft and Coombs, 2003; Croft et al., 2006). Therefore, newdrugs or
combinations are needed (Alvar et al., 2006; Chappuis et al., 2007;
Mishra et al., 2007). This scenario favors the exploration of alterna-
tive drugs. Among them, allicin (diallyl thiosulfinate = 2-Propene-
1-sulfinothioic acid S-2-propenyl ester), a natural product present
inplantsof the FamilyAlliaceae, includinggarlic, has shownantibac-
terial activity against Helicobacter pylori (O’Gara et al., 2000;
Cañizares et al., 2004) and methicillin-resistant Staphylococcus
aureus (MRSA) (Cutler and Wilson, 2004) besides a full range of
medicinal and antimicrobial effects (Lawson, 1998; Ankri and
Mirelman, 1999). Reports on the antifungal (Candida) (i.e. Khodav-
andi et al., 2011) and antiprotozoal (Mirelman et al., 1987: Ent-
amoeba; Coppi et al., 2006: Plasmodium; Waag et al., 2010:
Plasmodium and Trypanosoma) activity of this molecule have been
published. Ankri and Mirelman (1999) referred to unpublished re-
sults on the inhibition of Leishmania major growth by 30 lM allicin.
Moreover, McClure et al. (1996) observed that allicin, besides other
garlic extracts,waseffective against the in vitro growthofLeishmania
mexicana and L. chagasipromastigotesbutno further testingwas car-
ried out. On these groundswe have tested the potential antiprolifer-
ative effect of allicin on promastigotes and amastigotes of the two
major causative agents of visceral leishmaniasis, L. donovani and L.
infantum. Our results showed thatmicromolar concentrations of alli-
cin are able to inhibit the proliferation of both stages and species.
2. Material and methods
2.1. Parasites
An autochthonous isolate of L. infantum (UCM 9), obtained from
affected dogs in the area of Madrid (Spain) by the Clinical Service of
the Department of Animal Health, Faculty of Veterinary Medicine
(UCM), and ‘‘Khartoum 1246’’ isolate from L. donovani, provided
by the Department of Immunology, Instituto de Salud Carlos III,
Madrid, were routinely maintained as promastigotes in RPMI
1640 medium (Lonza Group, Switzerland) at 26 C supplemented
with heat inactivated (30 min at 56 C) fetal bovine serum (FBS)
(Sera Laboratories International, Horsted Keynes, UK), 100 U/mL
penicillin + 100 lg/mL streptomycin (BioWhittaker, Verviers, Bel-
gium) and 1% L-glutamine in 25 ml culture flasks.
2.2. Promastigote assay
Promastigotes were cultured in 10 mL sterile polystyrene tubes.
Allicin was obtained as liquid Allisure from Allicin International
Ltd. (Rye, East Sussex, UK). Dilutions of the compound were added
up to 2 mL final volume. After 24, 48 and 72 h at 26 C, live prom-
astigotes were counted in an improved Neubauer chamber. Results
from treated cultures were expressed as % of the multiplication ob-
tained in untreated control cultures. Cultures were performed at
least in triplicate and cultures treated with 0.1 lM amphotericin
B (AmB) were included as control.
2.3. Cell cytotoxicity assay
2.3.1. MTT assay
MTT assay was employed to determine the toxicity of allicin for
both J774 cells andmouse peritonealmacrophages. Peritonealmac-
rophages were isolated from female BALB/c mice. Cell suspension
with RPMI-1640medium (supplementedwith 10% heat-inactivated
FCS, 1% penicillin/streptomycin, 1% L-Glutamine) were seeded in 96
well flat-bottomed cell culture plates (Corning, New York, USA).
Plates were incubated overnight in a humidified atmosphere 5%
CO2/air atmosphere at 37 C to ensure cell adherence. After 24 h,
cells (4  106 peritoneal macrophages/mL; 5  103/mL J774 cells)
were treated with increasing concentrations of allicin (1–120 lM).
Non-treated cells were included as a negative control. At the end
of the drug exposure period (24 h), the medium from all the wells
was removed and the cells were fed with 200 lL of fresh medium,
and plates were incubated for another 24 h. The viability of cells
was determined by the MTT reduction assay as described before
(Plumb, 2004). Briefly, 200 lL of fresh medium and 50 lL of the
MTT (Sigma, St. Louis, USA) solution (5 mg/mL in PBS) were added
to all wells; plates were incubated for 4 h protected from light in a
humidified atmosphere at 37 C. The remaining formazan crystals
were dissolved by adding 200 lL of DMSO (Sigma, St. Louis, USA)
and 25 lL/well of Sorensen’s glycine buffer were added to stop the
reaction.Absorbancewas readat 570 nm.The approximate IC50 con-
centration was determined as the allicin concentration required to
reduce the absorbance to half that of the untreated control wells
(considered as 100% viable). Three independent experiments, with
eight replicates, were carried out for assessing the cytotoxicity of
allicin with this method.
2.4. Amastigote assay
In the amastigote assay, infectionwas carried out using amodifi-
cation of themethods developed by us (Méndez et al., 1996;Wert et
al., 2011) and the procedure described by Yao et al. (2008) to isolate
metacyclic promastigotes. Depending on the experiment, infections
with Leishmaniawere carried out in vitro, using the murine macro-
phage cell line J774, and ex vivo, with peritoneal macrophages from
BALB/c mice. Stationary phase Leishmania promastigotes (day 7)
were centrifugedwithout brake (365g, 10 min) through a Ficoll gra-
dient (0, 10% inMedium199, and30% in sterile PBS). Parasites recov-
ered from the interphase between 0% and 10% Ficoll were washed
with fresh medium and opsonised with 15% normal mouse serum
in a solution 1:1 (v/v) RPMI medium and HBSS, 0.15 mM CaCl2 and
1 mMMgCl2 for 30 min at 37 C. Murine J774 cells (2.5  104 cells/
well) were cultured in 8-well Lab-Tek chambers (Nunc, Roskilde,
Denmark), for 16 h with mitomycin C (Calbiochem, Merck, USA) at
1 lg/mL was to avoid cell proliferation. The washed parasites were
added to the macrophage cultures (parasite: macrophage ratio
10:1) andmaintained at 33 C in 5% CO2 overnightwithoutmitomy-
cin. Non-internalized promastigotes were eliminated by thorough
washing three times with fresh medium. Compounds were added
at appropriate concentrations and maintained for 24 or 48 h
depending on the experiment carried out.
In the ex vivo experiments, peritoneal macrophages were ob-
tained from female BALB/c mice and cultured as described above
except for the absence of mitomycin treatment. Macrophage con-
centration was adjusted to 2.5  105/well up to a final volume of
200 lL/well. Metacyclic promastigotes were isolated and opson-
ised as previously described and parasite: macrophage ratio was
5:1. After a contact period overnight, Labtek plates were washed
with RPMI 1640 and the compounds were added at different
concentrations and times, and kept at 37 C for 24, 48 or 72 h
depending on the experiment. Slides were fixed and stained
(May- Grünwald-Giemsa, Merck Darmstadt, Germany) and the
number of amastigotes/100 cells and % of infected cells was deter-
mined. Cultures were performed at least in triplicate.
2.5. Solid phase microextraction (SPME) and gas chromatography/
mass spectrometry (GC/MS)
The SPME technique was carried out using a 85 lm Light Blue
Carboxen/PDMS fiber coated with polydimethylsiloxane. Samples
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(100 lL) from the experimental cultures were prepared in extrac-
tion vial of 20 mL. RPMI, PBS and internal standards (1 lL) were in-
cluded as control samples. Extractionwas performed at 40 Cduring
60 min under agitation (250 rpm) using an automatic injector Mul-
tifiber Change CTC Analysis model Mps2xl. Thermal desorption of
analytes from the fiber was carried out in the chromatograph injec-
tor port at 220 C in splitless mode. GC was performed with an Agi-
lent Technologies model 5975C gas chromatograph, at a constant
flowof1 mL/min for 5 minusingaVA624column(60 m  0.25 mm;
1.4 lm). Oven temperature programme employed included an ini-
tial isothermal time at 35 C for 5 min, followed by a 5 C/min ramp
up to 240 C setting during 30 min in isothermalmode.MSwas per-
formedwithAgilent Technologiesmodel7890Amassanalyzerwith-
out solvent delay in scan mode and in the 35–650m/z mass range.
Analysis was performed at the MS Unit-UCM.
2.6. Transmission electron microscopy (TEM)
The specimens were fixed for 3 h in a solution of glutaraldehyde
2.5% + paraformaldehyde 4% in PBS at 4 C followed by 2% osmium
tetroxide + 3% potassium ferrocyanide for 1 h, room temperature,
darkness. Samples were dehydrated with increasing concentra-
tions of acetone in water and soaked in resin SPURR (Fedelco
Madrid, Spain). The resin was polymerized at 70 C for 72 h. Thin
slices, 0.5 lm thick, were dyed with Richardson’s methylene blue
and observed by light microscopy. Ultra thin slices, 70 nm thick,
were treated with 2% uranyl acetate, as well as Reynold’s lead cit-
rate solution and examined with a Zeiss EM 902, transmission elec-
tron microscope (Carl Zeiss, Germany) at the SME-UCM.
2.7. Statistical analysis
Statistical significance of differences between mean values
obtained in the different groups was performed by one-way and
two-way ANOVA, repeated measures analysis and Bonferroni test.
Differences were considered significant when p < 0.05.
3. Results
3.1. Allicin inhibits the multiplication of Leishmania promastigotes
Micromolar concentrations of allicin effectively inhibited the
growth of promastigotes of L. infantum and L. donovani in a dose-
and time-dependent manner (p < 0.0001) (Fig. 1a and b). Only a
moderate anti-leishmanial activity (ca. 30–40% reduction as com-
pared to control) was observed with the lowest concentration
(30 lM) whereas 60 lM and 120 lM provoked a reduction over
80% of the initial population of promastigotes after 24 h (p < 0.05).
Addition of 120 lM allicin completely eliminated the promastig-
otes after 72 h. There was a certain recovery of Leishmania cultures
treated with 30 lM allicin from day 1 onwards. Microscopical
observation showed active cell division with this concentration
(not shown) and the motility of promastigotes was higher after
72 h than in similarly treated cells during 48 h. As expected,
0.1 lM amphotericin provoked a reduction bewteen 80% and 90%
of the promastigote number after 24 h. Treatment with allicin (60
and 120 lM) provoked important ultrastructural alterations of
Leishmania promastigotes (Fig. 2). Cellular swelling with reduction
of electrodense material in the cell cytoplasm and generalized
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Fig. 1. Effect of allicin on the proliferation of Leishmania infantum (Fig. 1a) and Leishmania donovani promastigotes (Fig. 1b). Compounds were added at time 0. d: 30 lM;
j: 60 lM; N: 120 lM; .: amphotericin (0.1 lM). Results are the means of three experiments ± standard deviation.
Fig. 2. Transmission electron micrographs of promastigotes of Leishmania infantum treated with 60 lM (B and B0), 90 lM (D) and 120 lM (C, C0 , C00) as compared to untreated
control cultures (A and A0). Treated promastigotes showed generalized vacuolization, reduction of electrodense material in the cytoplasm, cellular swelling(C00), loss of
integrity of mitochondrial and kinetoplast membranes (B and C), and chromatin condensation in the nucleus (C0) and kDNA (C). n: nucleus, k: kinetoplast, fp: flagellar pocket,
f: flagellum, m: mitochondrion. Magnifications are given on each micrograph.
Ma. Jesús Corral-Caridad et al. / Experimental Parasitology 132 (2012) 475–482 477
vacuolisation were observed. In addition, there was deforma-
tion and loss of integrity of membranes from both mitochondrion
and kinetoplast, and chromatin condensation in the nucleus and
kDNA.
3.2. Toxicity of allicin for mammalian cells
Toxicity of a range of allicin concentrations on the murine
macrophage cell line J774 and mouse peritoneal macrophages was
examined (Fig. 3) with MTT method. Apparently, all concentrations
of allicin affected cell viability (p < 0.0001) and 10 lM almost com-
pletely arrested cell proliferation of J774 after 24 h (Fig. 3a). How-
ever, results obtained with MTT did not correlate with the
microscopical examination of May-Grünwald-Giemsa stained cul-
tures. Cultures treated up to 60 lM allicin did not show significant
microscopic alterations as can be observed in Fig. 4(c and c0). The
apparent discrepancy could be related to the lack of discrimination
between cytotoxic and cytostatic effects from these colorimetric
methods. On these grounds toxicity was tested in non-dividing pri-
mary cells, mouse peritonealmacrophages (Fig. 3b). Results showed
that allicindid not induce any significant (p < 0.0001) toxicity up to a
concentration of 60 lM and the cell viability was reduced only by
10% after exposition of macrophages to this concentration.
3.3. Allicin also inhibits the multiplication of intracellular amastigotes
of Leishmania
The apparent low toxicity prompted us to examine the anti-
leishmanial activity of allicin on intracellular amastigotes of Leish-
mania. Given our initial experimental design, the effect of allicin
was tested on previously infected J774 cells. The modification of
the infection procedure developed was highly successful since ca.
70% of the J774 cells were infectedwith Leishmania amastigotes. Re-
sults obtained showed that the compound was effective against
Leishmania amastigotes multiplication after 24 h incubation. This
anti-leishmanial effect was observed in both L. donovani and L.
infantum in spite of the higher amastigote burden in L. donovani
infections (Fig. 4). Apparently the compound behaved as leishma-
niostatic since no notable reduction in the infection rate was appre-
ciated in any of the species tested whereas a significant (p < 0.05)
reduction in the amastigote burden was induced. Antileishmanial
effect of allicin was dose-dependent (Fig. 5) and dose–response
curves yielded an approximate IC50 value of 10 lM for both species.
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Fig. 3. Effect of different concentrations of allicin on the viability of J774 cells (a) and BALB/c mice peritoneal macrophages (b). Cytotoxicity was determined by MTT assay.
Results are means of eight determinations.
Fig. 4. Effect of allicin on the infection of J774 macrophages with Leishmania donovani (upper row) and Leishmania infantum (lower row): a and a0: infected and untreated
control cultures; b and b0: cultures treated with 30 lM allicin; c and c0: cultures treated with 60 lM allicin. Micrographs are representative images stained with May-
Grünwald-Giemsa of the triplicate cultures. Bar: 50 lm.
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3.4. Thermal degradation of allicin
The apparent recovery of promastigotes cultures of L. donovani
and L. infantum treated with 30 lM allicin (see Fig. 1) suggested
the possibility of degradation of the compound in the experimental
conditions established. Mass spectrometry analysis of allicin in
RPMI 1640 medium, exposed for 24 h at the culture temperatures
for promastigotes and amastigotes, 26 and 37 C respectively,
showed that the molecule was degraded at both temperatures
(Fig. 6). Our technique did allow us to detect 19 peaks in fresh un-
treated allicin preparation (Fig. 6a) whereas only 12 peaks were
found after treatment at 37 C for 24 h (not shown). Thermal degra-
dation products included diallyl sulfides (DAS), diallyl disulphides
(DADS) and a vinyldithiin although no evidence of allicin or ajoene
was obtained. Significantly simpler chromatograms were observed
in cultures containing allicin (120 lM) treated at 26 C. Only DADS
(Fig. 6b) and2-Butoxyethyl acetate andBenzaldehyde, 3–5dimethyl
were found; the last two compounds corresponded to the culture
medium, RPMI 1640 (Fig. 1c). Consistently with the degradation of
allicin, anti-leishmanial activity of the preparation was greatly im-
provedwhen this productwas freshly added every 24 h. Fig. 7 shows
the results obtained with L. donovani and comparable results were
obtained with L. infantum (not shown). All concentrations induced
a reduction in the number of promastigotes, after 24 h exposition
to the drug, in a concentration related manner (p < 0.05) and no
recovery of the cultures could be appreciated along the experiment.
Adifferentpatternof inhibitionwasobservedonwards (48 and72 h)
depending on the concentration of allicin. Cultures with the lower
concentrations tested (1, 5 and10 lM)didnotmultiply for the dura-
tion of the experiment. By its part, the antileishmanial effect of 30
and 60 lM, added every 24 h, provoked a strong reduction of the
promastigote number and, eventually, promastigote clearance with
the highest concentration tested after 48 h. These results suggested
a leishmaniostatic effect of allicin at low concentrations whereas
concentrations over 30 lM behaved as leishmanicidal for prom-
astigotes under our conditions.
The effect of the addition of allicin every 24 h on the actual stage
causing the leishmanial infection in mammals, amastigotes, was
evaluated in an ex vivo assay with mouse peritoneal macrophages
infected with L. donovani (Table 1).The modification of the infection
procedure was very efficient since over 90% of the macrophages
were infected with amastigotes after 24 h. Infection rate was only
slightly affected by both treatment with allicin, and time. The effect
of the compound on the number ofmacrophages infectedwasmod-
erate and actually with the highest concentration used (30 lM),
after 72 h infection rate was 60% ± 6.5% as compared to 86% ± 2.6%
in the untreated cultures (p < 0.05). More relevant was the effect
of allicin on the intracellular amastigote burden. Untreated control
cultures displayed active multiplication along the experiment,
reaching965.7 ± 59.9 amastigotes/100macrophages fromthe initial
burden of 489 ± 24.2 after 24 h. Antiproliferative effect of allicinwas
concentration and time dependent (p < 0.0001, F = 12.64). Both
amastigote burden (number of amastigotes/100 macrophages) and
relative parasite growth inhibition were significantly reduced with
all concentrations of allicin (p < 0.05–0.01). After 24 h, 10 lMallicin
reduced by ca. 40% the number of amastigotes as compared to the
untreated control cultures and over 67% after 72 h (p < 0.05), with
three administrations of allicin. More importantly, 5 lM allicin
significantly (p = 0.0014) reduced by ca. 50% the number of intracel-
lular Leishmania amastigotes after 48 h.
4. Discussion
A significant inhibitory effect of allicin on the multiplication of
both L. donovani and L. infantum has been found by us. Inhibition
was time- and dose-dependent against promastigotes and intracel-
lular amastigotes in vitro (J774 cells) and ex vivo (mouse perito-
neal macrophages). Very few reports have been published on the
effect of allicin against Leishmania promastigotes. The approximate
IC50 value obtained (10–30 lM, 24 h exposition) by us for prom-
astigotes from both species is in the line of the value indicated
by Ankri and Mirelman (1999) (30 lg mL1) for promastigotes of
L. major and slightly higher than that reported by McClure et al.
(1996) for L. chagasi and L. mexicana. Allicin, in the micromolar
range, effectively inhibited the multiplication of amastigotes with-
in J774 murine line cells and peritoneal macrophages. As far as we
know this is the first report on the inhibitory effect of allicin
against intracellular amastigotes. Mechanism of action of allicin
has been related to the rapid reaction with thiol groups (Rabinkov
et al., 1998) but the actual intracellular targets responsible of the
cytostatic/cytocidal effects are largely unknown. It has been re-
ported that allicin induces apoptosis (Oomen et al., 2004) and
our TEM results showed condensation of nuclear chromatin and
kDNA and loss of integrity of mitochondrial and kinetoplast mem-
brane. Ledezma et al. (2002) also observed nuclear alterations in
L. amazonensis promastigotes treated with the related compound
ajoene. Antioxidant systems of glutathione and trypanothione/try-
panothione reductase participate in the protection of Leishmania
against the toxic effect of nitrogen-derived reactive species from
macrophages (Romão et al., 2006). Interference of allicin with
these thiol-redox proteins could lead to amastigote destruction
and this possibility should be explored. Besides this interaction
other cell targets (i.e. other thiol-dependent enzymatic systems,
cysteine proteinases, microtubule disruption) (Ankri and Mirel-
man, 1999; Prager-Khoutorsky et al., 2007; Miron et al., 2010;
Waag et al., 2010) should be involved since comparable IC50 values
for allicin, administered as a single dose, were found by us in intra-
cellular amastigotes in J774 cells and extracellular promastigotes.
The modified method employed in the macrophage infection
with L. infantummetacyclic promastigotes (Ficoll gradient + opson-
isationwith 15%mouse serum) allowed to obtain higher yields than
those achieved with previously used methods (Méndez et al., 1996;
Wert et al., 2011). Comparative advantage of the methodology was
particularly evident in the ex vivo experiments with mouse perito-
neal macrophages and provides us with a valuable tool for in vitro
drug screening against intracellular amastigotes of this species. Un-
der our conditions, toxicity of allicin in the concentration range
used was low and no significant effect on mouse macrophages
was observed up to 40 lM as estimated by MTT method. Moreover,
the absence of substantial toxicity of the compound was confirmed
by microscopical examination without any noticeable cell
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Fig. 5. Effect of the single administration of different concentrations of allicin on
the intracellular amastigote burden of J774 cells infected with Leishmania donovani
(s) and Leishmania infantum (d). Results are the mean ± standard deviation of three
experiments.
Ma. Jesús Corral-Caridad et al. / Experimental Parasitology 132 (2012) 475–482 479
alteration up to 60 lM in both J774 cells and BALB/c peritoneal
macrophages. A lack of correlation between the results of toxicity
obtained with the colorimetric method in J774 cells and the find-
ings in peritoneal macrophages was found. This apparent inconsis-
tency could be related to the limitations of colorimetric methods to
distinguish between cytostatic and cytotoxic effects of a drug
(Plumb, 2004). Our results showed that allicin is a potent cytostatic
agent but of scarce toxicity for mammalian cells as confirmed by
the results obtained in non-dividing peritoneal macrophages. In
addition it stresses the need of performing direct microscopic
observation of the cells besides indirect methods when testing
potentially useful drugs against intracellular parasites.
Administration of allicin every 24 h greatly increased the anti-
leishmanial activity of the compound. This finding suggested the
degradation of the diallyl thiosulfinate at 26 and 37 C and is consis-
tent with the reported thermo-sensitivity of the molecule (McClure
et al., 1996; Cañizares et al., 2004). The degradation of the allicin
preparation employed by us after 24 h at 26 and 37 C was
confirmed by mass spectrometry. Allicin is a highly reactive thio-
sulfinate which is rapidly transformed to other types of organosul-
fur compounds, particularly diallyl disulfides (DADS), diallyl
sulfides (DAS), ajoene and vinyldithiins (Amagase, 2006). Our re-
sults showed the presence of sulfides and vinyldithiins but not ajo-
ene (E or Z) and allicin were found in any of the analysis. Simpler
Fig. 6. Mass spectrometry representative chromatograms of 120 lM allicin + RPMI 1640 medium treated for 24 h at 26 C (b). For comparative purposes fresh untreated
allicin (5000 ppm) (a) and RPMI 1640 medium treated for 24 h at 26 C (c) chromatograms are included.
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Fig. 7. Effect of different concentrations of allicin added every 24 h on the
multiplication of Leishmania donovani promastigotes. Arrows: days of treatment
with allicin. d: untreated control cultures; j: 1 lM; N: 5 lM; .: 10 lM; : 30 lM;
s: 60 lM. Results are means ± standard deviation of three experiments.
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chromatograms of culture samples are probably related to the low-
er concentrations of allicin (<120 lM) as compared to the standard
sample. The absence of allicin and ajoene could be due to their short
half life at the culture temperatures (26 and 37 C) (i.e. ajoene, less
than 1 min) and the analytical method employed. It is possible that
less stringent analysis (HPLC) (Lanzotti, 2006) would allow the
detection of these compounds. It is noteworthy to indicate that
most studies on the degradation of allicin have been carried out
with free allicin whereas our experiments were performed with a
stabilized form of this molecule. Whether or not the actual antile-
ishmanial agent in our studies is allicin or some other degradation
product requires further experimentation. It has been indicated
that thermal sensitivity of allicin at physiological temperature as
well as its rapid transformation to other types of organosulphur
compounds (Amagase, 2006) could rule out its therapeutic use.
However, it has been shown that decline of allicin is accompanied
by its transformation into other compounds (i.e. ajoene) (Fujisawa
et al., 2008) with strong anti-leishmanial activity (Ledezma et al.,
2002). Moreover, the metabolism of allicin, and therefore its bio-
availability, is unknown for themost part. Recently, oral and perito-
neal administration of methanolic extracts of garlic significantly
reduced the L. donovani burden in spleens of hamster infected with
L. donovani (Wabwoba et al., 2010). Chemotherapy of leishmaniasis
is far from ideal (Alvar et al., 2006; Chappuis et al., 2007) and new
drugs and combinations are required. Value of IC50 found by us
in vitro and ex vivo (5–10 lM) against intracellular amastigotes
possibly excludes allicin as monotherapy against leishmanial infec-
tions. However, low cost and scarce toxicity of this compound
would allow its use in combined therapy with other well estab-
lished anti-leishmanial drugs.
In conclusion, allicin (=diallyl thiosulphinate) has shown a sig-
nificant in vitro effect on the multiplication of promastigotes of L.
donovani and L. infantum. Allicin exhibited a scarce toxicity for
J774 cells and mouse macrophages. Moreover, it has been shown
for the first time the inhibition of multiplication of intracellular
amastigotes of Leishmania. Consistent infections of macrophages
(J774 cells, mouse peritoneal) with L. infantum have been obtained
with a modified method to isolate metacyclic promastigotes.
Inhibitory concentrations of allicin were in the micromolar range
for both Leishmania species and stages. More stable galenic prepa-
rations are probably needed. However, low toxicity for mammalian
cells of this compound suggests the interest of testing this
molecule in vivo in combined therapy against leishmanial
infections.
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In Vitro Synergistic Effect of Amphotericin B and Allicin on
Leishmania donovani and L. infantum
M. J. Corral, E. González-Sánchez, M. Cuquerella, J. M. Alunda
Department of Animal Health, Faculty of Veterinary Medicine, Universidad Complutense de Madrid, Madrid, Spain
Current monotherapy against visceral leishmaniasis has serious side effects, and resistant Leishmania strains have been identi-
fied. Amphotericin B (AmB) has shown an extraordinary antileishmanial efficacy without emergence of resistance; however, tox-
icity has limited its general use. Results obtained showed, using a fixed-ratio analysis, that the combination of diallyl thiosulfi-
nate (allicin) and AmB ranged frommoderately synergic to synergic at low concentrations (0.07MAmB plus 35.45Mallicin
induced 95% growth inhibition). None of the treatments, alone or in combination, had noticeable adverse effects onmacro-
phages (M) in the concentration range examined (allicin, 0.5, 1, 5 and 10M; AmB, 0.05, 0.075, and 0.1M). Allicin, AmB, or
the combination did not affect the infection rate (percentage of infectedM) of Leishmania. Allicin enhanced the activity of
AmB on intracellular amastigotes of Leishmania donovani and L. infantum (ca. 45% reduction of amastigote burden with 0.05
MAmB plus 10Mallicin); this represented nearly a 2-fold reduction in the 50% inhibitory concentration (IC50) of the antibi-
otic added alone. Results point toward the possible utility of testing this combination in vivo to reduce the toxicity associated
with monotherapy with AmB.
Human Leishmania infections are present in all inhabited con-tinents, with around 12 million people infected, 2 million
new cases every year, and estimates of around 350 million people
living in areas at risk (http://who.int/health-topics/leishmaniasis
.htm). Leishmaniasis is a spectral infection with a range of clinical
presentations, from self-healing dermal infections to deadly pro-
cesses. Cutaneous leishmaniasis is by large the most common dis-
ease, but visceral leishmaniasis (caused by Leishmania donovani
and L. infantum [L. chagasi]) is also present in all continents,
and the infections produce severe disease. The distribution of
these infections has greatly expanded, and coinfection of Leishma-
nia and HIV is very frequent (1). In addition to human cases,
canine leishmaniasis caused by L. infantum (Mediterranean Ba-
sin) and L. chagasi (South America) constitutes a first-order pa-
thology in veterinary clinics besides the zoonotical importance of
dogs as reservoirs. The main control system of leishmaniasis in
both humans and dogs is chemotherapy. However, antileishma-
nial drugs have some important shortcomings, including high
toxicity and teratogenicity in some cases, absence of parasitologi-
cal cure in most cases, and unaffordable prices for some of the
compounds and presentations. Moreover, in some areas, Leish-
mania strains resistant to commonly used drugs, particularly an-
timonials, have emerged (2). Liposomal amphotericin (AmB),
paromomycin, and miltefosine were considered the most prom-
ising drugs for chemotherapy of leishmaniasis (http://www.who
.int/tdr/diseases-topics/leishmaniasis/en/). However, for the large
part, these drugs were introduced over 40 years ago, and new
active compounds or combinations against Leishmania are
needed (3, 4).
The pharmaceutical industry has experienced a contraction
during recent years, resulting in very few companies being present
in the market. It is anticipated that investment and intercompany
competition and consequently the launch of new antiparasitic
agents will be reduced (5). One of the alternative chemotherapeu-
tic approaches is the use of combinations of effective existing
drugs whose toxicity precluded them from being widely used with
chemically unrelated compounds of reduced toxicity. The antibi-
otic AmB, besides being the standard treatment for systemic
fungal infections, has shown an extraordinary antileishmanial
efficacy. Its main mechanism of action, binding to ergosterol-
containing membranes of Leishmania (6), probably explains the
lack of significant emergence of resistance to the compound.
However, toxicity has limited its general use, and different low-
toxicity preparations have been developed (i.e., liposomes), but
their high price limits their standard use (7). Some low-cost vehi-
cles for the antibiotic have been tested in vitro and in vivo (i.e.,
albuminmicrospheres [8] and polylactic-co-glycolic acid [PLGA]
[9, 10]), although without further development. For its part, alli-
cin (diallyl thiosulfinate  2-propene-1-sulfinothioic acid S-2-
propenyl ester), a natural product present in plants of the family
Alliaceae, with antibacterial (11), antifungal (Candida) (12), and
antiprotozoal (Plasmodium and Leishmania promastigotes) (13,
14) activities, has been found to exhibit a notable antileishmanial
effect on the intracellular stages of L. donovani and L. infantum
without substantial cytotoxicity for mammalian cells (15).
On these grounds, our approach was the exploration of the
potential synergistic or additive antileishmanial effect of the com-
bination of AmB and allicin (low micromolar concentrations of
AmB plus micromolar allicin), thus avoiding the toxic concentra-
tions needed with AmB inmonotherapy. Results obtained in vitro
against both promastigotes and intracellular amastigotes of L.
donovani and L. infantum showed that allicin significantly en-
hanced the leishmanicidal activity of AmB and therefore reduced
the required amount of AmB to eliminate intracellular infection
of M by Leishmania.
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MATERIALS AND METHODS
Parasites. L. infantum (MCAN/ES/2001/UCM-9) is an autochthonous
isolate obtained at the Clinical Service of the Department of Animal
Health, Faculty of Veterinary Medicine (UCM), from a naturally
infected dog (Madrid, Spain). L. donovani isolate Khartoum 1246
(MHOM/SD/43/124) was provided by A. Toraño (Department of Immu-
nology, Instituto de Salud Carlos III, Madrid, Spain). Both species were
routinely maintained as promastigotes in 25-ml culture flasks at 26°C in
RPMI 1640 medium (Lonza Group, Switzerland) supplemented with
10% heat-inactivated (30 min at 56°C) fetal bovine serum (FBS; Sera
Laboratories International, Horsted Keynes, United Kingdom) and 100
U/ml of penicillin plus 100 g/ml of streptomycin (BioWhittaker, Ver-
viers, Belgium).
Drugs. Fungizone (deoxycholate-dispersed amphotericin B)was a gift
from Bristol-Myers Squibb (France). Stabilized allicin was obtained as
liquid Allisure (5,000 ppm) from Allicin International Ltd. (Rye, East
Sussex, United Kingdom). For the in vitro experiments, 10 mM stock
solutions of amphotericin B deoxycholate (AmB) in dimethyl sulfox-
ide (DMSO; Sigma, St. Louis, MO) were prepared. Further dilutions
were freshly made in RPMI 1640 medium. The final DMSO concen-
tration never exceeded 0.5% in the culture medium and had no effect
on cell growth. Dilutions of allicin were directly performed in culture
medium.
Promastigote assay. (i) Cell counts. Preliminary tests to determine
the 50% inhibitory concentrations (IC50s) of the individual drugs were
performed. For the combination assay, the IC50s of the single drugs, pre-
viously determined by cell counts, were combined. Leishmania log-phase
promastigotes were cultured in 10-ml sterile polystyrene tubes (initial
concentration, 106 parasites/ml; 2 ml/tube) and treated with 0.07 M
AmB or 30Mallicin or the combination of both (0.07MAmB plus 30
M allicin). Cultures were counted 24, 48, and 72 h posttreatment in a
Neubauer chamber, and the viability was determined with trypan blue
exclusion dye (0.4% in phosphate-buffered saline [PBS]). Experiments
were performed in triplicate.
(ii) alamarBlue assay for promastigote proliferation and synergism
of the drug combination. Mid-log-phase promastigotes were seeded in
96-well culture plates (Corning, New York, NY) at an initial plating den-
sity of 2.5 105 cells/well (200l/well). Cultures were exposed for 24 h to
various concentrations of the drugs and their combinations. Promastigote
proliferation and inhibition were determined with alamarBlue reagent
(AbDSerotec Ltd., United Kingdom) (10%, vol/vol) by following the
manufacturer’s recommendations by reading fluorescence intensity
(550-nm excitation wavelength and 590-nm emission wavelength) in a
FLUOstar Omega (BMG Labtech) fluorimeter after 72 h of incubation
with the dye. Untreated cultures, wells without cells and the maximal
concentration from each compound and their combinations, and wells
with culture medium and alamarBlue (10%, vol/vol) were included as
controls. Results for growth inhibition were expressed as percentage of
growth in untreated control cultures. Cultures were performed at least in
triplicate.
alamarBlue assays with increasing concentrations of the single drugs
were performed first, and appropriate drug combination ratios were
tested according to the results obtained. Drugs were combined at constant
ratios (0.01:5, 0.01:10, and 0.01:20 [MAmB/Mallicin]) by following a
modifiedfixed-ratiomethod (16), and their dose-effect relationshipswere
assessed by the Chou-Talalay combination index (CI) method using
CalcuSyn software (17, 18). This method is based on the multiple-drug
effect equation derived from the median-effect principle and the mass
action law. Results provide a quantitative determination for synergism
(CI  1), additivity (CI  1), and antagonism (CI  1). The software
allows the calculation of the dose reduction index (DRI), a parameter
which indicates the fold dose reduction allowed in a drug combination to
reach a given degree of inhibition compared to the drug as a single agent.
It provides other dose-effect-related parameters such as the potency (Dm)
of the drugs alone or in combination, this representing the concentration
which inhibits cell growth by 50%, and the shape of the dose-effect curve
(m), where m of 1,1, and1 indicate hyperbolic, sigmoidal, and flat
sigmoidal curves, respectively. The linear correlation coefficient (r) of
the median-effect plot represents the conformity of the data to the
mass action law.
Cytotoxicity assay for mammalian cells. Toxicity for mammalian
cells was determined ex vivo in murine (female BALB/c mice; Harlan
Barcelona, Spain) peritoneal M isolated by peritoneal lavage, resus-
pended in RPMI 1640 medium supplemented with 10% FBS, and seeded
in 96-well culture plates (4 106 cells/ml; 200 l/well). Plates were incu-
bated overnight to allow cell adherence at 37°C in a 5% CO2–95% air
mixture. Different concentrations of allicin (10, 30, and 40M)plusAmB
(0.1 and 0.5 M) were added to the cultures. At the end of the drug
exposure period (24 h), themediumwas removed; wells were replenished
with fresh medium and incubated for another 24 h. The viability of cells
was determined by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) reduction assay as described previously (19).
Briefly, 50l ofMTT (Sigma) solution (5mg/ml in sterile PBS)was added
to the wells, and the plates were kept for 4 h at 37°C in a humidified
atmosphere protected from light. Formazan crystals were dissolved with
200l ofDMSOand 25l/well of Sorensen’s glycine buffer (0.1Mglycine
and 0.1 MNaCl, adjusted to pH 10.5 with 1 MNaOH) and added to stop
the reaction. Absorbance was read at 570 nm in a microplate reader. Un-
treated cells and wells without cells and the maximal concentration from
each compoundwere included. Three independent experiments were car-
ried out.
Amastigote assay and determination of the synergism of the drug
combination. Infection of M was carried out with the modification
developed by us (15, 20). In brief, 2.5 104 J774 cells/well (200 l/well)
were cultured in 8-well Lab-Tek chambers (Nunc, Roskilde, Denmark)
for 16 h to ensure adherence. Stationary-phase Leishmania promastigotes
(day 7 to 10)were centrifuged (370 g, 10min, without brake) in a 5810R
centrifuge (Eppendorf, Germany) through a Ficoll gradient (0, 10% in
medium 199, and 30% in sterile PBS). Metacyclic parasites recovered
were washed and opsonized with 15% normal mouse serum (Jackson
ImmunoResearch, United Kingdom) in a solution (1/1, vol/vol) of RPMI
medium and Hanks’ balanced salt solution (HBSS; Sigma), 0.15 mM
CaCl2, and 1 mM MgCl2 for 30 min at 37°C and 5% CO2. Infection was
carried out overnight at 33°C at a parasite/M ratio of 10:1 in 5% CO2.
Noninternalized promastigotes were removed by thorough washing, and
fresh media containing the appropriate compounds dilutions were added
to the wells. Cultures were treated with AmB (0.05, 0.075, and 0.1 M)
and allicin (0.05, 1, 5, and 10M) administered alone and in combination
for 48 h. Unless otherwise stated, mitomycin C (Calbiochem, Merck,
USA) at 1 g/ml was added to avoid cell line proliferation. Untreated
cultures, cultures treated with mitomycin C, and cultures treated with
0.5% DMSO were included as negative controls. Slides were fixed and
stained (May-Grünwald Giemsa; Merck Darmstadt, Germany), and the
number of amastigotes/100 cells and percent infected cells were deter-
mined. Drug activity was expressed as percentage of growth inhibition
compared to that in untreated cultures. Three independent experiments
were performed at least in triplicate.
Statistical analysis.Graphs were generated and statistical analysis was
performed using GraphPad Prism 5. Statistical significance of differ-
ences between mean values obtained in the different groups was deter-
mined by repeated-measures generalized linear model analysis, one-way
analysis of variance (ANOVA), andBonferroni test. Differenceswere con-
sidered significant at a P value of0.05.
RESULTS
Figure 1 shows the results obtained by cell counting in the prelim-
inary test on the effect of the combination of AmB and allicin.
Similar results were obtained with both species, L. donovani (Fig.
1A) and L. infantum (Fig. 1B). Both compounds, AmB (0.07M)
and allicin (30 M), reduced by more than 50% the Leishmania
Interaction of Amphotericin and Allicin on Leishmania
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growth after 24 h of exposure, although a certain recovery of cell
multiplication was observed on the 48-h and 72-h samplings.
Combination of AmB (0.07 M) and allicin (30 M), however,
provoked the cell death of the majority of the leishmanial popu-
lation, and actually, after 72 h, L. infantum counts reached a mere
3  103 ml1, this representing a reduction of more than 99%
compared to the untreated cultures. These results were suggestive
of a positive interaction (additive or synergic) between the com-
pounds. To determine the effect of the combination, drugs were
tested at constantmicromolar ratios (0.01:5, 0.01:10, and 0.01:20)
(AmB/allicin); growth inhibition was estimated with the alamar-
Blue fluorimetric method. The two Leishmania species behaved
similarly; Table 1 shows the results obtained for L. infantum pro-
mastigotes. In all cases, data obtained agreed withmass law action
(r) and inhibition followed a sigmoid curve (m  1). Dm values,
corresponding to IC50s, obtained for the individual drugs tested
were in the range of the previously estimated concentrations (22.1
M for allicin and 0.09 M for AmB). Growth inhibition results
showed the significantly higher effect of the combination with
allicin evenwith 0.01MAmB. Thus, whereas AmB administered
alone did not induce at this concentration any inhibition of pro-
mastigotes’ multiplication, the combination with 20 M allicin
provoked a 37.5% growth reduction. This effect of allicin was
more evident with 0.02 M AmB, since when the antibiotic was
combined with 20Mallicin, 50% inhibition was reached (IC50),
and with 40 M allicin, 89% (IC90) of the multiplication was
stopped. Similarly, an AmB concentration of 0.08M, close to the
IC50 of this compound, with 40 M allicin reduced almost com-
pletely the multiplication of the promastigotes. It is noteworthy
that microscopic examination of the promastigotes subjected to
FIG 1 Effects of 30 M allicin (), 0.07 MAmB (Œ), and the combination (30 M allicin plus 0.07 MAmB) (Œ) on the multiplication of L. donovani (A)
and L. infantum (B) promastigotes after 24, 48, and 72 h. , untreated control cultures. Data are means	 standard deviations of an experiment in triplicate.
TABLE 1 Effects of AmB and allicin and their combination on promastigotes of Leishmania infantum determined by alamarBlue assaya
D1-D2 combination
ratio AmB concn (M)
Allicin
concn (M)
Growth
Inhibition (%)b m Dm (M) r
0.01:5 0.0025 1.25 3.5	 0.59
0.005 2.5 3.4	 0.98
0.01 5 3.5	 0.45
0.02 10 3.6	 2.84
0.04 20 15.0	 1.32
0.08 40 99.0	 0.03
0.16 80 99.0	 0.02 2.655 11.71 0.90
0.01:10 0.0025 2.5 3.1	 1.54
0.005 5 3.3	 1.49
0.01 10 4.0	 2.02
0.02 20 52.0	 2.22
0.04 40 97.0	 1.65
0.08 80 99.0	 0.11
0.16 160 99.0	 0.12 1.998 21.96 0.91
0.01:20 0.0025 5 1.42	 1.05
0.005 10 2.09	 1.13
0.01 20 37.5	 1.52
0.02 40 89.0	 2.31
0.04 80 99.0	 0.07
0.08 160 99.0	 0.04
0.16 320 99.0	 0.02 2.478 26.30 0.94
a Drugs were combined at constant ratios (0.01:5, 0.01:10, and 0.01:20) and their dose-effect parameters were assessed by the Chou-Talalay method (17) using CalcuSyn software.
Dm (median-effect dose) signifies the potency and it is the concentration which inhibits cell growth by 50%; m is the shape of the dose-effect curve, where m values of 1,1, and
1 indicate hyperbolic, sigmoidal, and flat sigmoidal curves, respectively; r represents the linear correlation coefficient of the median-effect plot (conformity of the data to the mass
action law principle). The m, Dm (M), and r values for AmB (drug 1 [D1]) were 1.451, 0.09, and 0.86, respectively, and those for allicin (D2) were 2.066, 22.13, and 0.90,
respectively.
b Results are expressed as the means	 standard deviations of three independent experiments.
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the combinations showed that they were not viable and that no
recovery of the cultures was found (data not shown). The com-
bined effect of the two compounds in terms of synergism-antag-
onism was complex, as shown at Table 2. Generally speaking, all
combinations allowed reduction of the concentrations required
for AmB (DRI), and synergism (CI 1) was evident only with the
fixed ratio (0.01 M AmB plus 5 M allicin) (Fig. 2). Combina-
tion allowed a 7- to 10-fold reduction of the AmBdose required to
provoke a 90 to 95% reduction in the promastigotes’ multiplica-
tion.
Given the results obtained with the extracellular stage of Leish-
mania, interaction was tested on intracellular amastigotes. Toxic-
ity of the combination of AmB plus allicin was assayed on peri-
toneal M from BALB/c mice. None of the concentrations of
allicin employed (10 through 40 M) in the combination in-
duced any significant toxicity as assessed byMTT assay (Fig. 3).
However, 0.5 M AmB, irrespective of the allicin concentra-
tion used, significantly (P  0.001) inhibited the viability of
M, more than 60%. As expected, no toxicity for mammalian
cells was found with 0.1 M AmB. This value is in the range of
reported IC50s for Leishmania and supported the exploration of
the combined treatment with allicin on the multiplication of in-
tracellular amastigotes of Leishmania given the apparent absence
of toxicity of the dialylsulfide up to 40 M. Only concentrations
below 0.1 M AmB and 10 M allicin were tested (Table 3). For
comparative purposes, the effect of both compounds adminis-
tered alone was also included. Since antileishmanial effect was
determined by cell counting, drugs were combined at a noncon-
stant ratio in a checkerboard manner. As expected, AmB alone
showed an approximate IC50 of 0.1M, and themaximal concen-
tration of allicin (10M) reduced by ca. 30% themultiplication of
amastigotes. Tested concentrations of the drugs, added alone or in
combination, did not significantly affect the viability and infection
rate of M under our experimental conditions; infection rates
ranged from 47.3% 	 3.8% to 67.0% 	 3.5%, and the results
obtained with the two Leishmania species (L. infantum and L.
donovani) were similar (data not shown). An interaction between
the compounds was found from moderately synergistic with the
lowest concentrations to antagonistic with the highest concentra-
tion used (0.1 M AmB plus 10 M allicin) (Fig. 4A). In spite of
this deduced interaction (CI), the most significant finding of the
experimentwas that 10Mallicin could induce ca. 50% reduction
of amastigotes’ multiplication when administered with 0.05 M
AmB. It should be pointed out that for the particular L. infantum
TABLE 2 Dose-effect relationships of the combination of AmB and allicin on Leishmania infantum promastigotesa
D1-D2 combination
ratio
% growth inhibition
(EDn) CI
DRI Dose required (M)
AmB Allicin AmB Allicin
0.01:5 50 0.79 (moderate synergism) 3.89 1.89 0.023 11.69
75 0.65 (synergism) 5.48 2.13 0.035 17.69
90 0.54 (synergism) 7.73 2.39 0.053 26.75
95 0.49 (synergism) 11.52 2.74 0.071 35.45
0.01:10 50 1.23 (moderate antagonism) 4.14 1.01 0.022 21.94
75 1.16 (slight antagonism) 5.31 1.03 0.037 36.49
90 1.09 (nearly additive) 6.81 1.05 0.061 60.71
95 1.05 (nearly additive) 8.06 1.07 0.085 85.82
0.01:20 50 1.33 (moderate antagonism) 6.92 0.84 0.015 31.22
75 1.19 (slight antagonism) 9.47 0.91 0.023 47.48
90 1.07 (nearly additive) 12.96 1.01 0.036 72.23
95 0.99 (nearly additive) 16.05 1.06 0.048 96.07
a Drugs were combined at constant ratios (0.01:5, 0.01:10, and 0.01:20), and their dose-effect relationships were assessed by the Chou-Talalay method (17) using CalcuSyn software.
CI was calculated by the combination index equation. CI of1, 1, and1 indicate synergism, additive effect, and antagonism, respectively, at different effective doses (ED50, ED75,
ED90, and ED95). Synergistic effects (CI 1) are in bold. DRI indicates the fold dose reduction allowed in a drug combination to reach a given degree of inhibition compared to the
drug as a single agent. Computer-simulated dose-required values of each drug in combination to reach a given effect level are included.
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FIG 2 Representative normalized isobolograms of the interaction of AmBwith allicin at a fixed ratio (0.01MAmB to 5Mallicin). Lines intersect at the x and
y axes at the normalized concentrations corresponding to the EC50 () (A), EC75 () (B), and EC90 (Œ) (C) when the compounds were administered alone. The
same symbols are used for the concentrations found with the AmB-plus-allicin combination to elicit the same effect as the drugs added alone (EC50, EC75, and
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 M allicin); EC, effective concentration.
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isolate employed, this AmB concentration administered alone had
almost no effect (7.3% 	 5.5% growth inhibition) on the multi-
plication of intracellular amastigotes. This represents a 2-fold re-
duction in the dose required for the antibiotic.
DISCUSSION
The aim of this work was the evaluation of the in vitro antileish-
manial effect of the combination of AmB and allicin with the final
purpose of reducing the required doses of the antibiotic and there-
fore the toxicity associated with its use. Results showed, using
a fixed-ratio analysis with the extracellular stage (17, 18) and a
checkerboard analysis with amastigotes, that the combination of
the two compounds was from moderately synergic to synergic at
low concentrations against both promastigotes (0.07 M AmB
plus 35.45 M allicin induced 95% growth inhibition) and amas-
tigotes (ca. 45% reductionwith 0.05MAmBplus 10Mallicin);
this represents nearly a 2-fold reduction in the IC50 of the antibi-
otic added alone (15, 21). The differences observed between pro-
mastigotes, with a 7- to 11-fold reduction of AmB, and amasti-
gotes, with a ca. 2-fold reduction, support an interest in using
intracellular amastigotes in drug screening (9, 21, 22). It is clear
that in vitro and ex vivo tests measure only the antiparasitic effect
and that no direct prediction of the effect in vivo can be drawn
from the results (23). Analysis showed that some drug combina-
tions were classified as antagonist in spite of reaching a highly
inhibitory effect in amastigotes and particularly promastigotes.
This finding, previously observed in anti-Plasmodium screening
(24, 25), suggests that even drugs associated with an indifferent
effect in vitro could be useful therapeutic partners in vivo. In ad-
dition, differential interaction between AmB and allicin found in
promastigotes and amastigotes of Leishmania could give us some
clues on the mechanism of action of the drugs used. The main
mechanism of action of AmB against Leishmania is related to the
preferential binding to ergosterol (6), which impairs the permea-
bility of membranes, resulting in loss of small cations and causing
cell death (26, 27). This mechanism is also responsible for the
FIG 3 Effect of the combination of AmB and allicin on the ex vivo survival of
mouse peritoneal macrophages (M). Numbers on the x axis represent the
concentration (M) of AmB plus concentration (M) of allicin. Solid bar,
untreated controlM; gray bars,M cultures treatedwith 0.1MAmB;white
bars,M cultures treatedwith 0.5MAmB. Results are themeans	 standard
deviations of three independent experiments.
TABLE 3 Effects of AmB, allicin, and their combination on the multiplication of intracellular amastigotes of Leishmania infantum in J774 cellsa
Drug combination
nonconstant ratio (M)
% infectionb
% growth
inhibitionb CI
DRI
AmB Allicin AmB Allicin
0 0 64.7	 2.5 0
0.05 67.0	 3.5 7.3	 5.5
0.075 64.7	 4.5 25.8	 5.1
0.1 58.3	 2.1 50.1	 5.5
0.05 60.3	 2.1 1.3	 4.2
1 61.7	 5.7 15.7	 4.6
5 56.7	 3.1 24.9	 1.8
10 63.0	 4.4 32.8	 3.9
0.05 0.05 62.7	 3.1 26.1	 3.1** 0.75 (moderate synergism) 1.51 11.28
1 60.0	 4.0 28.5	 4.4** 0.80 (moderate synergism) 1.55 6.04
5 56.7	 1.5 34.2	 6.3*** 1.30 (moderate antagonism) 1.67 1.42
10 56.3	 1.5 45.6	 8.5*** 1.58 (antagonism) 1.91 0.94
0.075 0.05 56.0	 9.5 47.4	 4.5*** 0.82 (moderate synergism) 1.29 19.68
1 54.0	 8.2 55.8	 10.9*** 0.79 (moderate synergism) 1.42 11.96
5 59.0	 4.4 54.8	 2.0*** 1.13 (nearly additive) 1.41 2.34
10 59.0	 2.6 54.0	 3.6*** 1.58 (antagonism) 1.39 1.15
0.1 0.05 47.3	 3.8 61.4	 3.8* 0.90 (slight synergism) 1.13 27.58
1 53.3	 3.8 61.5	 3.3* 0.95 (nearly additive) 1.13 13.86
5 53.0	 3.6 64.5	 5.0** 1.18 (slight antagonism) 1.17 3.00
10 47.7	 1.5 64.9	 0.9** 1.50 (antagonism) 1.18 1.51
a Drugs were combined at a nonconstant ratio and their dose-effect relationships assessed by the Chou-Talalay method (17) using CalcuSyn software. CI was calculated by the
combination index equation. CI of1, 1, and1 indicate synergism, additive effect, and antagonism, respectively, at the different drug combination doses. Synergistic effects
(CI 1) are in bold. DRI indicates the fold dose reduction allowed in a drug combination at the different data points compared with each drug alone. Statistical differences
between the effects of AmB alone and the combination of AmB plus allicin are indicated as follows: *, P 0.05; **, P 0.001; and ***, P 0.0001.
b Values are means	 standard deviations.
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fungicidal activity of the antibiotic. The part mechanistic basis of
the antiproliferative, and in particular the leishmanial, activity of
allicin (15, 19) is not clearly understood, although several cellular
targets have been incriminated (28). Apparently allicin produces
an enhancement of fungicidal activity of AmBby inhibiting ergos-
terol trafficking from the plasma membrane to the vacuole mem-
brane in Candida (a member of the Fungi) (29). Leishmania also
has considerable amounts of ergosterol on the plasmamembrane.
Resistance to AmB in clinical isolates of L. donovani has been
associated, besides the presence of cholesta-5,7, 24-trien-3-ol in-
stead of ergosterol, with the upregulation of the thiol metabolic
pathway (30). No thiol contents have been yet determined by us in
allicin-treated Leishmania, but interference with thiols has been
considered the main mechanism of action for allicin (28, 31). The
synergy observed could be related to the impairment of the thiol
metabolic pathway provoked by allicin, thus enhancing the effect
of AmB. Whether or not this enhancement of AmB effect in the
presence of allicin is responsible for the synergism found by us in
amastigotes and, particularly, promastigotes of Leishmania needs
further experimentation, which is under way.
Chemotherapy of leishmaniasis, both human and animal, is
not yet solved in spite of the substantial efforts made on basic
aspects of Leishmania biology. An alternative approach to mono-
therapy is the combination of drugs using well-established che-
motherapeutic agents (i.e., miltefosine plus amphotericin B or
antimonials plus amphotericin B) (32); in addition, these drug
combinations have been common in veterinary clinical practice.
Our results showed the apparently synergistic effect of allicin and
AmB in the micromolar range. Data obtained with drug combi-
nations in vitro have many limitations in spite of the dose-effect
relationship analysis carried out (i.e., unforeseen interactions and
pharmacokinetics) (18). However, the 2-fold reduction in the re-
quired dose of AmB against intracellular amastigotes and the pos-
sibility of using higher nontoxic doses of allicin (10M) suggest
exploration of this combination in vivo.
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Objectives: To evaluate the efficacy of the combination of allicin and amphotericin deoxycholate (AmB) in the
chemotherapy of Leishmania infantum infection with the final aim of reducing the dose of AmB in the chemo-
therapy of visceral leishmaniasis.
Methods: Hamsters were intraperitoneally (ip) infected with L. infantum (107 stationary phase promastigotes).
On day 45 post-infection animals were treated ip with AmB (1 or 5 mg/kg/day), allicin (5 mg/kg/day) or a com-
bination of AmB (1 mg/kg/day)+allicin (5 mg/kg/day) for 5 days. Animals were clinically and biopathologically
monitored and the antibody response (IgG, IgG1, IgG2) was determined. Parasite burdens were estimated by
limiting dilution and AmB biodistribution was determined by HPLC in plasma, kidney, spleen and liver.
Results: No clinical signs or liver and kidney alterations were observed. AmB (1 mg/kg/day) did not clear the
Leishmania infection and no parasites were detected in two animals treated with 5 mg/kg/day allicin.
Combination therapy (5 mg/kg allicin+1 mg/kg AmB) reduced the L. infantum burden by .95%. Antileishmanial
activity of the combination was comparable (P,0.05) to the standard AmB treatment (5 mg/kg).
Conclusions: Allicin alone (5 mg/kg/day for 5 days) significantly reduced the Leishmania burden in spleen and liver of
infected hamsters. Co-administration of allicin (5 mg/kg/day for 5 days) and AmB (1 mg/kg/day for 5 days) showeda
partial additive effect on the reduction of leishmanial burden in both target organs.
Keywords: Leishmania, hamster, amphotericin, allicin, visceral leishmaniasis
Introduction
Visceral leishmaniasis, a disease that is fatal unless treated,
is caused by Leishmania donovani and Leishmania infantum
(¼L. chagasi) and is responsible for 40000 human deaths per
year.1 As such, this infection is second only to malaria among
human parasitic diseases. Moreover, L. infantum infection is a
first-order pathology in veterinary medicine since in endemic
regions infection reaches a prevalence sometimes exceeding
25% of the total dog population, besides its role as a reservoir
for the human population. Visceral leishmaniasis is among the
frequent coinfections found in immunodepressed patients (e.g.
HIV+ or solid organ transplant recipients). No available vaccine
for humans has been developed and the present immunoprophy-
laxis of dog infections has important drawbacks (e.g. annual revac-
cination, adverse effects). Chemotherapy, both of humans anddogs,
is imperfect and relies on the use of drugs discovered.50 years ago.
In addition, important resistances have been described against
some of the first-line drugs (i.e. antimonials) employed in endemic
areas.2 The long half-life of some of the alternative treatments (e.g.
miltefosine) and easy selection of resistant lines of L. donovani to
others (e.g. paromomycin)3 suggests that emergence of resistance
has to be expected when used in monotherapy.
Amphotericin B (AmB) has been extensively used against sys-
temic fungal infections and as a second-line treatment against
leishmaniasis. It is a very effective antileishmanial drug and the
main mechanism of action that has been described, binding to
ergosterol-containing Leishmania membranes, does not favour
the appearance of resistance.4,5 The main inconvenience of this
drug has been the toxicity associated with its use as the deoxy-
cholate,6,7 but this limitation has been partially circumvented by
the use of low-toxicity vehicles (e.g. lipid carriers).8 However, the
high price of liposomal preparations makes the treatment
unaffordable in most endemic areas for human use and simply
# The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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irrelevant for veterinary purposes. Among the possible strategies
to manage the problems with the currently available antileish-
manial compounds—inefficacy, price, toxicity and induction of
resistance—combination therapy and the use of new molecules
have been indicated as research areas worth exploration.9 Allicin
(2-propene-1-sulfinothioic acid S-2-penyl ester; dialylsulphur) has
shown activity against some protozoa, including Leishmania.10,11
The main mechanism of action of allicin is related to its high per-
meability through cell membranes and interaction with thiols.12
Stabilized allicin has shown a significant antiproliferative effect,
in the micromolar range, against amastigotes (the stage present
in the infected hosts) of L. donovani and L. infantum without
evidence of toxicity for mammalian cells.13 Apparently allicin
enhances the antifungal (Candida) activity of AmB by inhibiting
ergosterol trafficking.14 Recently, a synergistic effect of low con-
centrations of allicin and AmB has been reported against these
species using an intracellular ex vivomodel (mouse macrophages
and amastigotes).15We have tested the effect of the combination
of AmB at a 5-fold reduced dose with allicin on experimental
infections of hamsters with L. infantum. The final aim of the
research is the reduction of the required dose of AmB and there-
fore the toxicity associated with the antibiotic if used in mono-
therapy of leishmaniasis.
Materials and methods
Leishmania culture media and drugs
L. infantum (MCAN/ES/97/10.445) zymodeme MON-1 was obtained
from a naturally infected dog and has been routinely maintained by sub-
passage in hamsters and as promastigotes in RPMI 1640 medium (Lonza)
in 25 mL culture flasks at 268C supplemented with 10% heat-inactivated
(30 min, 568C) fetal bovine serum (FBS; TDI), 1% L-glutamine (Lonza) and
100 U/mL penicillin+100 mg/mL streptomycin (Lonza). Fungizonew
(deoxycholate-dispersed amphotericin B) was from Bristol-Myers Squibb
and stabilized allicin was obtained as liquid Allisurew (15000 ppm) from
Allicin International Ltd.
Experimental infection of hamsters and follow-up
Female hamsters were purchased from Janvier SAS. At the time of their
arrival their weight ranged from 80 to 90 g. After a quarantine period of
30 days, animals were randomly allocated to six matched groups of six
hamsters each except group 1 (five animals). Group 1 was the uninfected
control group; group 2was infected but untreated; group 3was treatedwith
5 mg/kg/day AmB for 5 days; group 4 was treated with 1 mg/kg/day AmB
for 5 days; group 5 was treated with 5 mg/kg/day allicin for 5 days; and
group 6 was treated with 1 mg/kg/day AmB plus 5 mg/kg/day allicin for
5 days. Dilutions of the compounds were made with 5% dextrose solution
to a final volume of 500 mL. All treatments were administered by the
intraperitoneal (ip) route. Animals, except those in group 1, were infected
with 107 stationary phase promastigotes in 500 mL by ip injection on day
0 of the experiment. From day 45 post-infection (p.i.) onwards, the
hamsters were treated with the appropriate drug or drug combination.
The uninfected control group received the same volume (200 mL) of
dextrose 5% solution. On day 30 p.i. one of the animals in the infected,
untreated group (group 2) was euthanized to assess the infection. Ten
days after the last treatment animals were anaesthetized with isoflurane,
bled by intracardiac puncture and sacrificed by anaesthetic overdose.
Experimental animals were dissected and the liver, kidneys and
spleen were removed, weighed and used to estimate the parasite burden
(liver and spleen) and to perform the pharmacological determinations.
During the entire experiment the animals were housed at the facilities of
the Instituto de Salud Carlos III, Majadahonda, Madrid (ISCIII) with a 12 h
light/dark cycle, fed with pellets and given water ad libitum. Animals were
observed daily for undesired reactions to the infection and treatments and
body weight was determined weekly. Blood samples (serum and plasma)
were obtained at the end of the experiment to determine the levels of
renal and liver function markers [urea, creatinine, glutamic oxaloacetic
transaminase (GOT), glutamic pyruvic transaminase (GPT) and alkaline
phosphatase (ALP)] by standard clinical laboratory techniques (DLV
Laboratorio Veterinario, Madrid). Experimental design and procedures
were approved by the ethics committee of the ISCIII and followed the
recommendations of EC Directive 2010/63/EU.
ELISA
The peripheral specific antileishmanial antibody response (IgG, IgG1 and
IgG2) was determined by ELISA using serum samples from all experimen-
tal animals. Microtitre 96-well plates (Nunc) were coated with 25 mg/mL
(50 mL/well) of soluble L. infantum extract or fixed promastigotes (108 pro-
mastigotes/mL; 50 mL/well) overnight at 48C. For the latter, mid-log-phase
promastigotes were fixed with 0.025% formaldehyde solution (Panreac)
for 2 h at room temperature (RT) and washed three times with PBS.
To ensure cell adhesion, prior to blocking, promastigote-coated plates
were centrifuged (500 g, 10 min, RT). Plates were blocked with 2% BSA
(100 mL/well) at 378C for 1 h. Animal sera were used at dilution 1/50
(50 mL/well), as established by prior ELISA chequerboard titrations (not
shown), and incubated for 2 h at 378C. After washing, secondary anti-
bodies (50 mL/well) were added and the plates were incubated for 1 h at
RT. Antibodies were diluted in PBS–Tween at 1/2000 dilution for total IgG
[Goat Anti-Hamster IgG(H+L)-HRP, Southern Biotech] and at 1/1000 dilu-
tion for biotinylated mouse anti-Armenian hamster IgG1 (Abcam) and
mouse anti-Armenian hamster IgG2 (Abcam), both of which react with
heavy chains of Syrian hamster IgG isotypes. After washing, IgG1 and
IgG2 plates were further incubated with 50 mL/well HRP-conjugated strep-
tavidin (Southern Biotech) at a dilution of 1/2000 and incubated for 30 min
at RT. Finally, a 1 mg/mL solution of O-phenylenediamine (Sigma) and
H2O2 (1/1000) were added (100 mL/well). The reaction was stopped with
50 mL of 3 N H2SO4 and absorbance was read at 492 nm.
Efficacy of treatments
Besides clinical observation of the experimental hamsters, at the end of
the experiment the antileishmanial efficacy of drugs and combinations
was estimated by determining the parasite burden by limiting dilution
assay as previously described.16 Briefly, livers and spleens were removed,
weighed and homogenized in Schneider’s medium (Sigma) supplemented
with 20% heat-inactivated FBS, 2% sterile human urine, 20 mM HEPES
(Lonza), 1% L-glutamine (Lonza) and 100 U/mL penicillin+100 mg/mL
streptomycin (Lonza). Organ homogenates were filtered through a cell
strainer to ensure a single-cell suspension. Further dilutions of the hom-
ogenate were done in the same medium to a final concentration of
10 mg/mL; 200 mL/well of this cell suspension was added to the first
well of a 96-well culture plate (Corning) and serial 4-fold dilutions were
made across the plate. Plates were incubated for 2 weeks at 268C and
the presence of parasites was assessed by microscopy. The parasite bur-
den (number of parasites/g of organ) was calculated as described by
Buffet et al. (1995).17
Amphotericin B biodistribution in treated hamsters
Blood samples were obtained at the end of the experiment from group 3
(hamsters treated with 5 mg/kg AmB), group 4 (treated with 1 mg/kg
AmB) and group 6 (treated with 1 mg/kg AmB +5 mg/kg allicin). Plasma
was obtained and samples were stored at –208C until analyses were
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performed. Plasma samples (100 mL) were spiked with meloxicam
(Fagro´n SL) as internal standard at a final concentration of 10 mg/mL.
Two extractions were carried out with methanol (300 mL each) and a
third extraction with acetonitrile (300 mL). After every extraction, the mix-
turewas vortexed and centrifuged at 9000 rpm, 10 min, 48C. The superna-
tants were collected (300 mL×3) and evaporated off in a concentrator
(Savant, SpeedVacw) at 358C. Samples were reconstituted with 200 mL
of a 1:1 mixture of methanol : mobile phase (acetonitrile :acetic acid :
water) (52:4.3:43.7, v/v/v). The reconstituted samples were centrifuged
(9000 rpm, 5 min) and the supernatants were analysed by the validated
HPLC method described below.
HPLCwas equipped with a Jasco PU-1580 pump, a Jasco AS-2050 Plus
autosampler and a Jasco UV-1575 UV–visible detector. Integration of
the peaks was performed with the program Borwin 1.5 for PC (JMBS
Developments). AmB was isocratically eluted using a Thermo Hypersil
BDS C18 reverse-phase column (200×4.6 mm, 5 mm) and a mobile
phase as above with a flow rate of 1 mL/min. Absorbance was monitored
at 406 nm and the injection volume was set at 100 mL. Under these con-
ditions, the relative retention times of AmB and the internal standard were
7.9 and 5.1 min, respectively. PlasmaAmB concentrations were calculated
from linear regression calibration curves of the AmB/internal standard
peak height ratio. The linear range in plasma was 0.01 to 10 mg/mL
(y¼0.2191x20.0026; R2¼0.9986).
Liver samples (0.5 g) were spikedwithmeloxicam (10 mL at 200 mg/mL)
as internal standard. Samples were homogenized with PBS (pH 7.4,
0.25 mL). Then, AmB was extracted with methanol (1 mL). The mixture
was vortexed and then centrifuged (5000 rpm, 20 min). The supernatants
were filtered through a 0.45 mm filter (Milliporew Millex PVDF) and then
analysed by the HPLC method previously described. Liver AmB concentra-
tions were calculated from linear regression calibration curves of the AmB/
internal standard peak height ratio. Similarly, kidney samples (0.15 g) and
spleen samples (0.075 g) were analysed. Spleen samples were pooled
(three animals/group) to obtain the required amount of tissue.
Statistical analysis
Graphs and statistical analysis were performed using GraphPad Prism
5. The statistical significance of differences between mean values
obtained in the different groups was determined by one-way analysis of
variance followed by Tukey’s test. In all cases a P value of P,0.05was con-
sidered significant.
Results
Clinical follow-up
No clinical signs were noted during the experiment as a conse-
quence of either infection with L. infantum alone (group 2) or
infection and treatments administered. Similarly, no important
alterations were found in any of the biochemical parameters
determined in the experimental hamsters (Figure 1) since renal
(urea, creatinine) and liver function markers (ALP and GOT/GPT
ratio) were comparable in all experimental groups irrespective of
infection and the treatments administered. The only exception
was the blood urea nitrogen level in infected, untreated hamsters
(group 2), which was significantly higher than levels in uninfected
control animals and animals receiving AmB (5 mg/kg), allicin
(5 mg/kg) or the allicin+AmB combination. However, creatinine
values were in all cases ,0.2 mg/dL. ALP levels were in the
range of 214–251 U/L and the GOT/GPT index was ,1.0 in all
groups. These results suggest that allicin, AmB or the combination
(allicin+mB) with the doses and treatment schedule followed in
our experiment did not induce any significant toxicity in the
infected animals.
Antibody response
Comparable results were obtained with the two antigens,
although higher OD values were obtained with the cell-based
assay. L. infantum infection elicited a significant rise in anti-
Leishmania IgG against the soluble extract of the parasite
(Figure 2) and fixed promastigotes (Figure 3) as assessed by the
results observed in infected+untreated hamsters (group 2).
Using fixed promastigotes of Leishmania, animals treated with
the lowest AmB dose (group 4) displayed values not significantly
different from those found in infected, untreated hamsters
(group 2) (Figure 3a). However, animals treated with allicin
alone (group 5) or together with a low dose of AmB (group 6)
showed significantly lower antibody values (P,0.05). Values
in animals treated with the combination were not different from
those in animals treated with standard dosage of AmB (group 3;
5 mg/kg/day, 5 days) (P.0.05) or the uninfected control group
(group 1). The pattern found for the specific IgG2 response was
more complex (Figures 2b and 3b). Excluding the uninfected con-
trol hamsters, the lowest antibody values were found in animals
receiving 5 mg/kg/day AmB (group 3) and the highest IgG2 levels
in hamsters treatedwith allicin alone (group 5). Moreover, group 3
hamsters were significantly different (P,0.05) from the group
treated with allicin alone (group 5) but not from the infected con-
trol group (group 2) or those treated with the lowest AmB dose
(group 4) or the combination of allicin+AmB (group 6). The
IgG1 response was very low in all groups and no significant differ-
ences between them were found (Figures 2c and 3c).
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Figure 1. Values of renal and kidney function markers at the end of the experiment. G1, uninfected control; G2, infected with Leishmania infantum;
G3, infected and treated with 5 mg/kg/day AmB; G4, infected and treated with 1 mg/kg/day AmB; G5, infected and treated with 5 mg/kg/day allicin; G6,
infected and treated with 1 mg/kg/day AmB +5 mg/kg/day allicin. ALP, alkaline phosphatase; GPT, serum glutamate pyruvate transaminase; GOT, serum
glutamic oxaloacetic transaminase. Data are means+SEM.
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Liver and spleen Leishmania burden
Figure 4 shows the results obtained in the determination of
L. infantum burden in liver and spleen. The infection procedure
(ip administration) was efficient and all infected control hamsters
(group 2) had detectable infections. Spleen burdens of Leishmania
(6.0 log10 units) were, in general, significantly higher than those
found in the liver (3.0 log10 units). The negative control group
(group 1) did not show any parasites. The curative effect of AmB
was dependent on the dose administered. With the highest dose
(5 mg/kg AmB; group 3) no parasites were detected in two ani-
mals and the average reduction of L. infantum burden was
94.5% in the spleen and 90.6% in the liver. However, none of
the hamsters treated with 1 mg/kg AmB (group 4) was free of
infection, although the parasite burden was reduced by 70%
in the spleen and a similar reduction was found in the liver.
Allicin, administered alone (group 5), cleared Leishmania infection
in two of the hamsters and both liver and spleen parasite burdens
were significantly lower than those found in the infected,
untreated group (P,0.05). Results with the combination of
1 mg/kg AmB and 5 mg/kg allicin) (group 6) showed a partially
additive effect. The reduction in Leishmania burden was signifi-
cantly (P,0.05) higher than that obtained with 1 mg/kg AmB
and slightly better than that obtained with the higher dose of
allicin (5 mg/kg). In three out of six hamsters in group 6 no
Leishmania were recovered from the liver and in two out of six
no parasites were detected in the spleen. Results in terms of
organ clearance were similar to those found with the standard
AmB treatment (5 mg/kg AmB).
Amphotericin B pharmacokinetics
Very low AmB plasma concentrations were found in all experi-
mental animals (Figure 5). However, AmB was detected in all
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Figure 2. Serum specific antibody responses against soluble Leishmania
infantum antigen (SLA) estimated by ELISA on day 60 of the experiment.
(a) Total IgG (H+L). (b) IgG2. (c) IgG1. G1–G6, experimental groups as in
Figure 1. DOD, increase in OD. Values are means+SEM.
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Figure 3. Serum specific antibody response to fixed promastigotes of
Leishmania infantum estimated by ELISA on day 60 of the experiment.
(a) Total IgG (H+L). (b) IgG2. (c) IgG1. G1–G6, experimental groups as in
Figure 1. DOD, increase in OD. Values are means+SEM.
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organs analysed (kidney, liver and spleen). Animals in group 3
(5 mg/kg AmB) exhibited significantly higher AmB levels in liver,
kidney and spleen than animals in groups 4 (1 mg/kg AmB) and
6 (1 mg/kg AmB+5 mg/kg allicin) but no differences were
observed in plasma among groups. AmB levels in group 6 ham-
sters were higher than those in group 4, although the difference
was not statistically significant.
Discussion
Successful chemotherapy of leishmaniasis remains a challenge in
spite of the research that has been done on the fundamental
biology of the aetiological agents. In practice only a handful
drugs are currently used and clinical isolates of L. donovani have
shown notable resistance to the pentavalent antimonials.18
Moreover, given the relatively easy selection of resistant
Leishmania lines to paromomycin3 and miltefosine,4 together
with the oral administration of the latter and risks associated
with self-medication, clinical resistance after monotherapy with
these drugswill probably appear.19 AmB is probably the best exist-
ing drug against leishmaniasis, with cure rates exceeding 95%9,20
and negligible levels of resistance after being employed as the ref-
erence drug against systemic fungal infections for .50 years.5
The main mechanism of action of AmB is still controversial,21–23
although it is generally considered that binding of AmB to ergos-
terol in the Leishmaniamembrane is the first or the unique event5
causing cell destruction. The few reports of clinical resistance in
Leishmania are related to a modification of ergosterol to the
closely related lipid cholesta-5,7,24-trien-3b-ol.24 To cope with
the shortage of available drugs against leishmaniasis, combin-
ation therapy with a variety of drugs and schedules25,26 has
some potential advantages, such as delaying or preventing the
development of resistance and shortening of treatment regi-
mens.27 Since the main shortcoming of AmB is toxicity,6,7 our
approach used a combination of allicin with the antibiotic AmB
with the aim of reducing the amount of AmB required and there-
fore the potential toxicity of the antibiotic. The experimental
model employed (L. infantum and hamster) produced consistent
infections with significantly higher parasite burdens in the spleen
than in the liver, thus confirming its value28–32 and its suitability
for in vivo testing of antileishmanial agents. Moreover, the limiting
dilution assay allowed the detection of the parasite 2 months
after infection in both the spleen and the comparatively less para-
sitized liver. No clinical signs or biopathological alterations were
observed in any of the infected or infected+treated animals, indi-
cating the lack of toxicity of AmB and allicin at the doses adminis-
tered. The levels of ALP found in our experiment were higher than
the reference range of 50–186 U/L. This could be related to the
age of the hamsters, since immature animals have higher ALP
levels than adults due to release of the enzyme from growing
bone.33 The alteration in blood urea nitrogen level in group 2 ham-
sters provided evidence of renal compromise in infected animals.
Moreover, higher values of urea, observed in all groups compared
with the reference range (12–26 mg/dL), were probably due to
diet (i.e. high protein content) and sex (i.e. female).33 In our
experiment, 5 mg/kg allicin administered by the ip route, to
avoid the potential degradation induced by the conditions in the
stomach, elicited a clear antileishmanial effect in hamsters since
two out of six animals were cleared of L. infantum in both spleen
and liver. As far as we know this is the first evidence of the anti-
leishmanial activity of allicin in vivo without apparent toxicity in
infected, treated animals. The combination of allicin+AmB signifi-
cantly improved the efficacy of low-dose AmB (group 4), and was
slightlymore efficacious than allicin at 5 mg/kg. The low-dose com-
bination of AmB+allicin (group 6) cleared the leishmanial infection
in three out of six hamsters. Moreover, the reduction in the
Leishmania spleen burden was almost as great as that obtained
with standard AmB chemotherapy in this model (5 mg/kg,
5 days, ip) (96.57% versus 94.5%).34 These results suggest a
partial additive antileishmanial effect of the combination in vivo.
Results obtained with either drug administered alone to hamsters
support the predictive value of the in vitro and ex vivo model
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Figure 4. Leishmania infantum burden (parasite burden, PB) determined
by limiting dilution. G1–G6, experimental groups as in Figure 1. White
bars, spleen burden; grey bars, liver burden. Values are means+SEM.
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Figure 5. Amphotericin B (AmB) concentrations in plasma, liver, kidney and
spleen of hamsters infected and treatedwith 5 mg/kg/day AmB (black bars)
(group 3), 1 mg/kg/day AmB (grey bars) (group 4) and 1 mg/kg/day
AmB+5 mg/kg/day allicin (white bars) (group 6). Values are means+SD.
Statistically significant differences (P,0.0001) were found between
groups 3 and 4 (*) and between groups 3 and 6 (#).
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(Leishmania-infectedmacrophages) for drug screening of antileish-
manialmolecules.35 No information on themechanismof action of
the combination against Leishmania is available. However, in fungi
(e.g. Candida albicans) the enhanced fungicidal activity of this com-
bination36 has been related to the inhibition of ergosterol trafficking
by allicin in the presence of non-lethal concentrations of AmB.14,37
AmB levels in treated hamsters suggested, but did not demon-
strate conclusively, that allicin improves the accumulation of the
antibiotic in the target organs, and this should be explored.
Resolution of Leishmania infection after vaccination or successful
therapy seems to be associated with a Th2-to-Th1 switch with a
dominant IgG2 response.
30,38–41 Our results showed a degree of
correlation between total IgG (H+L) and Leishmania burden.29
However, hamsters treated with 5 mg/kg AmB (group 3) had
lower levels of specific IgG2 than animals treated with 1 mg/kg
AmB. This suggests that the relationship of the IgG1 and IgG2 pat-
tern to the outcome of leishmanial infections in hamsters is not
clear. In fact, hamsters treated with AmB showed antibody levels
comparable to those of infected, untreatedhamsters.42 In addition,
slightly different patterns were obtained with fixed promastigotes
and soluble extracts of Leishmania. These variations are probably
related to the different sets of antigens recognized by the sera of
infected hamsters. Allicin apparently enhances proinflammatory
responses (IFN-g, TNFand IL-12p70) in mice,43 which could explain
the relatively high IgG2 response in animals treated with allicin or
allicin+AmB. Whether or not the role of these cytokines is similar
inmice and hamsters or, alternatively, allicin has immunostimulat-
ing properties should be clarified. More research is needed (refining
of the dosage and time schedule), but our results point to the inter-
est of this combination as a means of reducing the dose of AmB
needed in the chemotherapy of leishmaniasis.
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